

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/18022 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04**,  
21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/12, 15/63,  
15/85, 15/86

(21) International Application Number: PCT/US00/24008

(22) International Filing Date: 31 August 2000 (31.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/152,317 3 September 1999 (03.09.1999) US  
60/152,315 3 September 1999 (03.09.1999) US

(71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NI, Jian** [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). **BAKER, Kevin, P.** [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). **BIRSE, Charles, E.** [GB/US]; 13822 Saddleview Drive, North Potomac, MD 20878 (US). **FISCELLA, Michele** [US/US]; 6308 Redwing Road, Bethesda, MD 20817 (US). **KOMAT-SOULIS, George, A.** [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). **SOPPET, Daniel, R.** [US/US]; 15050 Stillfield Place, Centreville, MD 22020 (US). **YOUNG, Paul, E.** [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). **EBNER, Reinhard** [DE/US]; 9906 Shelburne Terrace, #316, Gaithersburg, MD 20878 (US). **DUAN, D., Roxanne** [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). **OLSEN, Henrik, S.** [DK/US]; 182 Kendrick Place, #24, Gaithersburg, MD 20878 (US).

**LAFLEUR, David, W.** [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). **MOORE, Paul, A.** [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). **SHI, Yanggu** [US/US]; Apt. 102, 437 West Side Drive, Gaithersburg, MD 20878 (US). **WEI, Ying-Fei** [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). **FLORENCE, Kimberly, A.** [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US).

(74) Agents: **HOOVER, Kenley, K.** et al.; c/o Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- With (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 52 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.



WO 01/18022 A1

## 52 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of  
5 such polynucleotides, polypeptides, and antibodies, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of



the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As

shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of  
5 microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an  
10 overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the  
15 polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight  
20 incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X  
25 SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and  
30 commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-  
5 Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as “low complexity” regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments  
10 generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters (“seg” and “xnu”) which “mask” the low complexity regions in a  
15 particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character “X”. This is then used as the input sequence (sometimes referred to herein as “Query” and/or “Q”) to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a  
20 negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of “X”s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such  
25 stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as “Subject”, “Sbjct”, and/or “S”) indicated  
30 in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

5

### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

10 The translation product of this gene shares sequence homology with env protein (see, e.g., Genbank accession number AAD34324.1 (AF108843); all references available through this accession are hereby incorporated by reference herein.), a protein with similarity to retroviral envelope glycoproteins.

15 The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 493 to about 509 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing from about amino acids 510 to about 563 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

20 This gene is expressed primarily in fetal tissues, placenta, fetal liver spleen, infant brain, and total fetus and to a lesser extent in tumors (poorly differentiated ovarian adenocarcinoma and endometrial tumor), human adult (K.Okubo) and PC3 prostate cell line.

25 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: fetal development disorders, cancer and other proliferative disorders, particularly endometrial and ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
30 tissues or cells, particularly of the endometrium and ovary, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g., fetal, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 83 as residues: Gln-88 to Lys-97, Glu-128 to Ser-133, Asn-166 to Pro-175, Thr-191 to Asn-196, Asn-207 to Lys-212, Cys-232 to Gly-238, Ala-256 to Ala-263, Thr-268 to Thr-280, Pro-311 to Cys-317, Val-347 to Leu-362, Glu-396 to Leu-406, Pro-429 to Ala-436, Ala-464 to Lys-469, Arg-513 to Asn-520. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution and homology to retroviral envelope proteins indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, detection, prevention and/or treatment of cancer and other proliferative disorders, particularly of the endometrium and ovary.

The tissue distribution in infant brain indicates the protein product of this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.



The expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2205 of SEQ ID NO:11, b is an integer of 15 to 2219, where both a and b correspond to the positions of  
5 nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 2

This gene shares sequence homology with members of the B7 family of ligands (i.e., B7-1 (See Genbank Accession 507873)). These proteins and their corresponding receptors play vital roles in the growth, differentiation and death of T  
15 cells. For example, some members of this family (i.e., B7-H1) are involved in co-stimulation of the T cell response, as well as inducing increased cytokine production. Therefore, antagonists such as antibodies or small molecules directed against the translation product of this gene are useful for treating T cell mediated immune system disorders.

20 In additional nonexclusive embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:  
LEVQVPEDPVVALVGTDATLCCSFSPGFSLAQLNLIWQLTDTKQLVHSFAE  
GQDQGSAYANRTALFPDLLAQGNASRLRLQVRVADEGSFTCFVSIRDFGSAA  
VSLQVAAPYSKPSMTLEPNKDLRPGDTVITICSSYQGYPEAEVFWQDGQGVP  
25 LTGNVTTSQMANEQGLFDVHSILRVVLGANGTYSCLVRNPVLQQDAHSSVTI  
TGQPMTF (SEQ ID NO: 158). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
30 conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the

invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also preferred are polypeptides comprising, or alternatively consisting of, fragments of the mature extracellular portion of the protein demonstrating functional activity. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Such functional activities include, but are not limited to, biological activity (e.g., T cell costimulatory activity, ability to bind ICOS, and ability to induce or inhibit cytokine production), antigenicity, immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

Additionally, the translation product of this gene shares sequence homology with butyrophilin and butyrophilin-like molecules (See, e.g., Genbank Accession No. emb|CAB38473.1| (AL034394) dJ1077I5.1 and gb|AAC05288.1| (AF050157); in addition to the following Geneseq Accession Nos. W46488, W97816, W71592, and W78917; all information and references available through these accessions are hereby incorporated herein by reference):

```

20  gb|AAC05288.1| (AF050157) butyrophilin-like [Mus musculus] >sp|O70355|O70355
    BUTYROPHILIN-LIKE (FRAGMENT).
    Length = 452

25  Plus Strand HSPs:

    Score = 255 (89.8 bits), Expect = 2.9e-23, Sum P(2) = 2.9e-23
    Identities = 80/292 (27%), Positives = 137/292 (46%), Frame = +1

30  Query:   613 GPGDMVTITCSSYQGYPEAEVFWQDGGQGVPLTGNVTTSQMANEQGLFDVHSILRVVLGAN 792
          G G+ V + C+S +PE EV W+ G L + + + + E GLF V L V +
    Sbjct:  156 GEGE-VQLVCTSRGWFPPEPEVHWEGIWGEKLM-SFSENVHPGEDGLFYVEDTLMVRNDSV 213

35  Query:   793 GTYSCLVRNPVLQDDAHSSVTITPQ-RSPTGAVEVQVPEDPVVALVGTDLHCSFSPEP 969
          T SC + + L++ +++ ++ + ++ +V V P VG + L C SP+
    Sbjct:  214 ETISCFIYSHGLRETQEATIALSERLQTELASVSVIGHSQPSPVQGENIELTCHLSPQT 273

40  Query:   970 GFSLTQLNLIWQLTDTKQLVHSFTEGR----DQGSAYANRTALFPDLLAQGNASLRLQRV 1137
          L + W + VH + G +Q Y RT+L D + +G +L++
    Sbjct:  274 --DAQNLEVRWLRSRYPYPAVHYANGTHVAGEQMVEYKGRSLVTDALHEGKLTQLQHNA 331

45  Query:  1138 RVADEGSFTCFVSIRD--FGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDVTITCSSYRG 1311
          R +DEG + C +D + A V +QV A S P +T E KD G + + C+S
    Sbjct:  332 RTSDEGQYRCLFG-KDGVYQEARVDVQVMAVGSTPRITREVLKD---GG-MQLRCTSDGW 386

    Query:  1312 YPEAEVFWQDGGQGVPLTGNVTTSQMANEQGLFDVHSLRVVLGANGTYSCLVRNPVLQQ 1488
          +P V W+D G + Q +++ LF V ++L V G+ +C + P+ Q+
    Sbjct:  387 FPRPHVQWRDRDGKTMPSFSEAFQQGSQE-LFQVETLLLVTNNGSMVNVTCISISLPLGQE 444

```

Score = 194 (68.3 bits), Expect = 4.6e-11, P = 4.6e-11  
Identities = 58/210 (27%), Positives = 103/210 (49%), Frame = +1

5 Query: 901 PEDPVVALVGTDATLHCSFSPEPGFSLTQNLNLIWQLTDTKQLVHSFTEGRD-QG---SAY 1068  
P P++A VG DA L C P+ + + W +D V + +G + G Y  
Sbjct: 34 PNLPIAKVGEDALLTCQLLPKR--TTAHMEVRWYRSDPMPVIMYRDGA EVTGLPMEGY 91

10 Query: 1069 ANRTALFPDLLAQGNASRLRQVRVADEGSFTCFVSIRD FG-SAAVSLQVAAPYSKPSMT 1245  
R D +G+ +L+++V+ +D+G + C D+ +V LQVAA S P++  
Sbjct: 92 GGRAEW MEDSTEEG SVALKIRQVQPSDDGQYWC RFQEGDYWRETSVLLQVAALGSSPNIH 151

15 Query: 1246 LEPNKDLRPGDVTITCSSYRGYPEAEVFWQDQGVP L TGNVTT SQMANEQGLFDVH SVL 1425  
+E L G+ V + C+S +PE EV W+ G L + + + + E GLF V L  
Sbjct: 152 VE---GLGEGE-VQLVCTSRGWFP EPEVHWEGIWGEKLM-SFSENHVPGEDGLFYVEDTL 206

20 Query: 1426 RVVLGANGTY SCLVRNPVLQQDAHGSVTTITGQPM T 1530  
V + T SC + + L++ ++ ++ + T  
Sbjct: 207 MVRNDSVETISCFIYSHGLRETQEATIALSERLQT 241

Score = 105 (37.0 bits), Expect = 0.24, P = 0.21  
Identities = 30/100 (30%), Positives = 44/100 (44%), Frame = +2

25 Query: 254 PVVALVGTDATLCCSFSP EPGFSLAQNLNLIWQLTDTKQLVHSFAEGQ---DQGSAYANR 421  
P VG + L C SP+ L + W + VH +A G +Q Y R  
Sbjct: 254 PSPVQVGENIELTCHLSPQT--DAQNLEVRWLR SRYP AVHVYANGTHVAGEQMVEYKGR 311

30 Query: 422 TALFLDLLAQGNASRLRQSVRVADEGQLHLLREHPGFRQRCR 547  
T+L D + +G +L++ + R +DEGQ L G Q R  
Sbjct: 312 TSLVTD AIHEGKLT LQIH NARTSDEGQYRC LFGKDG VYQEAR 353

Score = 97 (34.1 bits), Expect = 2.9e-23, Sum P(2) = 2.9e-23  
Identities = 25/88 (28%), Positives = 44/88 (50%), Frame = +2

35 Query: 245 PEDPVVALVGTDATLCCSFSP EPGFSLAQNLNLIWQLTDTKQLVHSFAEGQD-QG---SAY 412  
P P++A VG DA L C P+ + A + + W +D V + +G + G Y  
Sbjct: 34 PNLPIAKVGEDALLTCQLLPKR--TTAHMEVRWYRSDPMPVIMYRDGA EVTGLPMEGY 91

40 Query: 413 ANRTALFLDLLAQGNASRLRQSVRVADEGQ 502  
R D +G+ +L+++ V+ +D+GQ  
Sbjct: 92 GGRAEW MEDSTEEG SVALKIRQVQPSDDGQ 121

45 Butyrophilin is thought to be important in the process of lactation and milk secretion. Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with butyrophilin and/or oligodendrite proteins. Such activities are known in the art, some of which are described elsewhere herein.

50 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

ARLGRVPESQSRRGAAGAAFHHGEPSCQPPHRKMLRRRGSPGMGVHVGAAL  
55 GALW  
FCLTGALEVQVPEDPVVALVGTDATLCCSFSP EPGFSLAQNLNLIWQLTDTKQL

VHSFAEGQDQGSAYANRTALFLDLLAQGNASRLQSVRVADEGQLHLLREH  
PGFRQRCRQPAGGRSLLEAQHDPGAQQGPAARGTW (SEQ ID NO: 155).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptides of the invention comprise, or  
5 alternatively consist of, the following amino acid sequence:  
PWSPTRTCGPGDMVTITCSSYQGYPEAEVFWQDGQGVPLTGNVTTSQMANE  
QGLFDVHSILRVVLGANGTYSCLVRNPVLQQDAHSSVTITPQRSPTGAVEVQ  
VPEDPVVALVGTDATLHCSFSPEPGFSLTQLNLIWQLTDTKQLVHSFTEGRDQ  
GSAYANRTALFPDLLAQGNASRLQRVRVADEGSFTCFVSIRDFGSAAVSLQ  
10 VAAPYSKPSMTLEPNKDLRPGDTVTITCSSYRGYPEAEVFWQDGQGVPLTGN  
VTTSQMANEQGLFDVHSVLRVVLGANGTYSCLVR  
NPVLQQDAHGSVTITGQPMTFPPEALWVTVGLSVCLIALLVLPFVCWRKIK  
QSCEENAGAEDQDGE GSKTALQPLKHSDSKEDDGQEIA (SEQ ID NO:  
156). Moreover, fragments and variants of these polypeptides (such as, for example,  
15 fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the  
polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
encoding these polypeptides, or the complement thereof are encompassed by the  
invention. Antibodies that bind polypeptides of the invention are also encompassed by  
20 the invention. Polynucleotides encoding these polypeptides are also encompassed by  
the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
15. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 15.

25 This gene is expressed primarily in dendritic cells and to a lesser extent in  
fetal liver and spleen, normal colon, and normal liver. It is also expressed in various  
tumors including ovary, glioblastoma, germ cell tumors, pancreatic tumor, and  
germinal center B-cell cancer.

Polynucleotides and polypeptides of the invention are useful as reagents for  
30 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to  
cancer and immune disorders including autoimmune diseases and immuno-deficiency

disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 84 as residues: Glu-72 to Gly-77, Arg-115 to Arg-125, His-138 to Pro-146. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The dendritic cell distribution and homology to the butyrophilin family indicates that polynucleotides and polypeptides corresponding to this gene are useful for down-regulation or stimulation of the immune-response. Dendritic cells play a pivotal role in immune surveillance- they are responsible for the capture and processing of antigens from the periphery and subsequent presentation of these antigens to B and T lymphocytes in lymphoid organs. Dendritic cells also produce and secrete numerous immuno-modulatory proteins. The butyrophilin family appears to have a receptor like structure having an extracellular domain, transmembrane domain and intracellular region. The encoded protein may act as a membrane bound receptor to mediate the interaction of dendritic cells with other cells of the immune system. This interaction could be with either soluble factors produced by other immune cells or with membrane proteins present on other immune cells. Such interactions may result in a stimulation or down-regulation of dendritic cell function. Subsequently the immune system may be stimulated to respond against specific antigens, or the response may dampened as is seen in tolerance of self- antigens. The inability to effectively inhibit immune responses to self antigens could result in autoimmune disease. Conversely the inability to stimulate correct responses could result in an immuno-deficiency syndrome and subsequent susceptibility to infectious agents.

Additionally, the expression of this gene in numerous tumors may reflect the role that this molecule plays in the body's normal anti-tumor surveillance system; tumor cells may express this protein in order to stimulate an immune response (e.g.; targeting of cytotoxic T-cells against the tumor cells). Alternately, the molecule may  
5 be used by tumors to dampen the cytotoxic immune response and thus be a means by which tumors escape killing.

Moreover, the tissue distribution in fetal liver spleen and germinal center B-cell indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the  
10 "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or  
15 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,  
20 inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia,  
25 rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of  
30 various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional

supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3422 of SEQ ID NO:12, b is an integer of 15 to 3436, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 3

The translation product of this gene shares sequence homology with matrilin and other cartilage matrix proteins (see, e.g, Genbank Accession Nos. emb|CAA06889.1| (AJ006140); and/or emb|CAA30915.1|; all references available through these accessions are hereby incorporated in their entirety by reference herein). Matrilins are members of a superfamily with von Willebrand factor type A-like modules, which is thought to be important in forming an extracellular, filamentous network.

Moreover, the translation product of this gene also shares sequence homology with the kidney injury associated molecule (KIM) protein (See Geneseq Accession No. W86326; all references and information available through this accession are hereby incorporated herein by reference). Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with matrilin, cartilage matrix proteins and KIM proteins. Such activities are known in the art, some of which are described elsewhere herein.

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group:



KXPCXYRSGIPGSTHASVPSAPRPSRAMLPWTAXGLALSLRLALARSGAERG  
 PPASAPRGDLMFLLDSSASVSHYEFSSRVREFVGQLVAPLPLGTGALRASLVHV  
 GSRPYTEFPFGQHSSGEAAQDAVRASAQRMGDTHTGLALVYAKEQLFAEAS  
 GARPGVPKVLVWVTDGGSSDPVGPPMQELKDLGVTVFIVSTGRGNFLELSAA  
 5 ASAPAEEKHLHFVDVDDLHIIVQELRGSILDAMRP (SEQ ID NO: 159);  
 APAWGGPQGRWSRHLSPTPALWAPLAGHLMLQQTAVPWHRPAPGQCCHP  
 CAGQKHAPHPGQPHPSACAGRRGTRCMADCPRAPDWHAGPRCPGAVEPPAAP  
 QTPEPGRTRSERRWLSCPAGTSGPLGGLMLVDRAPRRSAPAPAASSGPGRXPS  
 RGASRARDGARSARTRGSTREFRTGXCRVXSX (SEQ ID NO: 160),  
 10 HASVPSAPRPSRAMLPWTALGLALSLRLALARSGAERGPPASAPRGDLMFLL  
 DSSASVSHYEFSSRVREFVGQLVAPLPLGTGALRASLVHVGSRPYTEFPFGQHS  
 SGEAAQDAVRASAQRMGDTHTGLALVYAKEQLFAEASGARPGVPKVLVWV  
 TDGGSSDPVGPPMQELKDLGVTVFIVSTGRGNFLELSAAASAPAEEKHLHFVD  
 VDDLHIIVQELRGSILDAM (SEQ ID NO: 165); FLLDSSASVSHYEFSSRV (SEQ  
 15 ID NO: 161), GALRASLVHVGSRP (SEQ ID NO: 162), GVPKVLVWVTDG (SEQ  
 ID NO: 163), and VGPPMQELKDLGVT (SEQ ID NO: 164). Moreover, fragments  
 and variants of these polypeptides (such as, for example, fragments as described  
 herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%  
 identical to these polypeptides, or polypeptides encoded by a polynucleotide which  
 20 hybridizes, under stringent conditions, to the polynucleotide encoding these  
 polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of  
 the invention and polynucleotides encoding these polypeptides are also encompassed  
 by the invention.

This gene is expressed primarily in uterus, brain, lung, colon, kidney,  
 25 placenta, dendritic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to:  
 renal, neural, endothelial, developmental, and reproductive diseases and/or disorders,  
 30 particularly disorders resulting from tissue structural damages or abnormalities,  
 Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
 providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the uterus, placenta, kidney, lung, brain, and colon, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, neural, endothelial, developmental, reproductive, and cancerous and  
5 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution kidney, combined with the homology to the matrilin  
10 and KIM proteins indicates that polynucleotides and polypeptides corresponding to this gene would be useful for treatment, prevention, detection and/or diagnosis of disorders involving tissues with structural damages or abnormalities, particularly organs or tissues such as uterus, placenta, kidney, lung, brain, and colon. Matrilin may be also involved in extracellular transport, storage, barrier of molecular factors  
15 such as growth factors, hormones, thereby modulating the organ functions. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "Infectious Disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein.

In addition expression in the placenta indicates that polynucleotides and/or  
20 polypeptides corresponding to this gene would be useful in treating, preventing, detecting and/or diagnosing placental related function or diseases, e.g. induced abortion or spontaneous abortion; hyperplastic abnormalities; factors involved in circulation, nutrient transport; prevention of multiple gestation; gestational trophoblastic diseases, such as hydatidiform mole as well as placental site  
25 trophoblastic tumor and choriocarcinoma; uterus related function, e.g., disorders during the menstrual cycle or pregnancy, inflammatory changes, such as pyometra, endometritis and dysfunctional bleeding; contraceptives, abortion and birth control; infertility caused by blastocyst, embryo or fetus implantation problems; utilities in surrogate pregnancy; tumors or hyperplasia of the uterus, with epithelium, stroma or  
30 smooth muscle origins; brain related functions, e.g., trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, toxic neuropathies induced by neurotoxins, inflammatory diseases such

as meningitis and encephalitis, demyelinating diseases, neurodegenerative diseases such as Parkinson's disease, Huntington's disease, Alzheimer's disease, peripheral neuropathies, multiple sclerosis, neoplasia of neuroectodermal origin, etc; as well as diseases implicated in lung, colon functions. Polynucleotides and/or polypeptides of the invention can be used to promote growth and/or survival of damaged tissue (e.g., renal tissue), since KIM proteins are upregulated in injured or regenerating (especially renal) tissues. Fusion proteins of the invention, conjugates, antibodies and vectors can also be used therapeutically, e.g., these or KIM proteins (or a protein having KIM activity) may be included with an acceptable carrier in pharmaceutical compositions, useful for therapy/prophylaxis of conditions associated with dysfunction/dysregulation of genes or proteins of the invention, especially renal diseases or impairments of renal function in humans (e.g., acute renal failure, acute nephritis). The polynucleotides can be used to produce antisense sequences which, when internalized into cells, can disrupt expression of a cellular gene, also useful in therapy (e.g., to block the growth of tumors dependent on polynucleotides or polypeptides of the invention for growth) or compositions. The proteins and polynucleotides would be useful diagnostically e.g., to detect and quantify renal injury/disease (indicative of increased risk, or presence of, renal injury or impaired function), or abnormal responses to tissue injury (indicative of increased risk, or presence of, an autoimmune response or abnormal tissue growth arising from/affecting renal tissue). The proteins can also be used to locate cells producing the invention (especially specific loci, e.g., tissue masses abnormally producing/expressing polynucleotide or polypeptides of the invention such as tumors arising from/affecting renal tissue), by contacting cells with an imaginable reagent which binds to polynucleotides or polypeptides of the invention and imaging reagent accumulation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 720 of SEQ ID NO:13, b is an integer of 15 to 734, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The translation product of this gene shares sequence homology with Liv-1 which is thought to be an estrogen-regulated gene associated with breast cancer. The polypeptide of this gene has been determined to have seven transmembrane domains at about amino acid positions 3-19, 400-436, 433-457, 493-512, 736-753, 758-781, and/or 800-827 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

Included in this invention as preferred domains are zinc finger, C2H2 type, and cytochrome c family heme-binding site signature domains, which were identified using the ProSite analysis tool (Copyright, Swiss Institute of Bioinformatics). 'Zinc finger' domains [1-5] are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins.

A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides.

A schematic representation of a zinc finger domain is shown below:

x x x x x x x x x x C H x / x x Zn x x / x C H x x x x x x x x x

Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports

5 have demonstrated the zinc- dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains may be present. In

10 addition to the conserved zinc ligand residues it has been shown [6] that a number of other positions are also important for the structural integrity of the C2H2 zinc fingers. The best conserved position is found four residues after the second cysteine; it is generally an aromatic or aliphatic residue. The consensus pattern is as follows: C-x(2,4)-C-x(3)-[LIVMFYWC]-x(8)-H-x(3,5)-H (The two C's and two H's are zinc

15 ligands). The following references are referred to above and are hereby incorporated herein by reference: [ 1] Klug A., Rhodes D., Trends Biochem. Sci. 12:464-469(1987); [ 2] Evans R.M., Hollenberg S.M., Cell 52:1-3(1988); [ 3] Payre F., Vincent A., FEBS Lett. 234:245-250(1988); [ 4] Miller J., McLachlan A.D., Klug A., EMBO J. 4:1609-1614(1985); [ 5] Berg J.M. Proc. Natl. Acad. Sci. U.S.A. 85:99-

20 102(1988); and [ 6] Rosenfeld R., Margalit H., J. Biomol. Struct. Dyn. 11:557-570(1993).

In proteins belonging to cytochrome c family [1], the heme group is covalently attached by thioether bonds to two conserved cysteine residues. The consensus sequence for this site is Cys-X-X-Cys-His and the histidine residue is one

25 of the two axial ligands of the heme iron. This arrangement is shared by all proteins known to belong to cytochrome c family, which presently includes cytochromes c, c', c1 to c6, c550 to c556, cc3/Hmc, cytochrome f and reaction center cytochrome c. The consensus pattern is as follows: C-{CPWHF}-{CPWR}-C-H-{CFYW}.

The following reference is referred to above and is hereby incorporated herein by

30 reference: [ 1] Mathews F.S., Prog. Biophys. Mol. Biol. 45:1-56(1985).

Preferred polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence: CLICLLTFIFHHCNHCHEEHDH (SEQ ID NO:

166) and LLTFIFHHHCNHCHEEHDHGPEA (SEQ ID NO: 167). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further preferred are polypeptides comprising the zinc finger, C2H2 type, and cytochrome c family heme-binding site signature domains of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues may be N-terminal or C-terminal to the zinc finger, C2H2 type, and cytochrome c family heme-binding site signature domains.

Alternatively, the additional contiguous amino acid residues may be both N-terminal and C-terminal to the zinc finger, C2H2 type, and cytochrome c family heme-binding site signature domains, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to zinc finger, C2H2 type, and cytochrome c family heme-binding site signature domains containing proteins. Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with zinc finger and/or cytochrome proteins. Such activities are known in the art, some of which are described elsewhere herein.

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

This gene is expressed primarily in brain and hematopoietic tissues and to a lesser extent in breast and pancreas islet cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

cancer, particularly breast, brain, and pancreatic cancers; immune system dysfunction; pancreatic disorders and diabetes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
5 tissues or cells, particularly of the immune, CNS, endocrine, and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual  
10 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 86 as residues:  
15 Cys-22 to Asp-30, Glu-45 to Ser-52, Gln-54 to Lys-61, Arg-70 to Arg-76, Ser-125 to His-134, Asn-136 to Thr-141, Ser-146 to Thr-159, Asp-189 to His-194, Phe-196 to Asp-225, Pro-229 to Asn-243, Phe-251 to Val-272, Pro-283 to Leu-305, Thr-308 to Ala-313, Lys-326 to His-333, Ile-388 to Pro-396, His-483 to Leu-489, Tyr-521 to Trp-530, Lys-533 to Glu-538, Lys-544 to Trp-558, Asp-575 to Glu-581, Leu-585 to  
20 Asn-595, His-628 to Lys-638, His-645 to His-652, Gly-786 to Gly-794.

Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in neural tissues, combined with the homology to Liv-1 indicates that polynucleotides and polypeptides corresponding to this gene are useful for the potential diagnosis and/or treatment of cancer, and particularly, though not  
25 limited to, brain cancers.

Expression of Liv-1 has been demonstrated to correlate with the incidence of breast cancer; therefore, expression of this Liv-1 homolog may be diagnostic or causative in the development or progression of similar cancers, notably of the breast, brain, and/or pancreas.

30 Expression of this gene product in hematopoietic cells and tissues also suggests that it may play a role in the normal function of the immune system. Representative uses are described in the "Regeneration" and "Hyperproliferative

Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 5316 of SEQ ID NO:14, b is an integer of 15 to 5330, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

5

The translation product of this gene shares sequence homology with prostatic acid phosphatase which is thought to be important in the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial cancers such as lung squamous cell carcinoma of the vulva and gliomas), potent effects on cell growth and development, diseases related to growth or survival of nerve cells including Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.

15 This gene is expressed primarily in infant brain and fetal heart and to a lesser extent in smooth muscle cells and fibroblasts.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

20 fibrosis; neurodegenerative disorders; myocardial infarction; heart defects; cardiac arrhythmias; mucosal lesions; impaired digestive function; cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, CNS, endocrine, and digestive systems, expression of this gene at significantly higher

25 or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cardiovascular, developmental, and, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the

30 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 87 as residues: Thr-34 to Arg-46, Lys-108 to Glu-113, Asn-121 to Lys-128, Lys-186 to Asp-198, Thr-204 to Leu-211, Phe-225 to His-234, Val-249 to Gln-261, Leu-266 to Tyr-275, 5 Glu-330 to Tyr-341, Arg-359 to Glu-369, Asp-410 to His-417, Phe-434 to Pro-445. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution and homology to prostatic acid phosphatase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of clinical disorders. Expression of this gene 10 product in brain suggests a possible role or utility in the treatment of neurodegenerative disorders, such as Alzheimers, ALS, or schizophrenia. Expression of this gene product in fibroblasts and smooth muscle cells suggests a possible involvement in the development or progression of fibrotic disorders. Homology to prostatic acid phosphatase suggests a possible involvement in preservation and 15 maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, 20 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including 25 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine 30 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2739 of SEQ ID NO:15, b is an integer of 15 to 2753, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 6

The translation product of this gene shares sequence homology with leptin receptor gene-related protein (OB-RGRP).

This gene is expressed primarily in ovary tumors and a variety of hematopoietic cells and tissues, including dendritic cells and T cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system dysfunction; ovarian cancer; T cell lymphomas; inflammation; susceptibility to infection. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 88 as residues:  
5 Ala-88 to Gln-98. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in hematopoietic cells and tissues, combined with the homology to a leptin receptor gene-related protein (OB-RGRP) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the  
10 diagnosis and/or treatment of a variety of disorders, including hematopoietic and immune diseases and/or disorders. Homology to leptin receptor gene-related protein (OB-RGRP) suggests that it may play a role in functions mediated by leptin, such as normal appetite. Elevated expression of this gene product in hematopoietic cells and tissues suggests a possible role in normal hematopoiesis, and in the control of the  
15 proliferation, survival, activation, and differentiation of blood cell lineages.

Notably, expression on T cells suggests a possible involvement in antigen recognition and the mounting of normal immune responses. Expression on ovarian cancer suggests a possible diagnostic or causative role in the development or progression of this cancer. Representative uses are described in the "Immune  
20 Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or  
25 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,  
30 inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host

diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1339 of SEQ ID NO:16, b is an integer of 15 to 1353, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

## **25 FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

The translation product of this gene shares sequence homology with injury-associated molecule, KIM (see, e.g., GeneSeq Accession No. W86309; all references available through this accession are hereby incorporated in their entirety by reference herein) which is thought to be important in promoting tissue growth and regeneration.

The polypeptide of this gene has been determined to have transmembrane domains at about amino acid positions 78 to about 94 and at about 7 to about 23 of the

amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

When tested against human T cells, supernatants removed from cells  
5 expressing this gene induced expression of the secreted cytokine, IL-10. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines, e.g. TNF-alpha, IL-1, IL-10, IL-12. Thus, it is likely that the product of this gene is involved in the activation of T cells, in addition to other immune cell-lines or immune tissue cell  
10 types. Accordingly, polynucleotides and polypeptides related to this gene may have uses which include, but are not limited to, activating immune cells, such as during an inflammatory response.

This gene is expressed primarily in umbilical vein endothelial cells and to a lesser extent in hepatocellular tumors, breast cancer and bone marrow.

15 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders, breast cancer and tissue necrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
20 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, and/or immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid  
25 and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 89 as residues:  
30 Phe-63 to Phe-70, Arg-107 to Thr-114. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution, homology to injury-associated molecule, and induction of the IL-10 secretion indicates that polynucleotides and polypeptides corresponding to this gene would be useful for tissue / blood vessel regeneration.

Expression in bone marrow indicates that polynucleotides and polypeptides  
5 corresponding to this gene would be useful for the diagnosis, detection, prevention  
and/or treatment of a variety of immune system disorders. Representative uses are  
described in the "Immune Activity" and "Infectious Disease" sections below, in  
Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
expression of polynucleotides and polypeptides corresponding to this gene indicates a  
10 role in regulating the proliferation; survival; differentiation; and/or activation of  
hematopoietic cell lineages, including blood stem cells. Polynucleotides and  
polypeptides corresponding to this gene may be involved in the regulation of cytokine  
production, antigen presentation, or other processes indicating a usefulness in the  
treatment, detection and/or prevention of cancer (e.g., by boosting immune  
15 responses). Since the gene is expressed in cells of lymphoid origin, polynucleotides  
and polypeptides corresponding to this gene may be involved in immune functions.  
Therefore it would also be useful as an agent for immunological disorders including  
arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid  
arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne,  
20 neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated  
cytotoxicity; immune reactions to transplanted organs and tissues, such as host-  
versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as  
autoimmune infertility, lense tissue injury, demyelination, systemic lupus  
erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
25 disease, and scleroderma. Moreover, the protein may represent a secreted factor that  
influences the differentiation or behavior of other blood cells, or that recruits  
hematopoietic cells to sites of injury. Thus, polynucleotides and polypeptides  
corresponding to this gene are thought to be useful in the expansion of stem cells and  
committed progenitors of various blood lineages, and in the differentiation and/or  
30 proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise  
antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents

that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, polynucleotides and polypeptides corresponding to this gene may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer (particularly of the breast), autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1024 of SEQ ID NO:17, b is an integer of 15 to 1038, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

5           This gene is expressed primarily in macrophage and dendritic cells and to a lesser extent in neutrophils.

          Polynucleotides and polypeptides of the invention would be useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders, such as, asthma, arthritis, and chronic inflammatory conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be  
10           routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in  
15           healthy tissue or bodily fluid from an individual not having the disorder.

20           Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 90 as residues: Pro-55 to His-61. Polynucleotides encoding said polypeptides are also encompassed by the invention.

          The tissue distribution in macrophage, dendritic cells, and neutrophils  
25           indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product  
30           indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 704 of SEQ ID NO:18, b is an integer of 15 to 718, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

5 YXKVRLQVPVRNSRVDPRVRAEVLRA TRGGAARGNAAPGRALEMVPGAAG  
WCCLVLWLPACVAAHGFRIHDYLYFQVLSPGDIRYIFTATPAKDFGGIFHTRY  
EQIHLVPAEPPEACGELSNGFFIQDQALVERGGCSFLSKTRVVQEHGGRAVII  
SDNAVDNDSFYVEMIQDSTQRTADIPALFLLGRDGYMIRRSLEQHGLPWAIIIS  
IPVNVTSIPTFELLQPPWTFW (SEQ ID NO: 168). Moreover, fragments and

10 variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention and  
15 polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 2. Accordingly, polynucleotides related to this invention would be useful as a marker in linkage analysis for chromosome 2.

Contact of human T cells with supernatant expressing the product of this gene  
20 was shown to increase the expression of cell surface molecules, specifically, CD69, CD71 and CD152. Thus it is likely that the product of this gene is involved in the activation of T cells, in addition to other cell-lines or tissue cell types. Therefor, polynucleotides and polypeptides related to this gene have uses which include, but are not limited to, activating immune cells, particularly T cells, such as during an  
25 inflammatory response.

This gene is expressed primarily in ovary tumor, and fetal kidney and to a lesser extent in fetal tissues like heart, kidney, liver, bone and broad range distribution in many tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for  
30 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental, reproductive, and renal diseases and/or disorders, particularly

disorders of the ovary or kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system or urinary system,  
5 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, reproductive, renal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression  
10 level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 91 as residues: Asp-131 to Ala-137. Polynucleotides encoding said polypeptides are also encompassed by the invention.

15 The tissue distribution in ovarian tissue and activity in cell surface marker assays indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, detection, prevention and/or treatment of reproductive disorders, particularly ovary related disease, such as ovarian cancer, as well as cancers of other tissues where expression has been indicated. The expression in  
20 ovarian cancer tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary,  
25 ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor). In addition, polynucleotides and polypeptides corresponding to this gene would be useful as a hormone or endocrine factor with either systemic or reproductive functions; growth factors for germ cell maintenance and in vitro culture; fertility control; sexual dysfunction or sex development  
30 disorders; Ovarian tumors, such as serous adenocarcinoma, dysgerminoma, embryonal carcinoma, choriocarcinoma, teratoma, etc. Representative uses are described here and elsewhere herein.

The protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to  
5 Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies  
10 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1184 of SEQ ID NO:19, b  
20 is an integer of 15 to 1198, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

25

The polypeptide of this gene has been determined to have three transmembrane domains at about amino acid position 1 to about 27, at about amino acid position 74 to about 93, and at about amino acid position 103 to about 126 of the amino acid sequence referenced in Table 1 for this gene. Based upon these  
30 characteristics, it is believed that the protein product of this gene shares structural features to type IIIb membrane proteins.

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group:

HELKMDAEYSGNEFPRSEGERDQHQRPGKERKSGEAGRGTGELGQDGRLLS  
STLSLSSNRSLGQRQNSPLPFQWRITHSFRWMAQVLASELSLVAFILLVMAF  
5 SKKWLDLSRSLFYQRWPVDVSNRIHTSAHVMSMGLLHFCKSRSCSDLENGK  
VTFIFSTLMLFPINIWIFELERNVSIPIGWSYFIGWLVLILYFTCAILCYFNHKSF  
WSLILSHPSGAVSXSSSFGSVEESPRAQTITDTPITQEGVLDPEQKDTHV (SEQ  
ID NO: 169) and

GTSSRWMQSTLGMSSPGQKEKETNIRDLERKGRVGRQDGAQVSWDKMGDC  
10 CPPPSPSVVTGPWASARTLRCPFNGESHTASAGWPRCWPLSSAWLPLSYYWS  
WPSPRNGWTSLGASSTSAGPWMSATESTHQPTLCPWGSCTFANPGAVLT  
(SEQ ID NO: 170). Moreover, fragments and variants of these polypeptides (such as,  
for example, fragments as described herein, polypeptides at least 80%, 85%, 90%,  
95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides  
15 encoded by a polynucleotide which hybridizes, under stringent conditions, to the  
polynucleotide encoding these polypeptides) are encompassed by the invention.  
Antibodies that bind polypeptides of the invention and polynucleotides encoding  
these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the testes.

20 Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
reproductive diseases and/or disorders, particularly testicular tumors. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
25 immunological probes for differential identification of the tissue(s) or cell type(s). For  
a number of disorders of the above tissues or cells, particularly of the reproductive  
system, expression of this gene at significantly higher or lower levels may be  
routinely detected in certain tissues or cell types (e.g., reproductive, testis, and  
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal  
30 fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an  
individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 92 as residues:  
5 Lys-62 to Lys-73. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution primarily in testis indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, detection, prevention and/or treatment of cancers of the testis. Polynucleotides and polypeptides  
10 corresponding to this gene would be useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) which would be  
15 useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as  
20 hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

In addition, the predicted membrane localization indicates that polynucleotides and/or polypeptides corresponding to this gene would be a good target for antagonists, particularly small molecules or antibodies, which block  
25 functional activity (such as, for example, binding of the receptor by its cognate ligand(s); transport function; signaling function). Accordingly, preferred are antibodies and or small molecules which specifically bind an extracellular portion of the translation product of this gene. The extracellular regions can be ascertained from the information regarding the transmembrane domains as set out above. Also  
30 provided is a kit for detecting testicular cancer. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting testicular cancer in an individual

which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above  
5   embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed  
10   against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of  
15   the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1019 of SEQ ID NO:20, b  
20   is an integer of 15 to 1033, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

25

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

ARAEVILCTKEVSVGARKNAFALLVEMGHAFLRFGSNQEEALQCYLVLIIYPG  
LVGAVTMVSCSILALTHLLFEFKGLMGTTSTVEQLLENVCLLLASRTRDVVKS  
30   ALGFIKVAVTVMDDVAHLAKHVQLVMEAIGKLSDDMRRHFRMKLRNLFTKFI  
RKFGFELVKRLLPEEYHRVLVNIRKAEARAKRHRALSQAAVEEEEEEEEEEEEP  
AQGKGDSIEEILADSEDEEDNEEEERSRGKEQRKLARQRSRAWLKEGGGDEP



LNFLDPKVAQRVLATQPGPAGQEEGPQLQGERRWPADHKGGGRRQQDGGR  
GRCQRRR (SEQ ID NO: 171). Moreover, fragments and variants of these  
polypeptides (such as, for example, fragments as described herein, polypeptides at  
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides  
5 and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
conditions, to the polynucleotide encoding these polypeptides, or the complement  
there of are encompassed by the invention. Antibodies that bind polypeptides of the  
invention are also encompassed by the invention. Polynucleotides encoding these  
polypeptides are also encompassed by the invention.

10 This gene is expressed primarily in immune cells (e.g., B-cells and T-cells),  
haemopoietic cells and cancer cells (e.g., ovary tumor).

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
15 immune and haemopoietic disorders and cancers. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the immune and haemopoietic  
system, expression of this gene at significantly higher or lower levels may be  
20 routinely detected in certain tissues or cell types (e.g., cancerous and wounded  
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or  
another tissue or sample taken from an individual having such a disorder, relative to  
the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more immunogenic epitopes shown in SEQ ID NO: 93 as residues:  
Leu-77 to Arg-82, Glu-139 to Ser-157, Ser-165 to Arg-191, Glu-196 to Pro-202, Pro-  
219 to Arg-235, Ala-238 to Arg-259. Polynucleotides encoding said polypeptides are  
also encompassed by the invention.

30 The tissue distribution in immune cells indicates the protein product of this  
clone is useful for the diagnosis and treatment of a variety of immune system  
disorders. Representative uses are described in the "Immune Activity" and "Infectious

Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1718 of SEQ ID NO:21, b is an integer of 15 to 1732, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

5

## FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed primarily in germinal B-cells, colon tumor, testes, and anaplastic oligodendrolioma cells and to a lesser extent in a variety of normal and transformed tissues including pooled human melanocyte, fetal heart and pregnant, activated monocytes, chronic lymphocytic leukemia.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cancer and other proliferative disorders, especially colon tumor, immune disorders, and anaplastic oligodendrolioma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the colon, brain and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 94 as residues: Leu-53 to Lys-64, Ile-122 to Trp-128, His-149 to Arg-161, Leu-183 to Leu-195. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The expression within fetal tissue and other cellular sources marked by proliferating cells indicates that polynucleotides and/or polypeptides corresponding to this gene may play a role in the regulation of cellular division, and may show utility

in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, including but not limited to colon cancer, prostate cancer, testicular cancer and/or cancer of immune cells), and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and

5 "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain

10 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating,

15 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

20 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the tissue distribution in immune cells indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the

25 "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in immune cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Polynucleotides and/or polypeptides of the invention may be involved in the

30 regulation of cytokine production, antigen presentation, or other processes indicating that it may be useful in the treatment, and/or prevention of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the

natural gene product would be involved in immune functions. Therefore polynucleotides and/or polypeptides of the invention would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory  
5 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
10 disease, and scleroderma. Moreover, polynucleotides and/or polypeptides of the invention may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, polynucleotides and/or polypeptides of the invention would be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in  
15 the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
20 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 826 of SEQ ID NO:22, b is an integer of 15 to 840, where both a and b correspond to the positions of  
30 nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 53 to about 69 of the amino acid sequence  
5 referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 70 to about 138 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in fetal tissue, placenta and breast cancer  
10 lymph nodes.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental disorders and breast cancer. Similarly, polypeptides and antibodies  
15 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the human fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,  
20 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
25 consist of, one or more immunogenic epitopes shown in SEQ ID NO: 95 as residues: Pro-36 to Ala-44, Ile-72 to Trp-77, Gln-94 to Gln-100. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The expression within fetal tissue and other cellular sources marked by proliferating cells indicates that polynucleotides and/or polypeptides corresponding to  
30 this gene may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are

described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some  
5 cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, polynucleotides and/or polypeptides of the invention may have applications in the adult for tissue regeneration and the treatment of cancers. It may  
10 also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus polynucleotides and/or polypeptides corresponding to this gene may modulate apoptosis or tissue differentiation and would be useful in  
15 the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Polynucleotides and/or polypeptides of the invention would be useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution  
20 in placenta indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that polynucleotides and/or polypeptides of the invention may play a role in the proper establishment and maintenance of placental function. Alternately, polynucleotides and/or polypeptides  
25 of the invention may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that polynucleotides and/or polypeptides corresponding to this gene may be produced more generally in endothelial cells or within the circulation. In  
30 such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the

proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to  
5 its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 926 of SEQ ID NO:23, b is an integer of 15 to 940, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

When tested against K592 cell lines, supernatants removed from cells  
25 containing this gene activated the ISRE (interferon-sensitive responsive element) promoter element. Thus, it is likely that this gene activates leukemia cells, and to a lesser extent other cells and tissue cell types, through the JAK-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large,  
30 signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE



element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

When tested against HUVEC cells, supernatants removed from cells containing this gene induced phosphorylation of ATF-2. The phosphorylation of  
5 ATF-2 occurs as a result of the signaling cascade induced during cell proliferation, thus the phosphorylation state of ATF-2 can be used as a measure of cell proliferation.

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

10 GTREGEGRKCPWKGLRARTGMGQEVHGSWALGAGGGQRQWVGRSMPPL  
APQLCRAVFLVPILLLLQVKPLNGSPGPKDGSQTEKTPSADQNQEQQFEEHFVA  
SSVGEMWQVVDMAQQEEDQSSKTA AVHKHSFHL SFCFS  
LASVMVFSGGPLRRTEFPNIQLCFMLTH (SEQ ID NO: 172). Moreover, fragments  
and variants of these polypeptides (such as, for example, fragments as described  
15 herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%  
identical to these polypeptides, or polypeptides encoded by a polynucleotide which  
hybridizes, under stringent conditions, to the polynucleotide encoding these  
polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of  
the invention and polynucleotides encoding these polypeptides are also encompassed  
20 by the invention.

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 32 to about 48 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 31 of this protein has also been  
25 determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in the testes.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
30 and for diagnosis of diseases and conditions which include but are not limited to: reproductive diseases and/or disorders, particularly testis tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 96 as residues: Leu-26 to Glu-52, Gln-71 to Lys-79. Polynucleotides encoding said polypeptides are also encompassed by the invention.

15 The tissue distribution in testis, combined with the detected ISRE and ATF-2 biological activity, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, detection, prevention and/or treatment of reproductive system disorders, including cancers of the testis. Polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. Polynucleotides and/or polypeptides of the invention would also be useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, polynucleotides and/or polypeptides of the invention are believed to be useful in the treatment, prevention, detection and/or diagnosis of testicular cancer. 25 The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. In addition, 30 the predicted membrane localization indicates that polynucleotides and/or polypeptides corresponding to this gene would be a good target for antagonists,

particularly small molecules or antibodies, which block functional activity (such as, for example, binding of the receptor by its cognate ligand(s); transport function; signaling function). Accordingly, preferred are antibodies and or small molecules which specifically bind an extracellular portion of the translation product of this gene.

5 The extracellular regions can be ascertained from the information regarding the transmembrane domains as set out above. Also provided is a kit for detecting testicular cancer. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting testicular cancer in an individual which comprises a step of contacting an  
10 antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein.  
15 Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 787 of SEQ ID NO:24, b is an integer of 15 to 801, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a  
30 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with EMILIN (see, e.g., Genbank Accession No. gb|AAD42161.1|AF088916\_1 (AF088916); all references available through this accession are hereby incorporated in their entirety by reference herein). EMILIN (elastin microfibril interface located protein), an  
5 extracellular matrix glycoprotein, is thought to be important in cell adhesion and cell-to-cell communication, especially in elastic tissues.

This gene is expressed in pregnant uterus, uterine cancer, breast cancer, pancreatic cancer, fetal kidney, whole embryo, and to a lesser extent, in human  
10 thymus and colon.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: circulatory, growth and developmental defects, including, but not limited to cancer.  
15 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and musculoskeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,  
20 reproductive, developmental, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 97 as residues: Phe-30 to Cys-37, Arg-91 to Gly-98, Pro-170 to Ala-177, Pro-183 to Gly-193, Pro-206 to Gly-235, Pro-243 to Pro-260, Phe-283 to Gly-311. Polynucleotides encoding said polypeptides are also encompassed by the invention.

30 The tissue distribution in uterus, combined with the homology to EMILIN indicates that polynucleotides and polypeptides corresponding to this gene would be useful for study, treatment, prevention, detection and/or diagnosis of disorders of

growth and development, blood vessel and other elastic tissue integrity and function, and fibrotic and neoplastic conditions. Polynucleotides and/or polypeptides of the invention would be useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it may be involved in controlling the digestive process, and such actions as peristalsis. Similarly, it may be involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1955 of SEQ ID NO:25, b is an integer of 15 to 1969, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

The polypeptide of this gene has been determined to have transmembrane domains at about amino acid positions 9-25, 32-48, and 188-204 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is

believed that the protein product of this gene shares structural features to type IIIb membrane proteins.

Moreover, in specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid

5 sequence:MDFIQHLGVCCCLVALISVGLLSVAACWFLPSIIAAAASWIITCVLLCC  
SKHARCFILLVFLSCGLREGRNALIAAGTGIVILGHVENIFHNFKGLLDGMTCN  
LRAKSFSIHFPLLKKYIEAIQWIYGLATPLSVFDDLVS WNQTLAVSLFSPSHVL  
EAQLNSKGEVLSVLYQMATTTEVLSSLGQKLLAFAGLSLVLLGTGLFMKRF  
LGPCGWKYENIYITRQFVQFDERERHQQRPCVLPLNKEERRKFISGFQS (SEQ  
10 ID NO: ). Moreover, fragments and variants of these polypeptides (such as, for  
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
encoding these polypeptides , or the complement there of are encompassed by the  
15 invention. Antibodies that bind polypeptides of the invention are also encompassed by  
the invention. Polynucleotides encoding these polypeptides are also encompassed by  
the invention.

This gene is expressed primarily in macrophages, monocytes, dendritic cells,  
T-cell lymphoma and osteoclastoma.

20 Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
immunodeficiency, infection, lymphoma, auto-immunity, cancer, inflammation,  
anemia (leukemia) and other hematopoietic disorders. Similarly, polypeptides and  
25 antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the immune system, expression  
of this gene at significantly higher or lower levels may be routinely detected in certain  
tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids  
30 (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 98 as residues:  
5 Asp-229 to Gln-236, Asn-244 to Lys-250, Trp-258 to Asn-266. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in immune cells (e.g., dendritic cells and macrophage) indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the  
10 "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or  
15 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,  
20 inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia,  
25 rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of  
30 various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional

supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1350 of SEQ ID NO:26, b is an integer of 15 to 1364, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The polypeptide of this gene has been determined to have a transmembrane domains at about amino acid positions 10-26, 157-173, and 67-83 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIb membrane proteins.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

MAGGWAAEAVWAGFGVVVARRLVLLPLLHPGFQQLLLVLLLPHEQLHH  
 25 EHLLLVDLLADV LGDVRDDPVHKVAHEHDQVLEDDDKRQPGCQDGPEVLG  
 DVVLVFRPRRLSVVFIPADLHLVAQVQGVIGGRAVLEVTDVEGGEGVVDEA  
 VHGPVLTVHVHVEVHQARDEVRRREGDHEGIDDDSKLPNASEDIVPDSDFGSDS  
 YRPSELSDKLFGVQADLDDVVQQRKQWGQGEGGDKQGDEAKLDDH  
 FHVLWGEAREGLQVVIHLV (SEQ ID NO: 173). Moreover, fragments and  
 30 variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,



under stringent conditions, to the polynucleotide encoding these polypeptides , or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5           This gene is expressed primarily in pituitary tissue, fetal heart, B-cell lymphoma, testes, ovarian cancer, prostate, tumors of the endometrium, parathyroid, pancreas, and to a lesser extent in activated T-cells and broad range of tissues at lower levels.

          Polynucleotides and polypeptides of the invention are useful as reagents for  
10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders related to ovary function, endocrinological disorders, cancer of the endometrium, parathyroid, B-cells, colon, and cancer, in general, as well as, cardiovascular diseases. Similarly, polypeptides and antibodies directed to these  
15 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, endocrine system or cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded  
20 tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise, or alternatively  
25 consist of, one or more immunogenic epitopes shown in SEQ ID NO: 99 as residues: Asp-113 to Leu-124, Arg-134 to Lys-152, Arg-207 to Leu-215, Glu-221 to Ala-238. Polynucleotides encoding said polypeptides are also encompassed by the invention.

          The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders related  
30 to endocrine disorders, such as disorders of growth, somatic and sexual development, reproductive functions, and metabolic regulation, either as the result of hypopituitarism or hyperpituitarism.

The expression in ovary indicates the gene function as hormone with either systemic or reproductive functions; growth factors for germ cell maintenance and in vitro culture; fertility control; sexual dysfunction or sex development disorders; Ovarian tumors, such as serous adenocarcinoma, dysgerminoma, embryonal carcinoma, choriocarcinoma, teratoma, etc; The expression in heart indicates the gene function and uses in heart failure, congenital heart diseases, ischemic heart diseases, rheumatic/hypersensitivity diseases, cardiomyopathy, lumatic heart disease, inflammatory diseases of the heart, hypertensive heart disease, nutritional, endocrine, and metabolic diseases of the heart.

The tissue distribution in testes tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of male reproductive and endocrine disorders. It may also prove to be valuable in the diagnosis and treatment of testicular cancer, as well as cancers of other tissues where expression has been observed.

Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of

degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2357 of SEQ ID NO:27, b is an integer of 15 to 2371, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 103 to about 119 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 120 to about 127 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention would be useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in fetal tissue, ovary tumor, kidney tumor, brain and to a lesser extent in many other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental, neurological and behavioral disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 100 as residues: Leu-18 to Ile-28, His-72 to Trp-93. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated

expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, polynucleotides and/or polypeptides of the invention would be involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The expression within fetal tissue and other cellular sources marked by proliferating cells indicates that polynucleotides and/or polypeptides of the invention may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, polynucleotides and/or polypeptides of the invention may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus, polynucleotides and/or polypeptides corresponding to this gene may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Polynucleotides and/or polypeptides of the invention would be useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 853 of SEQ ID NO:28, b is an integer of 15 to 867, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The polypeptide of this gene has been determined to have transmembrane domains at about amino acid position 4-20 and 38-54 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

PRAAGIRHELIHGLWNLVFLFSNLSLIFLMPFAYFFTESEGFAGSRKGVLRVY  
 25 ETVVMLMLLTLLVLGMVWVASAIVDKNKANRESLYDFWEYYLPYLYSCISF  
 LGVLLLLGECTGSGREWAGSLDQSNQARRKGNGGHVREGVESRVWQVTGS  
 CPYSVYSTGSRPHVLRHWEAASQAPAAGRPGGA AVL LSL (SEQ ID NO: 174).

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the

invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 This gene is expressed primarily in vascular endothelial cells, immune cells (T-cells, neutrophils, and dendritic cells), small intestine, and tumors such as ovary tumor, and to a lesser extent in a wide variety of human tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

10 immune disorders, cancers such as ovary tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain

15 tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 101 as residues: Asp-21 to Ser-29, Thr-58 to Trp-64, Asp-69 to Gly-81. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides

25 corresponding to this gene are useful for diagnosis and treatment of cancers and diseases related to blood vessel abnormality such as ischemia. The tissue distribution in immune cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in

30 Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including

blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions.

5 Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and

10 graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to

15 sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in

20 addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

30 general formula of a-b, where a is any integer between 1 to 1591 of SEQ ID NO:29, b is an integer of 15 to 1605, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

5

The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

10 This gene is expressed primarily in breast, infant brain and 9 week early human, fetal liver spleen, and to a lesser extent in fetal brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurodevelopmental, reproductive, immune, and hematopoietic diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., 15 neural, reproductive, breast, brain, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast milk, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 102 as residues: Arg-125 to Gly-130, Lys-138 to Phe-144. Polynucleotides encoding said polypeptides are also encompassed by the invention.

30 The tissue distribution in infant brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurodevelopmental disorders. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,

15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal  
5 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in  
10 normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment,  
15 and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may  
20 show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of  
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1320 of SEQ ID NO:30, b  
30 is an integer of 15 to 1334, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

In another embodiment, polypeptides comprising the amino acid sequence of  
5 the open reading frame upstream of the predicted signal peptide are contemplated by  
the present invention. Specifically, polypeptides of the invention comprise, or  
alternatively consist of, the following amino acid sequence:

HSAFFGTRALLSVSLPPPCMLHWVLSFFFLLSCPRTGLPGLYCPGCSQCPG  
RGMWPGDPGPGIQQGPGLDLRTGMEATGAQQPTLSSPHCLLSLPTLPARAVQL  
10 RWDLSISRAGGRVAVLGLCLEPGGSLLLPPSALPE  
TDPCAACPPCPFVPMMSGGGGRPTVPEAGHQ (SEQ ID NO: 175).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in ovarian tumor and to a lesser extent in B-  
cells (stimulated), Primary Breast Cancer, melanocyte, Pituitary, subtracted, Breast  
15 Cancer Cell line, angiogenic, 12 Week Old Early Stage Human, Osteoblasts, Soares  
adult brain N2b5HB55Y, and Hemangiopericytoma.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
20 ovarian cancer, developmental, reproductive, and immune diseases and/or disorders.  
Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
female reproductive system, expression of this gene at significantly higher or lower  
25 levels may be routinely detected in certain tissues or cell types (e.g., reproductive,  
skeletal, developmental, and cancerous and wounded tissues) or bodily fluids (e.g.,  
serum, plasma, breast milk, amniotic fluid, urine, synovial fluid and spinal fluid) or  
another tissue or sample taken from an individual having such a disorder, relative to  
the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
30 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more immunogenic epitopes shown in SEQ ID NO: 103 as residues:

Ser-29 to Met-36, Gly-60 to Ser-67. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in ovarian cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of  
5 ovarian cancer. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the “Hyperproliferative Disorders”  
10 and “Regeneration” sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain  
15 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,  
20 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in  
25 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
30 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 997 of SEQ ID NO:31, b is an integer of 15 to 1011, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 22

15

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 15 to about 31 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 14 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

20

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group:

SHTRPTEQPSVLPLFMMYVMMAYLTLFQMGSWMSFSLSLCSLLFILTGHCLS  
 ENFYVRGDGTRAYFFTKGEVHSMFCKASLDEKQNLVDRRLQVNRKKQVKM  
 HRVWIQGGKFQKPLHQTQNSSNMVSTLLSQD (SEQ ID NO: 176); and  
 ARESSWDHVKTSATNRFSRMHCPTVPDEKNHYEKSSGSSEGSQSKTESDFSNL  
 DSEKHKKGPMETGLFPGSNATFRILEVGCGAGNSVFPILNTLENSPESFLYCC  
 DFASGAVELVKSHSSYRATQCFAFVHDVCDDGLPY  
 PFPDGILDVILLVFLVSSIHDPDRTLFI (SEQ ID NO: 177). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical

30

to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention and polynucleotides encoding these polypeptides are also encompassed by the invention.

5           This gene is expressed primarily in bone marrow as well as osteoclastoma, breast, prostate and colon cancers.

          Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

10   diseases and/or disorders of immune cells and tissues, breast, prostate, colon, in addition to leukemia, osteoclastoma and other cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic

15   systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., breast, prostate, colon, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, breast milk, seminal fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

20   expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 104 as residues: Phe-35 to Thr-42, Leu-61 to Val-68, Asn-75 to Val-80, Gly-89 to Ser-102.

25   Polynucleotides encoding said polypeptides are also encompassed by the invention.

          The tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene may be useful in the treatment and diagnosis of cancers and pathologies associated with neoplastic or proliferative states. The expression in bone marrow would suggest a role in hematopoietic conditions, anemias

30   (leukemias), auto-immunities, immunodeficiencies, immuno-suppressive conditions (e.g., transplantation), inflammation and general microbial infection. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below,

in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Polynucleotides and/or polypeptides of the invention would be useful in modulating the immune response to aberrant polypeptides, as may be present in rapidly proliferating cells and tissues, including cancers. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1294 of SEQ ID NO:32, b is an integer of 15 to 1308, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

This gene is expressed primarily in activated monocytes.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include but are not limited to: immunodeficiency, infection, lymphoma, auto-immunity, cancer, inflammation, anemia (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 105 as residues: Gln-36 to Leu-43, Phe-50 to Thr-57. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in activated monocytes indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as



autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1420 of SEQ ID NO:33, b is an integer of 15 to 1434, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

## **25 FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

This gene is expressed primarily in fetal and adult brain, esp. in cortical structures, and to a lesser extent in lung.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological and pulmonary conditions. Similarly, polypeptides and antibodies

directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and cardiopulmonary systems, expression of this gene at significantly higher or lower levels may be routinely  
5 detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 106 as residues: Val-40 to Thr-51. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in brain indicates the protein product of this clone is  
15 useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease,  
20 Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,  
25 and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may  
30 also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies

directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2170 of SEQ ID NO:34, b is an integer of 15 to 2184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

HEQEPLPAPVAEAAALPSARNSSVLASLSPHTGPAGLLRDSSVQVSTLGCLLGC  
20 GGRMFFPCLPTLXLRIL  
HSGWVGLFLLISSRAPSSSLAWKHGPGELWWPRXPLRSCTGLASCG (SEQ ID NO: 178). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 This gene is expressed primarily in salivary gland, pancreas tumor and cerebellum.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neuroendocrine, metabolic conditions and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of general hormonal, metabolic, neuroendocrine and memory disorders and neoplasms. The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in

pancreas suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-,  
5 hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies  
10 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1282 of SEQ ID NO:35, b  
20 is an integer of 15 to 1296, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

25

This gene is expressed primarily in neutrophils and T-cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
30 immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from  
5 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 108 as residues:  
10 Ser-22 to His-40. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in immune cells (e.g., neutrophils and T-cells) indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune  
15 Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or  
20 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease,  
25 inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia,  
30 rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene

product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
5 identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 1284 of SEQ ID NO:36, b is an integer of 15 to 1298, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

## 20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 28 - 44 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 45 to 97 of this protein has also been determined. Based upon these characteristics, it is  
25 believed that the protein product of this gene shares structural features to type Ib membrane proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

30 This gene is expressed primarily in brain and to a lesser extent in skeletal muscle, pregnant uterus.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurodegenerative disease states, behavioral disorders and in general disorders of the CNS, and developmental conditions and diseases, skeletal muscle diseases. .

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection, treatment, and/or prevention of a variety of CNS disorders, including neurodegenerative disease states, behavioral disorders. In addition, polynucleotides and polypeptides corresponding to this gene are useful for detection, treatment, and/or prevention of developmental disorders, skeletal muscle diseases. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse



formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 539 of SEQ ID NO:37, b is an integer of 15 to 553, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

LTPALPSPRSASPLLSPESLQSPQWPSSSLSIHSLPVAGKPSLITSLFTEPCDGFM  
AIRGSNTQGLTMMTMTSDRWFSMAWASCSLSRPPLTPSCSCQQPATVALLQ  
TISVCSAQQADPLSPPRACRPXRQFPVLQSAGPPHSPHVYAFVLFVSSRWQG  
GDFCXICCCFPQCLGRCLHTRCSINPX (SEQ ID NO: 179). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which

hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast cancer tissue.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

reproductive diseases and/or disorders, particularly cancer and other hyperproliferative diseases and/or conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system or secretory/ductile tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, breast, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast fluid, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 110 as residues: Gln-49 to Cys-60. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in breast cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection, treatment, and/or prevention of breast neoplasia and breast cancers, such as, but not limited to fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Representative uses are

described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions. Protein, as well as,  
5 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of  
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 587 of SEQ ID NO:38, b  
15 is an integer of 15 to 601, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

20

This gene is expressed primarily in IL-1 and LPS induced neutrophils

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
25 immune system disorders and sepsis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell  
30 types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level,

i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 111 as residues:  
5 Glu-17 to Lys-30, Val-43 to Asn-53. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene would be useful for modulating the response of activated neutrophils and may thus be important for regulating acute allergic  
10 responses such as occurs in sepsis. In addition, polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene  
15 product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes indicating a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the  
20 natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to  
25 transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other  
30 blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of

various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
5 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1880 of SEQ ID NO:39, b is an integer of 15 to 1894, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

20 In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:  
RLCRETALMSLCLVLMRRMGWIDLLLPELGALRVFLHLFLVALRTRKRWIFRT  
LGQLTCVNILGDSRKKRECRLNKRQLQFGKTLQVPERLVVRHSPF (SEQ ID  
NO: 180). Moreover, fragments and variants of these polypeptides (such as, for  
25 example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention and polynucleotides encoding  
30 these polypeptides are also encompassed by the invention.

This gene is expressed primarily in spinal cord, retina and prostate.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: retinal dysplasia, retinitis, choroideremia, diabetic retinopathy, retinal degeneration, retinal detachment, prostate disorders, prostate cancer, spinal trauma, meningitis, spina bifida, spinal tumors and neoplasms, as well as other developmental and neurodegenerative conditions of the spinal cord and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the retina and nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, neural, reproductive, visual, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, aqueous humor, vitreous humor, seminal fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 112 as residues: Gly-45 to Gln-59, Phe-62 to Leu-67. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The expression in retina indicates that polynucleotides and polypeptides corresponding to this gene would be useful for treatment, prevention, detection and/or diagnosis of retinal dysplasia, retinitis, choroideremia, diabetic retinopathy, retinal degeneration and detachment. The expression in prostate indicates that polynucleotides and polypeptides corresponding to this gene would be useful in the treatment, prevention, detection and/or diagnosis of prostate disorders, particularly prostate cancer, as well as cancers of other tissues where expression has been indicated. Expression in prostate tissue indicates the gene or its products would be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders,

including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions.

Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. In

5 addition, the expression in spinal cord indicates a role for the polynucleotides and polypeptides corresponding to this gene in the treatment, prevention, detection and/or diagnosis of spinal trauma, meningitis, spina bifida, spinal tumors and neoplasms as well as other developmental and neurodegenerative conditions of the spinal cord and central nervous system. Furthermore, the protein may also be used to determine  
10 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3265 of SEQ ID NO:40, b is an integer of 15 to 3279, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a  
25 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

This gene is expressed primarily in ovarian tumor.

30 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

disorders of the reproductive system, including ovarian cancer and/or other cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g., vaginal pool, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in ovarian tumor indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the detection, diagnosis, prevention and/or treatment of developmental anomalies, fetal deficiencies, pre-natal disorders or ovarian and endometrial cancers, as well as cancers of other tissues where expression has been indicated. The expression in ovarian cancer tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor). In addition, the expression in this particular form of cancer, may suggest a role in the treatment and diagnosis of other cancers or pathologies associated with neoplastic or proliferative states. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to



control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3081 of SEQ ID NO:41, b is an integer of 15 to 3095, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 18-34 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 - 17 of this protein has also been determined. Based upon these characteristics, it is

believed that the protein product of this gene shares structural features to type II membrane proteins.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

5 MLLPFIKLPTTGNSLAKIQTVGQNQQKVNRVLMGPRSIQKRHFKEVGRQSIRR  
EQGAQASVENAAEEKRLGSPAPRELEQPHTQQGPEKLAGNAIYTKPSFTQEH  
KAAVSVLTPFSKGAPSTSSPAKALPQVRDRWKDNTHTISILESAKARVTNMK  
ASKPISHSRKKYRFHKTRSRMTHRTPKVKKSPKFRKKSYSRLMLANRPPFSA  
AKSLINSPSQGAFSSLGDLSPQENPFLEVSAPSEHFIETTNIKDTTARNALEENV  
10 FMENTNMPEVTISENTNYNHPPEADSAGTAFNLGPTVKQTET NSC (SEQ ID  
NO: 181). Moreover, fragments and variants of these polypeptides (such as, for  
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
15 encoding these polypeptides , or the complement there of are encompassed by the  
invention. Antibodies that bind polypeptides of the invention are also encompassed by  
the invention. Polynucleotides encoding these polypeptides are also encompassed by  
the invention.

This gene is expressed primarily in fetal tissue (e.g., lung, heart), brain,  
20 immune cells (e.g., T-cells, B-cell lymphoma) duodenum, ovary tumor, cheek  
carcinoma, adipose tissue, CD34+ cells and to a lesser extent, ubiquitously expressed  
in many tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
25 and for diagnosis of diseases and conditions which include but are not limited to:  
immune disorders, disorders of the CNS, gastrointestinal tract disorders, ovary  
dysfunctions, or neoplasia. Similarly, polypeptides and antibodies directed to these  
polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
30 tissues or cells, particularly of the CNS, immune system, gastrointestinal and  
reproductive systems, expression of this gene at significantly higher or lower levels  
may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and

wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 114 as residues: Glu-35 to Phe-44. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides  
10 corresponding to this gene are useful for diagnosis and treatment of gastrointestinal disorders, such as gastritis, peptic ulcer disease, neoplasia of duodenal and/or ovarian origins. The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are  
15 described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,  
20 congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the  
25 brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in immune cells (e.g., B-cells, T-cells) indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses  
30 are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation;

survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed

5 in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity;

10 immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the

15 differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within fetal tissue and other cellular sources marked

20 by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental

25 tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

30 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2306 of SEQ ID NO:42, b is an integer of 15 to 2320, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

This gene is expressed primarily in colon cancer, Gessler Wilms tumor, brain, breast cancer, fetal tissue and to a lesser extent in ovary tumor, adrenal gland and many other tissues at lower levels.

30

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include but are not limited to: disorders of the developing fetus, central nervous system (CNS), colon cancers or tumors of other origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
5 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cancers of colon and ovary, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from  
10 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 115 as residues:  
15 Lys-60 to Ser-74. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in ovary cancer and colon indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of colon cancer, ovary cancer or other cancer types. The tissue  
20 distribution in kidney suggests that this gene or gene product is useful in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities  
25 such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. The expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are  
30 described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can

result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and

5 differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein

10 may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation.

15 The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not

20 limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive

25 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,

30 homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions,

in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2393 of SEQ ID NO:43, b is an integer of 15 to 2407, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

This gene is expressed primarily in osteoclastoma.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: bone disorders, for example osteoclastoma and osteoporosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



The tissue distribution in osteoclastoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of osteoclastoma and osteoporosis. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1916 of SEQ ID NO:44, b is an integer of 15 to 1930, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 35

5

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

10 LKEMAELHHGRSTSLCILPLQRTRIHMSASLWCFRSQQSIPMRC  
 HRSLSSEIPEDFQMNRSTRSYRCWATWPRLGWALPCCMNSLRKGRKFSQITTS  
 LMASVSSASMVSRRRRPL PKHPVTTTSTATALLGTSSTWSKS (SEQ ID NO:  
 182). Moreover, fragments and variants of these polypeptides (such as, for example,  
 fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
 15 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the  
 polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
 encoding these polypeptides, or the complement thereof are encompassed by the  
 invention. Antibodies that bind polypeptides of the invention are also encompassed by  
 the invention. Polynucleotides encoding these polypeptides are also encompassed by  
 20 the invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

TRPDWVLPSEVEVLESIYLDLQVIKGNRTSPWEIYITLHPATAEDQDSQYV  
 CFTLVLPVPAEYPHEVPQISIRNPRGLSDEQIHTILQVLGHVAKAGLGTA (SEQ  
 25 ID NO: 183) and  
 MLYELIEKGKEILTDNNIPHGQCVICLYGFQEKEAFTKTPCYHYFHCHCLARY  
 IQHMEQELKAQGQEQEQERQHATTKQKAVGVQCPVCREPLVYDLASLKAAP  
 EPQQPMELYQPSAESLRQQEERKRLYQRQQERGGIIDEAERNRYFISLQQPP  
 APAEPESAVDVSKGSQPPSTLAAELSTSPAVQSTLPPPLPVATQHICEKIPGTRS  
 30 NQQLRGETQKAMLDPPKPSRGPWRQPERRHPKGGECHAPKGTRDTQELPPPE  
 GPLKEPMDLKPEPHSQGVEGPPQEKGPGSWQGPPRRTRDCVRWERSKGRTP  
 GSSYPRLPRGQGAYRPGTRRESLGLESKDGS (SEQ ID NO: 184). Moreover,

fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in Pooled human melanocyte, fetal heart, and pregnant and to a lesser extent in Adult Testes, and germinal center B cell.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: integumentary, cardiovascular, and developmental diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., integumentary, cardiovascular, and developmental, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 117 as residues: Met-1 to Thr-13, Ser-27 to Phe-34, Arg-53 to Pro-59, Ser-77 to Ser-82.

Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in human melanocyte indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "Infectious Disease", and "Regeneration"

sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm).

Moreover, the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1445 of SEQ ID NO:45, b is an integer of 15 to 1459, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

This gene is expressed primarily in ovarian tumor and to a lesser extent in Adult Pulmonary.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: reproductive diseases and/or disorders, particularly ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary lavage, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 118 as residues: Pro-28 to Ser-35. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in ovarian tumor tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular

division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the “Hyperproliferative Disorders” and “Regeneration” sections below and elsewhere herein. Briefly, developmental

5 tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types

15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new

20 insight into the regulation of cellular growth and proliferation. The protein is useful in the detection, treatment, and/or prevention of pulmonary diseases and/or disorders, which include, but are not limited to ARDS and emphysema. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

25 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

30 related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 989 of SEQ ID NO:46, b is an integer of 15 to 1003, where both a and b correspond to the positions of  
5 nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

10 The translation product of this gene shares sequence homology with vesicle trafficking protein (see, e.g., Genbank Accession number AAD02171.1 (AF039568); all references available through this accession are hereby incorporated by reference herein.) which is thought to be important in the elaborate transport machinery and cell trafficking system. The polypeptide of this gene has been determined to have  
15 transmembrane domains at about amino acid positions 114-130 and 150-166 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

This gene is expressed primarily in melanocytes, fetal tissue, placenta, and  
20 testes and to a lesser extent in many other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: fetal development and endocrine disorders. Similarly, polypeptides and antibodies directed  
25 to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,  
30 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Homology to vesicle trafficking protein and the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of



the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
5 general formula of a-b, where a is any integer between 1 to 1344 of SEQ ID NO:47, b is an integer of 15 to 1358, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 38

This gene is expressed primarily in Saos2 cell line (Dexamethosome Treated), IL-1/TNF stimulated Synovial Fibroblasts, osteoblasts, pancreas tumor, retina, hepatocellular tumor (re-excision), and 8 Week Whole Embryo.

15 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
20 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
25 sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 120 as residues:  
30 Pro-8 to Gly-21, Cys-44 to Tyr-52, Thr-60 to Glu-75, Asp-205 to Ala-223, Thr-372 to Arg-385, Gly-468 to Thr-483, Arg-491 to Gln-500, Lys-537 to Asp-543, Asp-573 to

Ser-583, Pro-586 to Ala-593. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The expression of this gene product in synovium indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful in the  
5 detection, diagnosis, prevention and/or treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as  
10 dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial arthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).

The protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
15 that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or  
20 induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for  
25 control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of  
30 the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2595 of SEQ ID NO:48, b is an integer of 15 to 2609, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

This gene is expressed primarily in placenta, prostate and neutrophils.

Polynucleotides and polypeptides of the invention are useful as reagents for  
20 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune and endocrine disorders, as well as, disorders of developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell  
25 type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, developing system and endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from  
30 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in placenta suggests that the protein product of this clone is useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta suggests that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also suggests that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. The expression in prostate may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions.

The tissue distribution in neutrophils indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated

cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1884 of SEQ ID NO:49, b is an integer of 15 to 1898, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in HL-60 myeloid leukemia cell line, uterus, ovarian tumor, synovium, lung, brain and to a lesser extent in wide variety of human tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: myeloid leukemia, ovarian cancer and disorders of the central nervous system (CNS). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and CNS expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as

autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
5 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease  
10 states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,  
15 encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and  
20 perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to  
25 isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1794 of SEQ ID NO:50, b is an integer of 15 to 1808, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 41

10

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

HDTRLPLPGQHGRGAWVCLTVLCSTVDSNDSLYGGDSKFLAENNKLCET  
VMAQILEHLKTLAKDEALKRQSSLGLSFFNSILAHGDLRNNKLNQLSVNLWH  
15 LAQRHGCADTRTMVKTLE YIKKQSKQPDMTHLTEALRLPLQTRT SEQ ID

15

NO: 185(SEQ ID NO ) Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides , or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

20

This gene is expressed primarily in fibroblasts, retina, multiple sclerosis, testes, fetal tissue, synovial sarcoma, and hepatoma and to a lesser extent in many other tissues.

25

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: wound healing/connective tissue disorders, endocrine disorders, eye disorders, synovium and liver cancers or tumors of other origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological

30



probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the synovium, fibroblasts, retina, testes, and liver expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded  
5 tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
10 consist of, one or more immunogenic epitopes shown in SEQ ID NO: 123 as residues: Ser-33 to Thr-44. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in testes indicates the protein product of this clone would be useful for the detection, treatment, and/or prevention of various endocrine  
15 disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus),  
20 adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism) , hypothalamus, and testes. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of  
25 developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell  
30 death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, 5 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in 10 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, 15 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 941 of SEQ ID NO:51, b 25 is an integer of 15 to 955, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 42**

30

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

MLFVDSGSTRRLRKKTLSGDFIFMNRCQSSRQPRPAGV NKHLWGCPASSRTSH  
EWLLWPKAVLQAKQTALGWNSPT (SEQ ID NO: 186),  
CQSSRQPRPAGV NKHLWGCPASSRTSHEWLLWPKAVLQAKQTALGWNSPT  
(SEQ ID NO: 187), KWGCFCKGSSFTPHSCPPEAPLFPVLLVSTLG (SEQ ID  
5 NO: 188), and CPPEAPLFPVLLVSTLG (SEQ ID NO: 189). Moreover, fragments  
and variants of these polypeptides (such as, for example, fragments as described  
herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%  
identical to these polypeptides and polypeptides encoded by the polynucleotide which  
hybridizes, under stringent conditions, to the polynucleotide encoding these  
10 polypeptides, or the complement thereof are encompassed by the invention.  
Antibodies that bind polypeptides of the invention are also encompassed by the  
invention. Polynucleotides encoding these polypeptides are also encompassed by the  
invention.

15 This gene is expressed primarily in endometrial tumor, kidney, fetal tissue,  
uterine cancer, skin cancer, pancreas and to a lesser extent in many other tissues

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to: fetal  
development disorders, disorders of the endocrine and exocrine system, cancers of the  
20 endometrium, uterus, skin and cancer, in general. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the endocrine and exocrine  
system, expression of this gene at significantly higher or lower levels may be  
25 routinely detected in certain tissues or cell types (e.g., immune, cancerous and  
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal  
fluid) or another tissue or sample taken from an individual having such a disorder,  
relative to the standard gene expression level, i.e., the expression level in healthy  
tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more immunogenic epitopes shown in SEQ ID NO: 124 as residues:

Arg-66 to Gly-74. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in immune cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The tissue distribution in pancreas and kidney suggests that the protein product of this clone is useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity,

raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1833 of SEQ ID NO:52, b is an integer of 15 to 1847, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a  
15 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

The polypeptide of this gene has been determined to have a transmembrane  
20 domain at about amino acid position 148-164 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 165-253 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

25 This gene is expressed primarily in brain, immune cells, testes and to a lesser extent in many other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
30 disorders of the central nervous system (CNS), testes, and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, CNS, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 125 as residues: Glu-34 to Leu-46, Glu-58 to Asn-65, Pro-93 to Glu-98, Pro-122 to Ser-127.

Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

The tissue distribution in immune cells (e.g., T-cells) indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in

regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in testes tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of male reproductive and endocrine disorders. It may also prove to be valuable in the diagnosis and treatment of testicular cancer, as well as cancers of other tissues where expression has been observed. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2149 of SEQ ID NO:53, b  
5 is an integer of 15 to 2163, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

10

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

EGADKMATSVGHRCLGLLHGVPWRSSLHPCEITALSQSLQPLRKLPFRAFR  
TDARKIHTAPARTMFLRLPILLVTGGGYAGYRQYEKYRERELEKLGLEIPP  
15 KLAGHWEVALYKSVPTRLLSRAWGRLNQVELPH WLRRPVYSLYIWTXGG

(SEQ ID NO: 190) Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under stringent conditions, to the  
20 polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention and polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in synovial sarcoma, retina, fetal tissue, brain, and immune cells (e.g., T-cells).

25

Polynucleotides and polypeptides of the invention would be useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
30 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell



types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 126 as residues: Gln-22 to Leu-31. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

The tissue distribution in T-cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation

of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, 5 rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as 10 autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful 15 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of 20 developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell 25 death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may 30 also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types

of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in  
5 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,  
10 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 734 of SEQ ID NO:54, b  
20 is an integer of 15 to 748, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

25

This gene is expressed primarily in tumors of the parathyroid gland, skin, prostate and colon. .

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
30 and for diagnosis of diseases and conditions which include but are not limited to: integumentary, reproductive, and endocrine diseases and/or disorders, particularly cancers of the prostate, skin, parathyroid and colon. Similarly, polypeptides and

antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, skin, parathyroid and colon expression of this gene at significantly higher or lower levels may be

5 routinely detected in certain tissues or cell types (e.g., integumentary, reproductive, gastrointestinal, endocrine, prostate, skin, colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily

10 fluid from an individual not having the disorder.

The tissue distribution in skin indicates that polynucleotides and polypeptides corresponding to this gene would be useful for treatment, prevention, detection and/or diagnosis of cancers of the prostate, skin, parathyroid and colon. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "Infectious

15 Disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e., nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e., keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's

20 disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e., wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e., lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such

25 disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e., cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, polynucleotides and/or polypeptides of the invention may also be useful for the treatment, prevention, detection and/or diagnosis of various connective tissue

30 disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and

chondrodysplasias (i.e., spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Expression in prostate tissue indicates the gene or its products would be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. In addition, polynucleotides and/or polypeptides corresponding to this gene would be useful in the treatment of male infertility, and/or could be used as a male contraceptive. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1184 of SEQ ID NO:55, b is an integer of 15 to 1198, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

This gene is expressed primarily in fibroblasts, placenta, pancreas, brain, monocytes and to a lesser extent in many other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system and/or neurodegenerative disorders, including but not limited to brain disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neural, nervous, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 128 as residues: Ala-62 to Ser-87. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in

normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

In addition, the tissue distribution in immune tissues indicates that

5 polynucleotides and/or polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation;

10 survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions.

15 Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and

20 graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to

25 sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to

30 its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 953 of SEQ ID NO:56, b is an integer of 15 to 967, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene shares sequence homology with motilin which has gastrointestinal motor stimulating activity and binds with high affinity to the motilin receptor and mimics the peristaltic effects of motilin on gastrointestinal tissue.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, an amino acid sequence selected from the group: REQLSCFSSHTWCPWEGVLWAPQAQGVMSAPPPHPQPPAAPTSTRNYTEIREK LRSRLTRRKEELPMKGGTLGGIPGEPVDHRDVELLEFINSTEPKVPNSARA AKRARHKLKKKVGVGRAQLCRLSSLRTLAPTPRTSGA (SEQ ID NO: 191) and ARGSGQGEEAVQKSHKVKRRGPLVRVEQLRIEEMKVIKLLVTFELGVIILILE MTKLRLTKTR (SEQ ID NO: 192). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.



This gene is expressed primarily in brain frontal cortex.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

5 disorders of central nervous system and gastrointestinal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, CNS, expression of this gene at significantly higher or lower levels may be  
10 routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 129 as residues: Pro-41 to Thr-46, Cys-48 to Gly-59, Pro-79 to Trp-84, Ala-86 to Gly-94. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The homology to motilin indicates that polynucleotides and polypeptides  
20 corresponding to this gene are useful for diagnosis and treatment of gastrointestinal disorders, such as malabsorption, diarrheal diseases, gastroenteritis, tumors, colitis and bowel diseases. The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.  
25 Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,  
30 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1133 of SEQ ID NO:57, b is an integer of 15 to 1147, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 48

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
TLLKGTKLELHRGGGRSRTSGSPGLQEFGRPTPGVWSCPTATPWASGSRRK  
NLARESKGRPRPTEITRPYLCPPHYPHTAPCLGSHPSACRCSRSCPHSLLLPP  
SITRECPGSHRVPQMPVFPQTILSSRINSIAIQMSPHQPMQVSSSKTILWLVLSC  
LCPSSPHPVISGLPQWYIGVLGIVPVAPIRPGDSGLDLQREGPQPIL  
SQGLNRRT (SEQ ID NO: 193). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at

least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in immune cells (e.g., T-cells) and to a lesser extent in breast cancer, kidney, and ovary.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders and breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 130 as residues: Met-1 to Pro-6, Gly-73 to Thr-78. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in T-cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation

of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 961 of SEQ ID NO:58, b is an integer of 15 to 975, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 49**

The translation product of this gene shares sequence homology with alpha  
5 mannosidases thought to be important in oligosaccharide processing (see, e.g.,  
Genbank Accession No. gb|AAA82446.1, and Geneseq Accession No. W48265; all  
information and references available through these accessions are hereby incorporated  
herein by reference). Based on the sequence similarity, the translation product of this  
clone is expected to share at least some biological activities with mannosidase  
10 proteins. Such activities are known in the art, some of which are described elsewhere  
herein.

In specific embodiments, polypeptides of the invention comprise, or  
alternatively consist of, the following amino acid sequence:

VDGAAMAACEGRRSGALGSSQSDFLTPVGGAPWAVATTVVMYPPPPPPPH  
15 RDFISVTLSEGESYDNSKSWRRRSCWRKWKQLSRLQRNMILFLLAFLFCGLL  
FYINLADHWKALAFRLEEEQKMRPEIAGLKPANPPVLPAPQKADTDPENLPEI  
SSQKTQRHIQRGPPHLQIRPPSQDLKDGTEATKRQEAPVDPRPEGDPQRTV  
ISWRGAVIEPEQGTELPSRRAEVPTKPPLPPARTQGTPVHLNRYRQKGVIDVFL  
HAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWILGLRKEFEE  
20 ARKWVSKKLHFEKDVDVNLFEISTIRILGGLLSAYHLSGDSLFLRKAEDFGNRL  
MPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSLQLEFREL SRLTGDKK  
FQEAVEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYEY  
LLKQWIQGGKQETQLLEDYVEAIEGV RTHLLRHSEPSKLT FVGELAHGRFSA  
KMDHLVCFLPGTLALGVYHGLPASHMELAQELMETCYQMNRQMETGLSPEI  
25 VHFNLYPQPGRRDVEVKPADRHNL RPETVESLFYLYRVTGDRKYQDWGWE  
ILQSFSRFTRVPSGGYSSINNVQDPQKPEPRDKMESFFLGETLKYLFLLFSDDP  
NLLSLDAYVFNTEAHPLPIWTPA (SEQ ID NO:194). Moreover, fragments and  
variants of these polypeptides (such as, for example, fragments as described herein,  
polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical  
30 to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes,  
under stringent conditions, to the polynucleotide encoding these polypeptides) are

encompassed by the invention. Antibodies that bind polypeptides of the invention and polynucleotides encoding these polypeptides are also encompassed by the invention.

When tested against human T cells, supernatants removed from cells expressing this gene induced expression of the secreted cytokine, IL-13.

5       An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines, e.g. TNF-alpha, IL-1, IL-10, IL-12. Thus, it is likely that the product of this gene is involved in the activation of T cells, in addition to other immune cell-lines or immune tissue cell types. Accordingly, polynucleotides and polypeptides related to this gene  
10       may have uses which include, but are not limited to, activating immune cells, such as during an inflammatory response.

This gene is expressed primarily in endocrine organs but also in normal and transformed cell types from other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for  
15       differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: metabolic, infectious, and growth diseases, disorders, and defects, including cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell  
20       type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine organs, and/or immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, metabolic, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
25       taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 131 as residues:  
30       Glu-32 to Arg-38, Gln-56 to Asn-64, Ser-69 to His-83, Arg-87 to Gln-118, Leu-137 to Thr-146, Pro-148 to Gly-157, Trp-177 to Ala-184, Asp-188 to Ser-194, Lys-221 to Arg-227, Arg-283 to Pro-289, Pro-302 to Asp-308, Thr-328 to Phe-333, Ser-348 to

Gly-353, Gly-392 to Leu-400, Arg-416 to Lys-422, Tyr-493 to Glu-502, Thr-527 to Trp-535, Asn-559 to Met-572. Polynucleotides encoding said polypeptides are also encompassed by the invention.

5 The tissue distribution in endocrine tissues, combined with the homology to mannosidases indicates that polynucleotides and polypeptides corresponding to this gene would be useful for study, prevention, detection, diagnosis and/or treatment of hormonal, metabolic and immune/host defense disorders and neoplasms. The protein product of this clone would be useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the

10 "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism),

15 thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Based upon the strong homology to mannosidases, the protein is likely to be useful in correcting secretory protein defects at the level of protein metabolism. Moreover, antagonists of this protein would be useful in the treatment of rapidly proliferating cells and tissues, including cancers. The protein,

20 including variants thereof, could also be useful in creating novel glycosylated proteins. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show

25 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

30 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 2719 of SEQ ID NO:59, b is an integer of 15 to 2733, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 50**

This gene is expressed primarily in immune (e.g., dendritic cells and B-cells), haemopoietic, and fetal cells and to a lesser extent in several other tissues and cells.

10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune and haemopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and haemopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system  
25 disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation  
30 of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in



immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in

modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1654 of SEQ ID NO:60, b is an integer of 15 to 1668, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 51**

The translation product of this gene shares sequence homology with the complement C1q A chain precursor (See Genbank Accession No. gb|AAD32626.1; in addition to the following Geneseq Accession Nos. Y01481 and Y12319; all information contained within these accessions in combination with the references referred to therein are hereby incorporated herein by reference). The present invention is believed to represent a novel splice variant of the complement C1q A chain precursor protein.

This gene is expressed primarily in primary dendritic cells, breast lymph node, colon tumor, normal colon, human adult pulmonary, and to a lesser extent, in ulcerative colitis, thymus, bone marrow, and human adipose.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune and hematopoietic diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, gastrointestinal, pulmonary, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 133 as residues: Pro-29 to Gly-46, Lys-48 to Gly-55, Lys-67 to Gly-80, Gly-89 to Asn-99. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in hematopoietic cells and tissues, combined with the homology to complement C1q A chain precursor indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, detection, and/or prevention of various immune and hematopoietic diseases and/or disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia,

rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1007 of SEQ ID NO:61, b is an integer of 15 to 1021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 52**

This gene is expressed primarily in fetal liver spleen, cem cells/cyclohexamide treated, and to a lesser extent in glioblastoma cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune, hematopoietic, developmental, and hepatic diseases and/or disorders.

5 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune,  
10 hematopoietic, developmental, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more immunogenic epitopes shown in SEQ ID NO: 134 as residues: Gln-30 to Gly-38. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in fetal/liver spleen indicates that polynucleotides and  
20 polypeptides corresponding to this gene are useful for the treatment, detection, and/or prevention of immune, hemapoietic, and developmental diseases and/or disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the  
25 proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in  
30 immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis,

acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 899 of SEQ ID NO:62, b is an integer of 15 to 913, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HETHR73	PTA-623 09/02/99	Uni-ZAP XR	11	2219	1	2219	207	207	83	1	44	45	563
2	HDPFB02	PTA-622 09/02/99	pCMVSPORT 3.0	12	3436	1	3436	173	173	84	1	19	20	152
2	HDPFB02	PTA-622 09/02/99	pCMVSPORT 3.0	63	1517	1	1517	139	139	135	1	28	29	316
2	HMWDB84	PTA-622 09/02/99	Uni-ZAP XR	64	2751	1	2751	218	218	136	1	18	19	302
3	HNTEO78	PTA-623 09/02/99	pCMVSPORT 3.0	13	734	1	734	89	89	85	1	18	19	215
4	HDPFY41	PTA-622 09/02/99	pCMVSPORT 3.0	14	5330	1	5330	158	158	86	1	25	26	831
5	HDPFE85	PTA-622 09/02/99	pCMVSPORT 3.0	15	2753	1	2753	57	57	87	1	25	26	480
6	HDPOE32	PTA-622 09/02/99	pCMVSPORT 3.0	16	1353	1	1353	118	118	88	1	34	35	151
7	HLQEM64	PTA-623 09/02/99	Lambda ZAP II	17	1038	1	702	42	42	89	1	29	30	132
8	HNGIR58	PTA-623 09/02/99	Uni-ZAP XR	18	718	1	718	52	52	90	1	33	34	110

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HMAMI21	PTA-725 09/20/99	Uni-ZAP XR	65	2150	1	2150	13	13	137	1	1	2	374
9	HOEEK12	PTA-623 09/02/99	Uni-ZAP XR	19	1198	80	1152	131	131	91	1	21	22	188
9	HJPAY76	209852 05/07/98	Uni-ZAP XR	66	1161	1	1161	134	134	138	1	21	22	127
10	HTLIT63	PTA-623 09/02/99	Uni-ZAP XR	20	1033	1	1033	249	249	92	1	23	24	179
11	HNEBY54	PTA-622 09/02/99	Uni-ZAP XR	21	1732	1	1732	176	176	93	1	21	22	259
12	HFKKS66	PTA-623 09/02/99	Uni-ZAP XR	22	840	1	830	7	7	94	1	39	40	239
13	HFVJP07	PTA-623 09/02/99	pBluescript	23	940	1	940	108	108	95	1	18	19	138
14	HTEAM34	PTA-623 09/02/99	Uni-ZAP XR	24	801	87	801	136	136	96	1	28	29	122
14	HTEAM34	209463 11/14/97	Uni-ZAP XR	67	734	1	734	63	63	139	1	28	29	122
15	HUFGH53	PTA-623 09/02/99	pSport1	25	1969	1	1969	36	36	97	1	22	23	459
16	HMAJ14	PTA-622 09/02/99	Uni-ZAP XR	26	1364	15	1364	278	278	98	1	68	69	352



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
16	HMADJ14	PTA-622 09/02/99	Uni-ZAP XR	68	1583	1	1583	264	264	140	1	26	27	257
16	HMADJ14	PTA-622 09/02/99	Uni-ZAP XR	69	1444	91	1444	125	125	141	1	26	27	257
16	HMADJ74	PTA-622 09/02/99	Uni-ZAP XR	70	1892	619	1855	264	264	142	1	38	39	291
16	HMABG70	209076 05/22/97	Uni-ZAP XR	71	1439	18	1316	276	276	143	1	19	20	21
17	HETAY39	PTA-622 09/02/99	Uni-ZAP XR	27	2371	1	2371	54	54	99	1	24	25	257
18	HFPPK57	PTA-623 09/02/99	Uni-ZAP XR	28	867	1	867	78	78	100	1	19	20	127
19	HSICO66	PTA-622 09/02/99	Uni-ZAP XR	29	1605	1	1605	176	176	101	1	20	21	136
20	HUFBC44	PTA-622 09/02/99	pSport1	30	1334	1	1334	87	87	102	1	20	21	144
21	HAAAI67	PTA-622 09/02/99	pSport1	31	1011	1	1011	62	62	103	1	19	20	151
21	HFKIA71	PTA-736 09/21/99	Uni-ZAP XR	72	1395	213	1361	349	349	144	1	41	42	173
22	HOSNU69	PTA-623 09/02/99	Uni-ZAP XR	32	1308	269	1142	408	408	104	1	32	33	112

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
23	HMSCM88	PTA-622 09/02/99	Uni-ZAP XR	33	1434	1	1434	236	236	105	1	25	26	80
24	HSXAZ05	PTA-622 09/02/99	Uni-ZAP XR	34	2184	1	2184	125	125	106	1	27	28	51
25	HTPCW21	PTA-622 09/02/99	Uni-ZAP XR	35	1296	1	1296	171	171	107	1	35	36	60
25	HTPCW21	PTA-622 09/02/99	Uni-ZAP XR	73	1293	1	1293	171	171	145	1	35	36	60
26	HNGOW62	PTA-622 09/02/99	Uni-ZAP XR	36	1298	1	1298	167	167	108	1	19	20	54
27	HAVVG36	PTA-622 09/02/99	Other	37	553	1	553	139	139	109	1	25	26	97
28	HBGNP63	PTA-622 09/02/99	Uni-ZAP XR	38	601	1	601	203	203	110	1	48	49	122
29	HNNHB29	PTA-623 09/02/99	Uni-ZAP XR	39	1894	1	1894	40	40	111	1	20	21	53
30	HPJCL28	PTA-623 09/02/99	Uni-ZAP XR	40	3279	1	3279	309	309	112	1	29	30	80
31	HOFNC14	PTA-623 09/02/99	pCMVSPORT 2.0	41	3095	1	3095	155	155	113	1	13	14	72
32	HELHN47	PTA-622 09/02/99	Uni-ZAP XR	42	2320	1	2320	102	102	114	1	36	37	45

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HELHN47	PTA-622 09/02/99	Uni-ZAP XR	74	3147	842	3147	935	935	146	1	36	37	45
32	HELHN47	PTA-622 09/02/99	Uni-ZAP XR	75	1989	883	1989	778	778	147	1	30	31	404
33	HFKET18	PTA-622 09/02/99	Uni-ZAP XR	43	2407	1	2407	137	137	115	1	14	15	74
34	HSRFZ57	PTA-622 09/02/99	Uni-ZAP XR	44	1930	1	1925	82	82	116	1	18	19	41
35	HAMFP32	PTA-622 09/02/99	pCMVSPORT 3.0	45	1459	1	1459	247	247	117	1	20	21	82
36	HLHDL42	PTA-622 09/02/99	Uni-ZAP XR	46	1003	1	1001	198	198	118	1	20	21	53
36	HAPQU71	PTA-181 06/07/99	Uni-ZAP XR	76	1879	1264	1807	1324	1324	148	1	20	21	53
36	HAPQU71	203917 04/08/99	Uni-ZAP XR	77	1879	1264	1807	1324	1324	149	1	20	21	53
37	HKMLX18	PTA-622 09/02/99	pBluescript	47	1358	1	1358	154	154	119	1	27	28	180
38	HFIUW36	PTA-623 09/02/99	pSport1	48	2609	1	2609	319	319	120	1	1	2	599
39	HNGOU82	PTA-622 09/02/99	Uni-ZAP XR	49	1898	1	1646	83	83	121	1	24	25	45

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HSODB85	PTA-622 09/02/99	Uni-ZAP XR	50	1808	1	1808	509	509	122	1	21	22	57
41	HFICR14	PTA-622 09/02/99	pSport1	51	955	1	955	272	272	123	1	29	30	50
41	HFICR14	PTA-499 08/11/99	pSport1	78	955	1	955	272	272	150	1	29	30	50
42	HSIDQ93	PTA-622 09/02/99	Uni-ZAP XR	52	1847	1	1847	155	155	124	1	26	27	74
43	HSLGM81	PTA-622 09/02/99	Uni-ZAP XR	53	2163	1	2163	248	248	125	1	20	21	253
43	HSYBM41	PTA-987 11/24/99	pCMVSPORT 3.0	79	2309	89	2092	129	129	151	1	20	21	253
44	HLQGP82	PTA-623 09/02/99	Lambda ZAP II	54	748	29	748	202	202	126	1	18	19	89
44	HSSDG41	209076 05/22/97	Uni-ZAP XR	80	2619	25	2080	202	202	152	1	18	19	127
45	HRACI26	PTA-623 09/02/99	pCMVSPORT 3.0	55	1198	1	1198	55	55	127	1	19	20	49
46	HMSMD07	PTA-623 09/02/99	Uni-ZAP XR	56	967	1	967	450	450	128	1	18	19	90
47	HFXDK20	PTA-622 09/02/99	Lambda ZAP II	57	1147	1	1147	348	348	129	1	27	28	94

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
48	HTXKF95	PTA-622 09/02/99	Uni-ZAP XR	58	975	170	966	421	421	130	1	28	29	78
48	HTXKF95	PTA-622 09/02/99	Uni-ZAP XR	81	884	79	875	330	330	153	1	28	29	78
49	HUSBA88	PTA-623 09/02/99	Lambda ZAP II	59	2733	27	2733	270	270	131	1	15	16	615
50	HNEDD37	PTA-622 09/02/99	Uni-ZAP XR	60	1668	1	1668	29	29	132	1	19	20	42
51	HBJNC59	PTA-622 09/02/99	Uni-ZAP XR	61	1021	1	1021	66	66	133	1	22	23	99
51	HAPQT56	PTA-909 11/02/99	Uni-ZAP XR	82	1086	45	1012	64	64	154	1	22	23	245
52	HCABW07	PTA-622 09/02/99	Uni-ZAP XR	62	913	1	913	33	33	134	1	31	32	57

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also

5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the

15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the

20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Code" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue expression.

Table 3, column 1, provides a nucleotide sequence identifier, "SEQ ID NO:X," that matches a nucleotide SEQ ID NO:X disclosed in Table 1, column 5. Table 3, column 2, provides the chromosomal location, "Cytologic Band or Chromosome," of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was



determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, the OMIM reference identification number of the morbid map entry is provided in Table 3, column 3, labelled "OMIM ID." A key to the OMIM reference identification numbers is provided in Table 5.

10           Table 4 provides a key to the Library Code disclosed in Table 2. Column 1 provides the Library Code disclosed in Table 2, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was derived.

15           Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 3, column 3. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web  
20           URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 3, column 2, as determined using the Morbid Map database.

Table 2

Clone ID	Library Codes
HETHR73	H0031 H0039 H0046 H0059 H0144 H0150 H0164 H0180 H0181 H0196 H0208 H0213 H0253 H0254 H0255 H0266 H0271 H0309 H0333 H0381 H0383 H0413 H0424 H0427 H0441 H0445 H0486 H0488 H0506 H0518 H0521 H0529 H0538 H0539 H0553 H0555 H0575 H0581 H0587 H0599 H0606 H0617 H0619 H0620 H0634 H0638 H0644 H0647 H0658 L0105 L0362 L0499 L0581 L0603 L0605 L0612 L0659 L0662 L0666 L0731 L0743 L0747 L0749 L0751 L0770 L0775 L0789 L0794 L0800 L0809 S0001 S0027 S0028 S0031 S0037 S0038 S0044 S0045 S0046 S0049 S0050 S0052 S0116 S0126 S0152 S0222 S0278 S0308 S0360 S0364 S0376 S0390 S0428 T0004 T0048 T0110
HDPFB02	H0039 H0050 H0056 H0059 H0063 H0123 H0124 H0131 H0132 H0135 H0246 H0250 H0252 H0265 H0292 H0295 H0341 H0355 H0391 H0393 H0413 H0478 H0494 H0519 H0520 H0521 H0522 H0529 H0539 H0545 H0546 H0547 H0551 H0553 H0561 H0580 H0586 H0606 H0628 H0633 H0658 H0662 H0668 H0670 H0672 H0686 H0696 L0386 L0439 L0523 L0581 L0595 L0597 L0638 L0645 L0650 L0651 L0658 L0659 L0663 L0666 L0731 L0740 L0744 L0747 L0748 L0751 L0755 L0756 L0757 L0759 L0761 L0766 L0768 L0769 L0770 L0772 L0774 L0775 L0776 L0777 L0779 L0783 L0806 L0809 S0002 S0028 S0040 S0046 S0049 S0126 S0144 S0212 S0222 S0294 S0354 S0358 S0376 S0388 S0418 S0420
HNTEO78	H0519 H0638 H0653 L0731 L0750 L0755 L0770 L0771 L0773 L0774 L0779
HDPFY41	H0008 H0144 H0163 H0409 H0428 H0486 H0521 H0615 H0624 H0658 H0661 H0662 H0672 L0375 L0439 L0591 L0602 L0649 L0650 L0655 L0659 L0661 L0662 L0665 L0666 L0717 L0731 L0754 L0756 L0759 L0766 L0777 L0779 L0791 L0792 L0803 L0806 S0003 S0011 S0036 S0114 S0152 S0356 S0426 S6024
HDPIE85	H0046 H0050 H0124 H0144 H0208 H0266 H0286 H0288 H0411 H0412 H0445 H0486 H0521 H0539 H0542 H0547 H0549 H0555 H0560 H0575 H0599 H0616 H0622 H0623 H0624 H0634 H0660 H0682 L0363 L0439 L0455 L0471 L0564 L0565 L0591 L0592 L0599 L0602 L0605 L0635 L0645 L0659 L0662 L0663 L0664 L0731 L0740 L0747 L0748 L0750 L0754 L0757 L0758 L0759 L0766 L0777 L0779 L0783 L0789 L0790 L0794 S0027 S0028 S0031 S0038 S0052 S0126 S0192 S0212 S0222 S0242 S0250 S0276 S0282 S0360 S0390 S0418 S0420 S3014 S6028 T0060
HDPOE32	H0039 H0040 H0052 H0264 H0331 H0343 H0422 H0435 H0506 H0522 H0529 H0530 H0543 H0551 H0556 H0591 H0620 L0005 L0521 L0581 L0740 L0751 L0752 S0046 S0152 T0042
HLQEM64	H0370 H0393 H0412 H0413 H0510 H0551 H0574 H0581 H0696 L0595 L0663 L0754 L0794 S0212
HNGIR58	S0052
HOEEK12	H0011 H0014 H0031 H0038 H0041 H0052 H0083 H0085 H0123 H0135 H0144 H0255 H0266 H0341 H0412 H0415 H0458 H0510 H0529 H0543 H0545 H0556 H0560 H0587 H0618 H0619 H0620 H0626 H0631 L0371 L0471 L0526 L0655 L0659 L0663 L0747 L0749 L0750 L0751 L0757 L0758 L0764 L0766 L0769 L0773 L0774 L0776 L0779 L0780 L0784 L0786 L0803 L0804 L0809 S0126 S0144 S0294 S0328 S0358 S0360 S0366 S0374 S0408 S3014 T0008

HTLIT63	H0253 H0618 L0758 L0794
HNEBY54	H0040 H0069 H0179 H0265 H0280 H0416 H0423 H0486 H0529 H0542 H0559 H0617 H0634 H0635 H0637 H0647 H0657 H0658 H0682 H0688 L0021 L0372 L0608 L0626 L0638 L0646 L0662 L0666 L0731 L0749 L0751 L0758 L0759 L0768 L0771 L0777 L0788 L0794 L0800 L0803 L0809 S0027 S0038 S0044 S0046 S0051 S0116 S0142 S0364 T0004 T0060
HFKKS66	H0085 H0125 H0135 H0253 H0341 H0424 H0494 H0543 H0556 H0559 H0561 H0618 H0620 H0633 H0634 H0637 L0595 L0606 L0645 L0649 L0653 L0662 L0663 L0731 L0747 L0749 L0752 L0754 L0757 L0758 L0761 L0766 L0769 L0772 L0773 L0776 L0777 L0779 L0780 L0787 L0788 L0794 L0805 L0806 L0809 S0002 S0051 S0134 S0212 S0328 S0330 S0388 S0420 T0023
HFVJP07	H0370 H0393 L0748 L0755 L0780
HTEAM34	H0038 H0616 H0618 L0758 L0794
HUFGH53	H0012 H0059 H0087 H0483 H0506 H0529 H0540 H0617 H0622 H0624 H0625 H0660 H0672 H0687 L0617 L0639 L0663 L0731 L0747 L0750 L0752 L0755 L0764 L0769 L0783 L0787 L0794 L0800 L0803 L0809 S0038 S0354 S0374 S0418 S6026
HMADJ14	H0068 H0364 H0521 H0575 H0591 H0638 L0776 L0791 L0806 S0002 S0003 S0122 S0144 S0214 S0278 S0344
HETAY39	H0015 H0046 H0105 H0318 H0352 H0369 H0478 H0494 H0510 H0549 H0596 H0598 H0615 H0622 H0689 L0439 L0631 L0640 L0647 L0659 L0662 L0663 L0664 L0665 L0666 L0752 L0758 L0763 L0779 L0780 L0789 L0805 L0809 S0146
HFPFK57	H0670 L0375 L0439 L0601 L0653 L0731 L0749 L0750 L0751 L0759 L0769 L0775 L0777 L0779 L0800 L0803 L0809 S0222 S0364
HSICO66	H0004 H0009 H0024 H0036 H0038 H0040 H0041 H0046 H0052 H0056 H0059 H0063 H0068 H0083 H0087 H0090 H0100 H0135 H0188 H0216 H0252 H0255 H0265 H0271 H0318 H0352 H0370 H0392 H0393 H0402 H0421 H0422 H0423 H0428 H0436 H0437 H0484 H0486 H0494 H0506 H0520 H0521 H0522 H0543 H0547 H0551 H0555 H0556 H0561 H0581 H0587 H0595 H0598 H0599 H0602 H0615 H0616 H0617 H0618 H0638 H0641 H0657 H0658 H0659 H0660 H0670 H0677 H0686 H0690 L0002 L0163 L0357 L0362 L0369 L0372 L0375 L0382 L0438 L0471 L0483 L0485 L0499 L0513 L0515 L0523 L0595 L0596 L0600 L0601 L0639 L0646 L0650 L0653 L0655 L0657 L0659 L0663 L0664 L0665 L0666 L0731 L0740 L0741 L0747 L0748 L0749 L0750 L0751 L0752 L0754 L0755 L0757 L0758 L0761 L0763 L0764 L0766 L0768 L0769 L0770 L0771 L0772 L0774 L0776 L0777 L0779 L0787 L0791 L0794 L0800 L0803 L0809 S0001 S0002 S0010 S0026 S0028 S0051 S0132 S0142 S0150 S0152 S0218 S0278 S0344 S0348 S0354 S0358 S0360 S0374 S0424 S3014 T0006 T0041 T0049 T0109
HUFBC44	H0144 H0478 H0506 L0372 L0438 L0589 L0601 L0659 L0665 L0763 L0769 L0791 S0222
HAAAI67	H0024 H0030 H0086 H0122 H0165 H0170 H0171 H0181 H0188 H0213 H0222 H0255 H0294 H0309 H0333 H0373 H0411 H0436 H0444 H0484 H0485 H0486 H0521 H0540 H0542 H0543 H0545 H0547 H0555 H0560 H0561 H0580 H0583 H0587 H0617 H0620 H0638 H0646 H0650 H0656 H0657 H0658 H0661 H0664 H0670 H0672 H0674 H0677 H0682 H0683 H0689 L0055 L0157 L0382 L0529 L0542 L0581 L0601 L0622 L0623 L0638 L0655 L0657 L0659 L0662 L0665 L0666 L0717 L0731 L0740 L0742 L0743 L0747 L0750 L0751 L0753 L0754 L0755 L0757 L0758 L0759 L0764 L0766 L0768 L0769 L0770 L0776 L0777 L0803 L0809 S0022 S0026 S0052 S0132 S0142 S0176 S0194 S0250 S0358 S0360 S0374 S0390 S0420 S0434 S6024 T0006 T0010 T0040

HOSNU69	H0222 H0341 H0370 H0423 H0529 H0543 H0581 H0591 H0619 H0662 L0526 L0533 L0558 L0770 L0771 S0003 S0360 S0424
HMSCM88	S0002
HSXAZ05	H0024 L0809 S0007 S0010 S0036 S0049 S0051
HTPCW21	H0039 H0052 H0478
HNGOW62	H0556 S0428
HAVVG36	H0038 H0051 H0251 H0413 H0423 H0509 H0543 H0551 H0553 H0652 H0665 H0670 H0672 H0682 L0021 L0055 L0485 L0545 L0662 L0664 L0731 L0748 L0752 L0754 L0756 L0758 L0764 L0766 L0767 L0779 L0794 L0803 L0806 S0192 S0196 S0214 S0356 S0360 S0414
HBGNP63	H0617
HNHNB29	S0216
HPJCL28	L0589 L0779 S0031 S0152
HOFNC14	H0415
HELHN47	H0009 H0013 H0031 H0032 H0050 H0052 H0057 H0059 H0090 H0131 H0201 H0265 H0266 H0318 H0339 H0344 H0393 H0409 H0413 H0423 H0441 H0445 H0458 H0522 H0538 H0561 H0566 H0581 H0593 H0672 H0707 L0352 L0366 L0438 L0439 L0455 L0456 L0471 L0493 L0542 L0591 L0636 L0637 L0648 L0650 L0653 L0659 L0665 L0666 L0731 L0740 L0745 L0747 L0748 L0749 L0750 L0751 L0752 L0756 L0758 L0759 L0761 L0764 L0766 L0769 L0774 L0776 L0779 L0783 L0789 S0005 S0007 S0028 S0045 S0046 S0126 S0134 S0136 S0150 S0152 S0212 S0222 S0348 S0360 S0364 S0366 S0386 S0388 S0422 S0426 S0446 T0003 T0041 T0060 T0069 T0082
HFKET18	H0012 H0013 H0087 H0100 H0107 H0183 H0188 H0255 H0265 H0318 H0341 H0352 H0445 H0486 H0529 H0543 H0544 H0549 H0556 H0583 H0597 H0617 H0618 H0619 H0620 H0644 H0660 H0674 H0690 L0055 L0438 L0439 L0646 L0657 L0663 L0666 L0717 L0731 L0740 L0747 L0750 L0751 L0756 L0758 L0759 L0761 L0763 L0764 L0766 L0768 L0769 L0771 L0774 L0794 L0804 L0809 S0028 S0046 S0182 S0358 S0360 S0402 S0418 S0456
HSRFZ57	S0014 S0022
HAMFP32	H0042 H0063 H0265 H0266 H0373 H0484 H0486 H0489 H0542 H0543 H0547 H0556 H0560 H0594 H0617 H0618 H0637 H0685 H0698 L0371 L0655 L0766 L0770 L0774 L0777 L0789 L0803 L0804 L0805 L0809 S0028 S0116 S0192 S0218 S0328 S0360 S0418 S0420 S0436 S3012
HLHDL42	H0024 H0042 H0046 H0477 H0575 H0658 H0663 H0670 H0672 H0685 H0690 L0527 L0599 L0639 L0657 L0662 L0664 L0665 L0666 L0751 L0755 L0775 L0806 S0016
HKMLX18	H0002 H0013 H0014 H0031 H0038 H0046 H0052 H0123 H0144 H0187 H0194 H0264 H0266 H0294 H0341 H0352 H0423 H0431 H0436 H0494 H0506 H0519 H0521 H0529 H0538 H0539 H0547 H0553 H0556 H0598 H0615 H0616 H0623 H0631 H0634 H0641 H0657 H0672 H0687 L0375 L0438 L0471 L0600 L0638 L0646 L0655 L0659 L0663 L0666 L0731 L0740 L0743 L0745 L0747 L0748 L0749 L0750 L0752 L0755 L0757 L0758 L0759 L0761 L0763 L0766 L0771 L0773 L0774 L0777 L0790 L0794 L0803 L0804 L0805 L0809 S0010 S0028 S0046 S0126 S0150 S0152 S0222 S0242 S0280 S0328 S0344 S0356 S0364 S0378 S0422 S6024
HFIUW36	H0013 H0039 H0046 H0083 H0090 H0265 H0327 H0423 H0521 H0539 H0555 H0574 H0581 H0599 H0615 H0622 H0628 H0631 H0649 H0656 H0694 L0002 L0438 L0439 L0455 L0456 L0520 L0637 L0648 L0664 L0666 L0667 L0731 L0740 L0743 L0747 L0748 L0752 L0754 L0756 L0758 L0761 L0763 L0766 L0770 L0776 L0779 L0789 L0794 L0800 L0803 L0809 S0002 S0026 S0049 S0196 S0222 S0250 S0280 S0424

	T0041
HNGOU82	H0030 S0150 S0428
HSODB85	H0004 H0251 H0294 H0331 H0341 H0427 H0489 H0497 H0509 H0521 H0586 H0591 H0595 H0615 H0624 H0632 H0633 H0646 H0648 H0665 L0194 L0352 L0369 L0438 L0439 L0471 L0480 L0591 L0599 L0608 L0637 L0640 L0641 L0646 L0659 L0662 L0665 L0666 L0731 L0740 L0744 L0747 L0751 L0752 L0755 L0761 L0763 L0764 L0766 L0773 L0774 L0775 L0777 L0792 L0803 L0805 L0806 L0809 S0002 S0003 S0040 S0152 S0196 S0212 S0214 S0328 S0330 S0356 S0360 S0376 S0380 S0418 T0114
HFICR14	H0038 H0040 H0052 H0135 H0265 H0316 H0333 H0486 H0509 H0521 H0522 H0542 H0547 H0555 H0599 H0618 H0647 H0672 H0684 H0689 L0040 L0361 L0455 L0471 L0518 L0542 L0559 L0565 L0637 L0640 L0651 L0659 L0665 L0747 L0748 L0749 L0752 L0756 L0766 L0768 L0769 L0770 L0774 L0776 L0779 L0787 L0790 L0793 L0803 L0805 L0809 S0010 S0028 S0040 S0192 S0378 S0420 T0023
HSIDQ93	H0011 H0036 H0046 H0059 H0068 H0392 H0444 H0620 H0672 L0517 L0649 L0659 L0717 L0747 L0748 L0754 L0777 L0794 S0114 S0222 S0330 S0428 T0023
HSLGM81	H0009 H0013 H0031 H0038 H0050 H0051 H0052 H0144 H0156 H0201 H0253 H0284 H0341 H0373 H0393 H0435 H0445 H0455 H0519 H0521 H0538 H0542 H0547 H0551 H0553 H0575 H0581 H0583 H0586 H0591 H0622 H0632 H0633 H0697 H0701 L0351 L0352 L0438 L0439 L0592 L0630 L0731 L0742 L0748 L0752 L0758 L0769 L0775 L0776 L0789 L0791 N0005 S0007 S0010 S0028 S0031 S0036 S0045 S0049 S0052 S0112 S0126 S0134 S0222 S0282 S0310 S0346 S3012 T0039 T0041
HLQGP82	H0135 H0484 H0494 H0553 H0561 H0622 H0632 H0667 H0677 L0741 L0745 L0746 L0748 S0038 S0222 S0440
HRACI26	H0555 L0520 L0659 L0740 L0752 L0766 L0773 L0779 S0210 S0356
HMSMD07	H0009 H0014 H0040 H0052 H0056 H0081 H0250 H0261 H0264 H0266 H0268 H0286 H0427 H0441 H0445 H0478 H0506 H0510 H0521 H0538 H0544 H0551 H0553 H0575 H0581 H0586 H0593 H0600 H0620 H0623 H0644 H0648 H0662 H0670 L0021 L0163 L0351 L0372 L0438 L0439 L0483 L0523 L0581 L0637 L0646 L0659 L0662 L0731 L0743 L0744 L0747 L0748 L0749 L0757 L0770 L0774 L0775 L0776 L0777 L0783 L0789 L0790 L0791 L0794 L0800 L0803 L0804 S0010 S0022 S0027 S0028 S0032 S0036 S0038 S0040 S0045 S0051 S0126 S0210 S0276 S0278 S0282 S0330 S0354 S0360 S0426 S0474 S3014 T0010 T0040
HFXDK20	H0436 S0001
HTXKF95	H0030 H0050 H0051 H0124 H0144 H0265 H0305 H0422 H0441 H0506 H0543 H0553 H0555 H0556 H0569 H0586 H0599 H0616 L0363 L0471 L0599 L0603 L0605 L0644 L0659 L0662 L0665 L0666 L0731 L0747 L0748 L0749 L0750 L0751 L0754 L0755 L0764 L0769 L0770 L0775 L0779 L0783 L0794 L0800 L0803 L0804 L0806 S0046 S0358 S3012
HUSBA88	H0013 H0014 H0024 H0039 H0040 H0052 H0059 H0071 H0100 H0123 H0124 H0135 H0144 H0150 H0156 H0170 H0194 H0208 H0213 H0231 H0251 H0253 H0255 H0264 H0265 H0269 H0329 H0333 H0352 H0370 H0371 H0392 H0393 H0413 H0455 H0479 H0483 H0486 H0494 H0518 H0520 H0521 H0522 H0529 H0539 H0544 H0545 H0547 H0550 H0553 H0555 H0556 H0581 H0594 H0607 H0616 H0617 H0632 H0633 H0641 H0644 H0645 H0647 H0649 H0651 H0653 H0658 H0659 H0660 H0661 H0663 H0666 H0667 H0670 H0672 H0673 H0678 H0684 H0686 H0687

	H0689 H0690 H0696 L0021 L0040 L0163 L0351 L0374 L0378 L0384 L0439 L0462 L0527 L0549 L0592 L0596 L0602 L0605 L0619 L0637 L0639 L0644 L0645 L0657 L0659 L0663 L0664 L0665 L0666 L0698 L0717 L0731 L0740 L0742 L0745 L0747 L0748 L0749 L0750 L0751 L0752 L0753 L0754 L0757 L0758 L0759 L0761 L0763 L0764 L0765 L0766 L0768 L0769 L0770 L0771 L0772 L0773 L0774 L0775 L0777 L0779 L0783 L0794 L0796 L0800 L0803 L0806 L0809 S0002 S0005 S0010 S0027 S0028 S0038 S0040 S0051 S0114 S0126 S0132 S0140 S0146 S0152 S0194 S0206 S0212 S0222 S0276 S0334 S0358 S0360 S0374 S0380 S0390 S0418 S0420 S0426 S0444 S0448 S3014 T0041 T0067
HNEDD37	H0179 H0197 H0271 H0309 H0436 H0522 H0549 H0550 H0650 L0517 L0745 L0752 L0758 S0106 S0114
HBJNC59	H0009 H0015 H0030 H0031 H0039 H0042 H0045 H0087 H0100 H0120 H0124 H0252 H0254 H0255 H0309 H0318 H0327 H0352 H0375 H0411 H0421 H0424 H0427 H0445 H0455 H0506 H0509 H0510 H0521 H0522 H0538 H0550 H0555 H0575 H0581 H0583 H0587 H0602 H0617 H0632 H0637 H0638 H0641 H0647 H0649 H0653 H0661 H0663 H0672 H0687 H0689 L0375 L0378 L0385 L0540 L0545 L0547 L0603 L0629 L0636 L0644 L0648 L0651 L0653 L0655 L0657 L0659 L0747 L0749 L0750 L0754 L0755 L0762 L0763 L0767 L0768 L0769 L0772 L0774 L0775 L0776 L0777 L0783 L0806 S0044 S0116 S0260 S0280 S0292 S0332 S0356 S0358 S0360 S0374 S0376 S0380 S0404 S6022 T0082
HCABW07	H0125 H0351 L0748

**Table 3**

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):
25	22q12.1-q12.2	101000 123620 138981 188826 600850 601669
59	9	

Table 4

Library Code	Library Description
H0002	Human Adult Heart
H0004	Human Adult Spleen
H0008	Whole 6 Week Old Embryo
H0009	Human Fetal Brain
H0011	Human Fetal Kidney
H0012	Human Fetal Kidney
H0013	Human 8 Week Whole Embryo
H0014	Human Gall Bladder
H0015	Human Gall Bladder, fraction II
H0024	Human Fetal Lung III
H0030	Human Placenta
H0031	Human Placenta
H0032	Human Prostate
H0036	Human Adult Small Intestine
H0038	Human Testes
H0039	Human Pancreas Tumor
H0040	Human Testes Tumor
H0041	Human Fetal Bone
H0042	Human Adult Pulmonary
H0045	Human Esophagus, Cancer
H0046	Human Endometrial Tumor
H0050	Human Fetal Heart
H0051	Human Hippocampus
H0052	Human Cerebellum
H0056	Human Umbilical Vein, Endo. remake
H0057	Human Fetal Spleen
H0059	Human Uterine Cancer
H0063	Human Thymus
H0068	Human Skin Tumor
H0069	Human Activated T-Cells
H0071	Human Infant Adrenal Gland
H0081	Human Fetal Epithelium (Skin)
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES
H0085	Human Colon
H0086	Human epithelioid sarcoma
H0087	Human Thymus
H0090	Human T-Cell Lymphoma
H0100	Human Whole Six Week Old Embryo
H0105	Human Fetal Heart, subtracted
H0107	Human Infant Adrenal Gland, subtracted
H0120	Human Adult Spleen, subtracted
H0122	Human Adult Skeletal Muscle
H0123	Human Fetal Dura Mater
H0124	Human Rhabdomyosarcoma
H0125	Cem cells cyclohexamide treated
H0131	LNCAP + 0.3nM R1881
H0132	LNCAP + 30nM R1881



H0135	Human Synovial Sarcoma
H0144	Nine Week Old Early Stage Human
H0150	Human Epididymus
H0156	Human Adrenal Gland Tumor
H0163	Human Synovium
H0164	Human Trachea Tumor
H0165	Human Prostate Cancer, Stage B2
H0170	12 Week Old Early Stage Human
H0171	12 Week Old Early Stage Human, II
H0179	Human Neutrophil
H0180	Human Primary Breast Cancer
H0181	Human Primary Breast Cancer
H0183	Human Colon Cancer
H0187	Resting T-Cell
H0188	Human Normal Breast
H0194	Human Cerebellum, subtracted
H0196	Human Cardiomyopathy, subtracted
H0197	Human Fetal Liver, subtracted
H0201	Human Hippocampus, subtracted
H0208	Early Stage Human Lung, subtracted
H0213	Human Pituitary, subtracted
H0216	Supt cells, cyclohexamide treated, subtracted
H0222	Activated T-Cells, 8 hrs, subtracted
H0231	Human Colon, subtraction
H0246	Human Fetal Liver- Enzyme subtraction
H0250	Human Activated Monocytes
H0251	Human Chondrosarcoma
H0252	Human Osteosarcoma
H0253	Human adult testis, large inserts
H0254	Breast Lymph node cDNA library
H0255	breast lymph node CDNA library
H0261	H. cerebellum, Enzyme subtracted
H0264	human tonsils
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco
H0266	Human Microvascular Endothelial Cells, fract. A
H0268	Human Umbilical Vein Endothelial Cells, fract. A
H0269	Human Umbilical Vein Endothelial Cells, fract. B
H0271	Human Neutrophil, Activated
H0280	K562 + PMA (36 hrs)
H0284	Human OB MG63 control fraction I
H0286	Human OB MG63 treated (10 nM E2) fraction I
H0288	Human OB HOS control fraction I
H0292	Human OB HOS treated (10 nM E2) fraction I
H0294	Amniotic Cells - TNF induced
H0295	Amniotic Cells - Primary Culture
H0305	CD34 positive cells (Cord Blood)
H0309	Human Chronic Synovitis
H0316	HUMAN STOMACH
H0318	HUMAN B CELL LYMPHOMA
H0327	human corpus colosum
H0329	Dermatofibrosarcoma Protuberance
H0331	Hepatocellular Tumor
H0333	Hemangiopericytoma

H0339	Duodenum
H0341	Bone Marrow Cell Line (RS4,11)
H0343	stomach cancer (human)
H0344	Adipose tissue (human)
H0351	Glioblastoma
H0352	wilm's tumor
H0355	Human Liver
H0364	Human Osteoclastoma, excised
H0369	H. Atrophic Endometrium
H0370	H. Lymph node breast Cancer
H0371	Eosinophils-Hypereosinophilia patient
H0373	Human Heart
H0375	Human Lung
H0381	Bone Cancer
H0383	Human Prostate BPH, re-excision
H0391	H. Meningioma, M6
H0392	H. Meningioma, M1
H0393	Fetal Liver, subtraction II
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision
H0409	H. Striatum Depression, subtracted
H0411	H Female Bladder, Adult
H0412	Human umbilical vein endothelial cells, IL-4 induced
H0413	Human Umbilical Vein Endothelial Cells, uninduced
H0415	H. Ovarian Tumor, II, OV5232
H0416	Human Neutrophils, Activated, re-excision
H0421	Human Bone Marrow, re-excision
H0422	T-Cell PHA 16 hrs
H0423	T-Cell PHA 24 hrs
H0424	Human Pituitary, subt IX
H0427	Human Adipose
H0428	Human Ovary
H0431	H. Kidney Medulla, re-excision
H0435	Ovarian Tumor 10-3-95
H0436	Resting T-Cell Library,II
H0437	H Umbilical Vein Endothelial Cells, frac A, re-excision
H0441	H. Kidney Cortex, subtracted
H0444	Spleen metastatic melanoma
H0445	Spleen, Chronic lymphocytic leukemia
H0455	H. Striatum Depression, subt
H0458	CD34+ cell, I, frac II
H0477	Human Tonsil, Lib 3
H0478	Salivary Gland, Lib 2
H0479	Salivary Gland, Lib 3
H0483	Breast Cancer cell line, MDA 36
H0484	Breast Cancer Cell line, angiogenic
H0485	Hodgkin's Lymphoma I
H0486	Hodgkin's Lymphoma II
H0488	Human Tonsils, Lib 2
H0489	Crohn's Disease
H0494	Keratinocyte
H0497	HEL cell line
H0506	Ulcerative Colitis
H0509	Liver, Hepatoma

H0510	Human Liver, normal
H0518	pBMC stimulated w/ poly I/C
H0519	NTERA2, control
H0520	NTERA2 + retinoic acid, 14 days
H0521	Primary Dendritic Cells, lib 1
H0522	Primary Dendritic cells, frac 2
H0529	Myeloid Progenitor Cell Line
H0530	Human Dermal Endothelial Cells, untreated
H0538	Merkel Cells
H0539	Pancreas Islet Cell Tumor
H0540	Skin, burned
H0542	T Cell helper I
H0543	T cell helper II
H0544	Human endometrial stromal cells
H0545	Human endometrial stromal cells-treated with progesterone
H0546	Human endometrial stromal cells-treated with estradiol
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)
H0549	H. Epididymus, caput & corpus
H0550	H. Epididymus, cauda
H0551	Human Thymus Stromal Cells
H0553	Human Placenta
H0555	Rejected Kidney, lib 4
H0556	Activated T-cell(12h)/Thiouridine-re-excision
H0559	HL-60, PMA 4H, re-excision
H0560	KMH2
H0561	L428
H0566	Human Fetal Brain, normalized c50F
H0569	Human Fetal Brain, normalized CO
H0574	Hepatocellular Tumor, re-excision
H0575	Human Adult Pulmonary, re-excision
H0580	Dendritic cells, pooled
H0581	Human Bone Marrow, treated
H0583	B Cell lymphoma
H0586	Healing groin wound, 6.5 hours post incision
H0587	Healing groin wound, 7.5 hours post incision
H0591	Human T-cell lymphoma, re-excision
H0593	Olfactory epithelium, nasal cavity
H0594	Human Lung Cancer, re-excision
H0595	Stomach cancer (human), re-excision
H0596	Human Colon Cancer, re-excision
H0597	Human Colon, re-excision
H0598	Human Stomach, re-excision
H0599	Human Adult Heart, re-excision
H0600	Healing Abdomen wound, 70&90 min post incision
H0602	Healing Abdomen Wound, 21&29 days post incision
H0606	Human Primary Breast Cancer, re-excision
H0607	H. Leukocytes, normalized cot 50A3
H0615	Human Ovarian Cancer Reexcision
H0616	Human Testes, Reexcision
H0617	Human Primary Breast Cancer Reexcision
H0618	Human Adult Testes, Large Inserts, Reexcision
H0619	Fetal Heart
H0620	Human Fetal Kidney, Reexcision

H0622	Human Pancreas Tumor, Reexcision
H0623	Human Umbilical Vein, Reexcision
H0624	12 Week Early Stage Human II, Reexcision
H0625	Ku 812F Basophils Line
H0626	Saos2 Cells, Untreated
H0628	Human Pre-Differentiated Adipocytes
H0631	Saos2, Dexamethosone Treated
H0632	Hepatocellular Tumor, re-excision
H0633	Lung Carcinoma A549 TNFalpha activated
H0634	Human Testes Tumor, re-excision
H0635	Human Activated T-Cells, re-excision
H0637	Dendritic Cells From CD34 Cells
H0638	CD40 activated monocyte dendritic cells
H0641	LPS activated derived dendritic cells
H0644	Human Placenta (re-excision)
H0645	Fetal Heart, re-excision
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic
H0648	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot
H0649	Lung, Normal: (4005313 B1)
H0650	B-Cells
H0651	Ovary, Normal: (9805C040R)
H0652	Lung, Normal: (4005313 B1)
H0653	Stromal Cells
H0656	B-cells (unstimulated)
H0657	B-cells (stimulated)
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma
H0661	Breast, Cancer: (4004943 A5)
H0662	Breast, Normal: (4005522B2)
H0663	Breast, Cancer: (4005522 A2)
H0664	Breast, Cancer: (9806C012R)
H0665	Stromal cells 3.88
H0666	Ovary, Cancer: (4004332 A2)
H0667	Stromal cells(HBM3.18)
H0668	stromal cell clone 2.5
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma
H0672	Ovary, Cancer: (4004576 A8)
H0673	Human Prostate Cancer, Stage B2, re-excision
H0674	Human Prostate Cancer, Stage C, re-excision
H0677	TNFR degenerate oligo
H0678	screened clones from placental library
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma
H0683	Ovarian cancer, Serous Papillary Adenocarcinoma
H0684	Ovarian cancer, Serous Papillary Adenocarcinoma
H0685	Adenocarcinoma of Ovary, Human Cell Line, # OVCAR-3
H0686	Adenocarcinoma of Ovary, Human Cell Line
H0687	Human normal ovary(#9610G215)
H0688	Human Ovarian Cancer(#9807G017)
H0689	Ovarian Cancer
H0690	Ovarian Cancer, # 9702G001
H0694	Prostate cancer (adenocarcinoma)

H0696	Prostate Adenocarcinoma
H0697	NK Cells (NKYao20 Control)
H0698	NK Cells Yao20 IL2 treated for 48 hrs
H0701	NKYao15(control)
H0707	Stomach Cancer(S007635)
L0002	Atrium cDNA library Human heart
L0005	Clontech human aorta polyA+ mRNA (#6572)
L0021	Human adult (K.Okubo)
L0040	Human colon mucosa
L0055	Human promyelocyte
L0105	Human aorta polyA+ (TFujiwara)
L0157	Human fetal brain (TFujiwara)
L0163	Human heart cDNA (YNakamura)
L0194	Human pancreatic cancer cell line Patu 8988t
L0351	Infant brain, Bento Soares
L0352	Normalized infant brain, Bento Soares
L0357	V, Human Placenta tissue
L0361	Stratagene ovary (#937217)
L0362	Stratagene ovarian cancer (#937219)
L0363	NCI CGAP GC2
L0366	Stratagene schizo brain S11
L0369	NCI CGAP AA1
L0371	NCI CGAP Br3
L0372	NCI CGAP Co12
L0374	NCI CGAP Co2
L0375	NCI CGAP Kid6
L0378	NCI CGAP Lu1
L0382	NCI CGAP Pr25
L0384	NCI CGAP Pr23
L0385	NCI CGAP Gas1
L0386	NCI CGAP HN3
L0438	normalized infant brain cDNA
L0439	Soares infant brain 1NIB
L0455	Human retina cDNA randomly primed sublibrary
L0456	Human retina cDNA Tsp509I-cleaved sublibrary
L0462	WATM1
L0471	Human fetal heart, Lambda ZAP Express
L0480	Stratagene cat#937212 (1992)
L0483	Human pancreatic islet
L0485	STRATAGENE Human skeletal muscle cDNA library, cat. #936215.
L0493	NCI CGAP Ov26
L0499	NCI CGAP HSC2
L0513	NCI CGAP Ov37
L0515	NCI CGAP Ov32
L0517	NCI CGAP Pr1
L0518	NCI CGAP Pr2
L0520	NCI CGAP Alv1
L0521	NCI CGAP Ew1
L0523	NCI CGAP Lip2
L0526	NCI CGAP Pr12
L0527	NCI CGAP Ov2
L0529	NCI CGAP Pr6
L0533	NCI CGAP HSC1

L0540	NCI CGAP Pr10
L0542	NCI CGAP Pr11
L0545	NCI CGAP Pr4.1
L0547	NCI CGAP Pr16
L0549	NCI CGAP HN10
L0558	NCI CGAP Ov40
L0559	NCI CGAP Ov39
L0564	Jia bone marrow stroma
L0565	Normal Human Trabecular Bone Cells
L0581	Stratagene liver (#937224)
L0589	Stratagene fetal retina 937202
L0591	Stratagene HeLa cell s3 937216
L0592	Stratagene hNT neuron (#937233)
L0595	Stratagene NT2 neuronal precursor 937230
L0596	Stratagene colon (#937204)
L0597	Stratagene corneal stroma (#937222)
L0599	Stratagene lung (#937210)
L0600	Weizmann Olfactory Epithelium
L0601	Stratagene pancreas (#937208)
L0602	Pancreatic Islet
L0603	Stratagene placenta (#937225)
L0605	Stratagene fetal spleen (#937205)
L0606	NCI CGAP Lym5
L0608	Stratagene lung carcinoma 937218
L0612	Schiller oligodendroglioma
L0617	Chromosome 22 exon
L0619	Chromosome 9 exon II
L0622	HM1
L0623	HM3
L0626	NCI CGAP GC1
L0629	NCI CGAP Mel3
L0630	NCI CGAP CNS1
L0631	NCI CGAP Br7
L0635	NCI CGAP PNS1
L0636	NCI CGAP Pit1
L0637	NCI CGAP Brm53
L0638	NCI CGAP Brm35
L0639	NCI CGAP Brm52
L0640	NCI CGAP Br18
L0641	NCI CGAP Co17
L0644	NCI CGAP Co20
L0645	NCI CGAP Co21
L0646	NCI CGAP Co14
L0647	NCI CGAP Sar4
L0648	NCI CGAP Eso2
L0649	NCI CGAP GU1
L0650	NCI CGAP Kid13
L0651	NCI CGAP Kid8
L0653	NCI CGAP Lu28
L0655	NCI CGAP Lym12
L0657	NCI CGAP Ov23
L0658	NCI CGAP Ov35
L0659	NCI CGAP Pan1

L0661	NCI CGAP Mel15
L0662	NCI CGAP Gas4
L0663	NCI CGAP Ut2
L0664	NCI CGAP Ut3
L0665	NCI CGAP Ut4
L0666	NCI CGAP Ut1
L0667	NCI CGAP CML1
L0698	Testis 2
L0717	Gessler Wilms tumor
L0731	Soares pregnant uterus NbHPU
L0740	Soares melanocyte 2NbHM
L0741	Soares adult brain N2b4HB55Y
L0742	Soares adult brain N2b5HB55Y
L0743	Soares breast 2NbHBst
L0744	Soares breast 3NbHBst
L0745	Soares retina N2b4HR
L0746	Soares retina N2b5HR
L0747	Soares fetal heart NbHH19W
L0748	Soares fetal liver spleen 1NFLS
L0749	Soares fetal liver spleen 1NFLS S1
L0750	Soares fetal lung NbHL19W
L0751	Soares ovary tumor NbHOT
L0752	Soares parathyroid tumor NbHPA
L0753	Soares pineal gland N3HPG
L0754	Soares placenta Nb2HP
L0755	Soares placenta 8to9weeks 2NbHP8to9W
L0756	Soares multiple sclerosis 2NbHMSP
L0757	Soares senescent fibroblasts NbHSF
L0758	Soares testis NHT
L0759	Soares total fetus Nb2HF8 9w
L0761	NCI CGAP CLL1
L0762	NCI CGAP Br1.1
L0763	NCI CGAP Br2
L0764	NCI CGAP Co3
L0765	NCI CGAP Co4
L0766	NCI CGAP GCB1
L0767	NCI CGAP GC3
L0768	NCI CGAP GC4
L0769	NCI CGAP Brn25
L0770	NCI CGAP Brn23
L0771	NCI CGAP Co8
L0772	NCI CGAP Co10
L0773	NCI CGAP Co9
L0774	NCI CGAP Kid3
L0775	NCI CGAP Kid5
L0776	NCI CGAP Lu5
L0777	Soares NhHMPu S1
L0779	Soares NFL T GBC S1
L0780	Soares NSF F8 9W OT PA P S1
L0783	NCI CGAP Pr22
L0784	NCI CGAP Lei2
L0786	Soares NbHFB
L0787	NCI CGAP Sub1

L0788	NCI CGAP Sub2
L0789	NCI CGAP Sub3
L0790	NCI CGAP Sub4
L0791	NCI CGAP Sub5
L0792	NCI CGAP Sub6
L0793	NCI CGAP Sub7
L0794	NCI CGAP GC6
L0796	NCI CGAP Brn50
L0800	NCI CGAP Co16
L0803	NCI CGAP Kid11
L0804	NCI CGAP Kid12
L0805	NCI CGAP Lu24
L0806	NCI CGAP Lu19
L0809	NCI CGAP Pr28
N0005	Human cerebral cortex
S0001	Brain frontal cortex
S0002	Monocyte activated
S0003	Human Osteoclastoma
S0005	Heart
S0007	Early Stage Human Brain
S0010	Human Amygdala
S0011	STROMAL -OSTEOCLASTOMA
S0014	Kidney Cortex
S0016	Kidney Pyramids
S0022	Human Osteoclastoma Stromal Cells - unamplified
S0026	Stromal cell TF274
S0027	Smooth muscle, serum treated
S0028	Smooth muscle, control
S0031	Spinal cord
S0032	Smooth muscle-ILb induced
S0036	Human Substantia Nigra
S0037	Smooth muscle, IL1b induced
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb
S0040	Adipocytes
S0044	Prostate BPH
S0045	Endothelial cells-control
S0046	Endothelial-induced
S0049	Human Brain, Striatum
S0050	Human Frontal Cortex, Schizophrenia
S0051	Human Hypothalamus, Schizophrenia
S0052	neutrophils control
S0106	STRIATUM DEPRESSION
S0112	Hypothalamus
S0114	Anergic T-cell
S0116	Bone marrow
S0122	Osteoclastoma-normalized A
S0126	Osteoblasts
S0132	Epithelial-TNFa and INF induced
S0134	Apoptotic T-cell
S0136	PERM TF274
S0140	eosinophil-IL5 induced
S0142	Macrophage-oxLDL
S0144	Macrophage (GM-CSF treated)



S0146	prostate-edited
S0150	LNCAP prostate cell line
S0152	PC3 Prostate cell line
S0176	Prostate, normal, subtraction I
S0182	Human B Cell 8866
S0192	Synovial Fibroblasts (control)
S0194	Synovial hypoxia
S0196	Synovial IL-1/TNF stimulated
S0206	Smooth Muscle- HASTE normalized
S0210	Mesangial cell, frac 2
S0212	Bone Marrow Stromal Cell, untreated
S0214	Human Osteoclastoma, re-excision
S0216	Neutrophils IL-1 and LPS induced
S0218	Apoptotic T-cell, re-excision
S0222	H. Frontal cortex, epileptic, re-excision
S0242	Synovial Fibroblasts (IL1/TNF), subt
S0250	Human Osteoblasts II
S0260	Spinal Cord, re-excision
S0276	Synovial hypoxia-RSF subtracted
S0278	H Macrophage (GM-CSF treated), re-excision
S0280	Human Adipose Tissue, re-excision
S0282	Brain Frontal Cortex, re-excision
S0292	Osteoarthritis (OA-4)
S0294	Larynx tumor
S0308	Spleen/normal
S0310	Normal trachea
S0328	Palate carcinoma
S0330	Palate normal
S0332	Pharynx carcinoma
S0334	Human Normal Cartilage Fraction III
S0344	Macrophage-oxLDL, re-excision
S0346	Human Amygdala, re-excision
S0348	Cheek Carcinoma
S0354	Colon Normal II
S0356	Colon Carcinoma
S0358	Colon Normal III
S0360	Colon Tumor II
S0364	Human Quadriceps
S0366	Human Soleus
S0374	Normal colon
S0376	Colon Tumor
S0378	Pancreas normal PCA4 No
S0380	Pancreas Tumor PCA4 Tu
S0386	Human Whole Brain, re-excision
S0388	Human Hypothalamus, schizophrenia, re-excision
S0390	Smooth muscle, control, re-excision
S0402	Adrenal Gland, normal
S0404	Rectum normal
S0408	Colon, normal
S0414	Hippocampus, Alzheimer Subtracted
S0418	CHME Cell Line, treated 5 hrs
S0420	CHME Cell Line, untreated
S0422	Mo7e Cell Line GM-CSF treated (1 ng/ml)

S0424	TF-1 Cell Line GM-CSF Treated
S0426	Monocyte activated, re-excision
S0428	Neutrophils control, re-excision
S0434	Stomach Normal
S0436	Stomach Tumour
S0440	Liver Tumour Met 5 Tu
S0444	Colon Tumor
S0446	Tongue Tumour
S0448	Larynx Normal
S0456	Tongue Normal
S0474	Human blood platelets
S3012	Smooth Muscle Serum Treated, Norm
S3014	Smooth muscle, serum induced, re-exc
S6022	H. Adipose Tissue
S6024	Alzheimers, spongy change
S6026	Frontal Lobe, Dementia
S6028	Human Manic Depression Tissue
T0003	Human Fetal Lung
T0004	Human White Fat
T0006	Human Pineal Gland
T0008	Colorectal Tumor
T0010	Human Infant Brain
T0023	Human Pancreatic Carcinoma
T0039	HSA 172 Cells
T0040	HSC172 cells
T0041	Jurkat T-cell G1 phase
T0042	Jurkat T-Cell, S phase
T0048	Human Aortic Endothelium
T0049	Aorta endothelial cells + TNF-a
T0060	Human White Adipose
T0067	Human Thyroid
T0069	Human Uterus, normal
T0082	Human Adult Retina
T0109	Human (HCC) cell line liver (mouse) metastasis, remake
T0110	Human colon carcinoma (HCC) cell line, remake
T0114	Human (Caco-2) cell line, adenocarcinoma, colon, remake

**Table 5**

OMIM ID	OMIM Description
101000	Malignant mesothelioma, sporadic (3) Meningioma, NF2-related, sporadic (3) Schwannoma, sporadic (3) Neurofibromatosis, type 2 (3) Neurolemmomatosis (3)
123620	Cataract, cerulean, type 2, 601547 (3)
138981	Pulmonary alveolar proteinosis, 265120 (3)
188826	Sorsby fundus dystrophy, 136900 (3)
600850	Schizophrenia disorder-4 (2)
601669	Hirschsprung disease, one form (2) (?)

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### **Signal Sequences**

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough  
5 endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of  
10 the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal  
15 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of  
20 these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et  
25 al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

#### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the

complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%,  
10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
25 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, 5 Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' 10 deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 15 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected 20 score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query 25 sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score 30 calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the



deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, 5 Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological 10 functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic 15 activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the 20 art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural 25 selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid 30 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340

(1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger

or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

5           Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 10  
1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller  
15 by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also  
20 encompassed by the invention, as are polypeptides encoded by these polynucleotides.

          In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a  
25 part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90,  
30 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or

smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not



limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and  
5 ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of  
10 the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using  
15 colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another  
20 embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention  
25 identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another  
30 embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

### **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays

described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids

have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains

of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by

DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region,

CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described

herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The



invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., *Blood* 92(6):1981-1988 (1998); Chen et al., *Cancer Res.* 58(16):3668-3678 (1998); Harrop et al., *J. Immunol.* 161(4):1786-1794 (1998); Zhu et al., *Cancer Res.* 58(15):3209-3214 (1998); Yoon et al., *J. Immunol.* 160(7):3170-3179 (1998); Prat et al., *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard et al., *J. Immunol. Methods* 205(2):177-190 (1997); Liautard et al., *Cytokine* 9(4):233-241 (1997); Carlson et al., *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman et al., *Neuron* 14(4):755-762 (1995); Muller et al., *Structure* 6(9):1153-1167 (1998);

Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of

the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a

polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising  
5 culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

10 Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the  
15 CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such  
20 phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage  
25 including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods  
30 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809;

WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by  
5 reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells,  
10 yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references  
15 incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including  
20 in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing  
25 chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are  
30 antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with

the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce

chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the

5 immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human

10 antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825;

15 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

20 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

25 Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, *J. Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide

30 multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its

ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

5

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR



may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038-1041 (1988)).

#### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are

described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo  
5 genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT  
10 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an  
15 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell  
20 for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with  
25 the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast  
30 expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus

expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing

5 promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant

10 antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

15 In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified

20 may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-

25 5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa

30 protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript,

glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, 1993, TIB TECH 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

10       The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in  
15       culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

      The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second  
20       vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic  
25       free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

      Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any  
30       method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography),

centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

5           The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through  
10 linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention  
15 to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS  
20 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

          The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may  
25 be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example,  
30 Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or



conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991);  
5 Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to  
10 the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various  
15 domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or  
20 protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may  
25 hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

30 Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexahistidine provides for convenient purification of the fusion protein. Other peptide tags  
5 useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used  
10 diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent  
15 materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.  
20 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
25 fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include <sup>125</sup>I, <sup>131</sup>I, <sup>111</sup>In or <sup>99</sup>Tc.

30 Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, <sup>213</sup>Bi. A cytotoxin

- or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-
- 5 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU),
- 10 cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).
- 15 The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria
- 20 toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International
- 25 Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.
- 30 Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports

include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of  
5 Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And  
10 Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol.  
15 Rev. 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it,  
20 administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

#### Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of  
25 cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular  
30 populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with

antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### 10 Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the

art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., <sup>32</sup>P or <sup>125</sup>I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the

coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc.,  
5 New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the  
10 presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of  
15 interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

#### Therapeutic Uses

The present invention is further directed to antibody-based therapies which  
20 involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the  
25 invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment  
30 and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or

conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,



$10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### Gene Therapy

5 In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic  
10 acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al.,  
15 Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al.  
20 (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors  
25 that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other  
30 desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA

86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

5           Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

10           In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated  
15   retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by  
20   administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal  
25   degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination  
30   (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection  
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,  
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.  
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and  
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,  
30 neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical

composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,

including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.



In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. . Where necessary, the  
5 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the  
10 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.  
15 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

20 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the  
25 formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to  
30 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human

antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be  
5 reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such  
10 container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically  
15 bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body  
20 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,  
25 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With  
30 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of

actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of

99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

#### Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of

the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include  
5 a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled  
10 anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or  
15 colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the  
20 protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this  
25 diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### **Fusion Proteins**

30 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the

polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

5        Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

10        Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final  
15        preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

20        Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian  
25        immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

30        Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a

fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the



vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic  
5 Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or  
10 ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

15 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,  
20 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine  
25 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A

main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an

expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used,

depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

5           The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., *Exp. Hematol.* 20:1028-1035 (1992) (reporting  
10           pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues;  
15           those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

20           One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be  
25           performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be  
30           accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions,

substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention  
5 relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

10 Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These  
15 homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the  
20 multimer of the invention is a homodimer (e.g., containing polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

25 As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional  
30 embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example,

liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed  
5 when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid  
10 residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the  
15 consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number  
20 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for  
25 example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the  
30 invention separated by peptide linkers may be produced using conventional recombinant DNA technology.



Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine  
5 zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described  
10 in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

15 Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by  
20 reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations  
25 proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers  
30 of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome  
5 identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers  
10 (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an  
15 amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping  
20 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.  
25 This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to  
30 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are

more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinherance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinherance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue

sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

5           The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may  
10 be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents  
15 referenced supra are hereby incorporated by reference in their entirety herein.

          The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene  
20 chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt,  
25 L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because  
30 there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform

5 multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

10 The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

20 Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Gelman, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelman et al., supra) 25 It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelman et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelman et al., supra) 30 For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO

91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the



present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute  
5 biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of  
10 "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions  
15 of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from  
20 extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or  
25 surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an  
30 identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-

radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for  
5 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or  
10 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then  
15 preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is  
25 indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ  
30 preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

### **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldgrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations,

lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and  
5 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene;  
10 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters  
15 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters,  
20 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the  
25 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver,  
30 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular,

fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph  
5 fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated  
10 cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20  
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

20 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the  
25 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

30 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP



starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),  
dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine  
5 (DOPE) can be used in various combinations to make conventional liposomes, with or  
without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be  
prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas  
into a sonication vial. The sample is placed under a vacuum pump overnight and is  
hydrated the following day with deionized water. The sample is then sonicated for 2  
10 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an  
inverted cup (bath type) probe at the maximum setting while the bath is circulated at  
15EC. Alternatively, negatively charged vesicles can be prepared without sonication  
to produce multilamellar vesicles or by extrusion through nucleopore membranes to  
produce unilamellar vesicles of discrete size. Other methods are known and available  
15 to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar  
vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.  
The various liposome-nucleic acid complexes are prepared using methods well known  
in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983),  
20 which is herein incorporated by reference. For example, MLVs containing nucleic  
acid can be prepared by depositing a thin film of phospholipid on the walls of a glass  
tube and subsequently hydrating with a solution of the material to be encapsulated.  
SUVs are prepared by extended sonication of MLVs to produce a homogeneous  
population of unilamellar liposomes. The material to be entrapped is added to a  
25 suspension of preformed MLVs and then sonicated. When using liposomes containing  
cationic lipids, the dried lipid film is resuspended in an appropriate solution such as  
sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and  
then the preformed liposomes are mixed directly with the DNA. The liposome and  
DNA form a very stable complex due to binding of the positively charged liposomes  
30 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are  
prepared by a number of methods, well known in the art. Commonly used methods  
include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*,

394:483 (1975); Wilson et al., Cell , 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA , 76:145 (1979)); and  
5 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA , 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the  
10 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469  
15 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

20 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis  
25 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-  
30 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any

means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5           The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

10           In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional  
15           mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991);  
20           Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

          Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);  
25           Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and  
30           constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other

varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

5       The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor  
10   factor, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

15       Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

20       Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle  
25   accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium  
phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
30   rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is

administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide  
5 construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include  
10 recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection,  
15 aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present  
20 invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

25 Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of  
30 polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of

the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

## 5 **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological  
10 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

## **Immune Activity**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the  
15 present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B  
20 and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune  
25 system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to  
30 increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells.



Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion  
5 deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the  
10 stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or  
15 conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or  
20 scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate  
25 recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

30 Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following:

autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g., IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendocrinopathies, Purpura (e.g., Henloch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomyopathy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous, degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by

glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-linked agammaglobulinemia (XLA), Bruton's disease, congenital

agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired  
agammaglobulinemia, adult onset agammaglobulinemia, late-onset  
agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient  
hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia,  
5 agammaglobulinemia, common variable immunodeficiency (CVI) (acquired),  
Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non  
X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass  
deficiency (with or without IgA deficiency), antibody deficiency with normal or  
elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa  
10 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM  
immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular  
dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic  
aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia,  
short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof  
15 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase  
deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and  
severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the  
polypeptides or polynucleotides of the invention, and/or agonists thereof include, but  
20 are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and  
fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous  
candidiasis, natural killer cell deficiency (NK), idiopathic CD4<sup>+</sup> T-lymphocytopenia,  
immunodeficiency with predominant T cell defect (unspecified), and unspecified  
immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge  
25 anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated  
by, for example, administering the polypeptides or polynucleotides of the invention,  
or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering  
polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but  
30 are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID,  
autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia,  
Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative

syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or

stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional  
5 diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus (i.e., type 1 diabetes), and allogenic transplant rejection).

10 In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental  
15 allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention,  
20 and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose  
25 inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation  
30 associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced

lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1.).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741).

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an

adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.



As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

As an agent to induce higher affinity antibodies.

5 As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ  
10 transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation  
15 after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides,  
20 antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune  
25 deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from  
30 surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or

agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

5       As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

          As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were  
10       forced to proliferate more rapidly their susceptibility profile would likely change.

          As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

          As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

15       As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

          As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

          As a means of activating T cells.

20       As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

          As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

          As a means of regulating secreted cytokines that are elicited by polypeptides  
25       of the invention.

          Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

          All of the above described applications as they may apply to veterinary  
30       medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or practical application as:

5       A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

10       A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

      An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

15       An inhibitor of graft versus host disease or transplant rejection.

      A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

20       A therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

      A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

      A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

25       An immunosuppressive agent(s).

      Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

30       In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma, rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of  
5 neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including  
10 silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte  
15 infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular  
20 or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections,  
25 and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition  
30 associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL,

recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogenous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogenous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI), X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary

Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g.,

acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

#### **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.



Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to: hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferrably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference).

In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then  
5 be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said  
10 external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the  
15 destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in  
20 the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature  
25 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating  
30 and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and

the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

5           The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

10           By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

          Any amount of the polynucleotides of the present invention may be  
15 administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically  
20 inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

          The present invention is further directed to antibody-based therapies which  
25 involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may  
30 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-

specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,  
5 Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce  
10 apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).  
15 Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins  
20 (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present  
25 invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby  
30 incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells  
5 expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are  
10 useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

15

#### **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

20 Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus  
25 arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

30 Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac

arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.



Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, 5 thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

10 Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or 15 topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

## 20 Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound 25 healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. 30 A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*,

*Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days

after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and

antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within  
5 preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic  
10 response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance.  
15 The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly  
20 after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-  
25 3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide,  
30 antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other

embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided  
5 for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative  
10 diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for  
15 treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

20 Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,  
25 pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for  
30 example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft

rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochelle minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the

invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

5           Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or antagonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic  
10       compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied  
15       after hepatic resections for malignancy, and after neurosurgical operations.

          Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or antagonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may  
20       be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

          The polynucleotides, polypeptides, agonists and/or antagonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive  
25       Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

          Lighter "d group" transition metals include, for example, vanadium,  
30       molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.



Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST";

Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

#### **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic)

leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

**Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentopal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation,

and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet  
5 cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the  
10 invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate  
15 healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat  
20 glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or  
25 agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large  
30 intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel

disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery.

- 5 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various  
10 pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from  
15 smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II  
20 pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,  
25 thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists  
30 of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the

invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

5

### **Neurological Diseases**

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g.,

10 polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients)

15 according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical

20 injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is

25 destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease,

30 Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a

portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture;



(2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor-sensory Neuropathy (Charcot-Marie-Tooth Disease).

### **Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation

and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention  
5 may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of  
10 viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes  
15 Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a  
20 variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox,  
25 hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or  
30 antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention

are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

- 5           Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*,  
10   *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella*  
15   (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, Gonorrhea, Meningococcal), *Neisseria meningitidis*, Pasteurellaceae Infections (e.g., *Actinobacillus*, *Haemophilus* (e.g., *Haemophilus influenza* type B), *Pasteurella*),  
20   *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, *Shigella* spp., Staphylococcal, Meningococcal, Pneumococcal and Streptococcal (e.g., *Streptococcus pneumoniae* and Group B *Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to:  
25   bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy,  
30   Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues

could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

5           Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

10           Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases  
15           that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

            Similarly, nerve and brain tissue could also be regenerated by using a  
20           polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and  
25           stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the  
30           polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as  
5 inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection,  
10 hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can  
15 be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the  
20 present invention could be used as an inhibitor of chemotaxis.

### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules  
25 that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

30 Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology

1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

5            Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially  
10            containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

             The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the  
15            candidate compound results in a signal generated by binding to the polypeptide.

             Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate  
20            activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

             Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or  
25            indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

             Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., *Current Protocols in Immun.*, 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein  
30            polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided

into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition  
5 site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

10 As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein  
15 microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be  
20 employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol.  
25 Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide  
30 sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone



PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled

polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability  
5 of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers.  
10 The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention  
15 includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a  
20 biological activity ; and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are  
25 directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention.  
30 Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional

embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

## 5 **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be  
10 associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic  
15 acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

20 In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic  
25 effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing  
30 containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed

antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of  
5 benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

#### Drug Screening

10 Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the  
15 activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in  
20 solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present  
25 invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex  
30 between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound

form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

20

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix

formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

5           For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of  
10   oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then  
15   ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

          For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription  
20   thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

          In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or  
25   a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard  
30   in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in

the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al.,  
5 *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest.  
10 However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation  
15 may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard  
20 procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at  
25 inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should  
30 include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the

5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

5       The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g.,  
10   for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-  
15   triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

20       The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine,  
25   inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-  
30   isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),



5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,

5 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl  
10 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

15 The oligonucleotide is a 2-0-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are  
20 commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

25 While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published  
30 October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead

ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

5        Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a  
10        ribozyme directed to the polynucleotide of the present invention.  
invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

#### **Other Activities**

15        The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

20        The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

25        The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue  
30        transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

**Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about

the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
5 nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only  
10 A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said  
15 cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the  
20 ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
25 sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human  
30 cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

5 A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
10 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

15 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence  
20 determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic  
25 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
30 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.



Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino  
5 acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
10 at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
15 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino  
20 acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted  
25 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the  
30 amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of

polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in  
5 Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide  
10 molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected  
15 from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above  
25 group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an  
30 amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino

acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5 In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at  
10 least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number  
15 shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide  
20 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

30 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making

an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 6, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 6 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 6. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 6. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a

representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 6

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
2	HMWDB84	64	997408	R23544, AA488816, AA489064, AA872894, AA972544, AA913051, AI383891, AI418155, AI683629, AI798127, AI818208, AI933352, AW008595, AW024683, AW150924
3	HNTEO78	13	898200	W23661, AA031909, AA032010, AA587374, AA909360, AA910436, AI244855, AI283238, AI359648, AI421774, AI219587, AI220016
7	HLQEM64	17	897823	R80991, AA223534, AI206292
9	HOEEK12	19	897860	AA025494, AA025810, AA281207, AA281110, AA583008, AA573525, AA575895, AA766389, AA805511, AA862506, AA886103, AA903796, AA910259, AA247875, AA436439, AA481382, AA670356, AA707020, AA907598, AI090351, AI300932, AI201989, AI474935, AI571768, AI139120, AI625333, AI183990, AI193702, AI216895, AI217445, AI243103, AI669935
12	HFKKS66	22	897819	R27630, AA101419, AA237012, AA251103, AA251668, AA281473, AA404990, AA454923, AA568570, AA577414, AA579585, AA749330, AA766073, AA767545, AA814285, AA887846, AA977236, AA644151, AA723179, AA843499, AA885379, AA918582, AI073442, AI081117, AI091024, AA699331, AI270258, AI270269, AI341384, AI370244, AI198390, AI380887, AI382537, AI400803, AI475113, AI498786, AI142821, AI148458, AI188199, AI655439, AI538105
13	HFVJP07	23	897925	R92968, H67099, H80588, N55428, N55496, N68280, N76801, N80976, AI087961, AI148629
14	HTEAM34	24	898364	AA398805, AA435707, AI015821, AA693501, AI203905
16	HMADJ14	26	1099342	AI268407, AI831182, AW450309
16	HMADJ14	68	889659	AI268407
21	HFKIA71	72	900364	T70514, R25870, R73414, H01285, H19477, H19559, N33086, N44657, W03362, W17078, W95610, W95611, AA062594, AA076613, AA076614, AA464409, AA492284, AA508134, AA548685, AA826756, AA908169, AA922967, F19340, D81646, W30716, N90851, AA642347, AA284973, AA293334, AA401715, F20697, AA476287, AA455525, AA434038, AA434103, AA776502, AA779561, D20196, AI284573, AI382533, AI554787, AI479221, AI480421, AI184356, AI203707, AI266745, AI598276,

				AI337934, AI350693, AI589151
22	HOSNU69	32	898152	AA558031, AA888485, AI273419
27	HAVVG36	37	897944	N40203, AA132065, C21544, Z25204, AI222332
32	HELHN47	75	726157	H16917, R99750, R99927, W37841, AA058809, AA262900
36	HLHDL42	46	896650	AA459527, AA493655, AA525222, AA291423, AA292224, AA459296, AA477820, AA477819, AA482607, AA634679, AA434062, AI093119, AI273801, AI276354, AI301537, AI189904, AI654014, AI537880, AI587292
36	HAPQU71	76	864781	AA459527, AA525222, AA459296, AA477819, AA482434, AA482607, AA634679, AA434062, AA781487, AI276354, AI301537
36	HAPQU71	77	752580	AA459527
43	HSYBM41	79	901947	T90427, R25979, R26783, R27189, R27188, R35254, R50925, R70863, R74267, H02216, H06669, H06670, H40092, H40369, H41780, H51292, H51301, H51882, H51894, H61928, N23038, N28700, N33859, N68631, W01548, AA005325, AA027882, AA040832, AA043243, AA043346, AA043573, AA044655, AA148797, AA148528, AA150665, AA223940, AA224086, AA576520, AA665203, AA769018, AA809447, AA810023, AA811441, AA878010, AA886545, AA907519, AA916876, D45317, D45319, N56152, N56519, AA653886, AA218729, AA393565, AA446581, AA446708, AA450355, AA450354, AA453407, AA629981, AA779651, AA779771, AI016461, AI038677, AI095720, D20813, Z38274, Z42207, Z42332, Z42532, Z45060, F01736, F02049, F05255, F13593, AI146571, AI281124, AI358558, AI361131, AI371687, AI494243, AI566474, AI570091, AI192128, AI204438, AI207854
44	HLQGP82	54	898035	R00502, H38743, H85650, H86520, N77865, W00857, AA046738, AA887249, AA663549, T16152
44	HSSDG41	80	425964	T96009, R00502, R48771, R48874, R51102, R52265, R52264, R53399, R53964, R53993, R54847, R81531, R81532, R82184, R82229, H17906, H17907, H38339, H38661, H38743, R93136, R94341, H49045, H49474, H53071, H53175, H62728, H62814, H64497, H69648, H70495, H72255, H77464, H77465, H85650, H86520, H93532, H93772, H93993, H93994, N25894, N30173, N40819, N47783, N54928, N63934, N64034, N67042, N69437, N77865, N98260, W03262, W00857, W69452, W69460, W69536, W69544, AA007372, AA044074, AA044185, AA046738, AA088219, AA088640, AA149582, AA151798, AA158770, AA188377, AA215582, AA215768, AA255719, AA262681
48	HTXKF95	58	891275	AA742405, AA814605, AA831751, AA917582, C01813, AA775165, AI341301, AI418901, AI635420
48	HTXKF95	81	834438	AA742405, AA814605, AA831751, AA917582,

				C01813
51	HAPQT56	82	902207	T53693, T53694, R23643, R35066, W87494, AA533443, AA594172, AA603928, AA614344, AA617718, AA569858, AA740560, AA746624, AA804991, AA804997, AA829811, AA862333, AA864826, AA877343, AA902287, AA878942, AA937062, AA936631, AA961830, AA983420, AA991955, AA991995, AA995511, AI005351, AA642608, AA709070, AA779248, AI032697, AI245599, AI264768, AI266613, AI282722, AI289881, AI291076, AI335628, AI340221, AI369678, AI198965, AI190367, AI268176, AI276207, AI291890, AI312642, AI351218



Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.  
 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being  
 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.  
 30 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey

Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

10 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lacmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

25 The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5            Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10          The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15          These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20          SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is
- 25          1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30          the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The  
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
30 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

**Example 6: Purification of a Polypeptide from an Inclusion Body**

5       The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

10       Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15       The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20       The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

25       Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

30       To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive



Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL  
20 assays.

### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

#### **Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a  
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the  
30 plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription,  
5 translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including  
10 the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in  
15 Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment  
20 then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a  
25 commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified  
30 by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug  
5 of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded  
10 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,  
15 as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page  
20 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are  
25 harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the  
30 medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added.

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
5 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
10 mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
15 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
20 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

25 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
30 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused

protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
```

GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 **Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred  
10 method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal  
15 antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more  
20 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

25 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as  
30 described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.



Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with  
5 this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-  
10 specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using  
15 enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use  
20 "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et  
25 al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

##### **30 Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130

mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ;  
 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of  
 NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  
 $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 5 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic  
 Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of  
 Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of  
 Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-  
 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 10 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-  
 2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0  
 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-  
 $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-  
 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 15 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22  
 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-  
 Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of  
 Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of  
 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319  
 20 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na  
 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;  
 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of  
 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin  
 25 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)  
 with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L  
 DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for  
 endotoxin assay in 15ml polystyrene conical.

30 The transfection reaction is terminated, preferably by tag-teaming, at the end  
 of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
5 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
10 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and  
15 proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors  
20 called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at  
25 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,  
30 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>			<u>STATS</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
 25 TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGGCAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol  
 30 acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

#### **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.



Jurkat T-cells are lymphoblastic CD4<sup>+</sup> Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1-ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

- 5           Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10           These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example  
15   11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20   **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the  
25   EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).  
30   The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5            5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)  
             5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the  
10 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and  
15 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is  
20 done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine  
25 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640  
30 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200  $\mu$ l of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50  $\mu$ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ $\mu$ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### 10 **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:8), 18 bp of sequence

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

5 The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

10 PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

20

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

25 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

30 Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

**Example 17: Assay for SEAP Activity**

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

15 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for



20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four  
5 times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.  
10 The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

15 For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4  
20 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

25 **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth  
30 factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is  
5 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after  
10 detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

15 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for  
20 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>,  
25 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

30 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for  
5 one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
10 tyrosine kinase activity.

**Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine  
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,  
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are  
25 then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at  
30 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

5           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
10       procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15       **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
20       is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

          PCR products are then sequenced using primers labeled at their 5' end with T4  
25       polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

30       PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenin deoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

#### **Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials



(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,  
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped  
10 Therapeutics of the invention (see generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang  
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the  
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (see Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically  
30 acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.

5 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten  
15 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar  
20 alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or  
25 stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a  
30 stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5       The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use  
10       or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

      The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus  
15       deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,  
20       Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,  
25       whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic  
30       mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not  
5 limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are  
10 administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

15 In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),  
20 OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF),  
25 and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International  
30 Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment,

5 Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat

10 or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

15 ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

20 Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered

25 with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin,

30 beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,

erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be  
5 administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in  
10 combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific  
15 embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the  
20 Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

25 In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives,  
30 arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

5           In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-  
10 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl  
15 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and  
20 etoposide).

          In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with  
25 Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

          In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered  
30 with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered



with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,  
5 radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising  
10 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the  
15 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
20 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

25 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

30 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5           The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the  
10       packaging cells are now referred to as producer cells).

          Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is  
15       removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been  
20       efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

          The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25       **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

          Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent  
30       NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
10 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the  
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
25 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but  
30 the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
5 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a  
10 patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the  
15 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in  
20 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg



body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
5 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
10 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
15 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
20 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

25 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
30 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper

dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

5       The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are  
10       used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear  
15       microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic  
20       stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-  
25       mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
30       enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of  
5 heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of  
10 interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in  
15 ameliorating such diseases, disorders, and/or conditions.

#### **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*,  
20 see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding  
25 regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination,  
30 results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5           In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10   limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15   e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20   expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

          Alternatively, the cells can be incorporated into a matrix and implanted in the  
25   body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30           When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

### 10 **Example 31: Production of an Antibody**

#### a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line

(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which  
5 secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In  
10 accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention.  
15 Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells  
20 producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO  
25 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### b) Isolation Of Antibody Fragments Directed

polypeptide(s) of the invention From A Library Of scFvs

30 Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to



stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

### **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective  
5 ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the  
10 detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the  
15 polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as  
20 IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

25 Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The  
30 positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-  
5 arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell  
10 representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

15 Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

### **Example 33: T Cell Proliferation Assay**

#### **Proliferation assay for Resting PBLs.**

25 A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of <sup>3</sup>H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral  
30 blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.5 microcuries of <sup>3</sup>H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and  
5 incorporation of <sup>3</sup>H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood  
10 lymphocytes) is measured by the up-take of <sup>3</sup>H-thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the  
15 plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x10<sup>4</sup> cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T  
20 supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (\*), IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN)  
25 at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of <sup>3</sup>H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of <sup>3</sup>H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

30 (\*) The amount of the control cytokines IL-2, IFN $\gamma$ , TNF $\alpha$  and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

**Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

5

#### **Proliferation assay for preactivated-resting T cells.**

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve ) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the presence of 2ug/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1%FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of in 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the

control supernatants recombinant human IL-2 at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of  $^3\text{H}$ -thymidine(Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune

responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100  
5 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

10       Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the  
15 antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or  
20 LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25       Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be  
30 screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque



gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively  
5 lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free  
10 medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA  
15 fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is  
20 performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h  
25 and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$   
30 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is

removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the  
5 reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies  
10 to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays**

15 Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1  
20 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron  
25 survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is  
30 being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to

induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays

5 Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic

projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

10 It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyornithine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

30 Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons

would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10 **Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2-5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, 15 Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

20 An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the 25 invention.

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

30 For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was

performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

### **Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

10        Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate  
15        concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1%  
20        FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by  
25        counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


      The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
30        invention.

**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to



test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in**

5 **Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

10 CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500  
15 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in  
20 triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

30

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The

ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the

mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1

min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of

polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- 5 b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- 10 b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

- 15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 20 **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- 25 a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- 30 c) The ischemic muscle tissue is collected after ligation of the femoral

artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

5 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 48: Ischemic Myocardial Disease Model**

10

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

15 a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

20 c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
25 invention.

#### **Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on  
30 neovascularization. The experimental protocol includes:

a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.

c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).

d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention,  
5 within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing**

##### **Models**

15

##### ***A. Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and  
20 reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II  
25 diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin  
30 levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and

microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These  
5 homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

10 Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted  
15 according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of  
20 wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following  
25 wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of  
30 surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically



using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups  
5 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

10 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post  
15 treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

20 Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by  
25 treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit  
30 anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte

growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

#### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness

excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and

histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing

perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules

(CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

10 Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are

aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of  
5 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to  
10 each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  
15  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The  
20 template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell**

#### **Proliferation**

30 This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.



It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL-3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The

experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with  
5 TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide  
10 to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the  
15 inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+  
20 cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

#### 25 **Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

30 Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM.

Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$ ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA.

Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

15

**Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin,

2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 µg/ml hEGF, 5mg/ml insulin, 1µg/ml hFGF, 50mg/ml gentamycin, 50 µg/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains  
5 fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.  
10 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO<sub>2</sub> until day 5.

Transfer 60µl from each well to another labeled 96-well plate, cover with a  
15 plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

20 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of  
25 Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100  $\mu$ l/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

5 Add 100  $\mu$ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses  
10 of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculargenesis, both of the blood  
15 vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in  
20 the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the  
25 eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb  
30 angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the

gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

**Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are

incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with

5 PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in

10 each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-

15 conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated

20 inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a

25 source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

30 Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with



GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days.

- 5 After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

- 10 Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and
- 15 inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

20

**Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

- This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability,
- 25 modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

- 30 Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes,

inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

5 Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is  
10 adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D  
15 Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

20 Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

25 One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous  
modifications and variations of the present invention are possible in light of the above  
30 teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the contents of U.S. applications Serial Nos. 60/152,317 and 60/152,315 are all hereby incorporated by reference in their entirety.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>144</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>02 September 1999</u>	Accession Number <u>PTA-623</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer <u>Virginia Lily</u>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer
---	---

**ATCC Deposit No. PTA-623****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-623****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>144</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution <i>(including postal code and country)</i> <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>02 September 1999</u>	Accession Number <u>PTA-622</u>
C. ADDITIONAL INDICATIONS <i>(leave blank if not applicable)</i> <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <i>(if the indications are not for all designated States)</i>	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). <div style="text-align: right;">Continued on the Attached Pages 2 &amp; 3</div>	
E. SEPARATE FURNISHING OF INDICATIONS <i>(leave blank if not applicable)</i>	
The indications listed below will be submitted to the International Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-622****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.



**ATCC Deposit No.: PTA-622**  
**Page No. 3**

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

## **NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ043PCT	International application No.	UNASSIGNED
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>145</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 September 1999</u>	Accession Number <u>PTA-725</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")     	

<b>For receiving Office use only</b>	<b>For International Bureau use only</b>
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-725****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-725****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>145</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>07 May 1998</u>	Accession Number <u>209852</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p> <p><i>Virginia Lily</i></p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

**ATCC Deposit No. 209852****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 209852****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>145</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>14 November 1997</u>	Accession Number <u>209463</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")     	

For receiving Office use only	
<input checked="" type="checkbox"/>	This sheet was received with the international application
Authorized officer 	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	



**ATCC Deposit No. 209463****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 209463****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>146</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>22 May 1997</u>	Accession Number <u>209076</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer 	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

**ATCC Deposit No. 209076****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 209076****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>146</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 21 September 1999	Accession Number PTA-736
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-736****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-736****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.




Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>148</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>07 June 1999</u>	Accession Number <u>PTA-181</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-181****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-181****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.


**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>148</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>08 April 1999</u>	Accession Number <u>203917</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")          	
<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer 	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer

**ATCC Deposit No. 203917****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 203917****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>149</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 11 August 1999	Accession Number PTA-499
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-499****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.



**ATCC Deposit No.: PTA-499****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.


**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>149</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>24 November 1999</u>	Accession Number <u>PTA-987</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States) <u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")     	
<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer 	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer

**ATCC Deposit No. PTA-987****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-987****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**


The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file referencenumber	PZ043PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>150</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>02 November 1999</u>	Accession Number <u>PTA-909</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")     	

<b>For receiving Office use only</b>	<b>For International Bureau use only</b>
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer 	Authorized officer

**ATCC Deposit No. PTA-909**  
**Page No. 2**

#### **CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

#### **NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

#### **AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

#### **FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-909****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.



3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the  
15 full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

20

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

25 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

30

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

5 (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

10 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

15

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

20 (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

25 22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

30

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 52 Human secreted proteins

<130> PZ043PCT

<140> Unassigned

<141> 2000-08-31

<150> 60/152,317

<151> 1999-09-03

<150> 60/152,315

<151> 1999-09-03

<160> 194

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tccccccaaa	acccaaggac	accctcatga	120
tctcccggac	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	acccccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag	atttccccga	aatctagatt	tccccgaaat	gatttccccg	aaatgatttc	60
cccgaatat	ctgccatctc	aattag				86

<210> 4  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 gcggcaagct ttttgcaaag cctaggc

27

<210> 5  
 <211> 271  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
 aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
 gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
 ttttgagggc ctaggctttt gcaaaaagct t 271

<210> 6  
 <211> 32  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 gcgctcgagg gatgacagcg atagaacccc gg

32

<210> 7  
 <211> 31  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 gcgaagcttc gcgactcccc ggatccgcct c

31

<210> 8  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 ggggactttc cc

12

<210> 9  
 <211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60

caattagtca	gcaaccatag	tcccgccect	aactccgccc	atcccgccecc	taactccgccc	120
cagttccgccc	cattctccgc	cccattggctg	actaattttt	tttattttatg	cagaggccga	180
ggccgcctcg	gcctctgagc	tattccagaa	gtagtgagga	ggcttttttg	gaggccctagg	240
cttttgcaaa	aagctt					256

<210> 11  
 <211> 2219  
 <212> DNA  
 <213> Homo sapiens

<400> 11

ggcacgagct	ccatgagcag	atgaagttaga	cagctttact	cagtatctca	gaccaagaac	60
ttcatctcca	tctccaacta	gctgaaacat	cttccctcct	caacctggaa	aattctctga	120
cttagaaatt	taaacaaaac	cctccctttt	cattgaatct	ccattgtctg	gagtttgctt	180
gttttaattct	agcctgttcc	tccactatgg	gctccctttc	aaactatgcc	ctgcttcaac	240
taacccttac	tgcttttttg	acaattctag	tacaacctca	gcacctgctt	gctccagttt	300
tccggacact	atctatcttg	actaatcagt	ctaattgctg	gttatgtgaa	catctagata	360
atgcagaaca	acccgaacta	gtttttgttc	ctgccagtgc	aagcacctgg	tggacctatt	420
ctggacaatg	gatgtatgaa	aggggtgtgg	atccacaagc	agaagtacag	aatcactcta	480
cttctccta	tcgtaaagtg	acttggcact	gggaagcctc	catggaagct	caaggcttat	540
cctttgctca	agtaagggtta	ttggagggaa	atttttctct	ttgcgtagaa	aataaaaaatg	600
gcagtggacc	cttcctaggt	aatataccta	aacaatactg	taatcaaata	ctatggtttg	660
attctacaga	tggcaccttc	atgccctcta	tagatgttac	aatgaatcc	aggaacgatg	720
atgatgatcc	aagtgtttgc	ctaggcaacta	gacaatgttc	ctgggtttgca	ggttgacaaa	780
accggactcg	gaacagctca	gctgttccct	tgattgggtct	gcccataacc	caagactaca	840
aatgggtaga	tcgaaattct	ggattgacct	ggtcaggtaa	tgacacctgt	ctctatagct	900
gccaaaacca	aaccaaaggc	cttctgtacc	agctatttctg	caacctattt	tgtctcttatg	960
gcctgacaga	ggcacatggg	aaatggagat	gtgcagatgc	cagcataact	aatgacaaag	1020
gtcatgatgg	acaccggacc	cccacctggg	ggctcacagg	ttccaatctg	accttgtctg	1080
tgaacaactc	tggcctcttt	tttttgtgcg	gcaatggggg	gtacaaaagg	tttccacctc	1140
aatggctctg	gcgatgtgga	cttgggtatc	ttgtaccttc	cctcaccaga	tacctcacct	1200
taaatgctag	ccaaattaca	aacctgagat	ccttcattca	taaagtaaca	ccgcatagat	1260
gcaccaagg	agacacagac	aatccacctc	tgtattgcaa	ccccaggac	aattcaacaa	1320
taagggccct	ttttccaagt	ttgggaactt	atgatttaga	aaaggcaatt	ctaaacattt	1380
ccaaagcaat	ggaacaggaa	ttcagtgcga	ctaagcagac	cttgggaagca	caccaatcaa	1440
aagtttagcag	tttagcctct	gcaccccgaa	aggatcatgt	cttggatata	cgcaccacc	1500
aacgacaaac	ggcttgtgga	actgttggca	aacagtgttg	cctctatata	aattattcgg	1560
aagaaataaa	gtctaataata	cagcgtctcc	acgaagcatc	cgagaacctg	aagaatgtac	1620
cgttacttga	ttggcaaggc	atatttgcaa	aagtgggaga	ctgggttcaga	tcattggggct	1680
atgtgctttt	aattgttctt	ttctgcttat	tcactcttct	tttaattctat	gttcgtgtct	1740
ttcgcaaatc	tcgcagatcc	cttaactccc	aacctctgaa	cctagcctta	tctccacagc	1800
aatcagcaca	gctccttgct	agtgaacttc	catgtcaagt	ttcaaataagg	gcaatgaagg	1860
gactaacaac	ccatcaatat	gacacaagtc	tactttgaga	atatctgaac	aaacagcagc	1920
tgcagacaaa	aagccttagc	taaactttga	tgagtaaagc	aggtcttacc	gagaattcag	1980
ctgccaaaac	cctcctctga	gtgttccctc	tataagggca	cttagcacta	ggacctccca	2040
aggtattgta	aataagcctt	atcagaactt	tttgtagtct	cattctgaag	ccttaagaca	2100
cacaccataa	agctgatctg	taaaccttta	ccccttgctg	ttcagagagc	tactctttgt	2160
agtgttcttg	catgcatata	taataaatgt	tttttctatt	gaaaaaaaaa	aaaaaaaaaa	2219

<210> 12  
 <211> 3436  
 <212> DNA  
 <213> Homo sapiens

<400> 12

aattccccggg	tcgacccaag	cgtecgctcg	ctgcggcgcc	gactgagcca	ggctgggccc	60
cgtccctgag	tcccagagtc	ggcgcggcgc	ggcaggggca	gccttccacc	acggggagcc	120
cagctgtcag	ccgcctcaca	ggaagatgct	gcgtcggcgg	ggcagccctg	gcattgggtgt	180
gcatgtgggt	gcagccctgg	gagcactgtg	gttctgcctc	acaggagccc	tggaggcca	240
ggtccctgaa	gacccagtgg	tggcactggt	gggcaccgat	gccacctgt	gctgctcctt	300
ctccctgag	cctggcttca	gctgggcaga	gctcaacctc	atctggcagc	tgacagatac	360
caaacagctg	gtgcacagct	ttgctgaggg	ccaggaccag	ggcagcgctt	atgccaaccg	420
cacggccctc	ttcctggacc	tgctggcaca	gggcaacgca	tccctgaggc	tgacagagct	480
gcgtgtggcg	gacgaagggc	agcttcacct	gcttcgtgag	catccgggat	ttcggcagcg	540

ctgccgtcag	cctgcaggtg	gccgctccct	actcgaagcc	cagcatgacc	ctggagccca	600
acaaggacct	gcggccccgg	ggacatgggtg	accatcacgt	gctccagcta	ccagggctac	660
cctgaggetg	aggtgttctg	gcaggatggg	caggggtgtgc	ccctgactgg	caacgtgacc	720
acgtcgcaga	tggccaacga	gcagggtctt	tttgatgtgc	acagcatcct	gcgggtggtg	780
ctgggtgcaa	atggcaccta	cagctgcctg	gtgcgcaacc	ccgtgctgca	gcaggatgcg	840
cacagctctg	tcaccatcac	accccagaga	agccccacag	gagccgtgga	ggtccaggte	900
cctgaggacc	cgggtggtgg	cctagtgggc	accgatgcca	ccctgcactg	ctccttctcc	960
cccagacctg	gcttcagcct	gacacagctc	aacctcatct	ggcagctgac	agacacccaa	1020
cagctgggtg	acagttttac	cgaaggcccg	gaccagggca	gcgcctatgc	caaccgcacg	1080
gccctcttcc	cggacctgct	ggcacaaggc	aatgcatccc	tgaggctgca	gcgcgtgctg	1140
gtggcgagcg	agggcagctt	cacctgcttc	gtgagcatcc	gggatttcgg	cagcgtgccc	1200
gtcagcctgc	aggtggccgc	tcctactcgc	aagcccagca	tgaccttgga	gcccacaacg	1260
gacctggcgg	caggggacac	ggtgaccatc	acgtgtctca	gctaccgggg	ctaccctgag	1320
gctgagggtg	cttggcagga	tgggcagggg	gtgcctctga	ctggcaacgt	gaccacgtcg	1380
cagatggcca	acgagcaggg	cttgtttgat	gtgcacagcg	tcctgcgggt	ggtgctgggt	1440
gcgaatggca	cctacagctg	cctgggtgcgc	aaccccgctg	tgacgcagga	tgcgacgggc	1500
tctgtcacca	tcacagggca	gcctatgaca	tttccccag	aggccctgtg	ggtgaccgtg	1560
gggctctctg	tctgtctcat	tgcactgctg	gtggccctgc	ctttcgtgtg	ctggagaaag	1620
atcaaacaga	gctgtgagga	ggagaatgca	ggagccgagg	accaggatgg	ggaggagaa	1680
ggctccaaga	cagccctgca	gcctctgaaa	cactctgaca	gcaaagaaga	tgatggacaa	1740
gaaatagcct	gacctgagg	accagggagc	tgctacccct	ccctacagct	cctaccctct	1800
ggctgcaatg	gggctgcact	gtgagccctg	cccccaacag	atgcattcct	ctctgacagg	1860
tggtgctcct	ctccaaagga	tgcgatacac	agaccactgt	gcagccttat	ttctccaatg	1920
gacatgatcc	ccaagtcatc	ctgctgcctt	tttttcttat	agacacaatg	aacagaccac	1980
ccacaacctt	agttctctaa	gtcatctctg	ctgctgcctt	atttcacagt	acatacattt	2040
cttagggaca	cagtacactg	accacatcac	cacctctctc	ttccagtgtc	gcgtggacca	2100
tctggctgce	ttttttctcc	aaaagatgca	atattcagac	tgaactgacce	cctgccttat	2160
ttcaccaaag	acacgatgca	tagtcacccc	ggccttggtt	ctccaatggc	cgtgatacac	2220
tagtgatcat	gttcagccct	gcttccacct	gcatagaatc	ttttcttctc	agacagggac	2280
agtgcggcct	caacatctcc	tggagtctag	aagetgttct	ctttccctct	cttctctctc	2340
ttgctctage	cttaatactg	gccttttccc	tccttgcccc	aagtgaagac	agggcactct	2400
gcgccacca	catgcacagc	tgtgcatgga	gacctgcagg	tgacagtgtc	ggaacacgtg	2460
tggttccccc	ctggcccagc	ctcctctgca	gtgcccctct	cccctgcccc	tcctcccccac	2520
ggaagcatgt	gctggtcaca	ctggttctcc	aggggtctgt	gatggggccc	ctgggggtca	2580
gcttctgtcc	ctctgccttc	tcacctcttt	gttcccttct	tttcatgtat	ccattcagtt	2640
gatgtttatt	gagcaactac	agatgtcagc	actgtgttag	gtgctggggg	ccctgctgtg	2700
gaagataaag	ttcctccctc	aaggactccc	catccagctg	ggagacagac	aactaactac	2760
actgcacctt	cgggtttgca	gggggctcct	gcctggctcc	ctgctccaca	cctcctctgt	2820
ggctcaaggg	ttcctggata	cctcaccccc	atccccacca	taattcttac	ccagagcatg	2880
gggttggggc	ggaaacctgg	agagagggac	atagcccttc	gccacggcta	gagaatctgg	2940
tggtgtccaa	aatgtctgtc	caggtgtggg	caggtgggca	ggcaccagg	ccctctggac	3000
ctttcatagc	agcagaaaag	gcagagcctg	gggcagggca	gggccaggaa	tgccttgggg	3060
acaccgaggg	gactgcccc	cacccccacc	atggtgtctat	tctggggctg	gggcagctct	3120
ttcctggctt	gcctctggcc	agctccgggc	ctctggtaga	gtgagacttc	agacgttctg	3180
atgccttccg	gatgtcatct	ctcctgccc	caggaatgga	agatgtgagg	acttctaat	3240
taaatgtggg	actcggaggg	attttgtaaa	ctgggggtat	attttgggga	aaataaatgt	3300
ctttgtaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3360
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3420
aaaaaaaaaa	aaaaaa					3436

<210> 13  
 <211> 734  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (4)  
 <223> n equals a,t,g, or c

<400> 13						
atntagaag	ktaccctgca	gktaccggtc	cggaattccc	gggtcgaccc	acgcgtccgt	60
gccgagcgcg	ccccgtccct	cgcgcgcgat	gtccctctgg	acggcgytcg	gcctggccct	120
gagcttgccg	ctggcgctgg	cgcggagcgg	cgcggagcgc	ggtccaccag	catcagcccc	180
ccgagggggac	ctgatgttcc	tgctggacag	ctcagccagc	gtctctcact	acgagttctc	240

ccgggttcgg	gagtttgtgg	ggcagctggg	ggctccactg	cccctgggca	ccggggccct	300
gcgtgccagt	ctggtgcacg	tgggcagtcg	gccatacacc	gagttcccct	tcggccagca	360
cagctcgggt	gaggctgccc	aggatgcggg	gcgtgcttct	gcccagcgca	tgggtgacac	420
ccacactggc	ctggcgctgg	tctatgccaa	ggaacagctg	tttgctgaag	catcaggtgc	480
ccggccaggg	gtgcccacaa	tgctggtgtg	ggtgacagat	ggcggctcca	gcgaccctgt	540
ggggccccc	atgcaggagc	tcaaggacct	gggcgtcacc	gtgttcattg	tcagcaccgg	600
ccgaggcaac	ttcctggagc	tgtcagccgc	tgcctcagcc	cctgccgaga	agcacctgca	660
ctttgtggac	gtggatgacc	tgcacatcat	tgtccaagag	ctgaggggct	ccattctcga	720
cgcgatgcgg	ccgc					734

&lt;210&gt; 14

&lt;211&gt; 5330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

ccacgcgtcc	ggttaagaaa	tagtcgatca	gttgaggagt	agaggagtga	agaccttggg	60
aagttgccaa	aagcctcgag	aatttctcta	catgtgtgac	atgtttctcag	gactcaactt	120
tttcttttag	gtttgggaag	cccgcagaaa	aatagaaatg	aaggtacata	tgcacacaaa	180
attttgcctc	atttgtttgc	tgacatttat	ttttcatcat	tgcaaccatt	gccatgaaga	240
acatgaccat	ggccctgaag	cgcttcacag	acagcatcgt	ggaatgacag	aattggagcc	300
aagcaaattt	tcaaagcaag	ctgctgaaaa	tgaaaaaaaaa	tactatattg	aaaaactttt	360
tgagcgttat	ggtgaaaatg	gaagattatc	cttttttggg	ttggagaaaac	ttttaacaaa	420
cttgggcctt	ggagagagaa	aagtagttga	gattaatcat	gaggatcttg	gccacgatca	480
tgtttctcat	ttagatattt	tggcagttca	agagggaaaag	catttttact	cacataacca	540
ccagcattcc	cataatcatt	taaattcaga	aaatcaaact	gtgaccagtg	tatccacaaa	600
aagaaaccat	aaatgtgatc	cagagaaaag	gacagttgaa	gtgtctgtaa	aatctgatga	660
taaacatatg	catgaccata	atcaccgcct	acgtcatcac	catcgtttgc	atcatcatct	720
tgatcataac	aacactcacc	attttcataa	tgattccatt	actcccagtg	agcgtgggga	780
gcctagcaat	gaaccttcaa	cagagacca	taaaaccag	gaacaatctg	atgttaaact	840
accgaaagga	aagaggaaga	aaaaagggag	gaaaagtaat	gaaaattctg	agggtattac	900
accaggtttt	ccccctaacc	atgatcaggg	tgaacagtat	gagcataatc	gggtccacaa	960
acctgatcgt	gtacataaacc	cagggtcattc	tcattgtacat	cttccagaac	gtaatgggtca	1020
tgatcctggg	cgtggacacc	aagatcttga	tcctgataat	gaagggtgaac	ttcgacatac	1080
tagaaagaga	gaagcaccac	atgttaaaaa	taatgcaata	atttctttga	gaaaagatct	1140
aaatgaagat	gaccatcatc	atgaatgttt	gaacgtcact	cagttattaa	aatactatgg	1200
tcattgtgce	aactctccca	tctcaactga	tttatttaca	tacctttgcc	ctgcattggt	1260
atatcaaatc	gacagcagac	tttgtattga	gcattttgac	aaacttttag	ttgaagatat	1320
aaataaggat	aaaaacctgg	ttcctgaaga	tgaggcaaat	ataggggcat	cagcctggat	1380
ttgtggtatc	atttctatca	ctgtcattag	cctgctttcc	ttgctaggcg	tgatcttggg	1440
tcctatcatt	aaccaaggat	gcttcaaat	ccttcttaca	ttccttggtg	cattagctgt	1500
aggaacaatg	agtggagacg	cccttcttca	tctactgccc	cattctcagg	gtggacatga	1560
tcacagtcac	caacatgcac	atggggcatgg	acattctcat	ggacatgaat	ctaacaagtt	1620
tttggaagaa	tatgatgctg	tattgaaagg	acttggtgct	ctaggaggca	tttacttgct	1680
atttatcatt	gaacactgca	ttagaatggt	taagcactac	aaacaacaaa	gaggaaaaca	1740
gaaatgggtt	atgaaacaga	acacagaaga	atcaactatt	ggaagaaagc	tttcagatca	1800
caagttaaac	aatacaccag	attctgactg	gcttcaactc	aagcctcttg	ccgggaactga	1860
tgactcgggt	gtttctgaag	atcgacttaa	tgaaactgaa	ctgacagatt	tagaaggcca	1920
acaagaatcc	cctcctaata	attacctttg	tatagaagag	gagaaaaatc	tagaccattc	1980
tcacagtgat	ggattacata	ccattcatga	gcatgatctc	catgctgctg	cacataacca	2040
ccacggcgag	aacaaaactg	tgctgaggaa	gcataatcac	cagtggcacc	acaagcattc	2100
tcatcattcc	catggcccct	gtcattctgg	atccgatctg	aaagaaacag	gaatagctaa	2160
tatagcctgg	atggtgatca	tgggggatgg	catccacaac	ttcagtgatg	ggctcgcaat	2220
tggtgcagct	ttcagtgtcg	gattgacagg	aggaatcagt	acttctatag	ccgtcttctg	2280
tcattgaactg	ccacatgaat	taggagattt	tgcagttctt	cttaaagcag	gcatgactgt	2340
aaagcaagca	attgtataca	acctcctctc	tgccatgatg	gcttacatag	gcatgctcat	2400
aggcacagct	gttggtcagt	atgccaaata	catcacactt	tggatctttg	cagtcaactgc	2460
aggcatgttc	ctctatgtag	ccttggtgga	tatgcttcca	gaaatgttgc	atggtgatgg	2520
tgacaatgaa	gaacatggct	tttgtcctgt	ggggcaattc	atccttcaga	atttaggatt	2580
gctcttttga	tttgccatta	tgctggtgat	tgccctctat	gaagataaaa	ttgtgtttga	2640
catccagttt	tgacctttcc	cagtaatcac	tgttgattac	gagaatgtta	ccatgcagct	2700
ttgcatttgt	tccttgtaact	gtatgcacat	tgctcaaagg	aaagtcaagt	gcttgcaacta	2760
cttacaagtt	tcatagatatt	gagcctaacc	acaagaggct	ggtgcttagt	actgttttcc	2820
ctgcacgtag	gggtctttta	aaaatataaa	gcttgtgata	aagagaggag	aatatgggac	2880
tccatgaacc	agtgttgata	tgtttgatta	agacttttca	caaaataatc	atataaaaca	2940



ctagtctctt	tattagtaga	aacttctgtg	gctatgcaga	aatagagatc	gaacccaaaa	3000
aaatcattta	aactttaaaa	atattttaaa	tggacttttg	ggagacattt	tttgtgtgtt	3060
ttaagaatga	attgtagtgc	tctttaattc	agctacatat	attcatgtgg	tgatagggat	3120
caacttgaca	caactttgaa	actgcataaa	gtagacatag	gaactagagg	aaagctcagg	3180
ctgcattaga	gtatgaattt	agcattggga	aaagccctta	ttcttgaatc	tagagttact	3240
atttttgtat	atatttgcac	agtgtttaaa	cctgcagcct	aaactactga	aattttgtgat	3300
tgtatgtttg	tgtgagcttc	agttttaatga	aagattcata	atgggttctt	gtattattat	3360
aatacttggg	gttgggggtg	tctttctgtt	ttgtttttta	ctttaatttt	gttttgattt	3420
tttttttttt	tttttttttg	gctgggggtg	gtgagggttt	ggagcatgtg	gtctttttta	3480
aaaattgtaa	ccctctagaa	aatatcaaag	aaatgaacca	gacgtgggtt	aaatagtgtg	3540
ttttcctatt	ttaacagtac	caactagtta	attgggaaat	gtaagtcttg	aatgttcaca	3600
ttgctttacc	agtttggcac	tgggaaccaag	agcacatgtc	gtggctggct	acaaggttgt	3660
aaagcagaaa	atcgaagttt	accatgtctg	taatgtgtac	atgaagtgtc	aatttagaac	3720
agttactagg	ataaactcca	ttattgccat	ggctgtcatg	gtaccaagt	gacttggag	3780
atgcatttaa	attactcagc	tgaatacact	tgatcatctt	gtgccaagat	atgctgttgg	3840
tgcttgatag	ggattagtct	tttaggtgcc	ctgttctcct	accataattg	tgaatgattt	3900
gtgagaagtg	caagccatgt	ttatcctgaa	tttttactta	ataatttgta	ttactagtca	3960
tatgcatgta	gctttctgtt	tacatcctat	gccacatggt	cttcatttat	gccaggtaaa	4020
ctgtatttga	actatgtgca	gctagctttg	ttttaatctg	cttggcaacc	agtgtagctg	4080
ctgtaacaat	ctatcttatt	gttcaaatat	ataagagcca	aactcttttc	cattccatct	4140
aaaatgtttt	catttagtag	tcttctttcc	tcctactcta	tgaacttcaa	aacaaaaaca	4200
aaactttgag	agcagcacat	gcatccaggt	atttatagat	tattgccagt	gtcttttctg	4260
tatgctataa	gcaagggagc	ttaggtgtta	tttctttaat	ttatgcttga	atctgaaaaa	4320
ttattttctga	cttactccat	ggcctcctta	taataagtag	aagttttata	tataattaat	4380
tttcagcatt	gggcactgaa	ttaggacagt	cctcatctca	ttgcttggcc	cttcaagcaa	4440
cctagctaaa	aggtgctgat	attttattta	gtactgcca	cttcaagtga	tttagatata	4500
tatctatcta	gatttctgaa	ccaagatata	tttatagttc	acttttgggt	ttttataccc	4560
acggtaggat	tctgcattcc	agcattaaat	ctgcttcatt	ttagaacctt	tataaaaagca	4620
atagctggaa	tatactccca	gtttttaa	aaatgcctga	ttgattttaa	gcaagtaggt	4680
tatgctgaag	tatataaaga	agttttatat	tctctcaaaa	atgggtattat	ctttctttat	4740
ttgctagatt	cttacaatac	ttttaagagg	gctgtaacag	ttgctgctag	tattagggtt	4800
ccacatcatt	ctaattgtata	gtttcaagtc	ttaatagaca	atctgaattc	cactacattt	4860
cttttggctc	caacattcct	tttagcttga	ccagtcctaat	ttaaaatgtg	tttgttggag	4920
gtcattaacg	ttacttgtac	aatgctgtca	ctgtgtgaca	tccatatgaa	tttttggtata	4980
tatcaatcaa	tcaatcaatc	acattgcatt	caatcaatca	gctgtgattg	attgattatg	5040
cttagaaata	ctatagtaac	tagatgcagt	gtgaattttt	tccattaaca	aacaaacaag	5100
tcagtggctt	aaatgtgatt	atggctcctg	aaggtgatcc	ttgctaaaaa	atctaaactt	5160
ttgttttgtt	ttacttgaat	cattttttta	cttaaaaagc	tggaaaaatat	caaagtctgt	5220
tttttttttt	ttcattgtca	acagtgggtg	gtcattttat	gtatgttctt	aatgcttatg	5280
gaactcctcc	aaaataaagt	tactcaaaga	gagcaaaaaa	aaaaaaaaaa		5330

&lt;210&gt; 15

&lt;211&gt; 2753

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ccacgcgtcc	gccccgatttg	aggtgaaacc	atgaagagaa	aatagaatac	ttaataatgc	60
ttttccgcaa	ccgcttcttg	ctgctgctgg	ccctggctgc	gctgctggcc	tttgtgagcc	120
tcagcctgca	gttcttccac	ctgatcccg	tgctgactcc	taagaatgga	atgagtagca	180
agagtgcgaa	gagaatcatg	cccgaacctg	tgacggagcc	ccctgtgaca	gaccccgttt	240
atgaagctct	tttgtactgc	aacatcccca	gcgtggccga	gctgcagcatg	gaaggtcatg	300
ccccgcacat	ttttaagctg	gtctcagctg	atgtgttcat	tccgccacgga	gacaggtaac	360
cactgtatgt	cattcccaaaa	acaaagcgac	cagaaattga	ctgcactctg	gtggctaaca	420
ggaaaccgta	tcacccaaaa	ctggaagctt	tcattagtca	catgtcaaaa	ggatccggag	480
cctctttcga	aagccccctg	aactccttgc	ctcttttacc	aaatcaccca	tttgtgtgaga	540
tgggagagct	cacacagaca	ggagtgtgtg	agcatttgca	gaacggtcag	ctgctgaggg	600
atatctatct	aaagaaacac	aaactcctgc	ccaatgattg	gtctgcagac	cagctctatt	660
tagagaccac	tgggaaaagc	cggaccctac	aaagtgggct	ggccttgctt	tatggctttc	720
tcccagattt	tgactggaag	aagatttatt	tcaggcacca	gccaaagtgcg	ctgttctgct	780
ctggaagctg	ctattgcccc	gtaagaaacc	agtatctgga	aaaggagcag	cgtcgtcagt	840
acctcctacg	tttgaaaaac	agccagcttg	agaagacctc	cggggagatg	gccaaagatc	900
tggatgtccc	caccaagcag	cttagagctg	ccaaccccat	agactccatg	ctctgccact	960
tctgccacaa	tgctcagctt	ccctgtacca	gaaatggctg	tgttgacatg	gagcacttca	1020
aggtaattaa	gacccatcag	atcgaggatg	aaagggaaag	acgggagaag	aaattgtact	1080

tcgggtattc	tctcctgggt	gcccacccca	tcctgaacca	aaccatcggc	cggatgcagc	1140
gtgccaccga	gggcaggaaa	gaagagctct	ttgccctcta	ctctgctcat	gatgtcactc	1200
tgtcaccagt	tctcagtgcc	ttgggccttt	cagaagccag	gttcccaagg	tttgcagcca	1260
ggttgatctt	tgagcttttg	caagacagag	aaaagcccag	tgaacattcc	gtccggattc	1320
tttacaatgg	cgctgatgtc	acattccaca	cctctttctg	ccaagaccac	cacaagcggt	1380
ctcccaagcc	catgtgcccg	cttgaaaact	tggtccgctt	tgtgaaaagg	gacatgtttg	1440
tagccctggg	tggcagtggg	acaaattatt	atgatgcata	tcacaggga	ggattctaaa	1500
aggtatgcag	tacagcagta	tagaatccat	gccaatacag	agcataggga	aagggtccact	1560
tctagttttg	tctgttacta	agggtagaag	attattgctt	tttaaaggct	aaatattgtt	1620
tgtgggaacc	acagatgggt	ggggttgaac	agtaagcaca	ttgctgcaat	gtgggtacgtg	1680
aattgcttgg	tacaaaatgg	ccagttcaca	gaggaataga	aggtacttta	tcatagccag	1740
acttcgctta	gaatgccaga	ataatatagt	tcaagacctg	aagttgccaa	tccaagtttg	1800
cactcttctg	gcttgcccca	tggtactatg	tgatggaacc	agcacacctc	aacccaaaatt	1860
tttttaattct	tagacatttt	tacctgtctc	ttgttaagaa	tttcttgaag	tgatttatct	1920
aaaataaagg	ttggcaaaact	ttttctgtaa	agggccagat	tgtaaatatt	tcagactgtg	1980
tggaccaaaa	ggccacatac	agtctctgtc	ataactactc	aactctgttt	ctgaagcagg	2040
aaagccacca	cagacagtac	ataaaggaat	atgtgtagct	gggttcccag	gccggacaaa	2100
acagatgggtg	accagattttg	gcccctgggc	tgtagtttgc	tgacccctca	tctaaaaaat	2160
aggctatact	acaattgcac	ttccagcact	ttgagaacga	ggtgaatacc	aagaattatt	2220
caatgggttcc	tccagtaact	tctgctagaa	acacagaatt	tggtctgtat	ctgacactag	2280
aacaaaactt	gagggtaaat	aaacattgaa	ttagaatgaa	tcatagaaaa	ctgattagaa	2340
gaatacttga	tgtttatgat	gatttgtgta	caagatagtt	ttaagtatgt	tctaaatatt	2400
tgtctgctgt	agtctattttg	ctgtatatgc	tgaaattttt	gtatgccatt	tagtattttt	2460
atagtttagg	aaaatatattt	ctaagaccag	tttttagatga	ctcttatttc	tgtagtaata	2520
ttcaatttgc	tgtaacctgt	tggtgggttag	aaggaggcta	gaagatgaat	tcaggcactt	2580
tcttccaata	aaactaatta	tggtctcatc	cctttgacaa	aaaaaaaaaa	aaaaaaaaaa	2640
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2700
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa	2753

&lt;210&gt; 16

&lt;211&gt; 1353

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

ccacgcgtcc	gcgctgctgc	cgccgcgcgc	tcgggtcgtg	gagccaggag	cgacgtcacc	60
gcatggcag	gcatcaaagc	tttgattagt	ttgtcctttg	gaggagcaat	cggactgatg	120
tttttgatgc	ttggatgtgc	ccttccaata	tacaacaaat	actggccctt	ctttgttcta	180
tttttttaca	tcctttccacc	tattccatac	tgcatagcaa	gaagattagt	ggatgataca	240
gatgctatga	gtaacgcttg	taaggaactt	gccatctttc	ttacaacggg	cattgtcgtg	300
tcagcttttg	gactccctat	tgtattttgcc	agagcacatc	tgatggggcg	cctacccttc	360
ttcagcaaga	tggaacacgc	tgagtctgaa	ggaagagaaa	cactgacaca	gcagctgcct	420
ctcccagcag	ccgccatgag	aagattgtta	cctgcaagca	gagtgtccac	tcaaccgctg	480
ctgaggctgg	cagacagtgc	tgagtcactt	ctgggcaggc	ctgctctgtg	ggctctagga	540
ttcctgcttt	gccctccctc	tcaggcacaa	tgacaactac	tgctcagtgc	cagacactgc	600
accatgtagg	caacacgtgg	cagtgatgat	tagtcacaaa	atcacattta	tattcattct	660
aatgaaactg	ccattgcaaa	attataactg	agacagtga	agaagtctga	cctaaccaac	720
tccatcttgc	ttctaacctc	caagctgtcc	ttgttcattc	ctgggactca	ttttgggagg	780
aacttagtta	atagcttaca	gtttaaaaca	aagacaatca	cagacctttc	ccaaaacaaa	840
cccccttctt	gcctggaaac	tagactgcct	ttgtaggatt	aacaaattag	ccgaaagatt	900
agaaattatg	gtttaggagt	cacgcagctg	gagatgacaa	gattctgaca	ctcctccaat	960
tgctcctggg	gataacatta	ctattctaa	gcctaacatc	agtgtctgag	atgttttgta	1020
gacctgccc	ttgatggatc	agctgggtact	acccagaccg	ataaactggc	tcgtcttatc	1080
ttgtggcccc	caccaggag	ctgactcaat	gcaagaagac	tgttctgact	ccctatgatt	1140
tcacttccaa	cccaaccaag	cggcactgtc	aactcactgt	cctcccccta	cccaccaa	1200
tatccttaaa	aactcagatc	cccaaatgct	cagggaaact	gattatgatt	accccaaagc	1260
ttggagtaat	aataaaaactg	gcctgtctcc	cgcacagcca	aaaaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa			1353

&lt;210&gt; 17

&lt;211&gt; 1038

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (963)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1025)  
 <223> n equals a,t,g, or c

<400> 17  
 gcaacaagag ccacctctgg gtgraggagg aggtctggcg gatggagatc tacctctccc 60  
 tgggagtgcg ggccctcggc acgttggtccc tgctggccgt gacctcactg ccgtccattg 120  
 caaactcgct caactggagg gagttcagct tcgttcagtc ctactgggc tttgtggccc 180  
 tcgtgctgag cacactgcac acgctcacct acggctggac ccgcgccttc gaggagagcc 240  
 gctacaagtt ctacctgcct cccaccttca cgctcacgct gctgggtgcc tgcgtcgtca 300  
 tcctggccaa agccctgttt ctctgcct gcacagccg cagactcgcc aggatccgga 360  
 gaggtcggga gagggagagc accatcaagt tcacgctgcc cacagaccac gccctggccg 420  
 agaagacgag ccacgtatga ggtgcctgcc ctgggctctg gaccccgggc acacgaggga 480  
 cggtgccctg agcccgtag gttttctttt ctgggtggg caaagtggta taactgtgtg 540  
 caaataggag gtttgaggtc caaatctctg ggactcaaat gtatgcagta ctattcagaa 600  
 tgatatacac acatatgtgt atatgtattt acatatattc cacatatata acaggatttg 660  
 caattataca tagctagcta aaaagttggg tctctgagat ttcaacttgt agatttaaaa 720  
 acaagtgccg tacgttaaga gaagagcaga tcatgctatt gtgacatttg cagagatata 780  
 cacacacttt ttgtacagaa gaggtctgtg ctgtgggtggg ttcgatttat ccctgcccac 840  
 ccaycccca caacttcct tttgctactt cccaaggct cttgcagagc tagggctctg 900  
 aaggggaggg aaggcaacgg ctctgcccag agccatctct gagcatgtga gcagcgctgg 960  
 ctntttcttc cacttgggc agcacaggag gcctgggagg gggaaatcag cagtcggccc 1020  
 tgagntttgc ctggcccc 1038

<210> 18  
 <211> 718  
 <212> DNA  
 <213> Homo sapiens

<400> 18  
 ggcacgagct cagccacgtg accaaccggg tcacatggcc cgcgggacaa catggctgctg 60  
 cccgcactag ggctggtgtg tggacgttgc cctgagctgg gtctcgtcct cttgctgctg 120  
 ctgctctcgc tgctgtgtgg agcggcaggg agccaggagg ccgggaccgg tgcgggcgcg 180  
 gggtcctctg cgggttcttg cggctgcggc acgccccagc ggcctggcgc ccattggcagt 240  
 tcggcagccg ctacccgata ctgcgaggag gctaacgctc cgggccccgt acccgagag 300  
 cggcaactcg cgcactcaaa ggtgctccat cgattcctcc gargcgggk ggggctgctc 360  
 ggttcctgga cggggttggg tagggcaaa caaggcacta gtaggaaggg aagtaaagg 420  
 tataaccaca ccccaaactg agcacctgct gttcccgat gaggagttcc ttctccgtgc 480  
 ctacccgga gactccattt mattgacat tagggagttt ggtttgaggg ttattgttac 540  
 ttctttaccc cctatttctt tctccctcca acctgttctc ttaatgagga tctcataatt 600  
 ttaaggcaat caaattatgg tttaaatac catttcctct cttattaacg gaataaatta 660  
 ggatcctggg tctcagtatc ttcaccaggg ttgttgata cttatctgta gtctcctc 718

<210> 19  
 <211> 1198  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (7)  
 <223> n equals a,t,g, or c

<400> 19  
 ttatagnaag gtacgcctgc aggtaccggg ccggaattcc cgggtcgacc cacgcgtccg 60  
 ggctgaagtc ctgcgagcga cgcgcggcgg ggccggcgaga ggaaacgcgg cgccgggccc 120  
 ggccctggag atgggtcccc gcgcgcgggg ctgggtgttg ctctgctctt ggctccccgc 180  
 gtgcgtcgcg gccacggct tccgtatcca tgattatttg tactttcaag tgctgagtc 240

tggggacatt	cgatacatct	tcacagccac	acctgccaag	gactttggtg	gtatctttca	300
cacaaggtat	gagcagattc	accttgtccc	cgctgaacct	ccagaggcct	gcggggaact	360
cagcaacggt	ttcttcatcc	aggaccagat	tgctctggtg	gagagggggg	gctgctcctt	420
cctctccaag	actcgggtgg	tccaggagca	cggcgggchg	gcgggtgatca	tctctgacaa	480
cgcagttgac	aatgacagct	tctacgtgga	gatgatccag	gacagtaccc	agcgcacagc	540
tgacatcccc	gccctcttcc	tgctcggccg	agacggctac	atgatccgcc	gctctctgga	600
acagcatggg	ctgccaatgg	ccatcatttc	catcccagtc	aatgtcacca	gcataccccc	660
ctttgagctg	ctgcaaccgc	cctggacctt	ctggtagaag	agtttgtccc	acattccagc	720
cataagtga	tctgagctgg	gaaggggaaa	cccagggaatt	ttgctacttg	gaatttggag	780
atagcatctg	gggacaagtg	gagccaggta	gaggaaaagg	gtttgggchg	tgctaggctg	840
aaagggaagc	cacaccactg	gccttccctt	ccccagggcc	cccaagggtg	tctcatgcta	900
caagaagagg	caagagacag	gccccagggc	ttctggctag	aacccgaaac	aaaaggagct	960
gaaggcaggt	ggcctgagag	ccatctgtga	cctgtcacac	tcacctggct	ccagcctccc	1020
ctacccaggg	tctctgcaca	gtgaccttca	cagcagttgt	tgagtggtt	taaagagctg	1080
gtgtttgggg	actcaataaa	ccctcactga	cttttttagca	ataaagcttc	tcatacgggt	1140
taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	gcggccgc	1198

<210> 20  
 <211> 1033  
 <212> DNA  
 <213> Homo sapiens

<400> 20						
ggcacgagct	caagatggat	gcagagtact	ctgggaatga	gttccccagg	tcagaaggag	60
aaagagacca	acatcagaga	cctggaaaagg	aaaggaagag	tgaggaggca	ggacggggca	120
caggtgagct	gggacaagat	gggagactgc	tgtcctccac	cctctccctc	agtagtaaca	180
ggctccttggg	ccagcgccag	aactctccgc	tgccctttca	atggagaatc	acacacagct	240
tccgctggat	ggcccagggtg	ttggcctctg	agctcagcct	ggttgccttt	atcctactat	300
tggtcatggc	cttctccaag	aatggctgg	acctctctag	gagcctcttc	taccagcgct	360
ggcccgtgga	tgtcagcaac	agaatccaca	catcagccca	cgttatgtcc	atggggctcc	420
tgcaactttt	caaateccagg	agctgttctg	acttagagaa	tgaggaaagtc	accttcatct	480
tctccaccct	catgctattc	cccatataca	tctggatctt	cgagttggaa	aggaatgtat	540
ccatccccat	aggctggagc	tatttctattg	gttggctggg	gcttatccta	tacttcacct	600
gcgcgatcct	ttgctacttc	aaccataaaa	gtttctggag	tctgattctg	agccacccca	660
gtggtgccgt	gtccygcagc	agcagtttctg	gctcagtaga	agaatctcca	agggcacaga	720
cgatcacaga	cacccccatc	acccaggagg	gagtcctgga	tcctgagcag	aaggatacac	780
atgtgtaatc	ttttctgaac	tcctggcacc	aagttctgtc	cattcatctg	accccatctc	840
ctcatcctcc	cccagccctt	gaataggttg	gtcctcatca	ttgcaaggaa	tgagaaaggg	900
aggattttgc	actcctctgc	tttctccctg	ccttgattga	gcttgagtga	tgtggaataa	960
attgtccgtc	tcttctttct	caaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaa					1033

<210> 21  
 <211> 1732  
 <212> DNA  
 <213> Homo sapiens

<400> 21						
ggcacgagca	gaggtgatcc	tgtgcaccaa	ggaggtgtcg	gtgggcgcac	ggaagaacgc	60
ttttgcaactg	ctcgtggaga	tgggccatgc	tttcctaagg	tttggtctga	accaggaaga	120
ggccctgcag	tgctacctcg	tcctgatcta	ccctggcctg	gtgggcgcgg	tgaccatggg	180
cagctgcagc	atcctggccc	tgaccacact	ccttttctgag	tttaaaggctc	tgatggggac	240
cagtacagt	gagcagctgc	tggagaatgt	gtgcctgctt	ctggcctccc	gcacccgtga	300
cgtggtaaat	tctgcactgg	gcttcacata	ggtggcagtg	actgtcatgg	acgtggcgca	360
cctggccaaa	catgtgcagc	tggtgatgga	agccattggg	aagctttcag	atgacatgcg	420
gcggcacttc	cgcatagaagc	ttcggaacct	gttcaccaag	ttcatccgca	agtgttgatt	480
tgagctgggtg	aaaaggctgt	tgcccagagg	gtaccacaga	gtcctgggtca	acatccggaa	540
agctgaggcc	cgggccaaaga	ggcaccgagc	cctgagccag	gctgccgtgg	aggaggaaga	600
agaggaggag	gaggaggagg	agcccccccc	gggcaaagggt	gacagcattg	aggagatttt	660
agctgactca	gaggacgagg	aggacacaga	ggagaggaa	agaagccgag	gcaaggagca	720
gcggaagctg	gcacgacaga	ggagccgggc	atggctgaaa	gagggcgggtg	gggacgagcc	780
cctcaacttc	ctggatccca	aggtggccca	acgagtcctg	gccacgcagc	cagggccagc	840
cgggcaggaa	gaaggaccac	agcttcaagg	tgagcgccga	tgcccggtcg	atcataaggg	900
aggaggcaga	cggcaacaag	atggagggaag	aggaagggtg	caaaggcgaa	gatgaagaga	960

tggctgaccc	aatggaagat	gtgatcatca	ggaataaaaa	gcaccagaag	ctcaagcacc	1020
agaaaaggag	tgaggaggag	gagctggaga	tacccccctca	gtaccaagct	ggaggctctg	1080
gcattcatcg	ccctgtggcc	aagaaggcta	tgccctggggc	tgaatacaag	gccaagaaag	1140
caaaagggtga	tgtgaagaag	aaaggccggc	cggatcccta	tgccctacatc	cccctcaaca	1200
gaagcaagct	caaccgcagg	aagaagatga	agctgcaggg	acagttcaaa	ggcctggtga	1260
aggctgcccc	gcgagggttc	cagggtgggac	acaaaaaccg	cagaaaggat	cgctcgaccct	1320
gaggccagg	gcccctgggc	tgccctgtgg	tccagtctga	ggccctttca	gccccaggc	1380
tgccctgcca	ccagctccag	gtgctcaaga	ttctggcaga	gcctggactc	aggatgactt	1440
ggaactaggg	cttggtcttc	agaagtcctg	gattttggaa	actccaaatg	gaatcacccct	1500
tcagagacat	ccctgggtgc	tggagatggg	aatgtggcct	cagtgcctct	gagtaggtgc	1560
catgaggcac	ctttgtcttc	tgcccagagt	ggccatgagc	accagaacag	atgatctcca	1620
tttccgccag	ctgcctgtag	ccacgtggca	tcctgcctgt	ggtctgggtg	agatttactg	1680
tgaccagatg	tagaataaat	gtgtctcatc	ctgcaaaaaa	aaaaaaaaaa	aa	1732

<210> 22  
 <211> 840  
 <212> DNA  
 <213> Homo sapiens

<400> 22						
gtcctaattg	ctcctctcct	cccateccctc	cctcttcacc	tccacacctc	cctctgtctc	60
cgcctgtgtc	tctctctgtc	tctctcagcc	tggtctctct	ggtctcttcc	tctctgcgtc	120
tcaactctctg	cctcctaccc	tgcgtggcgg	cttctccccc	agctccacgg	ccgctctcgg	180
gagcagcgct	acaccaagct	agccgactgg	cagtacatcg	aggagtgcgt	gcaggccgcc	240
agccccatgc	ccctgttcgg	aaatggggac	atcttgctat	ttgaggatgc	caaccgcgcc	300
atgcagactg	gtgtcacccg	gatcatgatt	gcccgtggcg	ccctgctcaa	gccgtggctc	360
ttcacggaga	tcaaggagca	gcggcactgg	gacatctcgt	cgtccgagcg	cctggacatc	420
ctgcgggact	tcaccaacta	cggcctggag	cactggggct	cggacacgca	gggcgtggag	480
aagaccgggc	gctttctgct	cgagtggctg	tccttcctgt	gccggtacgt	gcccgtgggg	540
ctgctggagc	ggctcccaca	gaggatcaac	gagcggccgc	cctactacct	gggcccgcac	600
tacctggaga	cgctgatggc	cagccagaag	gcagccgact	ggatccgcat	cagcgagatg	660
ctccttgggc	cagtgcctcc	cagcttcgcc	ttcttgccga	agcacaaggc	caacgcgtac	720
aagtagcctc	aggctttccc	aggggcaccc	tggggcgagg	agagtacaat	aaattttatt	780
cttttaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	840

<210> 23  
 <211> 940  
 <212> DNA  
 <213> Homo sapiens

<400> 23						
tctaaaggaa	ctaagctgag	ctccccgcgg	tggcggcgct	ctagaactag	tggatcccc	60
gggctgcagg	aattcggcac	gagggctgaa	gacacaggcc	aggcggaatg	aagatgatgg	120
tggctcttgc	catgctgtcc	tcgctcagcc	ggctcctggg	cctcatgagg	ccatcatctc	180
tcaggcaata	cctggactct	gtgcccttgc	caccctgcc	ggagcaacag	ccaaaggcta	240
gtgccgagct	agaccacaag	gcctgctacc	tgtgccacag	cttgctgatg	ctggccgggg	300
tagttgttag	ctgccaggac	atcactccag	accagtgggg	cgagctgcag	ctgctgtgca	360
tgcagttgga	cgccacatc	agcacgcaga	tccgggagag	ccccaggcc	atgcaccgca	420
ccatgctcaa	ggacctggct	acccagacct	acatccgttg	gcaggagctg	ctgaccact	480
gccagcccca	ggcccagtat	ttcagccctc	ggaaagacat	ctaaagggac	agggtcaggg	540
cagcccagg	ctyctggctt	cagcaggaag	tgaacaggct	caggggaactg	gaggaagcga	600
agcatcaagg	ccagaggagg	ccacatgctg	accagcctga	tgaggcaaga	gcctgcccct	660
gccaccgccc	cgacccctct	cctctctgca	agagcctgcc	tctgccaccg	ccccgacccc	720
ctctcctctc	agcaagggat	ggcctctctc	gcctcgccca	cccctcagcc	ctcctcccag	780
ccatctcctc	ttccctaagg	cctctgtctc	catagctctg	gtttccctgg	gcctcagtc	840
tccccaccct	ccttctctctg	tctcctctgc	actaatgtga	ggtttctttg	tgcacattaa	900
agtcttcttt	cagcawmaaa	aaaaaaaaaa	aaactcgagg			940

<210> 24  
 <211> 801  
 <212> DNA  
 <213> Homo sapiens

```

<400> 24
ggcacgaggg aaggtgaggg gagaaaatgc ccctggaaaag ggtaagggc caggacagga      60
atggggcagg aggtgcacgg atcctgctgg gcactgggag cagggggcgg ccaaaggcag      120
tgggtgggca ggtccatgcc tcccctggcc cccagctct gcagggcagt gttcctgggt      180
cctatcttgc tgctgctgca ggtgaagcct ctgaacggga gccagggccc caaagatggg      240
agccagacag agaaaacgcc ctctgcagac cagaatcaag aacagttcga agagcacttt      300
gtggcctcct cagtgggtga gatgtggcag gtggtggaca tggcccagca ggaagaagac      360
cagtcgtcca agacggcagc tggtcacaag cactctttcc acctcagctt ctgctttagt      420
ctggccagtg tcatggtttt ctcaggaggg ccattgaggg ggacattccc aaatatccaa      480
ctctgcttca tgctcactca ctgacctccc ctccctcctg ggctccaggt cacaactccc      540
aaaggagatg caggcatggc tctctgcctc tgatcaccat cactgtatct caaggttcag      600
cagcagagat accagttgcc atcagtgtca actgactgcc tctccaggtt cggagtttca      660
tctcccaggg ccagagacag cagacccaca tccttctctc ccacacctct cctggttttg      720
ttcaggacag cagattagag gcaggaggca atgacaataa aataacgata aaatcctgaa      780
aacaacaaaaa aaaaaaaaaa a

```

```

<210> 25
<211> 1969
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (996)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (1040)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (1058)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (1068)
<223> n equals a,t,g, or c

```

```

<400> 25
ccacgcgtcc gcgcgcggag ggcgcctggt gcagcatggg cggccccgcg gcttgggcgc      60
tgctctgect cgggctcctg ctcccgggag gcggcgctgc gtggagcatc ggggcagctc      120
cgttctccgg acgcaggaaac tgggtgctcct atgtggtgac ccgcaccatc tcatgccatg      180
tgcagaatgg cacctacctt cagcgagtgc tgcagaactg cccctggccc atgagctgtc      240
cggggagcag ctacagaact gtggtgagac ccacatacaa ggtgatgtac aagatagtga      300
ccgcccgtga gtggaggtgc tgccctgggc actcaggagt gagctgcgag gaagttgcag      360
cttctcttgc ctcttggag cccatgtggt cgggcagtag catgcggcgg atggcgcttc      420
ggcccacagc cttctcaggt tgtctcaact gcagcaaagt gtcagagctg acagagcggc      480
tgaaggtgct ggaggccaag atgaccatgc tgactgtcat agagcagcca gtacctccaa      540
caccagctac ccctgaggac cctgccccgc tctgggggtcc cctcctgccc cagggcagcc      600
ccggagatgg aggcctccag gaccaagtcg gtgcttgggg gcttcccggg cccaccggcc      660
ccaagggaga tgccggcagt cggggcccaa tgggggatgag agggccacca ggtccacagg      720
gccccccagg gagccctggc cgggctggag ctgtgggcac ccctggagag aggggacctc      780
ctggggccacc agggcctcct ggccccctg ggccccagc ccctgttggg ccaccccatg      840
cccgatcttc ccagcatgga gacctattgc tgtccaacac cttcactgag accaacaacc      900
actggcccca gggacctact gggcctccag gcctccagg gcccatgggt ccccctgggc      960
ctcctggccc cacaggtgtc cctgggagtc ctggtnacat aggaccccca ggccccactg      1020
gacccaaagg aatctctggn caccaggag agaagggnga gaagaaanga ctgctgtggg      1080
agcctggccc ccaaggtctt gctgggcagc ggggggaacc tggccctaag ggagacctg      1140
gtgagaagag ccactggaac cagagctggg gtctgggcgg gccctgcccg cacaggcacc      1200
ccagcctcc ttcggggcaa gagggcggac atgcaaccaa ctaccgggat cgtggccccc      1260
aggagccggg acgagagagg ctgagggtgg tggcggcccc tgaggcagac caggccaggc      1320
tccccctcct acctggactc ggccagctgc ctccaggag cggccgtcca tatttattaa      1380

```

tgctctcagg	gtcccttctg	ccatctaggc	cttaggggta	agcagggtctc	agtccttgga	1440
ccatgcacat	gtctgaggct	gagcaagggc	tgagaggaga	ggcttgggccc	tcagtttccc	1500
tctgtgaagt	ggggggaggc	aggccttcaa	ggagggatag	aggtacaagg	cttcgtctca	1560
tctgtgtct	gagcatccag	gcccacaggc	actgaggag	tcaggagctg	gggctcggca	1620
catgcagaga	tgacagggca	gggggagctc	ttcctcccc	tccccgacca	aacctcgggg	1680
agccctcctg	tgcccttccc	tccttgttgt	ccagtgtctg	gttccccacc	ccgagggtcag	1740
gctgcccact	cctctgactg	gatcacccgg	ggcttcttgc	ctcagttctt	ccctctgagc	1800
ccccaggccc	tcccgcactc	cagggttggg	atggggacat	ggagagggaag	gggcccgccta	1860
ctcctgcaaa	tgcttgtgac	agatgccagg	aggtagatgt	gtgctggcca	ataaaggccc	1920
ctacctgatt	ccccgcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1969

<210> 26  
 <211> 1364  
 <212> DNA  
 <213> Homo sapiens

<400> 26						
cggcacgagg	cgaagaagaa	tctgaggaaa	cctgctgctt	tcacagagga	aggcatttgc	60
tggttttccc	aaggcaagaa	caatgaaaac	aaagtcatga	ggagttctct	ctacctcaaa	120
tgaaggccgc	agctcctgct	caagctatct	tggcagtcct	agagaacagt	acattctgaa	180
ccacattgac	gcagggagca	tgggtatctg	gacctcaggc	actgatctct	tcctaagtct	240
ttgggagatt	tacgtgtctc	caagaagccc	cggatggatg	gactttatcc	agcatttggg	300
agtttgcgtg	ttgggtgctc	ttatttcagt	gggcctcctg	tctgtggccg	cctgctgggt	360
tctgccatca	atcatagcgg	ccgctgcctc	ctggattatc	acgtgtgttc	tgctgtgttg	420
ctccaagcat	gcacgatgtt	ttattcttct	tgtctttctc	tcttgtggcc	tgctgtgaagg	480
caggaatgct	ttgattgcag	ctggcacagg	gatcgtcatc	ttgggacacg	tagaaaatat	540
ttttcacac	tttaaaggct	tcctagatgg	tatgacttgc	aacctaaagg	caaagagctt	600
ttccatacat	tttccacttt	tgaaaaata	tattgaggca	attcagtgga	tttatggcct	660
tgccactcca	ctaagtgtat	ttgatgacct	tgtttcttgg	aaccagaccc	tggcagtcct	720
tcttttcagt	cccagccatg	tcctggaggc	acagctaaat	gacagcaaag	gggaagtcct	780
gagcgtcttg	taccagatgg	caacaaccac	agaggtgttg	tcctccctgg	gtcagaagct	840
acttgccctt	gcagggcctt	cgctcgtcct	gcttggcact	ggcctcttca	tgaagcgatt	900
tttgggccc	tgtggttgga	agtatgaaaa	catctacatc	accagacaat	ttgttcagtt	960
tgatgaaagg	gagagacatc	aacagaggcc	ctgtgtgctc	ccgctgaata	aggaggaaag	1020
gaggaagtat	gtcatcatcc	cgactttctg	gccgactcct	aaagaaagga	aaaacctggg	1080
gctgttttct	ctccccatcc	ttatccatct	ctgcatctgg	gtgctgwttg	cagctgtaga	1140
ttatctgctg	tatcggtcca	ttttctcagt	gagcaagcag	tttcaaagct	tgccagggtt	1200
tgagggttcac	ttgaaactgc	acggagagaa	acaaggaact	caagatatta	tccatgattc	1260
ttcctttaat	atatctgtgt	ttgaacccaa	ctgtatccca	aaacctggc	aagctttgaa	1320
actgcttgct	cactgagaaa	atgagccgat	acagcagata	atct		1364

<210> 27  
 <211> 2371  
 <212> DNA  
 <213> Homo sapiens

<400> 27						
ggcacgagg	ggattacaac	ctggagccct	tcgcgggcct	caccccagag	tacatggaaa	60
tgatcatcca	gtttggcttc	gtcacccctg	ttgtcgctc	cttccccctg	gccccactgt	120
ttgcgctgct	gaacaacatc	atcgagatcc	gcctggacgc	caaaaagttt	gtcactgagc	180
tccgaaggcc	ggtagctgtc	agagccaaag	acatcggaat	ctggtacaat	atcctcagag	240
gcattgggaa	gcttgctgtc	atcatcaatg	ccttcgtgat	ctccttcacg	tctgacttca	300
tcccgcgcct	ggtgtacctc	tacatgtaca	gtaagaacgg	gacctatcac	ggcttcgtca	360
accacaccct	ctcctccttc	aacgtcagtg	acttcagaa	cggcacggcc	cccaatgacc	420
ccctggacct	gggctacgag	gtgcagatct	gcaggtataa	agactaccga	gagccggcgt	480
ggtcggaaaa	caagtacgac	atctccaagg	acttctgggc	cgctcctggc	gcccggctgg	540
cgtttgtcat	cgtcttccag	aacctgggtc	tgttcatgag	cgactttgtg	gactgggtca	600
tcccggacat	ccccaggac	atcagccagc	agatccacaa	ggagaagggtg	ctcatgggtg	660
agctgttcat	gcgggaggag	caagacaagc	agcagctgct	ggaaacctgg	atggagaagg	720
agcggcagaa	ggacgagccg	ccgtgcaacc	accacaacac	caaagcctgc	ccagacagcc	780
tcggcagccc	agccccagc	catgcctacc	acgggggcgt	ccgttagcta	tgccagcggt	840
gctgggcagg	ccagccgggc	atcctgaccg	atgggcaccc	tctcccagg	caggcggtct	900
cccgtcccca	ccagggcccg	gtgggtcctg	ggttttctgc	aaacatggag	gaccttttc	960
tgataggaca	ttttccttct	ttcttctgtg	tttcttctcc	ttgtttttgc	acaaagccat	1020

tatgcagggga	atatTTTTTTa	atctgtagta	ttcaagatga	atcaaaatga	tggtctggtaa	1080
tacggcaata	aggtagcaaa	ggcaggtgct	ttgcagaaag	aatgcttgga	aacttgagtc	1140
tccctagagg	tgaaaagtga	gcagaggccc	ctagaaaccc	tcctctgaat	cctcctaatt	1200
ccttaagata	gatgcaaaat	ggtaagccga	ggcatcgcgc	aaaagctggt	gcgatgcttc	1260
agggaaaaatg	gaaaaccac	gcaagaataa	tgattgattc	cggttccaaa	aggtgtcacc	1320
tacctgtttc	agaaaagtta	gactttccat	cgctttttcc	ttccatcagt	tgagtggctg	1380
agagagaagt	gcctcatccc	tgagccacac	agggggcgtg	ggagcatccc	agttatccct	1440
ggaaagctag	aaggggacag	aggtgtccct	gattaagcag	gaaacagcac	ccttggcgtc	1500
cccagcaggc	tccccactgt	cagccacaca	cctgccccca	tcacaccaag	ccgacctcag	1560
agttgttcat	cttccttatg	ggacaaaacc	ggttgaccag	aaaatgggca	gagagagatg	1620
acctcgggaag	catttccaca	gatggtgtca	gggtttcaag	aagtcttagg	gcttccaggg	1680
gtcccctgga	agcttttagaa	tatttatggg	tttttttttc	aaatatcaat	tatatggtag	1740
attgaggatt	ttttttctgt	agctcaaaag	tggaggaggt	ttattagtta	accaaataac	1800
gttgagagga	attttaaata	ctgttactac	caaagatttt	tattaataaa	ggcttatatt	1860
ttggtaacac	ttctctatat	ttttactcac	aggaatgtca	ctgttggaca	attattttta	1920
aagtgtataa	aaccaagtct	cataaatgat	atgagtgatc	taaatttgca	gcaatgatac	1980
taaacaactc	tctgaaattt	ctcaagcacc	aagagaaaca	tcatttttagc	aaaggccagg	2040
aggaaaaata	gaaataaatt	tgtcttgaag	atctcattga	tgtgatgtta	cattcccttt	2100
aatctgccaa	ctgtgggtcaa	agttcatagg	tgtcgtacat	ttccattatt	tgctaaaatc	2160
atgcaatctg	atgcttctct	ttctcttctg	acagtaagta	gtttgaagtg	ggttttgtat	2220
ataaatactg	tattaaaaat	taggcaatta	ccaaaaatcc	ttttatggaa	accatttttt	2280
taaaaagtga	atgtacacaa	atccacagag	gactgtggct	ggacattcat	ctaaataaat	2340
ttgaatatac	gacaaaaaaa	aaaaaaaaaa	a			2371

<210> 28  
 <211> 867  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (862)  
 <223> n equals a,t,g, or c

<400> 28						
ggcagagct	ctctgccatt	ggccctgtgt	ctatcatgag	gggagagcta	agaaagaaat	60
tctcctagga	agagctcatg	gcccagtaga	tcctagtaat	tattttaatt	agttttttgtt	120
ctgacagctt	gtcaggaagg	gcacagaatg	ggacagagat	aaaccagaca	gtcatttttga	180
tctgctctct	acgggtttttc	aagtcagagg	caattgatgc	ttgtctaatg	catccacaca	240
ctgcatgtct	gactggcgat	gccacgctcc	taagtagttc	tgccatgaaa	cataaaaagac	300
aaaggaaaag	ccgttacaca	tcacacagag	aacatttttcg	gggtcccacag	cggtgtgtggc	360
aggaagctca	ctctcgcgtc	agtattagag	tgtgtgtgtg	ggctctcgggg	atctcgggtgg	420
ctcccatctt	ccttcattgt	tctgaacatc	ctgtattgta	aacctgggt	gggggtgctaa	480
agtgcctgtg	aatcccgatg	tggaaaaaagc	tggagggtgaa	agctcagcat	accatgtatt	540
tacttttaaaa	acagaaaaaa	agacatgtat	ggatatgtct	attttttttt	tattggcaca	600
ttgtattttt	gtgttgactt	gttttttagaa	atgatgtgtc	cacacacgta	cccgtgtctc	660
ttctgcattt	ctgtgtcatg	gttctgtttc	ttaatcacgt	gcggcggtgt	ctaagtgggtg	720
ttaccagtgt	acgcgcagtg	accttggatg	acagtggctc	tttctcacag	cctcccctga	780
gctgtgagaa	acagctttct	ctgtacatat	gcaactccta	ataaaaggca	tatttcttcc	840
tgttaaaaaa	aaaaaaaaaa	aaaaaaa				867

<210> 29  
 <211> 1605  
 <212> DNA  
 <213> Homo sapiens

<400> 29						
cccccggtt	gcaggaattc	ggcagagct	catccatggc	ctctggaacc	ttgtttttct	60
cttctccaac	ctgtccctca	tcttctctat	gccctttgca	tatttcttca	ctgagtctga	120
gggttttct	gggtccagaa	aggtgtctct	gggcccgggtc	tatgagacag	tggtgatgtt	180
gatgtctctc	actctgctgg	tgctagggtat	gggtgtgggtg	gcatacagcca	ttgtggacaa	240
gaacaaggcc	aacagagagt	cactctatga	cttttggggag	tactatctcc	cctacctcta	300
ctcatgcate	tccttccttg	gggttctgct	gctcctgggt	gagtgtacag	gggtctgggag	360
ggaatgggca	gggtccttgg	accagagtaa	ccaggctaga	aggaaaggga	atgggggggca	420



tgtaggggaa	ggggtggaga	gcagggtctg	gcaagtgaact	ggctcttgct	cctacagtgt	480
gtactccact	gggtctcgcc	cgcatgttct	ccgtcactgg	gaagctgcta	gtcaagcccc	540
ggctgctgga	agacctggag	gagcagctgt	actgctcagc	ctttgaggag	gcagccctga	600
cccgcaggat	ctgtaatect	acttcctgct	ggctgccttt	agacatggag	ctgctacaca	660
gacaggctct	ggctctgcag	acacagaggg	tcctgctgga	gaagaggcgg	aaggcttcag	720
cctggcaacg	gaacctgggc	tacccccctg	ctatgctgtg	cttgcctggg	ctgaacggg	780
tgtctgtgct	cattgtggcc	atccacatcc	tggagctgct	catcgatgaa	gctgccatgc	840
cccgaggcat	gcaggtacca	agctgccttc	caccatatcc	tttggggagg	ccttaagaac	900
cagcttgggg	acgacgaagc	agaaagcttg	aggacaattg	ggaagctggg	ttgccggggt	960
agtgcctgatt	gttggggaaa	tgctcacagt	gatactgccc	cactctcagg	tacctcctta	1020
ggccaggctct	ccttctccaa	gctgggctcc	tttgggtgccc	tcattcaggt	ttgtactcat	1080
cttgatctct	tctggaaacc	catcattgcc	tctgttcagc	aaacctgtct	cctggggactc	1140
tagaccgagc	acttcttgga	ctttgtctcc	tttgggactc	tgagcaacgc	tgatgggaag	1200
tggggcagct	tttcatcaac	ctcaggttca	gaaagaagga	aaagacttaa	tttgaaagga	1260
gggctggtgg	ttcagtagaa	tctgatcaga	agaaaaataa	aagaggccag	gtgcagtgcc	1320
tcacacctgt	aatcctagca	ctttggggagg	ctgaggcggg	tagattgctt	gagtttagga	1380
tttcaagacc	agcctgagca	acatgggtgaa	acccggcctc	tacaaaaagt	acaaaaaatt	1440
agccagacgt	ggtggtgcgt	gcttgcatcc	ccagctacgt	gggaggctga	cgtgggaaga	1500
tcgcttaagc	ccagaaggtc	aaggttgacg	tgagctgaaa	tcgcaccact	gcactccagc	1560
ctgggtgaca	aagttagacc	ctgtctcaaa	aaaaaaaaaa	aaaaa		1605

<210> 30  
 <211> 1334  
 <212> DNA  
 <213> Homo sapiens

<400> 30						
ccacgcgtcc	gctctgcaag	ggccacagtg	gcagagcgtg	gaggaggcgt	tccccacat	60
ctactcccac	ggctgtgtcc	tgaaggatgt	ctgcagtgag	tgcaccagct	ttgtggcaga	120
cgtggtgcgt	tccagccgca	agagcgtgga	cgctctcaac	actacgccac	gacgcagtcg	180
ccagacccaa	tccctctaca	tccctaacac	caggactctt	gacttcaagt	gacagcccca	240
ggtggccagg	cctccaggag	gcaccaggca	ggcctgtat	caggctagga	cgctctgagc	300
tgtgcatgta	catatataca	tatatagata	cattttataat	atatacacac	agtctatata	360
tttatataca	ctgtttcctg	gccccagagc	tcattttgggt	tcaggcgcac	ttcaaaaccc	420
tccctggggg	aggctgtttc	ttctcaggat	tccttgccag	ggagggaagg	gagggaacag	480
ggtgggtttt	ctcactgaag	agagaaaagca	gaaggttcta	gatcctggca	cagactgcat	540
cccctgttcc	catgctcttc	tccgtcccca	ggaatgcgaa	cggcagtttc	ccttccccag	600
tggacgtcta	ggtggggaca	gggtatcttg	gctcccagct	ggaccagagt	gccctgcttg	660
cctctgctct	ccctttgtgg	ggactcaggc	agcagaggca	tctgggaagt	ctctgagtag	720
gcagggtcct	cctgggaggc	acccccacct	gtttgaaagg	tctggccagg	cgtggtgggt	780
caggcctgta	attccagcac	tttgggaggc	cgaggaggga	ggatcacctg	aggtcaggag	840
tttgagacca	gcctggccaa	catgatgaaa	tggtgtctct	actgaaaatg	caaaaattag	900
ccaggatatg	tggcaggaac	ctgtaatccc	agctacaggg	gaggctgagg	caggagaatc	960
gcttgaaccc	gggaggtgta	gggtgcagtg	agccgagatt	gcaccactgc	actccagcct	1020
gggcgacaga	gcgagactct	gtctcgaaaa	aaaaaaagg	ccgtgccaa	ctgctccctg	1080
cccttgccct	ttccctttcc	ctgggggtcca	aaccacatgt	gtcctgcctc	tcctggccct	1140
accacattct	ggtgctgtcc	tcactcgccc	ctggcccaga	ggctcctgaa	gatgctgggc	1200
ggtcctggca	cagggaggag	cagctctgta	aatctgtgca	catggccact	cttggcctaa	1260
taaaggaggt	ctcacagtca	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaa					1334

<210> 31  
 <211> 1011  
 <212> DNA  
 <213> Homo sapiens

<400> 31						
ccacgcgtcc	gctttctttg	gaacgagggc	tcttctgtcg	gtgtccctcc	cacccccatg	60
tatgctgcac	tgggttctct	ccttcttctt	cctgctgtcc	tgcccaagaa	ctgagggtct	120
ccccggcctc	tactgccctg	gctgcagtca	gtgcccagg	cgaggaaatg	ggccagggga	180
tccagaccct	gggatccagg	gccctgggct	ggacctcagg	acaggcatgg	aggccacagg	240
ggcccagcag	cccacccttt	cctctcccca	ctgcctcctc	tccttcccta	cactcccagc	300
tcgagccgtc	cagctgcggg	gggatctgag	tatatctagg	gcgggtgggc	gggtagcagt	360
gctgggcctg	tgtcttgagc	ctggaggagg	tctgctcctg	ccgcctctg	ccctgccaga	420

gacagaccca	tgcgctgcct	gcccaccgtg	cccccttgtc	cccatgtcag	gcggaggcgg	480
aaggcccacc	gtgccagagg	ctgggcacca	gccttaaccc	tcactctgct	agcacctcct	540
ccccctcccc	aaggtagcac	atctggctca	ctccccactc	cgtctctgga	gcccaccagg	600
gaaggccctc	atccccctgc	gctactttct	tggggaatgt	gggttccatc	caggattggg	660
ggcctctctg	ctcaccact	ctgcaccag	gacccatgct	ccctgccctc	tggcacagct	720
gcttcctgca	agaaagcaag	tctttggtct	ccctgagaag	ccatgtccct	cgtgctgtct	780
cttgccctgtc	ccacctgtgc	cctgccctcc	agcttggtat	taagtccctg	ggctgcccc	840
ttgggggtgcc	ccccgctccc	aggttcccc	ctggtgtcat	gtcaggcatt	ttgcaaggaa	900
aagccacttg	gggaaagatg	gaaaaggaca	aaaaaaatta	ataaatttcc	attggccctc	960
gggtgagctg	agggtttttg	caaggaaaaa	aaaaaaaaaa	aaaaaaaaaa	a	1011

<210> 32  
 <211> 1308  
 <212> DNA  
 <213> Homo sapiens

<400> 32						
ggcgagagaa	tcacatcatggg	atcatgtaaa	aactagtgtc	acaaatcggt	tctcaagaat	60
gcactgtcct	actgtgcctg	atgaaaaaaa	tcattatgag	aaaagttctg	gttcttcaga	120
agggtcaaagc	aaaacagaat	ctgatttttc	caacctagac	tctgaaaaac	acaaaaaagg	180
acctatggag	actggattgt	ttcctggtag	caatgccact	ttcaggatac	tagagggttg	240
ttgtggagct	ggaaatagtg	tgtttccaat	tttgaacact	ttggagaact	ctccggagtc	300
ctttctgtat	tgttgtgatt	ttgcttctgg	agctgtggag	ctcgtaaagt	cacactcgtc	360
ctacagagca	acccagtgtt	ttgcctttgt	tcattgatga	tgtgatgatg	gcttacctta	420
cccttttcca	gatgggatcc	tggatgtcat	tctccttgtc	tttgtgctct	cttctattca	480
tcctgacagg	acattgttta	tctgaaaatt	tttatgttcg	aggagatggg	accagagcat	540
atcttctttac	aaaaggggaa	gtccacagta	tgttctgcaa	agccagttta	gatgaaaagc	600
aaaatctggg	tgatcgccgc	ttacaagtta	ataggaaaaa	acaagtgaag	atgcaccgag	660
tgtggattca	aggcaaattc	cagaaaccat	tgcaccagac	tcagaatagc	tccaatatgg	720
tatctacact	ccctttcaca	gactgaactt	tgtaacatgt	taaggataca	agccagagga	780
ctgtgctatt	caaggactac	tgtaatgtct	ttgtttctca	aaagacaatg	agaaaaaagg	840
aagagaattt	gtatttctct	ccgttttgtc	atagggtgag	tccttttgtc	attttaagca	900
catgtaagt	gttcagcaca	gtatgccttt	ttctgtgctt	tgaaaacttg	atatgctcaa	960
gcttggttga	atctattaca	tctaaccatt	ttgcttgttc	cttgattttt	ataagcattc	1020
aattaagtta	gtattatgtc	aagtaatttt	gagaaaaatg	aacttgacat	tttttgcaag	1080
taaaaaaaat	tgtttatttg	tttaggctta	gtaaacacag	tcccaaacac	agtcagactc	1140
ttcccatgtg	catctgattg	cagagagaaa	gcacacctta	tttccaggga	aagctacaac	1200
aagcccaagg	tcaawgtgta	ttattttttg	tcttgttgtw	gggtctattt	ctcccaattt	1260
ttttttgaaa	ttcagaggct	catatctgaa	atagaatttt	tagttcct		1308

<210> 33  
 <211> 1434  
 <212> DNA  
 <213> Homo sapiens

<400> 33						
cctgtgctaa	tctctagggg	tacagtgggt	atcaaaaaag	tccacgttaa	tcaagtaatt	60
aaacagtttt	ataattatag	ctgtgataag	ggttgcaaag	aaaggacatg	tgctataaga	120
gcaagtgtct	caaggacctg	ccccacctag	tgttgggggt	ggcccggtgc	gaggcacatg	180
acatggcaca	catgctggga	gcaggagtc	ggccaggact	gcagatgtgg	gtaccatgtg	240
gcctagaatg	ctggctttct	caacttggtc	tgagtggctt	ctcttctccc	cactcccgca	300
gtctgtggga	tgtcctgggc	cccttgagtt	ttattgtgtc	caagacagga	gacccccctc	360
tctgccagat	gggtgctgat	atttctcttc	ccccaccgcg	atcacatcgt	cttctatttc	420
cccagctctg	agcctgcagg	ctcctgaagc	tggaggcttt	ctttccattc	caggctgagg	480
ggaaagtggg	gggtggggat	gggggtttgc	ttctcacttc	ctctgtagac	agcacctcac	540
ttcctgtccc	ccaggctaga	agaaggctaa	aactcttggc	tttctgtgct	cttctttctt	600
cctccctgac	tgttttctct	gaaagcctac	aggccttgaa	ggagcaaggc	agcatcaaag	660
ccagcagctt	atccctgaag	gccctgccga	gctccttacc	ccacccttac	cccgcacaag	720
ggacctggct	cctcagctgc	agtccttttc	tagatgggat	attcttctct	cctgtgccct	780
gcagggggag	ggagtcagag	tcagagggtc	cacccccatt	ttacaggaag	gaaactgagg	840
cccagagggg	tgccagcttc	acctagggtc	acgcgggttg	gtgcatgaa	tctcaggagc	900
agaatcccaa	aagcctgact	cctgtttgtg	atcacaaaca	agagcagagc	ccagtggggg	960
cttgtgggtg	aaccagagct	gttttctcct	cccagcgtag	agctgacagc	ttgggggtgtc	1020
acctctgggc	tctggctgga	tgggtgccac	tagctgagca	ctggagttgc	ttgagtgcag	1080

aaggcatatt	ggctggccag	agcctattct	ttttgtagaa	agaagccagg	agatgggggc	1140
ctgggtgcag	tggctcacgc	ctgtaatccc	agcacttttg	gaggccaagg	tgggtggatc	1200
acaaggtcag	gagatcgaga	ccatcctggc	taacacggtg	aaacaccgtc	tctactaaaa	1260
atacaaaaat	tagccaggca	taatggcacg	cgctgtagt	cccagctact	cgggaggctg	1320
aggcaggaga	atcgcttgaa	cccgggagat	ggaggttgca	gtgagccgag	atcgcgccac	1380
tgccttccag	cctgggcgac	agagcaaaac	tccatctcaa	aaaaaaaaaa	aaaa	1434

<210> 34  
<211> 2184  
<212> DNA  
<213> Homo sapiens

<400> 34						
ggcacgagag	gaaagtggca	gggattggag	gctcctggag	aaagggcaag	gctgaagggtt	60
gtcccatgta	ttttggccag	atattgattat	gtaatcgaga	atcatgagat	aattaagtgt	120
gttcatgtct	ctggagcctt	caaccagctc	ttttaacatc	ttgctcttcc	cagcattcct	180
tagggctctt	ggctgggctc	tgggatggat	gccatgggag	tacctttact	taagctctaa	240
agttaccaat	ggagagactg	ggactcaaag	aggaacttga	ttggacccca	gagaggtgag	300
gggtaagggc	tagaacctca	cacatgctgg	ttttgctgct	gcctggcagg	cccatgggaa	360
gaacttttaga	ggttccaagg	aattggaaaa	gggtcacaaag	atgggtggcc	aaactcccag	420
ctcaggcttg	attcctactg	tcaatgtggg	gatagtggag	aagggggctg	caggaagggc	480
tgagaaaagc	tgagaatgag	aagttataca	ggaggtagct	tggtgggagt	gaaacaaaaa	540
tgagtggttc	atgggcccagc	caggcatcct	gatttccagc	tcacagcagc	aggagcttca	600
gagaggaaga	aggagaggag	gagaaagcca	ggttgatgtt	agtaaaggtc	aaacaatttc	660
aggagcacct	ctgacctccc	tccacacagg	ttttcttacc	ttgactatgc	agagggtggt	720
ccatcttggc	actgaagatg	gaacccctc	ttccatggtc	tggggtgacc	ccatgcctgt	780
aactgaatgt	gctcagatcc	ttggggtgct	gggactgtag	ggggaggatt	tgaagggtgt	840
ggactgtcct	ggctggagac	cactgggtca	ggagaactcc	agtagagggt	ttgggtgctg	900
ggaaccagga	agagtggggg	aaggggcaga	gccaactcca	gaggcgatc	tcctggctga	960
ggacagaggg	tgtattgtcc	aagctggagg	ttgctgtagc	tgggcgggga	gcagctcagc	1020
tcgtctcttc	caaatctctt	ttgggggagg	gtaaggggaag	gcaagccccc	ctttacttgt	1080
ggccctgggg	gctacaatgg	ttgctgagaa	acaaggctta	tttgacaaat	aatgcttccc	1140
aggagcagat	gtgtagctct	ctcacttccc	gagaaaccag	atgctgtgag	ctcgcttagc	1200
acttgaggcg	acgccctcag	cacgaactgg	gaccctagtg	ccttgggatc	cagagtatag	1260
tgcttgattc	tattgagaag	aaacgaggct	aatgtggact	gggagacaca	cgggacctaa	1320
tcagcctcaa	gttagccctt	ttgaagtagg	ttgctgcacc	tgcactttcc	ccctactcgt	1380
ccactagttc	aagattttaca	agacgttgac	aatgagggct	gaccagtcct	ggttccactc	1440
ctgcagctgg	gggctctctc	ggtggaccca	cacttttttt	ttgagacagg	gtcttgctct	1500
gttgcccagg	ctggagtgtg	gtggtgtgat	cacagctcac	tgcagccttg	acctcctggg	1560
ttcaagtgat	ccttccctccc	aagtagctgc	gactatgggc	atacaccacc	atacctggat	1620
aattttttcta	ttttttttgta	gagacagggt	cttgccatgt	tgccctgact	agtctcaaac	1680
ttctaggctc	aagcgattct	cctgcctcat	cctcccaaag	tgctgggatt	acagggtgtg	1740
gcaaccattg	agacaagagt	ctcgctctgt	caccagggcc	ggagtgcagt	ggtgcgatcc	1800
cggctccactg	caacctccac	ttcccgggtt	caagcgattc	ttctgcctca	gcctcctgag	1860
tagctgggac	tacaggtgtg	caccaccatg	cctagctaat	ttttgtattt	ttagtagaga	1920
cggggtttca	ccctatttagc	caggctggtc	tagaactcct	gaccacatga	tctgcccgcc	1980
ttggcctccc	aaagtgtctgg	gattacagct	gtgagccatg	gcacctggcc	acacacgtct	2040
ttttaaat	aaatgaggat	gtggccatat	tacagcccag	gttttctctg	acttttagagt	2100
accttttggg	acatagggcc	ttcctctcta	ccctttctgt	acacagccat	cataaacctc	2160
tttcaacaaa	aaaaaaaaaa	aaaa				2184

<210> 35  
<211> 1296  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (1215)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1295)

<223> n equals a,t,g, or c

<400> 35

ggcacgagca	ggaacccctt	cctgcccccg	ttgccgaggg	agcactgccc	tctgctagga	60
acagctccgt	gttggcctct	ctgtccccac	acactggggc	tgcagggcct	ctccgagact	120
cttcagttca	ggtatcaacc	ctgggctgtc	tcctgggatg	tggggggcgr	atgttctttc	180
cttgccctcc	cagctctctc	ytgcggatcc	ttcactccgg	gtgggtcggc	ctcttctctc	240
tgatcagctc	cagagccccc	tctagttccc	tggcatggaa	acacggcccc	ggtgarctgt	300
ggtggccccg	gargcctctc	cgctcctgca	caggccttgc	ttcctgcggg	tgacgaggtc	360
ctggactctc	tcctgcccag	gcttctgggt	gctttcctta	gttcagcacc	agtgtctctg	420
gtgggcagcg	tctcccccca	ggatccgcag	ctccgggtta	cccgcaggcg	tccatctccg	480
gtatggtgct	gcccttcaact	gatcctgggt	gtattttctgt	ttcctgcttt	cctcatcgcc	540
tcctgtttcg	gttgattcct	tcttttttgc	ggtgcccgtc	tcacagtagc	ttcctgagaa	600
cggggacctg	gcaggtacac	ttcagacctc	ctgtgtctga	aatagtgtcc	tggttctgac	660
ctgcacttga	gtgtcgggtga	ggcctgggca	gggttccggg	tgggagctca	gtttctgtct	720
gagttttctc	ggccccaacc	atggcctgtg	gtggccttca	gggctacaag	gcaaaggacg	780
caaacgaaga	ggcttcacgt	gacaggggtg	tatgtctcag	cagctytgga	ggctggagtc	840
tgagctggca	gcactgacag	ggtcagctct	cctcggaggg	tgctggggaa	ggaacctcct	900
gcctctttcc	ggctccgggg	gcctctggca	cccccggtgt	ccccgggctt	ggagacgcag	960
cactcccatg	tctgcccgtt	ccccggccg	cctcctctgt	gtcattgtct	gttctcttca	1020
tatagggaca	ccagtcacgt	aattggaggt	tcactctact	caagtatgac	gtcaccgtga	1080
tttcaactgat	tttatgtccc	aggccgtatt	ctaacaaggg	cacatcctgt	gttctgggaa	1140
gggctgtctg	ctgggggaaat	actcttcacc	cggctgcaac	ctctcaactgt	agaactgcct	1200
ctgtggagaa	gccnaagggg	catttgccgg	ttctaggagg	caagtaggag	gaggctggga	1260
tccgtgtktc	aggcgggact	ccaggccttg	gcggnc			1296

<210> 36

<211> 1298

<212> DNA

<213> Homo sapiens

<400> 36

ggcacgagct	gagcccagcc	cggcctgcca	tcctggcaag	ccagggcagc	atggaggtag	60
cacagagtgg	cacccagcca	gcgtgaatgc	ataagaatct	gcacgtgaca	cagaagaaag	120
tctcttcatg	aagtaggttt	cactgggtccc	agccaaaacc	tgtggcatgt	ggccctttct	180
gcacctgctg	aacatgccat	tcaccttgac	ccaggtagtg	gcctcaccct	cctcttgtct	240
aaactggaaa	cctcagcatc	ctgaaatgcc	tcctcccca	atccattgca	cacatgtgtg	300
cctgtgtatg	cgtgtgtgtg	cacgtgtatg	aaccagcccc	ccagctgccc	actccattgc	360
ccctaaacag	gccccctcct	ggtgtcacct	ggcacatctc	cactggaagc	caaattggata	420
tttctaaact	gaaatctggg	cccacctcag	aacccttctc	acagttccct	taaagtctct	480
ttcctcattt	acatcaggat	cttcacaaatg	gggacccctg	gtcacctccc	aaccacaaca	540
acgtctcaaa	tgagccgcca	ctgcagaaac	tcattatggc	ccgggcagga	ctggcacatc	600
caagtatctg	accaggctgt	tccatctgcc	aggcagggtc	tgccctctct	ccaccacact	660
gtctaaacccc	tgcatcctca	agaccctact	tagctatggc	cctgtgtgaa	aggctccctc	720
ccatgtaccc	acagccattt	gttctctctc	atgtggccct	aacaggctgg	ggttctctgga	780
gactccatgg	ggagccaggc	atgaagatgg	catataccca	tgtgtcactc	cccagaacgt	840
gagctgcctg	ccctggcacc	atacacaag	ggactgacag	ccccagaatc	ccaaggggtg	900
cacctatgca	tatgggaaa	gcattgtttac	gggtgagaat	ggtccatcgt	tgggcttcag	960
gaggcatctg	acctgacgca	cgcccttctg	actttgtcct	tgtggcctgt	tgaaatgcca	1020
ctcctgcttt	acaaattcac	caactgtttg	atgagtcatt	tccacctcaa	tgagtaccag	1080
gtccttgagg	atggggaaaa	gtaagccacc	actgtggggg	tcctgggctc	ctaggtgcag	1140
aagaggctcc	agaaacaggc	caggctcgtg	gccatgaccc	cacactagcc	ctctggtccc	1200
tcacacgggt	ggattggggg	gctgtgtcac	gggatcttag	gatcttcaag	acaaagaccc	1260
aggacaagaa	cacaagccca	ctcccatctc	tcacaggc			1298

<210> 37

<211> 553

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> n equals a,t,g, or c

<400> 37  
 ttggcaaccc ngctcggatc cctagtaacg gccgccagtg tgctggaatt cggctttcga 60  
 gcggccgccc gggcaggtgt ttttgtttaag gcaaattgtct tcccttaata tccaaatatt 120  
 gctaataaac ggtagaagat gctttggaaa ttaaaattat ctgcgtgttg gtttagactta 180  
 acactgttaa tcttcagcca aatatcacat atggatcaaa ttattttctt ttttggttgtt 240  
 taccctatcc tcaacaacat ttttagttta aattattgta gagatttttt ttgtggtggt 300  
 tattttttat tttgctccaa aataataagg tgcaaagcta ttttatgctt aactgttgct 360  
 ctgtcaaaac agctatgcag tggagttgca tttgatgttc tagagtttga ttacatgcag 420  
 agttgtatat agccaaaact tctcttatca aactctgtta tgtaggcata tttatatata 480  
 cattaaagac tgttgacctc ggccgcgacc acgctaagcc gaattctgca gatatccatc 540  
 acactggcgg ccg 553

<210> 38  
 <211> 601  
 <212> DNA  
 <213> Homo sapiens

<400> 38  
 gctcacacct gctctgccat caccgaggtc tgcgtcacct ttactctcac ctgaatcgct 60  
 gcaaagcccc caatggcctt cctcctccct gtccattcat tctctcccag tggccggcaa 120  
 gccagtgctc atcacatcac tcttcacaga gccctgcgat ggcttcatgg ccatcagagg 180  
 aagcaacact caaggcttga caatgatgac aatgacaagt gacaggtggt tcagcatggc 240  
 ctgggcttcc tgctctctgt cccgtccccc tctaaccccc tcttgcctct gccagcagcc 300  
 tgccactgtg gccttgctat tgcagacaat ctctgtctgc tctgccagc aggccgaccc 360  
 cctctcacc cccagagcct gccgccccty caggcagttc cccgtccctc agagtgcggg 420  
 tctccccac agcccacacg tctatgcatt tgytctgttt cctgtcagtt ctgcgtggca 480  
 gggcgggggac ttctgtycta tttgctgctg tttccccaa tgcctaggac ggtgcctgga 540  
 acatacmaga tgctcaataa atccttgktg aatgaaaata aaaaaaaaaa aaaaaaaact 600  
 c 601

<210> 39  
 <211> 1894  
 <212> DNA  
 <213> Homo sapiens

<400> 39  
 ggcacgagca gtctacctgg aaattgtcac attatacaaa tgtcaacttt tgtgtgtgtg 60  
 tgtgtgtttt gttttgtttt gcggtcagag gcaagggcta aaagaaagca agatcagaga 120  
 aataccaaga ggtgtttact gactaaaggg caaagggatc tatcagttta ccaaagcaag 180  
 ataaatagaa ctgccaatga actttatatt ctgagaagca gtgagcaaag aacgctgcct 240  
 gaacaatgaa agtgttgtct caactttcat atttgctgtt gtctgcatgt aatttgtttc 300  
 cttttacata gaaatatgtg gtattaacag agggatgtga ttagaatacc agcgggaagct 360  
 ctctttgata ggagacacac aggcaggtgc ctaacagcct atggagatca ggacagtttc 420  
 tctccagtaa actcacaaat tgtggggacc atgatctgct taataagtaa aagggaatg 480  
 gggccaagat tacaatgttg aaaacatcca ggcttcccac ctggagtcct ggctcacag 540  
 taataataag aataaagatg tattgagata tatctagacc taactatata aatagacaga 600  
 tagatatata cacatacaca cactgtgcta agatgcttca catgaactcc ctcatctcac 660  
 cctcaaacia ccacagggtg gatggtttat caccgtttta gagataagaa aactccagtt 720  
 agtacgtcac tgaagatcta cacagtgcag tagatgttgt gatagacatt tcttaaaaaat 780  
 attccaatta atcctcagaa cacctgtgag aagtatacta aatatactaa gctccatttt 840  
 atgaatgagg aatcagagtc aaggagacga gataacatgt cccaggtgac ggtattagcg 900  
 gtcatagcag gatttgagcc cagctctgtc tgtcttcaaa actcatgttt aggagactct 960  
 tctgctttcc accaaagccc ttgatttgaa cctttgctct ctccctgaatc cacacttctc 1020  
 ctgaaggagg agcaagggtg agatgggata gggcacagga tggctgactc tctgactgga 1080  
 gggcctaaga aacccccact tgacacacac acagaaaact gtgccctggg tgggggtgtg 1140  
 gggcttcatg agaaaatcaa gtagcaagag agagtcttaa catgcttaga tggcatgtgc 1200  
 ctgttctcct gatttaaatg atgagaaaaa tgagatccag ggcaagggca gtgagatagt 1260  
 gagggtctct tagaatgagt acagccttca gggaccacc ccatgtaccc gtgggatcaa 1320  
 gacgagccag aggtacacct ctaagtaaga acagaaagaa cagaaaaccc ttaaggtttg 1380  
 ttgttggtgt tgtgacagaa tctcgctctg ttgcccaggc tggagagcag tggcacagtc 1440  
 tcggctcact gcaacttctg cctcccaggt tcaagcgatt ctctgcctc accctcccga 1500  
 gtagctggga ttacaggcac ccgccaccat gcctggctaa tttttgtatt ttttaatacag 1560  
 acgaggtttc accatgttgg ccaggctggg ctcaaactcc tgacctcaag tgatccaccc 1620

accccggect	cccaaagtgc	tgggattaca	ggcgtgagcc	accgcacctg	gcctgaaaac	1680
acgtatcata	cttgctatgt	gccagacaca	attctaacca	cttttccaca	gattaactca	1740
gccttcaaac	aatcctaaaa	agtaggtatg	attatttcct	gcattttaca	gccaaagaaa	1800
ctgaagcaca	gagagattaa	gaggacttgt	gcaaggteat	ggagggctat	agtcctacce	1860
tctgaagtaa	gttaaaccct	ctccagaaaa	agcc			1894

&lt;210&gt; 40

&lt;211&gt; 3279

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

ggcacgaggt	tttgaagg	cagaaatggc	agctgagtg	aaaatctttt	acccttctgc	60
cggggggttg	tagaatgttc	tcagtttaag	gctgtgagtg	tcagtggtgc	ttggctgtca	120
ctggacctca	atgagtttac	catcaggtgt	ttaattcagc	accttgcca	agcctccctt	180
tgttcagcac	cttgccagc	gccccactct	gttcagcacc	ttggccagta	cctcccctgg	240
gcaccgtagg	ctgaagactc	tgtagggaga	ctgcattaat	gagcctctgc	cttgtgtctca	300
tgcggaggat	gggctggatt	gatctcctct	tgcctgagtt	gggagctctc	agagtgttcc	360
ttcattttatt	tctgggtggc	ttgagaacaa	agaggtggat	ctttaggact	ctgggacagc	420
tgacatgtgt	gaatatcctg	ggagacagca	gaaagaaaag	ggaatgtagg	ttgaacaaaa	480
gacaattaca	gtttggggag	aagactcttc	aagtaccaga	gaggttggtt	gtcagacaca	540
gtccattcta	aggggttcac	agagacacat	cccggagcct	ggggcacagc	tgaatgcagc	600
accttcccat	cattcctgca	tctcgggggc	ctgcagtcac	cagctgggtg	attgcttgca	660
attcacttac	ccttactttt	gtaacctgag	tttacattta	tagcagtcgt	aggagaggaa	720
gggattcaag	aggaatttga	gacaagggag	agagccttaa	tgtagggctg	gtgttcattgt	780
ttgattggct	tcagcactaa	acttcccaga	tacccccaac	aattctaaca	aatggactga	840
gaagaaaaat	tctaagcctg	agcttttgtgt	gtcttttctt	aagagctgca	aaggaccctg	900
atgctgtggc	tgtaaaaaat	cacaaccacg	acaaggtgtg	ttgggcccacg	aacagccagg	960
ccaaagccac	caccatggag	tcttgtccat	ctctccagtg	ctgtgaaggt	tgtagaatgc	1020
atgccagttc	tgatccctcg	ccaccttgct	gttgtgacat	aaatgagggc	ctctgacttg	1080
ggaaagctgg	gcacaaaaat	cttcattgagc	aataatttctt	tcttaataga	atgttttatt	1140
attcaagtca	agttctagag	tgtttacata	ctattatata	atgtacagtg	ttattttctg	1200
tacttctgaa	taaatgtgca	atattggaaa	taatcctctg	cctccagtat	ttttgttagt	1260
tataaacatc	gcttatttaa	atatgtgtat	tacctacttt	gggatttggg	gtcactagct	1320
ggtaatatata	cattgcggtg	aaagaaagtt	agaaaatcaa	agtgtccagc	acatctccca	1380
ccctacaagg	aaaacacaca	ttgatattag	gacattttcca	atgtcagtc	cagctgacct	1440
caccagcttg	gagtagctcg	tccggctctc	ctgagagctg	tggctcgctgg	cacctagtct	1500
ctccaccacg	gataatggtc	cattcatcta	agacagtgag	aggagccagg	caggacctcc	1560
cttgcatata	agtcactctga	tctgtgtaaa	agaagtcctg	agctcagtg	cctcaagggg	1620
cacatttgga	aaaccagatt	tctcctgtcg	ccacccccag	atcgtcagag	cagggtgcctc	1680
ctttgtggat	cacgataaca	ctgatgtgag	ttgatccagc	catcagcatc	ttcaactata	1740
atagggactt	ccaccaaagc	ccagactttc	tggaccacag	tgagaaagca	aagaaatttt	1800
atctgaggat	agcaggtaaa	catgaggaat	gtgagcccc	tttaattatc	attcccagag	1860
aggaactgaa	atgaaacagc	agtcattgtc	cactgcccc	ttgagctaaa	taattacctc	1920
ctgaagccac	ttgctatatg	ggctctggac	taactgatgc	caagaagcca	taaaaatcca	1980
tacgtgggac	accaaactc	ataccttata	atccaaacct	gtagaaccaa	tcactaacca	2040
atgtcatctc	tgtaaaccag	tgagaattcc	tgtattagcc	actcctgac	acctttgcct	2100
tttttttttt	ttttttttgag	acacagctct	gctctgtccc	ccaggctggg	gtgcgggtggc	2160
gtgaccttgg	ctcactgcaa	cctccacctc	ctgggttcaa	gctattctcc	tgccctcagcc	2220
tcctgagtag	ctgggggttat	aggcatgtgc	caccatgccc	ggctaaattc	tgtattttta	2280
gtagagacag	ggtttcacca	tgttggccag	gctgggtctca	gactcctgac	ctcaaattgat	2340
ccaccacact	cggcctccca	aagtgtctgg	attacaggca	tgaaccactg	tgccctgcccc	2400
ctttgccttt	aagaacctac	tactaacagg	ccaagcagag	cacttcccaa	agcaacctgg	2460
aagtgcgtcc	cggccacggg	cctcaacctt	gggccaata	acctctctat	gttaattttg	2520
tttcagtttc	tttccttagg	tcaaggacag	caacaggtag	caggaagccc	tccctcgctt	2580
cttctgctcc	cagttgcctt	ctgttccggc	tccttcccc	aagcctcctg	gaactgcttt	2640
cgagcacgag	aaaggcataa	ccgtcatgta	tactcctctc	atgaactaaa	cccttgcttg	2700
tgaacatcac	atgtagacaa	tataaagaat	tattctagcc	tgggtaacac	agtgaggccc	2760
cgtctccacc	aaaaataaaa	ataaaaaaat	tagctggatg	tgggtgtcca	cacctgtagt	2820
cccagctccg	caggcattga	ggtggataat	ctgagccctg	gggggagggt	tcagtgaacc	2880
gggtctcacc	actgcactcc	agtctgagta	acagagtaag	actctgtctc	caaaaaataa	2940
aaataataaaa	taataattat	taactagtaa	cagttgggta	cctactaaag	gggtaaacag	3000
gaaaacagga	atagcaaatg	aaagaaacag	ctgtggcttc	cagggtgatg	gtgaacaagg	3060
gtggaaataa	gcactctggg	ggctgcctgc	tggctgaact	ccagggatct	gggcagagtg	3120
tgtgggagtc	ttgggaatat	tcaggattcc	cccaacctta	gtgctgggga	aacaggccag	3180

aggcaggcag	gcctagcagc	tctggagggg	ctgccgttgg	agccgagcaa	ctccctggag	3240
gctgccctga	gaccctcgtc	ctggaagtga	tctctcacc			3279

<210> 41  
 <211> 3095  
 <212> DNA  
 <213> Homo sapiens

<400> 41

ccacgcgtcc	gtccttccgc	agagaacgtg	gccagaagtg	ttgtattagg	aagcaagtaa	60
gaaagaaaag	gaaaaaaaaa	agaaatcttg	catttgacac	atgaaaaagt	aactaaaagc	120
ttgcacggag	atatattaag	cccttgcact	aaaaatgctg	gtactgttta	aattcctccc	180
gttgacttca	agtggcgct	ttttatccgt	aacattgtat	caccgggtgc	accaccagac	240
gtttttcgca	ggagcgaagt	cattctctcc	ggcgtctaca	cttaacttgt	atatttgttc	300
tagccaattt	cagtcacttc	agaaacttta	ctgtggcgta	attccagttc	ttaggtacgc	360
gagcatagag	tgaaaaata	gctgtgattg	ttcttatgta	aaaatcaaag	ctccaatgga	420
agttaatgaa	tacctttgta	ataatggaat	ctatttgccc	tttatttctt	aatcttctgt	480
tttaaactgc	tgctattaaa	aacacaccca	tggtattagg	tttacggaag	ttgagctgtc	540
gttcaagttc	ttggcgctcc	gaaagggtgc	cgtgccatgg	gcttgtgacc	cggtcctgga	600
tacaccagaa	acatcacctt	cttgccacct	aaaagagaat	cgcactcaca	aacgctgtca	660
caaccgtctt	tatgacatca	atctcccttg	ttccggttct	ctttttacaa	aaaagaattt	720
acttcattaa	acaatttccg	tctctagttt	aaacagaagg	tggaaaaaaa	tagaccccgg	780
tctagactca	ttttctccag	tccacattgg	aatgggttta	agaatatcct	cttccaaaca	840
aaacaagacg	atgtgtactt	tggtgtctaag	atgtctaaga	tgaacggttt	aaaactctga	900
ttaccacaat	ttggattttt	ttgttaaaat	caaattgtat	ttcaaactta	ctgtgttaca	960
atattatagt	taaaaagtac	agggagagca	gaagccctga	tctaagaggt	gagtcattgt	1020
cctcatgttg	ctgctaactt	gaattgcaga	agagaaaatc	tcagtgcctt	ctgcctggct	1080
ttttgatgga	gtttgcttaa	cacccttcat	ctttctgttt	ctctccatgt	aactaaatga	1140
cgtttttaaaa	attcagtgct	gaggtgtctg	ggtagcacag	cggttgagcc	tccgattttt	1200
ggtttcaact	caggtcacga	tctcaggggt	atgggacga	gccccacaac	aggctccacg	1260
ctcagccggg	agtgtgctta	agtttctcgc	tctgcccttg	cccttccctt	tccctctgtg	1320
cgtgcacctt	tgcaactctt	ctctcaaaat	aacaaataaa	tctttaaaaa	taaataaata	1380
aaacacagtg	cataccataa	aacattaagt	aatatgcgtt	aggggaagcat	ttgagatcat	1440
gcatagctta	tatatattca	aaaggatttg	ttcacatcag	tacaatagat	agatataaaa	1500
gaagcaattc	ttggagcgtc	tgggtaaaga	aggtagtgtc	ccggctcagc	aggctttccc	1560
gtcaagccac	tgatctccac	ccggctctcc	cgtgttccct	ttcaataact	gagtgcagtc	1620
tatgagcaga	tgctgccttc	tgccacataa	agtatcctta	acttttactt	tgctttgagt	1680
ttaaaccagc	attgaaatgt	aaatcacgtc	ttcctcatgc	atgaaattgt	gaggggaagtc	1740
agagaggttc	tctaagagtt	tatttagcaa	tgaggaaaca	ggacaaagag	gaggtagtcc	1800
catagtgggg	agggtgggag	gcgggtctg	ccgggcagca	ctgggtccag	cgtctccctt	1860
tccctagctt	tctcccaatt	ttcttttagga	aaaatgatgt	catagtgaga	tttccataaa	1920
cagaatgttt	ctaaggttca	ctgtatggac	ccagacccca	gacggttgtc	ttataagcga	1980
acttagaacg	gatgctggga	actaagtact	tgagtgttga	cttgcctcacc	tgcggtggac	2040
agagggacaa	gccagcaagc	ccccatgaag	tgacgggcag	ccccacctgg	gccttgagga	2100
gaccgacgca	ccctctcagc	tgggggtgcag	agaaaggatt	ggtttggggg	atagcagtg	2160
actgtcagaa	gaacttacgg	gacccatttg	taatgtaagc	tatgaatcag	gcttgctgtc	2220
ctgggactga	ggttgtaacc	cgtgaacgac	gcaccaacac	aggcagctga	tgcgtttgct	2280
ttggcttcca	atgtgttaat	ataaaaaatct	agacttggtt	catgaaaaca	ggacatttaa	2340
acattctatg	aatattcttc	aaaaatatatt	ggggaaacct	atgtacacat	ttctgttgga	2400
ctgacacctt	gaaatcaaat	tgttgtgaca	gaggatgtgc	ctatgttcag	cttcagtaaa	2460
tactgccgga	gagatctctg	aatgataaac	agttaacgga	aaatcgcacc	aaaccaggct	2520
gttggaggca	acaaccatt	gggctagttt	ctgggtggcct	gctgaaccac	gcagccaaca	2580
ctgggcttca	gactgcacgg	gactctcttt	gtccacctgt	cctgtgcctg	gccccacacc	2640
aggatgctgg	cgattatcaa	attcacttta	ctgggtgatta	cctttgagca	tatttgcttt	2700
cacaaatcag	ttctgtaact	ttgtgtgcac	tgggctaaat	tttacaaact	aatcattggg	2760
taaaaggaag	tggcctaagg	tccccagctc	tgctgatata	agggcagctg	ctcctttggg	2820
gttccctcgtc	ttccatgggt	gaagcatggg	agtgaggggc	cccatagggg	ggtcagcgat	2880
gccacacttg	ggggctgtcc	ctgctcagct	atgggcagac	ctacttttta	ggtttggttt	2940
gaggtcctca	ccatcaccac	tgctccttatt	caagtaaaact	aagtcctttg	ttatttttaa	3000
attaatgcaa	tgaaattatg	ttttagatca	ttattaagat	tattaaaaat	aaagacaaat	3060
aaaatcatat	atgcatatta	aaaaaaaaaa	aaaaa			3095

<210> 42  
 <211> 2320



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcacgagtt	tgtctcagtt	tgtttaacag	ttggccctaa	gttgaatgca	gtcccagcgg	60
aatctgcctc	aggaggatga	ttgtagtttg	tgttttcaga	gatggtgact	tctggcatgt	120
tagtggtttc	cataaaaaca	ttttcttcca	aggcatttct	tgcagttgtg	tcttttatat	180
tagtggtttc	tataaaatgt	tctgaaggag	cagatacttc	cagaaaagg	ttttcttgag	240
gactcaggtc	tcctaaggat	gaaaaagccc	cttgtgaagg	ggaatttatg	aggctcttcg	300
ctgcagagaa	cggaggcctg	tttgcgagca	tcagtctact	cagataactt	ttctttctga	360
actttggact	ctttttgacc	ttgggtgttc	tgtgggtcat	gcgggagcga	gttttgtgaa	420
agcggatatt	ttttctggaa	tgtgaaattg	gtttagaagc	cttcataatt	gtaactctag	480
cctttgcact	ttctaaaatg	gaaatagtgt	gtgtgtgtgc	tttccatctg	tctctcacct	540
tggttagggc	ttttgcaggg	ctggaggtag	aaggcgcgcc	cttggaagag	ggtgtcagca	600
cagagactgc	tgccttatgc	tcttgggtga	acgaaggctt	ggtgtagatg	gcgtttcccg	660
ctaacttctc	aggccctgc	tgtgtgtgag	gctgttccag	ctcccttggg	gctggactcc	720
cgagcctttt	ttcttcggca	gcgttctcca	cagatgcctg	ggcaccctgt	tccctcctga	780
tgtcttgcct	tcccacctct	ttgaagtgcc	ttttctggat	gctccttggg	cccatgagga	840
ctctattcac	tttttgcctg	ttttggccta	cagtttgaat	ctttgccagg	ctgtttcctg	900
tggttgggag	tttaaatgaac	ggtagtaaca	ttgattccac	atctaggttt	actgctgaga	960
aatatggcaa	atgtaactta	gtgcactgat	aacctcactc	tcgtcatttg	tgtctagctg	1020
ctcactccca	aagcctgaca	agttgatgcc	actgctgtct	gagggctcct	ccggctcaac	1080
agtcagctca	gtgcttgtgt	aattcttccg	ggcttgtaac	gtcttcatga	atgctccttc	1140
tggattccct	acagattctt	cttcagctgt	caaaaaagag	actgctttgc	tcatgaaaga	1200
tgatgggatg	ggatgcatca	gtccatagct	gtacacccca	gtcacacaga	gtaggagtca	1260
gcaaacattt	gagtgccatt	cagagaggag	acacacacac	ccaatcctaa	acctatgaaa	1320
tggcaacaac	aaaaggagaa	aatatatctt	ttgaaaacac	ggccatctac	ttggaacatt	1380
ccatagtgtg	acatagagta	actctgctta	ggattatttc	attgatcccc	aggggtccaat	1440
tgcccagtg	tcagtcaaag	cccaagggtg	aagacaagtg	cttccctgat	gagctgatga	1500
gctggcctct	ctgcagactg	ctccataccc	tgtgctgtcc	tgcctcagat	gcagagagag	1560
cacaaggctc	ccgctctcct	cgtcctcggt	gcgcctgtgt	tcttgcctacc	atcacagctg	1620
aatgcaatga	aaggcggtcc	tctgagagtg	gcaggggtga	gatgctaaag	tggaggcccc	1680
ctcccattgc	tgatagatcc	tcactctggca	tgcgctccac	ctccccattt	ctctgctccc	1740
acatatcgta	gccccatcac	agaagatgcg	acatggaaaa	aagcactgtg	tccaccctag	1800
ttcttaaatt	tgggcaggga	tttgggggtg	atgttaagag	tttttcaa	ttgccagatt	1860
ggatgcctat	gttggttaaat	acacagtgaa	tctctgggtat	gatagcagtt	tctggataaa	1920
cattacttga	ggctcctaaa	tgcagaagg	aaaaagcaac	ttttgtcaga	tgcctacttt	1980
gctttcattt	catctcta	attttggatg	gggaatcagc	caaagcttct	gactgcatga	2040
agggtcaagt	tgccagtgtg	cagctgggtt	tcttttccag	aattaaaagt	attttgggtg	2100
gtggtgaggg	tcagaggaag	aagtaaagat	tgtgagaaag	tggagaagag	atgggcttgg	2160
ggagaaccca	gaattggggc	cagaagacct	ggcactaggg	tacagcactt	agcacctctg	2220
atcttgtttt	tcttcatctg	taaaaggagg	ttacaaaagc	ttttctgccc	acttcttggg	2280
gagaagggaa	taatataatt	ggtaaaaaaa	aaaaaaaaaa			2320

&lt;210&gt; 43

&lt;211&gt; 2407

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

ggcacgagtc	cagaggtctt	caacaggaag	atgccagctg	gcaccactgc	actgtgatgg	60
gggcccctct	ctctgctgac	tctgccgttt	ctccaggcct	ccgctcagtg	atgagaccaa	120
gagatcggag	acaagcatgg	tgtgctgtgt	tctgctgctt	ctccagaaaa	tccctgggac	180
acctttgttc	cagcctgggt	tcctgggctg	ggctcaggaa	agctgccaaa	ttcagtccta	240
tgttgggtcc	aagctgcccc	tgtgctgttt	ctgtcaagcc	aggtgtggac	attccaagtt	300
catatgcgtg	aacaaaagaa	aagaggaacc	cagtggatgt	aacagaaccg	actccagttg	360
aatgtttaga	tttttgctaa	actgttttct	ttttcccttt	tttgcctgtg	tttgcattca	420
cggcagtagt	tagcccaggt	gtggggaaag	agagtgcact	gcatgatagc	gttctgggtga	480
gctgggaagg	acccaccact	gccactgagg	attgttttgg	aagaaaggaa	tatttttatc	540
ttggggacca	gctaagtctc	tgcagtgtgt	tgaatttcca	aatgggttgt	ttatcatttg	600
tttggtttac	caaaaaaag	gcagggaaaa	aaaaaaaaaa	caaccgtatg	agcgcatatg	660
cttgtctgcc	gcaggcacag	aagggtagaa	agccacagca	gggggcagtc	cagcagactc	720
tgactcaact	ttctaggcac	ctagcagaga	aagataagat	caaaagggtg	ttgggttttc	780
ttttaatttt	tattgtagtt	tttttgggtg	ggtgggggaa	gtaaactaga	ctgaagcgat	840
ggattttttt	ttttcttttt	tttcttttagt	gtttttccct	ttgttcttga	acacttttgc	900



cctgcagcct	cagttttgaa	ttcttttagc	aacttggatt	agagggggccc	atatgtcaga	960
agctcccagc	acctcctact	tgggagaaaa	gtgagccatc	tgctgggtcag	gaagtcctcc	1020
agagaggcag	cttttcccac	aatggtggca	ggaaactttg	gggaaagcag	gaatggtgtc	1080
cactgctgcg	gaggaactgc	cttcagagaa	ggtggggctg	gaaaagggtt	agaagcctcc	1140
tagctgggat	tgtctttgtt	tcacctttct	ttaaattaga	attacagaag	cccctgcccc	1200
gtgaacagat	aacaattggt	cttatgctcc	tccctttccc	ccattttttc	ttttgctgtt	1260
ttgttttttg	ttttttgttt	gtttgtttgt	ttttttgaga	cagagtcattg	ctctgtcacc	1320
cgggctggag	tgcagtgggtg	cgatctcagc	tcactgtaac	ctccgcctcc	cgggttcaag	1380
caattatttg	cctcagcctc	ccgagtagct	gggattatag	gcacccgcc	ccatgtctgg	1440
cttttagtag	agacgggggtt	tcaccatctt	ggccaggctg	gtcttggaac	tcctgacctc	1500
gtgagccacc	acgcccagcc	tcttttgctg	tttcattgct	gacagtgttc	aacaatatgc	1560
cccattcttta	tatatcctaa	gaaacactaa	tcctagggtta	ttgctagcca	aaatatTTTT	1620
gtcctgagta	gtgtcactgg	gccaaaagat	agatcaggac	gacagccttt	agttttcctg	1680
aaatcaccag	gtcaggcaca	aggagaaaaag	gttcctggat	actgactaac	ttgggtgggt	1740
ctagccagga	gaaagacagt	aacatgtgtt	ctgtactttc	tgggaagatc	cctgaagcca	1800
tcacagaggc	tcaccaactt	ctgagtcgcc	catctgttgc	tgtgggagtg	tgaacggatc	1860
gctgaaggag	agggagcttt	gctctctcta	ggtgggcaag	tttcttgggc	tctctgtgtt	1920
gcctccctct	ggcttcttcc	tcccgtgccc	tctccccgtg	tgccccaggg	ggatcaggga	1980
tcctcacctt	cctgaggccc	agtgggggag	aatgaacatg	gcttcatcca	ggttaactga	2040
tgctgccatt	tgcccagcct	cttccatccc	agccctgtca	gtgagcccag	gtctggtgca	2100
actgtctgag	gatgctgtga	gtagggaact	ctgggaagtgt	attgggctga	ggtgggattt	2160
tccttcccca	cagtgcactg	agcaatggag	ggtggtgagg	gagccatgct	gctgaattct	2220
ggttggcatt	tccttcattat	gtaaaatggg	gtgttgggta	gggcagactc	tgcttggggt	2280
tggttgtaag	ataaacctgg	aggagaagca	cagttgtccc	attgaattat	ttgagcaaaa	2340
actactgtaa	ataacttttt	tgtcttttgt	caaataaaaat	ttttttttgt	tttttttaaaa	2400
aaaaaaa						2407

&lt;210&gt; 44

&lt;211&gt; 1930

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

ggcacgagca	gaaatgaaaa	attacttgag	tgggatgagt	aggaaaaaaa	gtggtagtgt	60
cattcaattc	cagaggaaga	gatgaattta	atgggtgaggt	tactggcatt	gggactaata	120
tcagggatga	tgtctaatat	tactcaatca	cattcaagta	aaatatcagc	ctttggtatc	180
ttcattggag	cagaacagtt	tcttttagatc	ttcttatttc	tctttcaagc	ttcaacctta	240
aataataggc	aattgtgtag	cagaaaaaac	tttaaaccta	gaagtagaaa	tctataatca	300
aatcctcagc	caacttaaaa	acagtttgtt	gaccttggat	aagtcccata	gccggactgc	360
attctctaaa	ccagcagcta	taacgtttcc	tacctatta	gagtgtgggtg	tgaatgaaaa	420
tgtgaagaat	gcctaaaaaca	gagtcaggcc	ttgaatgcat	tagaaagttt	caggcagcca	480
ctcattccat	cacctgtctt	cactctttct	agtgacctag	ggctacttac	ctgtttttct	540
taatacaccc	caagtctttc	tcttgctctt	ctttgtagac	cagaattatt	cttgtgttca	600
tcaatatgga	ttgagtcaaa	aattttcaag	atctacctga	cttattactt	caaggatcca	660
tcatectctg	gcttccattt	ttttgtattt	ctataggcat	ggattcaaag	gggatattctg	720
actggctcag	gctagatcca	gatgaactcc	tcctacattt	gttgtccatc	ctgggtccaat	780
cagtggcagc	taagggagct	cagtcacttg	tttgaagtgt	gcccagtcaa	ggggctgtgg	840
aaggaagagg	aagttaattc	gagacaggat	tgtgacaggc	agaccaataa	acatgtctgt	900
ttacaatcta	aatattcata	aaattccaat	cccccaaat	ctcccacata	tgtatgtctt	960
tgtattcccc	tgagatagga	agggaggcat	gctcataacc	ccattttaca	gatgggaaga	1020
ataaagtgcc	aggaataactg	gtccctccat	tagggctact	taatgagcca	ctgggtgaaac	1080
aagaaataaa	tccgaattga	gagcttagac	tgcttgggtc	cctgttaaca	attaagactg	1140
caaaaatttc	aaaccatata	gcatgcacaa	taaatactgc	atctgaatca	attgtagaga	1200
caaagacaga	ggcacaggga	gaagacagat	ctatccaagg	tcactcaagt	gaggaaataa	1260
accagcttaa	aatagacttc	tgtctcagca	gcattgtgct	ttcactcctg	ggcaacttcc	1320
tgcttatata	gcaacattaa	tgccagcaag	gaaggaaact	gagggttaaa	tccttggccc	1380
cagccccaga	tagcaataca	gaacccacc	cccgtaatc	agtcaataaa	tagatgtccc	1440
tttcatacaa	gtttcagaaa	acacagttaa	tatacaacca	ctactcacia	attaaataag	1500
ttatcttact	gtaaaggata	taactatttt	attatctttg	caattaaaat	gaaatatgct	1560
aaaggtagaa	gcaatacaaa	acagctgctg	ccagaagtgt	caataaaaaga	tcactactgg	1620
gcacccttat	aactgtggga	ccattaggag	atttaaatgt	cttcttctct	ttgcccacgg	1680
tagggagtga	ggctgcactg	agaaacatca	ctggcatgag	gtctaattgc	ctgccctatg	1740
attaatgttg	ccaagtgaat	tcagaagtgt	tcacagttct	catcctatgg	tccaggctca	1800
tttataaaa	agagcaaagg	gagcccagtg	ctttgagaat	gccaatgcaa	aattataata	1860
attacttatt	acatgatata	gttgttaaa	tattttctgt	gttgttcaaa	aaaaaaaaaa	1920

aaaaactcga

1930

<210> 45  
 <211> 1459  
 <212> DNA  
 <213> Homo sapiens

<400> 45  
 ccacgcgtcc ggactgggtc cttccctctg aagttgaagt attggagtcc atctatctag 60  
 atgaactaca ggtgattaaa ggaaatggca gaacttcacc atgggagatc tacatcactt 120  
 tgcatectgc cactgcagag gaccaggatt cacagtatgt ctgcttcact ctggtgcttc 180  
 aggtcccagc agagtatccc catgagggtgc cacagatctc tatccgaaat ccccgaggac 240  
 tttcagatga acagatccac acgatcttac aggtgctggg ccacgtggcc aaggctgggc 300  
 tgggcactgc catgctgtat gaactcattg agaaagggaa ggaaattctc acagataaca 360  
 acatccctca tggccagtgt gtcactctgc tctatggttt ccaggagaag gaggccttta 420  
 ccaaaacacc ctgttaccac tacttccact gccactgcct tgctcggtag atccagcaca 480  
 tggagcaaga gctgaaggca caaggacagg agcaggaaca ggaacggcag catgctacaa 540  
 ccaaacagaa ggcagtcggg gtgcagtgtc cagtgtgcag agagcccctc gtgtatgatc 600  
 ttgcctcact gaaagcagcc cctgaacccc aacagcccat ggagctgtac cagcccagtg 660  
 cagagagctt gcgccagcaa gaagaacgca agcggctcta ccagaggcag caggagcggg 720  
 ggggaatcat tgaccttgag gctgagcgaa accgatactt catcagcctt cagcagcctc 780  
 ctgcccctgc ggaacctgag tcagctgtag atgtctccaa aggatcccaa ccaccagca 840  
 cccttgccagc agaactatcc acctcaccag ccgtccaatc cactttgcc a cctcctctgc 900  
 ctgtggcgac ccagcacata tgtgagaaga ttccagggac caggtcaa at cagcaaagggt 960  
 tgggcgaaac ccagaaagct atgctagatc ccccgaagcc cagtcgaggt ccctggcgac 1020  
 agcccgaacg gaggcaccca aagggagggg agtgccacgc ccctaaagggt acccgtgaca 1080  
 cccaggaact gccacctcct gagggggccc tcaaggagcc catggaccta aagccagaac 1140  
 cccatagcca aggagttgaa ggtcctccac aagagaaggg gcctggcagc tggcaggggc 1200  
 ccccaccccg caggactcgg gactgtgttc gctgggagcg ctctaaaggc cggacacccg 1260  
 gttcttctta ccctcgccctg cctcggggcc agggagcata ccggcctggg actcggaggg 1320  
 agtccctggg cctggaatct aaggatggtt cctagcagga cttgggtggg ggaacagggg 1380  
 attggggatg ggagggaggc aataaagata tttggcctta aaaaaaaaaa aaaaaaaaaa 1440  
 aaaaaaaaaa aaaaaaaaaa 1459

<210> 46  
 <211> 1003  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (28)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (810)  
 <223> n equals a,t,g, or c

<400> 46  
 acgggnaatc cccctcact aattgcnac aaaagccgga gctccaccgc ggtggcggcc 60  
 gctctagaac tagtggwtcc cccggkctgc aggaattcgg cacagtgca aagctccaga 120  
 tttttgggga aagctgtacc caactggact gccagtgaa ctgggatcat tgagtacagt 180  
 cgagcacacg tgtgtgcatg ggtcaaaggg gtgtgttctc tctcactcta gatgccttct 240  
 ctgtgccttc cacagcctcc tgccctgatta caccactgcc cccgcccac cctcagccat 300  
 ccaattctt cctggccagt gcgtccagc cttatctagg aaaggaggag tgggtgtagc 360  
 cgtgcagcaa gattggggcc tcccccatcc cagcttctcc accatcccag caagtcagga 420  
 tatcagacag tcttccctg accctccccc ttgtagatat caattcccaa acagagccaa 480  
 atactctata tctatagtca cagccctgta cagcattttt cataagttat atagtaaatg 540

gtctgcatga	tttgtgcttc	tagtgctctc	atttggaaat	gaggcaggct	tcttctatga	600
aatgtaaaga	aagaaaccac	tttgtatatt	ttgtaatacc	acctctgtgg	ccatgcctgc	660
cccgccact	ctgtatatat	gtaagttaaa	cccgggcagg	ggctgtggcc	gtctttgtac	720
tctggtgatt	tttaaaaaatt	gaatctttgt	acttgcattg	attgtataat	aattttgaga	780
ccaggctctg	ctgtgtttgct	caggctggtn	tcaaactcct	gagatcaagc	aatccgcccc	840
cctcagcctc	ccaaagtgtc	gagatyacag	gcgtgagcca	ccaccaggcc	tgattgtaat	900
tttttttttt	tttttttttac	tggttatggg	aaggggagaaa	taaaatcatc	aaacccaaaa	960
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaastcg	acc		1003

<210> 47  
 <211> 1358  
 <212> DNA  
 <213> Homo sapiens

<400> 47						
ggcacgagtg	attttttacca	caccecaagat	tttttggaaat	ggaggagacg	gctcaagagt	60
ttagccttgc	gactggccca	gtatccaggt	cgaggttctg	cagaagggtg	tgactttagt	120
atacattttt	cttcttttcgg	ggacgtggcc	tgcattggcta	tctgctcctg	ccagtgtcca	180
gcagccatgg	ccttctgctt	cctggagacc	ctgtgggtggg	aattcacagc	ttcctatgac	240
actacctgca	ttggccctagc	ctccaggcca	tacgtttttc	ttgagtttga	cagcatcatt	300
cagaaagtga	agtggcattt	taactatgta	agttcctctc	agatggagtg	cagcttggaa	360
aaaattcagg	aggagctcaa	gttgcagcct	ccagcgggtc	tactctgga	ggacacagat	420
gtggcaaatg	gggtgatgaa	tggtcacaca	ccgatgcact	tggagcctgc	tcctaatttc	480
cgaatggaac	cagtgcacagc	cctgggtatc	ctctccctca	ttctcaacat	catgtgtgct	540
gccctgaatc	tcattcgagg	agttcacctt	gcagaacatt	ctttacaggt	tgcccatgag	600
gaaattggaa	acattctggc	ttttcttggt	cctttcgtag	cctgcatttt	ccaggatcca	660
aggagctggg	tctgctgggt	ggaccaaacc	tcgtgagcca	gccaccctg	acccaaatga	720
ggagagctct	gattctccca	tccgggagca	gtgatgtcaa	acttctgctg	ctgggggaaat	780
ctcatcagca	gggagcctgt	ggaaaagggc	atgtcagtga	aatctgggaa	tggtctggatt	840
cggaaacatc	tgcccatgtg	tattgatggc	agagctgttg	cccacaagcg	ccttttattt	900
agggtaaaaat	taacaaatcc	attctattcc	tctgacccat	gcttagtaca	tatgaccttt	960
aacctttaca	tttatatgat	tctgggggtg	cttcagaagt	gttatttcat	gaatcattca	1020
tatgatttga	tccccagga	ttctattttg	gttaatgggc	ttttctacta	aaagcataaa	1080
atactgaggc	tgatttagtc	agggcaaaaac	catttacttt	acatattcgt	tttcaataact	1140
tgctgttcat	gttacacaag	cttcttacgg	ttttcttgta	acaataaata	ttttgagtaa	1200
ataatgggta	cattttaaca	aactcagtag	tacaacctaa	acttgtataa	aagtgtgtaa	1260
aaatgtatag	ccatttatat	cctatgtata	aattaaatga	ggtggcttca	gaaatggcag	1320
aataaatcta	aagtgtttat	taaaaaaaaa	aaaaaaaaa			1358

<210> 48  
 <211> 2609  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2597)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2603)  
 <223> n equals a,t,g, or c

<400> 48						
ccacgcgtcc	gggatgacag	gaacaggaat	gctggcccat	gagggtcctc	cagttcctca	60
caatcccaat	aagccctcag	ccgcccgtc	caccgaaggg	tctgccatct	tagatattgc	120
tggtctcgct	gcagtgactg	acaacagata	cgagccactg	atgctgagaa	agcctgaccg	180
caggcgaaca	caactcagac	gtggagtttc	cgagaaggaa	aactgacctg	tggtttacat	240
gggttggtcg	tccaggccaa	aggaggactt	tctggtttgt	ttgatggagc	tgaagtgttt	300
cttggctcctg	acacttccat	ggagcttttg	gggccagttc	cacctgaaca	acaatttatt	360
aatcaaaaaa	tgagacctgg	ttctggaatg	ttatccatca	gagtcattccc	agatggacca	420
actagagcac	tccagataac	agatttctgc	caccggaaaa	gcagccgttc	atatgaagtg	480
gatgaacttc	ctgtcaccca	acaagagctg	cagaaattaa	agaatccaga	tacagagcag	540

gaattggaag	tgcttgtgag	gttagaaggt	ggaattgggt	tgtccttaat	taataaagtc	600
ccagaagaac	tggtctttgc	aagtcttaca	ggaatcaatg	tgcactatac	acagctggca	660
accagtcaca	tgcttgaact	cagcatacag	gatgtacagg	tggacaatca	gctcattggg	720
accacgcagc	ccttcatgct	ctatgtgact	cccctgagca	atgagaatga	ggatcatcgag	780
accggccccag	ctgtgcaagt	caacgcagtg	aagttcccca	gtaagagtgc	actgaccaac	840
atctacaagc	atctgatgat	cacagctcag	agattcacag	tgcaaatgta	ggagaaactg	900
ctcctcaagc	tgctaagttt	ctttggctac	gatcaagcag	aatcagaggt	ggaaaaatat	960
gatgaaaacc	tccatgaaaa	gacagctgag	caaggtggaa	caccaattcg	atactacttt	1020
gaaaatctca	aaatcagcat	tcctcagatc	aagctaagtg	tgttcacctc	caacaagctc	1080
ccattggatc	ttaaggccct	aaaaagcacc	ttgggggttc	ctttgatacg	gtttgaagac	1140
gctgtgatta	atctagatcc	attcactcgg	gtacatccct	atgagaccaa	ggagttcatc	1200
atcaatgata	tcctcaaaca	tttccaggag	gaactcctca	gccaggcagc	tcgaatcctg	1260
ggatcagtg	atcttcttgg	caatcctatg	gggcttttga	atgatgtttc	tgaagggtt	1320
actggactga	taaaatatgg	aaatgtcggg	ggcctcatca	gaaatgttac	acacggagta	1380
tcaaaactctg	ctggcaagtt	tgctggaaca	ttatcagatg	gcttagggaa	gacgatggac	1440
aatcggcatc	agtcagagcg	ggagtacatc	aggtaccatg	cagccacaag	tggatgaacac	1500
cttgtagccg	gcacccatgg	cctggctcat	ggtatcattg	gtggactgac	cagtgttata	1560
acttcgacag	tggaaaggtg	gaaaacagaa	gggggtgtca	gcggtttcat	atctggcctt	1620
ggaaaagggc	ttgttggcac	tgtaaccaag	ccagtggcag	gcgccttggg	ttttgcatca	1680
gaacacgccc	aggcgttgag	agacacagcc	acactcagcg	gccccaggac	tcaagcacag	1740
agggttcggg	aaccgcgttg	ctgcacgggg	ccccaggggc	tgcttccccg	atattctgag	1800
agccaggcgg	aaggacagga	gcagctcttc	aaactcacag	acaacataca	ggacgaattc	1860
ttcatcgctg	tggagaacat	tgacagctac	tgctgtctca	tctcctccaa	agctgtttac	1920
ttcctgaaaa	gtggagacta	cgtggatcga	gaagccattt	tcctagaagt	caaatacgat	1980
gaccttctac	cactgccttg	tctccaaaga	ccatgggaag	gtgtatgtgc	aggtgaccaa	2040
gaaagccgtg	agcacgagca	gtggagtgtc	catccccggc	ccctccacc	agaagcccat	2100
gggtccatgtg	aaatctgagg	tccttctgtg	caagtgttca	caagaaataa	actacgcaaa	2160
gagcctctac	tatgaacagc	agcttatgtt	aagactcagc	gaaaaccgag	agcagctgga	2220
gctggactcc	tgaagccccg	ctgctgagat	gggcgctccc	gacacagcgc	agaccaccca	2280
ggaggaaaga	ggcccagctc	tcagctgacg	atggaggcag	aaccggagtc	gggtttgggg	2340
aagttgtcaa	ggaatgaggg	aaagtaaatc	ctcatgagga	aaagtacaaa	tggaaatcgt	2400
attaatttgt	gaggcagggg	gttattttag	attatgggaa	ataattttta	aaggtattgg	2460
ttaaataacg	tttaaaaaca	tgtactgaga	tgaatctaata	ttttagattg	ccctgtattt	2520
tggttaacatg	tatatatgta	caacagtggt	tttgtaaata	tataggaacc	tttctgaaca	2580
gggaaaaaaa	aaaaanaaaa	anaaaaaaa				2609

&lt;210&gt; 49

&lt;211&gt; 1898

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

gaaaaaaaaa	gatttcctcc	tctgtatgtt	gcagtagagt	cctcttgagc	actataatta	60
ttttaatttaa	aattcaagtt	gtatgtatcc	tccagtagct	ccctctttct	gggggtgtgt	120
ctgtttcttc	tgggcgggtc	cccttgtgtg	ttgcagagac	tcttggaagg	ggttatcact	180
cttcgttggc	tcagggggcc	tgggtctggt	ggagcactga	tggggtagt	gggcctgccc	240
tggtggggaga	gaaggcggct	cttctgtgtc	cagagcggac	cccgcattgac	cttcccttta	300
cttgtgggct	ctgggaactt	cagcgcacc	tgtctgtttg	cccctggagc	ctgggaatcc	360
aggcggagca	ctcaggatgg	ggctgggttt	cctccagggc	ccgcagtctc	tccaggccag	420
cctcccctga	ggcctttggc	tctaagatcc	tcctcctgag	gctctggtgc	tgggtctctc	480
agcttgagag	ggaagaagcc	ctacactgga	cctctccact	gggaactaca	ctgagtgcac	540
ccagccactt	cttctcagtg	ctgtagagac	agaaggggga	caagtggagg	gtgagargcg	600
atgttgggct	caamcatctt	cactcagata	cctgaaaggc	ttgatctcaa	ggaaaagagt	660
aaacattgac	agggcagcac	tccacttaaa	ttattttatt	tcacacttag	gtttaagtat	720
tgttatcccc	atgaaacaga	cgttggggaga	ttaagacact	tcgactgtaa	gtattagtgg	780
tagagtcaagg	aattgaatgg	ggtgtgcttt	ggtcaaaactc	ttaggtgctt	ttgcatccac	840
ccatgtttct	gttagagaag	aggcctggag	gcattgcttc	catagactaa	gcacttgggtg	900
ttagctgttc	ttgtctgata	ggactctaac	gacctcacia	ttacacaccg	atgggcagct	960
gggaagaaaa	tgatggagtg	atgtgcggtt	cacaaaggct	tgatcttgta	gttgcttgga	1020
tgaagacaag	gatccattaa	aagcagggtc	ccctaacaaa	cctcattctg	gaacatcaag	1080
ttcaatgggtc	ataaagcag	ttgctcaaag	ctaccatata	attggcagag	agtcacatgt	1140
gttctaccag	actaaatata	taatcattga	gacatattaa	aatgktgctg	gctgggcact	1200
ggggctcgtg	cctatcaacc	cagtgccttg	gaaggccaag	gtggaaggac	tgcttgagcc	1260
aaggagtttg	agaccagcct	gggcaacata	gcgagggcaa	gccaaggagt	ttgagaccaa	1320
cctgggcagc	aaaatctcta	caaaaaattt	taaaaattag	ccaggagtgg	tgggtatgtac	1380

ctgtagtcct	acctacttgg	gaggctaagg	cagcaggatt	gcttgagccc	aggagtttga	1440
ggctaaactc	agaggcaaaag	ccccctcccc	caacagttag	ctctcttcac	accactgcac	1500
tccaacttta	gtgacagagc	aagaccctgt	ctataaaaata	aaaagttaaa	atgttgctat	1560
tgctatcatt	aaaagctttt	tgtttgggtc	tgtagagata	gcttctcact	ttctatcttg	1620
agaagcggtc	ctggaccttc	ctcgagggca	gcgaggagag	gcgttagggc	acgtggactt	1680
ctgtgggcct	gcctaggccg	tgaactccca	ggcccaactcc	ctctaggggtg	atgacttgtg	1740
tgtgaacacg	gatgtcagtt	tcatttagaa	tcaactcaca	tggaatctgt	agctcacaag	1800
aaatgtgggt	acagaatatg	cttagtaatg	cttggcatgt	tcatttcttt	ttttttaagg	1860
aaagactgga	aaaatctgag	cctgaaagtt	tcattctgg			1898

&lt;210&gt; 50

&lt;211&gt; 1808

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

ggcagcagat	ggattgcttt	agtttgtaat	ttttctatgc	agttatatatt	ttctagtgtga	60
gctagactat	tttgtcatca	tgtaccacta	catttttgtt	tattttaatg	acaagctgta	120
taaatgcttt	acttctagct	atttaatggg	agcattactg	gggaactcag	acttccctct	180
tttaattctt	cttagtaaaa	gatactcatg	aaaaaagcag	ttttattttc	ctaacaaaaa	240
agaaagagct	cattatgtca	gtgtctatga	actgtaccca	tcccaactct	caaatcgttt	300
ggtttttttt	atcttgattg	agatcctctt	ctcactatgc	tagtggtgga	gatattgaca	360
aaatcctatt	tctttcaaag	aggaactttt	cacaccgaaa	aaagagcatg	gaattatttt	420
atattgtata	aaaatcccag	atgcaaat	ttttaatgcc	aattattaga	gcttctgggg	480
aaaaagtata	gttcacggaa	ataaaactat	gttctttcag	gggtgggtgg	ataggtggct	540
gctaggggtg	ctggctcctg	gcggctttgc	catccatgag	gcaagggtg	ggaacacagt	600
gtctttgcct	atggtagatc	catgtgaatg	tcaggaagcc	agctcttcag	tcttgagat	660
gatttctgct	acaattctgt	agaaagatta	aggatggcag	agtaaaaggt	taccaagaat	720
gccaggatgt	ttttcttggg	cgtaggagggt	ccagattact	ttcctttttg	atgaaagagt	780
ttggaagact	gtcccatctc	tctggcttga	gaaatctctg	ccatttttaa	catcactgtg	840
aaatagaact	tattatcatc	tgtatttagt	tttaacatta	cccacaacat	agaaataata	900
ggtaaaaatc	gtcttgccca	ctcattccaa	agatgatcaa	gtcattaatc	tagcaaagta	960
ttcatgtatc	agattttcta	tattttgaa	caaagctaac	taggaatggt	agatataaga	1020
atgtaatgat	attcatgcac	tgaattctaa	gccaatatga	acaaaaatgc	tgcatgaatg	1080
gcacatatag	gtcaccaaaag	ttcattcaca	ggtagaaaaa	acttggtgct	tcttttccat	1140
ctaaaaaaca	aaggagactt	tctttatctc	atttaaagaa	cagctctttg	aaattgaaat	1200
tgaccttttt	tgcttgacct	taaggagatt	agcttccagt	agatgagttt	gcaaaatact	1260
tttccctgtt	ttttgttttg	ctgggtattga	aaacatccca	ctaaatcaga	tgaagaggca	1320
tgggaggaaa	aatatccaaa	ttaattacta	aaatcgagaa	gagaaggcaa	actcttgaaa	1380
agtaaaaagg	tgtttgtgac	cttcagtatt	tattgaacag	aggaaataac	tgacaagggc	1440
aatacaattc	aatgttcatg	tagtaacatt	catgtcactt	ggtgaatttg	gttctcatat	1500
gtatattgca	tacacataaa	ttcaaaacta	aagtcgtcat	ttttgagcca	tcattcttaca	1560
ttcatgtaat	gaaattatgg	aagagagtaa	aaactagctc	tttaacttagt	aaatataata	1620
tggatatttaa	aatcagggtca	ctacagtaag	gttctaagta	ttgccaattg	aaaagctaga	1680
aatgggtatta	ctgttgcaaa	gtgttgtaaa	taattgactc	caatagcatt	gtaaataactt	1740
gtatcccaca	actatttttaa	acccaagcaa	taaaatggat	tttctaattc	aaaaaaaaaa	1800
aaaaaaaaa						1808

&lt;210&gt; 51

&lt;211&gt; 955

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ccacgcgtcc	gggggactct	gcaataaggc	agtgaagacc	ctagcccagt	gcctggcagc	60
tgctgtgatg	atgattatta	ttattaatgt	cacccccgct	ccccgccacg	cacacatggg	120
ctagaggggt	gacttccaca	cccctggctt	agactgtcct	gcaggctggg	tgttttcttt	180
gtgatcccca	aggccccaag	cccagtggga	aatttccgcc	acttccatgt	gccctgccac	240
gacttccctg	catctgctga	ctcgggtgtga	catgacacac	ggctgcctct	ccctggccag	300
catggccgcg	gggcttgggt	ctgtctcact	gttcttgttt	gttcaacagt	ggactccaac	360
gacagcctct	acgggggaga	ctccaagtcc	ctggcagaaa	acaacaagct	gtgtgagacg	420
gtgatggctc	agatccetaga	gcattctgaaa	accctggcca	aggacgaggc	cctgaagcgc	480
cagagctcgt	tgggcctttc	cttcttttaac	agcatcttgg	cccatgggga	cctacgcaac	540
aacaagctca	accagctctc	cgtcaacctg	tggcacctgg	cacagaggca	cggctgtgca	600

gacaccagga	ccatgggtgaa	aacgctagaa	tacatcaaga	agcaaagcaa	acaaccagac	660
atgactcatc	tgacggagct	ggccctcaga	ctccctctgc	aaacaaggac	ctgacccccg	720
ggcccatccc	caggctcagg	gactctggtg	cctaatccag	aaagatctgc	tctgctgccc	780
tgaactctta	cggcaattta	ggtttctcat	ttttcttttc	tttttacata	tgtacaaatt	840
gttttaagct	ttggcctcta	tccaggttat	tctgacaatg	aagaaatggg	agttgtcaga	900
gcattaaaat	gcaatcttca	ctaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa	955

<210> 52  
 <211> 1847  
 <212> DNA  
 <213> Homo sapiens

<400> 52						
ttctaacaac	tagcggaatc	caggagcagg	ccctccggac	ttttttcctt	gggtaccagg	60
gtactcgggg	cccaggaacc	tgggtctgag	ccctgctcag	gtttgtccca	gccggctcag	120
cgcactgggt	gtgtgttgct	gctcctacag	ctcaatgcac	tggaccttct	cgtccagcct	180
gggatgcctc	tatcatttct	ctttgtcttt	ctctggcctc	cataccgttc	tgaagagctc	240
accttcctct	aggttcctcc	tgccctgctc	ttcccaagtg	accagccct	cacctgtagg	300
gcagccaagg	ctggtggtgc	agctgcccc	agtgaaggct	attgggcac	gcactgggca	360
gtgcagaggt	ccaggctgag	gagttgagtg	gcgcgccc	cctggcgct	gtgcagagaa	420
cgggaggggg	gcccctggct	tggatcctag	aatcgggtgaa	gtctgagggc	ccccctgcag	480
tctcagcagg	acctgctcta	tcaaggggct	tcctccttcc	tttccccacc	ctgtctcctt	540
ggcggggagg	attagtcca	ggtgggggaa	gccagacatt	tgactgacgg	gagaggaagg	600
cttgccaggc	agcccgaaga	ctgttgtgaa	aatggggctg	cttttgcaag	ggaagctctt	660
ttactcccca	ttcctgtcct	ccagaggccc	cccttttccc	tgccgtgtta	ttggtgtcaa	720
ccctggggta	agtggctggc	tggactcacc	cctgctcccc	gtacacctgt	gcctgtgact	780
ggcgggtccaa	gctccccaca	cacacatctt	gctgggtgct	ttccctgaag	tcaccacca	840
ggggctggct	gtcatcagcc	cattcttgtc	ccagcagggt	accgaggga	tgataaaaca	900
gaatgtgttt	gaattacaca	caaaaatgtt	ccctgcagca	ggtcataaac	tctgtgaact	960
aatgaagctg	acaaacagag	ctggagtacg	tttccctca	cccttccttt	cctcctagct	1020
cagcaagggg	tgctcagggt	caggatgttg	tttgttgatt	caggctcaac	caggctccgc	1080
aagaaaacct	tatcaggaga	ttttattttc	atgaacaggt	gccagtcttc	ccgccagcca	1140
cgtccagctg	gcgtcaataa	gcctcttttg	ggatgtcctg	cctcctccag	gaccagccat	1200
gagtggctct	tatggccaaa	ggcgggtactg	caggccaagc	aaacggctct	gggctggaat	1260
agccctacct	gagtgccttg	tttgactccg	ccactatctg	ccatgtgagt	tgggcaaatt	1320
ggtgaccacc	tctgagcctt	gaaaaagtag	gaggttactt	tgtagagca	aaataataaa	1380
atttaatttt	aaaaaagaaa	acgtaggagg	ttcgtttgga	tgagctagtc	tcttccggtt	1440
gaaaagtctg	actcggtgag	catcctgacg	actccatttc	cttctgggtc	cccaccagct	1500
cttacacttg	gctgccatca	ataccacatg	ctctgaaggg	agagtgcctg	catgtacttt	1560
gccaaatcct	gtctgtctca	tctcagttga	atggaaaagg	agggaggtgg	ggctggtaga	1620
taggtgcttt	tggtgctagt	atccaccagg	ttttgtgtgc	atcccgtaat	gagcccactt	1680
cctgaaaaca	tttaaagaaa	aaagatatca	gctggagatg	gcagtgcgca	catgtaatcc	1740
cagctactcg	ggaggttgag	gtgggaggat	cactcaaacc	tgggagtttg	aggccagcct	1800
gggcaacacg	gcaagaccct	gtctttttta	aaaaaaaaaa	aaaaaaa		1847

<210> 53  
 <211> 2163  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (8)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (15)  
 <223> n equals a,t,g, or c

<400> 53						
accttttgnat	ccctngetcg	aaactaacc	tcactaaagg	gaacaaaagc	tggagctcca	60
ccgcgggtggc	ggccgctcta	gaactagtgg	atcccccg	ctgcaggaat	tcggcacgag	120
gctgctgcag	gcgtccggct	tggacgaacc	gccgttccca	gtgctgggac	cctttaagta	180

tgcaggtgat	agactagaga	acaagacctc	tgtctccgta	gcatacctgga	gcagtctgaa	240
tgccagaatg	gataaccgtt	ttgctacagc	atlttgtaatt	gcttgtgtgc	ttagcctcat	300
ttccaccatc	tacatggcag	cctccattgg	cacagacttc	tggtatgaat	atcgaagtcc	360
agttcaagaa	aattccagtg	atltgaataa	aagcatctgg	gatgaattca	ttagtgatga	420
ggcagatgaa	aagactttata	atgatgcact	ttttcgatac	aatggcacag	tgggattgtg	480
gagacgggtg	atcaccatac	ccaaaaacat	gcattgggtat	agcccaccag	aaaggacaga	540
gtcatttggat	gtgggtcaca	aatgtgtgag	tttcacacta	actgagcagt	tcattggagaa	600
atltgttgat	cccggaaaacc	acaatagcgg	gattgatctc	cttaggacct	atctttggcg	660
ttgccagttc	ctttttacct	ttgtgagttt	aggtttgatg	tgctttgggg	ctttgatcgg	720
actttgtgct	tgcatlttgcc	gaagcttata	tcccaccatt	gccacgggca	ttctccatct	780
ccttgcaggt	ctgtgtacac	tgggctcagt	aagttgttat	gttgctggaa	ttgaactact	840
ccaccagaaa	ctagagctcc	ctgacaatgt	atccggtgaa	tttggatggt	ccttctgcct	900
ggcttgtgtc	tctgtctcct	tacagttcat	ggcttctgct	ctcttcatct	gggctgctca	960
caccaaccgg	aaagagtaca	ccttaatgaa	ggcatatcgt	tgggcatgag	caagaaactg	1020
cctgtctttac	aattgccatt	tttatttttt	taaaataata	ctgatatttt	ccccacctct	1080
caattgtttt	taatttttat	ttgtggatat	accattttat	tatgaaaatc	tattttattt	1140
atacacattc	accactaaat	acacacttaa	taccactaaa	atltatgtgg	tttactttta	1200
gcatgacct	cttttcaata	aactaatcta	ggtctagaca	gaaagaaatg	gatagagact	1260
tgacacaaat	ttatgaaaga	aaattgggag	taggaatgtg	accgaaaaca	agttgtgcta	1320
atgtctgtta	gacttttcag	taaaactaaa	gtaactgtat	ctgttcaact	aaaaactcta	1380
tattagtttc	tttgggaaac	ctctcatcgt	caaaacttta	tgttcacttt	gctgttgtag	1440
atagccagtc	aaccagcagt	attagtgtctg	ttttcaaaga	tttaagctct	ataaaattgg	1500
gaaattatct	aagatcattt	tccctaagca	ttgacacata	gcttcatctg	aggtgagata	1560
tggcagctgt	ttgtatctgc	actgtgtctg	tctacaaaaa	gtgaaaaata	cagtgtttac	1620
ttgaaatttc	aactttgtaa	ctgcaagaat	tccagttcag	ccgggagagg	attagtatta	1680
tttttaactc	tccgtaagat	tttcagtacc	accaaattgt	tttggatttt	ttttctttcc	1740
tcttcacata	ccagggttat	taaaagtgtg	ctttcttttt	acattatatt	acagttacaa	1800
ggtaaaattc	ctcaactgct	atltattttat	tccagcccag	tactataaag	aacgtttcac	1860
cataatgacc	ctccagagct	gggaaacct	ccacaagatc	taaagtctctg	gctgtccatt	1920
aacctccaac	tatggtcttt	atltcttctg	gtaatatgat	gtgcctttcc	ttgcctaaat	1980
cccttctctg	tgtgtatcaa	cattatlttaa	tgtcttctaa	ttcagtcatt	tttttataag	2040
tatgtctata	aacattgaac	tttaaaaaac	ttatltattt	attccactac	tgtagcaatt	2100
gacagattaa	aaaaatgtaa	cttcataatt	tcttaccata	acctcaatgt	ctttttttaa	2160
aaa						2163

<210> 54  
 <211> 748  
 <212> DNA  
 <213> Homo sapiens

<400> 54						
cgctgagaag	gagcagacaa	gatggcgagc	tccgtggggc	accgatgtct	gggattactg	60
cacggggtcg	cgccgtggcg	gagcagcctc	catccctgtg	agatcactgc	cctgagccaa	120
tccctacagc	ccttacggaa	gctgcctttt	agagcctttc	gcacagatgc	cagaaaaatc	180
cacactgccc	ctgcccgaac	catgttctctg	ctgcgtcccc	tgcccattct	gttggtgaca	240
ggcggcgggg	atgcagggtg	ccggcagtat	gagaagtaca	gggagcgaga	gctggagaag	300
ctgggattgg	agattccacc	caaacttgct	ggtcactggg	aggtggcttt	gtacaagtca	360
gtgccaacgc	gcttgcgtgc	acgggccttg	ggtcgctcct	atcaggtgga	gctgccacac	420
tggctgcgca	ggcccgtcta	cagcctgtac	atctggacsy	ttgggtggata	gttgggtcagt	480
gcctggaaaa	cctgtcccag	tttatcagga	acgcaggcct	ggggagcccc	cagtggcggg	540
gacagggcca	gatttcatgt	tgaccctggg	gatgctgtga	atltctctctg	caggagagac	600
atcattgaat	tttttcaact	gtatcagtag	cacagtattt	ttgtatgaaa	agtgggagac	660
ttctgaacag	taattcattt	aattgcaaag	catttttga	taaaaaaaat	caaacttaaa	720
aaaaaaaaaa	aaaaactcga	ggggggggc				748

<210> 55  
 <211> 1198  
 <212> DNA  
 <213> Homo sapiens

<400> 55						
ccacgcgtcc	gcggacgcgt	gggttttttt	tagctcagtt	aaattcagca	tttaatgcag	60
gtgagttcct	gggtcgtttt	ccaactagtc	tggaacagtc	tggttctgac	tcaaactgg	120
ataaagcatt	atlttaggtt	ttctctttgc	cagtttttaa	gcagttataa	ccatgtaaat	180

caagatgtga	ggacatctat	atgaagtata	gtaaagaagt	gggtgtcagca	gatcaatatg	240
tgtgtcctgg	gtgtgctgct	ctcttaagt	agactttgtg	agactatact	ttaaatgcat	300
tattaccatt	gcttacattt	tgggggattt	tcttcctcct	caaaacttcc	atttctattg	360
taatattctt	aatgacaatc	tttttttttt	tttagcagt	tatgtttgaa	acagccaaag	420
atggcgatga	accaagtgt	aattgatcta	agcagcccat	gcagtttgtg	ttgaatcaac	480
aaacagtgt	ttgttgaagt	gaaattattt	tctgaaatga	cttgtagac	cagttttgag	540
gacatactca	aaagtagagt	aataatggct	cctgggatgg	agaaatatga	gatgaacctg	600
gaacattcta	ttatggtgcc	acaaaggaaa	tctaaaaaaa	aaaaaaaaaa	aaaaagtggg	660
tggctaggag	cagtggcaca	cgctgtgat	tccagcactt	tgggaggccg	aagtgggcag	720
gagttcaaga	ccagcctggc	caacatagtg	aaacctgtc	tctactaaaa	atacaaaaaa	780
tagccgggtg	tgggtggcggg	cgctgtaat	cccagctttt	caagaggctg	aggcagaaga	840
atcgcttgaa	cccgggagat	ggaggttgca	gtgagctgag	atcggtgccac	tgcactccag	900
cctgggcgtt	gcagtggagc	tccgtctcaa	caacaacaaa	aaggtggata	catgtcaaaa	960
gggcacagga	gccacttgaa	ggattatact	tgctaaatct	gtgtcaatta	tcaaaaataa	1020
ctggtagcaa	cgtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1080
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1198

<210> 56  
 <211> 967  
 <212> DNA  
 <213> Homo sapiens

<400> 56						
ccgaaaacat	cggatttatt	aggattagct	gtagtgtaca	ctgattcctt	tagctctaaa	60
tggatacata	tgtgccccgc	agacagtata	cacgcaggga	tgtgactgag	ccacagtgc	120
atagcaaacc	caacagctgg	cttgtgaagc	catcgtgatc	ccaacaaggt	ctatgttagc	180
aattgggtgaa	agaagaagag	agtgagatgg	gacccagggtg	ggcctggagg	tgggatcctg	240
tgggttttca	gagcaccac	cagtgtccc	ttggtgagcc	cagcaccacc	tgggaagtga	300
gggaagctgg	gtcgtgctg	gaagggagag	aggctgactc	tctacccctc	acctctgcaa	360
ggaactgagg	cctgtagggt	tgcggctgtc	actggctaca	ggcggcatct	ttctgtaaaa	420
agcttttcag	gcatgaaacc	catttctgta	tggactgggc	tgtgttgacg	gtgggtgctg	480
ggccttgtgt	gccaggcctc	tctgggtccc	ctccctggcc	tttgccttcc	tctcaccttc	540
tcgaggccaa	gctgtgcgag	acctggcatt	ccttccaaac	ctcagttcct	ccacgcccct	600
gcgctgggtg	gactccagag	ctcagaatgt	cagcacggag	ccgtcagtat	cgagaaggaa	660
ctcaacgcaa	ggcttcacag	ctttccaagg	acagggaccg	gctctggagt	ggcctgtcgt	720
gagatgtcag	gcacgctcac	acgcagggtc	ctgtgttggc	tccctgacca	gcagggggac	780
atgggtggcg	gatgtaccag	cccttctgga	taacatgaca	gtcccaattt	caggaaagtt	840
tttatttttaa	atattgggtga	ttctttaacc	aggaatgcaa	atgtactga	agtgtgtgtg	900
gtgtctctgt	gagagccttc	atataaataa	attggaattc	gatatcaagc	ttatcgatac	960
cgctcgac						967

<210> 57  
 <211> 1147  
 <212> DNA  
 <213> Homo sapiens

<400> 57						
ggcacgaggc	tctggccagg	gggaggaagc	agtgcagaag	tctcataagg	tgaagaggag	60
agggccgctg	gttagggtag	agcagctgag	gatagaagaa	atgaaagtaa	ttaaattgct	120
agtcaccttt	gagctagggg	ttattatcct	catttttagag	atgacaaaat	tgaggctcac	180
aaagactcgg	tgactcgccc	aaggtcatac	agcttcccag	tgacgaagcc	cgggctccaa	240
cttgtttttc	tggctcccca	gtcagtgttt	gccagctct	gccctgttcc	ctcctagtcc	300
cttcacccac	tgcgcctgg	attcagcctg	gctgagagg	tgaagccatg	tggccttggg	360
ggctaattgg	agagagaaca	gttgtcttgc	ttctcatcac	atacttgggtg	cccgtgggag	420
ggagtgtctg	gggcccccca	ggcccagggt	gtaatgtcag	cacctcccc	ccacccccag	480
ccacccgctg	ccccgacgag	tcggaactat	accgagatcc	gggagaagct	ccgctcgagg	540
ctgaccaggc	ggaaagagga	gctgcccattg	aaggggggca	ccctgggcgg	gatccctggg	600
gagcccgcgg	tggaccaccg	agatgtggat	gagctgtctg	aattcatcaa	cagcacggag	660
cccaaatgtc	ccaacagcgc	cagggcgcc	aagcgggccc	ggcacaagct	gaaaaagaag	720
gtgggtgtag	ggagagccca	gctctgccc	ctctcctccc	tgaggaccct	cgccccaaac	780
cccaggactt	ctggggcatg	aatgatgctg	gctgccaaag	gcctcagctt	ggctcactgt	840
tctgggaagg	tctgaatgag	tttgggaggc	atcagggtca	gggatcctgg	gggcaaataa	900
ctggaggaaa	aaacgtgtca	tggcctgaga	agttgcttgc	tggattcctc	caagctgagg	960



acttgcttca	gtcagtcatt	tattcattca	gcaaacactt	ctacaaatac	tggcagccaa	1020
agtgtgacac	agttaagttc	tcacccagaa	gaagctgtcc	agtggggaga	ctgacacaaa	1080
actggacaag	catattagca	tgtgacctcg	tgccgaattc	gatatcaagc	ttatcgatac	1140
cgctcgac						1147

<210> 58  
 <211> 975  
 <212> DNA  
 <213> Homo sapiens

<400> 58						
accctactaa	agggaacaaa	gctggagctc	caccgcggtg	gcggccgctc	tagaactagt	60
ggatcccccg	ggctgcagga	attcggcacg	aggccgacgc	ctgggggtgtg	gagctgcccc	120
accgccaccc	cgtgggagag	tggatcaaga	agaaaaaac	tggcccgaga	gtcgaagggc	180
cgccccaggc	caacagaaat	caccgcgcct	tacctctgtc	cccaccctta	ccttccccca	240
cataccgccc	cctgcttggg	ttcccacccc	agcgtttgcc	gctgctcccc	ctcctgtccc	300
cacagcctcc	tcctcccat	ctccatcacc	agggaatgcc	ccggttccca	cagggtcccc	360
cagatgcctg	tttlycctca	gaccatactt	tccagtcgga	tcaattctat	tgccattcag	420
atgtcccttc	atcagcccat	gcaggtttct	tcgtcgaaga	caattttatg	gttggtcctc	480
agctgcctat	gcccttcttc	cccacacccc	gttatcagcg	gcctgcccc	gtggtacata	540
gggggttttg	cagggtatcg	ccccgtggcc	cctatacgcc	ctggggacag	cggcctcgac	600
cttcaaagag	aaggggccca	gccaatcctg	agccaaggcc	tcaatagacg	gacctaggcc	660
ttatttcttc	tttatgaaca	tggattggac	agatctgaca	cttcccttcc	attgcttggc	720
ctgaacagag	tgacctgtgt	aacttaagcc	tggagtcctt	gcctcgtctt	ccttttgctc	780
attgctgtta	ccaagaaagc	caagggaagc	cagcctgact	cattcttctt	ggctgcagcc	840
tcttccccac	ttcctgggag	tgacccagcg	ttattcctgc	ctcctcactc	ctattctctt	900
tgccctttgtg	taaaaataaa	atggaaataa	acaagttgca	cagaaaaaaa	aaaaaaaaaa	960
aaaacccaag	ggggg					975

<210> 59  
 <211> 2733  
 <212> DNA  
 <213> Homo sapiens

<400> 59						
gtgttgacgg	cgctgcgatg	gctgcctgcg	agggcaggag	aagcggagct	ctcgggttct	60
ctcagtcgga	cttccctgacg	ccgccagtgg	gcggggcccc	ttggggccgc	gccaccactg	120
tagtcatgta	cccaccgccc	ccgccgcgcg	ctcatcgagg	cttcatctcg	gtgacgctga	180
gctttggcga	gagctatgac	aacagcaaga	gttggcggcg	gcgctcgtgc	tggaggaaat	240
ggaagcaact	gtcgagattg	cagcgggaata	tgattctctt	cctccttgcc	ttctgtctt	300
tctgtggact	cctcttctac	atcaacttgg	ctgaccattg	gaaagctctg	gctttcaggc	360
tagaggaaga	gcagaagatg	aggccagaaa	ttgctgggtt	aaaaccagca	aatccaccgc	420
tcttaccagc	tcctcagaag	gcggacaccg	accctgagaa	cttacctgag	atttcgtcac	480
agaagacaca	aagacacatc	cagcggggac	cacctcacct	gcagattaga	cccccaagcc	540
aagacctgaa	ggatggggacc	caggaggagg	ccacaaaaag	gcaagaagcc	cctgtggatc	600
cccggccgga	aggagatccg	cagaggacag	tcacacagctg	gaggggagcg	gtgatcgagc	660
ctgagcaggg	caccgagctc	ccttcaagaa	gagcagaagt	gccacccaag	cctcccctgc	720
caccggccag	gacacagggc	acaccagtgc	atctgaacta	tcgccagaag	ggcgtgattg	780
acgtcttctc	gcattgcattg	aaaggatacc	gcaagtttgc	atggggccat	gacgagctga	840
agcctgtgtc	caggtecttc	agttagtggt	ttggccctcg	tctcacactg	atcgacgcgc	900
tggacaccat	gtggatcttg	ggtctgagga	aagaatttga	ggaagccagg	aagtgggtgt	960
cgaagaagtt	acactttgaa	aaggacgtgg	acgtcaacct	gtttgagagc	acgatccgca	1020
tcttgggggg	gctcctgagt	gcctaccacc	tgctggggga	cagcctcttc	ctgaggaaag	1080
ctgaggatth	tggaaatcgg	ctaattgcctg	ccttcagaa	accatccaag	attccttact	1140
cggatgtgaa	catcggtact	ggagttgccc	acccgccacg	gtggacctcc	gacagcactg	1200
tggccgaggt	gaccagcatt	cagctggagt	tccgggagct	ctcccgtctc	acaggggata	1260
agaagtttca	ggaggcagtg	gagaaggtga	cacagcacat	ccacggcctg	tctgggaaga	1320
aggatgggct	ggtgcccattg	ttcatcaata	cccacagtgg	cctcttcacc	cacctgggag	1380
tattcacgct	gggcgccagg	gccgacagct	actatgagta	cctgctgaag	cagtggatcc	1440
agggcgggaa	gcaggagaca	cagctgctgg	aagactacgt	ggaagccatc	gaggggtgtca	1500
gaacgcacct	gctgcggcac	tccgagccca	gtaagctcac	ctttgtgggg	gagcttgccc	1560
acggccgctt	cagtgccaaag	atggaccacc	tggtgtgctt	cctgccaggg	acgctggctc	1620
tgggcgtcta	ccacggcctg	cccgccagcc	acatggagct	ggcccgagg	ctcatggaga	1680
cttgtttacca	gatgaaccgg	cagatggaga	cggggctgag	tcccagagatc	gtgcacttca	1740

acctttaccc	ccagccgggc	cgtcgggacg	tggagggtcaa	gccagcagac	aggcacaacc	1800
tgctgcggcc	agagaccgtg	gagagcctgt	tctacctgta	ccgcgtcaca	ggggaccgca	1860
aataaccagga	ctggggctgg	gagattctgc	agagcttcag	ccgattcaca	cgggtcccct	1920
cgggtggcta	ttcttccatc	aacaatgtcc	aggatcctca	gaagcccag	cctagggaca	1980
agatggagag	cttcttccctg	ggggagacgc	tcaagtatct	gttcttgctc	ttctccgatg	2040
acccaaacct	gtcagcctg	gacgcctacg	tgttcaacac	cgaagcccac	cctctgccta	2100
tctggacccc	tgccatagggt	ggatggctgc	tggtgtgggg	acttcgggtg	ggcagaggga	2160
ccttgctggg	tctgtggcat	tttccaaggg	cccacgtagc	accggcaacc	gccaagtggc	2220
ccaggctctg	aactggctct	gggctcctcc	tcgtctctgc	tttaatcagg	acaccgtgag	2280
gacaagttag	gccgtcagtc	ttggtgtgat	gcggggtggg	ctgggcccgt	ggagcctccg	2340
cctgcttcct	ccagaagaca	cgaatcatga	ctcacgattg	ctgaagcctg	agcaggtctc	2400
tgtgggcccga	ccagaggggg	gcttcgaggt	ggtccctggg	actgggggtga	ccgagtgga	2460
agcccagggt	gcagctctgc	ccgggctcgt	gaagcctcag	gtgtcccca	tccaagggtc	2520
tggaggggct	gccgtgactc	cagaggcctg	aggctccagg	gctggctctg	gtgtttacaa	2580
gctggactca	gggatcctcc	tggccgcccc	gcagggggct	tggagggctg	gacggcaagt	2640
ccgtctagct	cacgggcccc	tccagtggaa	tgggtctttt	cgggtggagat	aaaagttgat	2700
ttgctctaaa	aaaaaaaaaa	aaaaaaaaaa	aaa			2733

&lt;210&gt; 60

&lt;211&gt; 1668

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

ggtgggttat	ggtgagagat	ttatgtgaat	gctgtggctg	ggaactagtc	tcataattctc	60
aagtttttct	gcaagttttg	atggcgctcc	atttctctct	tcctggctct	tttgggtcttc	120
aggcagcagt	ccaaattccc	tcattcctcc	cttctagccc	tctcccagga	tccaggccct	180
agactgggcc	acttgctctg	tcccagtttg	attttttcat	cctaggcccc	ttctcctccc	240
tgtccgcgcc	cctctccctt	tcccccgcc	cgctgtcata	ataagagatt	caggctctga	300
aggggcttct	ggaaggttagc	aaaggtgctg	cggtgtctct	cccagagaca	ggacctccaa	360
cttctccgcc	ctgggtcttt	ggtaccaggc	cagcagatgt	gtacagtttg	ggagagagga	420
aaagccagag	ctgcaggaac	aagctgagga	gcgggcagat	gggagtcctg	aaaagagagc	480
caggcgtggg	ggggggaggt	gtggggaggg	ggcccccttc	ctactaatcc	tctctccagg	540
aatccctggc	tttgggacag	gacggctgtc	gttttggttg	gggaggcgcc	caggctgggt	600
gcatgtcctg	ggccaccagc	caagagaaca	tgatgttccc	aagtgcgctg	gccgccgccc	660
tctcgggctg	gccgcctccc	aaaccgctgc	ctctccagtc	tctccagcct	ccctgcccc	720
cattccagag	cagcttcgcc	ccgccccctt	cttccgcttt	gacgtcactg	ctgtctccc	780
ccccctcgcc	tccattgacg	gcagcagggc	ctggttactg	tggggacggt	gaagcaggac	840
aacaggagtc	ttgggagcaa	gcgggggctg	ctggagggtc	ggagcctttt	gtctatgcaa	900
aagacagggg	gatggaggcg	ggagatcaag	gactgcctgg	gttaggggag	atcacaccta	960
aatccctgaa	gggggagaaa	aacctatgtt	ccagggaaga	ggtatctgca	aacgagataa	1020
ggccaaagcc	acagtatgag	ttgggggtggg	gaggatcatt	ttcaggggaga	ggagactgag	1080
aatccaagct	cctgaatctt	tttttttttt	tttttaatag	agacgggggt	tctccatggt	1140
ggtcaggctg	gtctcgaact	cgctacctca	ggtgatccgc	ctgcctgggc	ctcccaaagt	1200
gctgggatta	caggccaccg	cgccccggct	ccaggctcct	gaatcttttg	ttttcctggt	1260
tcgatttttc	tgggttaatt	tataacacga	tcttgtctca	gcttttccac	agagccctcc	1320
ccttcaccct	tccctcattg	ttcaggaaaag	cttagggccac	gtgacagtga	ggggagtgcc	1380
cccacaatga	ttatgtcagc	agctgcttgg	aggcctgttc	atctactacc	cacgtttcca	1440
gggagccctg	cgaggaacta	ctcatcacgg	tcctggatgg	agggggctgt	gtaactgcag	1500
ctctcctgag	cccagactaa	cattttattg	cctgcaaata	gtgcccctgt	tctctttcta	1560
ggactactca	tctctttttag	agaatcagaa	ttcccagccc	cctttctcct	gttgacactc	1620
ttttccacc	tccccaacct	atccttggtt	aaaaaaaaaa	aaaaaaaaaa		1668

&lt;210&gt; 61

&lt;211&gt; 1021

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

ggcacaggga	ttctaggaca	gggatggggg	tgcagcactg	atccaggacc	cagaatggag	60
gcatcatgga	gggtcccgcc	ggatggctgg	tgctctgtgt	gctggccata	tcgctggcct	120
ctatgggtgac	cgaggacttg	tgccgagcac	cagacgggaa	gaaaggggag	gcaggaagac	180
ctggcagacg	ggggcgggcca	ggcctcaagg	gggagcaagg	ggagccgggg	gcccctggca	240
tccggacagg	catccaaggc	cttaaaggag	accaggggga	acctggggcc	tctggaaacc	300

ccggcaaggt	gggctaccca	gggcccagcg	gcccccttcg	gagcccgtgg	catcccggga	360
attaaaggca	ccaagggcag	cccaggaaac	atcaaggacc	agccgaggcc	agccttctcc	420
gccattcggc	ggaaccccc	aatggggggc	aacgtgggtca	tcttcgacac	ggtcatcacc	480
aaccaggaag	aaccgtacca	gaaccactcc	ggccgattcg	tctgcactgt	acccggtac	540
tactacttca	ccttccaggt	gctgtcccag	tgggaaatct	gcctgtccat	cgtctcctcc	600
tcaagggggc	aggtccgacg	ctccctgggc	ttctgtgaca	ccaccaacaa	ggggctcttc	660
caggtggtgt	cagggggcat	ggtgcttcag	ctgcagcagg	gtgaccaggt	ctgggttgaa	720
aaagacccca	aaaaggggtca	catttaccag	ggctctgagg	ccgacagcgt	cttcagcggc	780
ttcctcatct	tcccatctgc	ctgagccagg	gaaggacccc	ctccccacc	cacctctctg	840
gcttccatgc	tccgcctgta	aaatgggggc	gctattgctt	cagctgctga	agggaggggg	900
ctggctctga	gagccccagg	actggctgcc	ccgtgacaca	tgctctaaga	agctcgtttc	960
ttagacctct	tcctggaata	aacatctgtg	tctgtgtctg	ctgaaaaaaa	aaaaaaaaaa	1020
a						1021

<210> 62  
 <211> 913  
 <212> DNA  
 <213> Homo sapiens

<400> 62						
ggcacgagga	aggccctatc	tgacctgcag	tgatggggca	tttgactctg	ggagtttctg	60
ggaacttttt	cttccccaga	ctttctctgt	ttttactgtt	tgcttggtta	cagattacac	120
aggcaaata	gccaggctt	ccagggaat	attccattaa	agcaatcaaa	ataacaattt	180
gtatcacttt	tagaacttct	gcctgaggag	ctaagaaatc	tttgacttaa	attattaatt	240
ctgggttgta	ctgtaaggat	cttccccctac	aaacaaacaa	tttaatat	cttttttggt	300
gcaacagagg	acgagttctc	cgggtctcca	gatctgcctc	aaaaggagg	aggaggtatt	360
taaaccaga	ctgtgatact	tctaaggaaa	ctgcctaaca	gaatgtgtcc	cgtccctctc	420
ggaggaagg	atggactgtc	agcctcggtc	accttgttct	cagggacact	cggcgctccc	480
acttatggtc	gggctgcacc	tgtgctggcc	acatggcaag	gaggtaagag	ccagagctct	540
ggagtcctct	gtcctggaac	ctggcgtgct	tacctgctgg	ctgtgtgatt	gggatagttt	600
gctccccctc	actcagcatc	agtttctcca	tccacaagag	gagggtagcc	atgccgat	660
gctagcacag	agctgggtgt	aggctccctg	gtgtctccaa	agtcctggac	agtgcctggc	720
acgtgggaga	cgttcagagg	atgttatatta	ttattatttg	cattctcagg	gaatgtctca	780
gtgatataga	cacggctctg	cctttcacca	ggggcaacgg	gggtgggggt	cacagagagt	840
gtgtggggag	gaggatgagg	aagaggggtc	caggtaggga	agtggaaaga	ggaagaaaaa	900
aaaaaaaaaa	aaa					913

<210> 63  
 <211> 1517  
 <212> DNA  
 <213> Homo sapiens

<400> 63						
gggtcgaccc	acgcgtccgc	tcgctgcggc	ggcgactgag	ccaggctggg	ccgcgtccct	60
gagtcaccaga	gtcggcgcg	cgcggcagg	gcagccttcc	accacgggga	gccagctgt	120
cagccgcctc	acaggaagat	gctgcgtcgg	cggggcagcc	ctggcatggg	tgtgcatgtg	180
ggtgcagccc	tgggagcact	gtgggttctgc	ctcacaggag	ccctggagg	ccaggctccct	240
gaagacccag	tgggtggcact	ggtgggcacc	gatgccaccc	tgtgctgctc	cttctccct	300
gagcctgggt	tcagcctggc	acagctcaac	ctcatctggc	agctgacaga	taccacacag	360
ctgggtgcaca	gctttgctga	gggccaggac	cagggcagcg	cctatgccaa	ccgcacggcc	420
ctcttcccg	acctgctggc	acagggcaac	gcctccctga	ggctgcagcg	cgtgcgtgtg	480
gcggacgagg	gcagcttcac	ctgcttcgtg	agcatccggg	atttcggcag	cgtgcctg	540
agcctgcagg	tggcgcctcc	ctactcgaag	cccagcatga	ccctggagcc	caacaaggac	600
ctgcggcccg	gggacacggt	gaccatcacg	tgctccagct	accagggcta	ccctgaggct	660
gaggtgttct	ggcaggatgg	gcagggtgtg	cccctgactg	gcaacgtgac	cacgtcgcag	720
atggccaacg	agcagggtct	gtttgatgtg	cacagcatcc	tgcgggtggg	gctgggtgca	780
aatggcacct	acagctgcct	ggtgcgcaac	cccgtgctgc	agcaggatgc	gcacagctct	840
gtcaccatca	cagggcagcc	tatgacattc	ccccagagg	ccctgtgggt	gaccgtgggg	900
ctctctgtct	gtctcattgc	actgctgggtg	gccctggctt	tcgtgtgctg	gagaaagatc	960
aaacagagct	gtgaggagga	gaatgcagga	gccgaggacc	aggatgggga	gggagaaggc	1020
tccaagacag	ccctgcagcc	tctgaaacac	tctgacagca	aagaagatga	tggacacagaa	1080
atagcctgac	catgaggacc	agggagctgc	taccctccc	tacagctcct	accctctggc	1140
tgcaatgggg	ctgcactgtg	agccctgccc	ccaacagatg	catcctgctc	tgacaggtgg	1200
gtccttctc	caaaggatgc	gatacacaga	ccactgtgca	gccttatttc	tccaatggac	1260

atgattccca	agtcattcctg	ctgcctttttt	ttcttataga	cacaatgaac	agaccaccca	1320
caaccttagt	tctctaagtc	atcctgcttg	ctgccttatt	tcacagtaca	tacattttctt	1380
agggacacag	tacactgacc	acatcaccac	cctcttcttc	cagtgtctgcg	tggaccatct	1440
ggctgccttt	tttctccaaa	agatgcaata	ttcagactga	ctgacccct	gccttatttc	1500
accaagaca	cgatgca					1517

&lt;210&gt; 64

&lt;211&gt; 2751

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 64

taacctcac	ttaaaggaac	aaaagctgga	gctccaccgc	ggtggcggcc	gctctagaac	60
tagtggatcc	cccgggctgc	aggaattcgg	cacgagtaga	gccgatctcc	cgcgccccga	120
ggttgctcct	ctccgaggtc	tcccgcggcc	caagttctcc	gcgccccgag	gtctccgcgc	180
cccgaggtct	ccgcggcccc	aggtctccgc	ccgcaccatg	cggctgggca	gtcctggact	240
gctcttcctg	ctcttcagca	gccttcgagc	tgatactcag	gagaaggaag	tcagagcgat	300
ggtaggcagc	gacgtggagc	tcagctgcgc	ttgccctgaa	ggaagccgtt	ttgatttaaa	360
tgatgtttac	gtatatgtgc	aaaccagtga	gtcgaaaacc	gtggtgacct	accacatccc	420
acagaacagc	tccttggaaa	acgtggacag	ccgctaccgg	aaccgagccc	tgatgtcacc	480
ggccggcatg	ctgcggggcg	acttctccct	gcgcttggtc	aacgtcacc	cccaggacga	540
gcagaagttt	cactgcctgg	tggtgagcca	atccctggga	ttccaggagg	ttttgagcrt	600
tgaggttaca	ctgcatgtgg	cagcaaaact	cagcgtgccc	gtcgtcagcg	ccccccacag	660
cccctcccag	gatgagctca	ccttcacgtg	tacatccata	aacggctacc	ccaggcccaa	720
cgtgtactgg	atcaataaga	cggacaacag	cctgctggac	caggctctgc	agaatgacac	780
cgtcttcttg	aacatgcggg	gcttgataga	cgtggtcagc	gtgctgagga	tcgcacggac	840
ccccagcgtg	aacattggct	gctgcataga	gaacgtgctt	ctgcagcaga	acctgactgt	900
cggcagccag	acaggaaatg	acatcggaga	gagagacaag	atcacagaga	atccagtcag	960
taccggcgag	aaaaacgcgg	ccacgtggag	catcctggct	gtcctgtgcc	tgcttgtggg	1020
cgtggcgggt	gccataggct	gggtgtgcag	ggacggatgc	ctccaacaca	gctatgcagg	1080
tgcttgggct	gtgagtcggg	agacagagct	cactggccac	gtttgaccgg	agctcaccgc	1140
ccagagcgtg	gacagggcct	ccatgagacg	ccaccgtgag	aggccagggt	gcagcttgag	1200
catggactcc	cagactgcag	gggagcactt	ggggcagccc	ccagaaggac	cactgctgga	1260
tcccagggag	aacctgctgg	cgttggtgtg	gatcctggaa	tgaggccctt	tcaaaagcgt	1320
catccacacc	aaaggcaaat	gtccccaagt	gagtgggctc	cccgtgtca	ctgccagtca	1380
cccacaggaa	gggactgggt	atgggctgtc	tctaccggga	gcgtgcggga	ttcagcacca	1440
ggctcttccc	agtaccccag	acccactgtg	ggtcttccc	tggtatgcgg	gatcctgaga	1500
ccgaaggggt	tttggtttta	aaagaagact	gggcgtccgc	tcttccagga	cggcctctgt	1560
gctgctgggg	tcacgcgagg	ctgtttgcag	gggacacggt	cacaggagct	cttctgccct	1620
gaacgctccc	aacctgcctc	ccgcccggaa	gccacaggac	ccactcatgt	gtgtgcccc	1680
aagtgtagtt	agccgtccac	accgaggagc	ccccggaagt	ccccactggg	cttcagtgtc	1740
ctctgcccac	ttccctggga	ggaacaatgt	ccctcggtcg	ttccgggtgaa	aagttgagcc	1800
accttttgaa	gacgcacggg	tggtgtttgc	cagaagaaag	gctgtgccag	ggccgtgttt	1860
ggctacaggg	gctgccgggg	ctcttggtct	tgacgcgaga	aagacacagc	ccagcagggc	1920
tggagacgcc	catgtccagc	aggcgcaggc	ctggcaacac	ggtccccaga	gtcctgagca	1980
gcagttaggt	gcatggagag	ggtatcacct	ggtggccaca	gtcccccttc	tcacctcagc	2040
aatgatcccc	aaagtgcagc	gtggctcccc	cggcccccc	caccctcagc	agccccaccc	2100
cactcaaccc	tgagggtccc	cagggtcctg	atgaagacct	ccgaccccag	cgcagggtc	2160
ctcgagagccc	aacagtccca	agggggcagg	agacggggtg	gtccagtgtc	gaggggtaca	2220
gccctggggc	ctgaccagcc	ccggcacctg	ccatgctggt	tcccgggaatg	aatcagctgc	2280
tgactgtctc	cagaagggct	ggaaaggatg	ctgccagggt	acccgagggt	cactcgcccc	2340
agggagatgg	agtagacagc	ctggcctggc	cctcgggaca	cattgtctgc	cccgggrcta	2400
tgggcaaatg	cccctccttc	ttacttccca	gaatccccctg	acattcccag	ggtcagccag	2460
gacctgttac	agccctgggt	acttggaaact	gacagctgtg	tgaggcctgc	acttctcaga	2520
cccagactta	gaacaaaagg	aggagtggag	actcaaggct	acaatgaggt	tccagtactt	2580
gttacaagaa	attgggttttc	tgcaaaaaaa	gtccctacct	grgccttttag	gtgaatgtgg	2640
gatccactcc	cgcttttaac	atgaaagcat	tagaagatgt	gtgggtgttta	taaaaraaaa	2700
aaaaaaaaaa	ctcgaggggg	ggcccgtacg	ggaattcgcc	ctatagtgag	t	2751

&lt;210&gt; 65

&lt;211&gt; 2150

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 65

ggcacgagca	acatggctgc	gcccgcacta	gggctgggtg	gtggacgttg	ccctgagctg	60
ggtctcgtcc	tcttgctgct	gctgctctcg	ctgctgtgtg	gagcggcagg	gagccaggag	120
gccgggaccg	gtgcgggcgc	ggggctccct	gcgggttctt	gcggctgcgg	cacgccccag	180
cggcctggcg	cccatggcag	ttcggcagcc	gctcaccgat	actcgcggga	ggctaaccgt	240
ccgggccccg	taccgggaga	gcggcaactc	gcgcactcaa	agatgggtccc	catccctgct	300
ggagtattta	caatgggcac	agatgatcct	cagataaagc	aggatgggga	agcacctgcg	360
aggagagtta	ctattgatgc	cttttacatg	gatgcctatg	aagtcagtaa	tactgaattt	420
gagaagtgtg	tgaactcaac	tggctatttg	acagaggctg	agaagtgttg	cgactccttt	480
gtctttgaag	gcatgttgag	tgagcaagtg	aagaccaata	ttcaacaggc	agttgcagct	540
gctccctggt	ggttacctgt	gaaaggcgct	aactggagac	acccagaagg	gcctgactct	600
actattctgc	acaggccgga	tcatccagtt	ctccatgtgt	cctggaatga	tgcggttgcc	660
tactgcactt	gggcagggaa	gcggctgccc	acggaagctg	agtgggaata	cagctgtcga	720
ggaggcttgc	ataatagact	tttcccctgg	ggcaacaaac	tgccagccaa	aggccagcat	780
tatgccaaac	tttggcaggg	cgagtttccg	gtgaccaaca	ctgggtgagga	tggttccaa	840
ggaactgcgc	ctgttgatgc	cttcccctccc	aatgggttatg	gcttatacaa	catagtgggg	900
aacgcatggg	aatggacttc	agactgggtg	actgttcatc	attctgttga	agaaacgctt	960
aaccctaaaag	gtcccccttc	tgggaaagac	cgagtgaaga	aagggtggatc	ctacatgtgc	1020
cataggtctt	attgttacag	gtatcgctgt	gctgctcgga	gccagaacac	acctgatagc	1080
tctgtctcga	atctgggatt	ccgctgtgca	gccgaccgcc	tgcccactat	ggactgacaa	1140
ccaaggaaaag	tcttccccag	tccaaggagc	agtcgtgtct	gacctacatt	gggcttttct	1200
cagaactttg	aacgatccca	tgcaaagaat	ttccaccctg	agggtgggtta	catacctgcc	1260
caatggccaa	aggaaccgcc	ttgtgagacc	aaattgctga	cctgggtcag	tgcatgtgct	1320
ttatgggtgtg	gtgcatcttt	ggagatcatc	gccataatttt	acttttgaga	gtctttaaag	1380
aggaagggga	gtggagggaa	ccctgagcta	ggcttcagga	ggccccgcgc	ctacgcaggc	1440
tctgccacag	gggttagacc	ccaggtccga	cgcttgacct	tcctgggctt	caagtgcctt	1500
cccctatcaa	atgaagggat	ggacagcatg	acctctgggt	gtctctccaa	ctcaccagtt	1560
ctaaaaaggg	tatcagattc	tattgtgact	tcatagtgag	aatttatgat	agattatttt	1620
ttagctatatt	tttccatgtg	tgaaccttga	gtgatactaa	tcattgtaaag	taagagtctt	1680
cttatgtatt	attttcggaa	gaggggtgtg	gtgactcctt	tatatctgta	ctgcactttg	1740
tttttccaag	gaaatcagtg	tcttttacgt	tgttatgatg	aatcccatat	ggggccgggtg	1800
atggtatgct	gcagttcagc	cgttgaacac	ataggaaatg	ctgtgggggtg	actctactgt	1860
gctttatctt	ttaacattaa	gtgcctttgg	ttcagagggg	cagtcataag	ctctgtttcc	1920
ccctctcccc	aaagccttca	gcgaacgtga	aatgtgctgt	aaacggggaa	acctgtttta	1980
ttctagatat	agggaaaaag	gaacgaggac	cttgaatgag	ctatatcag	ggtatccggt	2040
attttghtaat	agggaaatagg	aaaccttggt	ggctgtggaa	tatccgatgc	tttgaatcat	2100
gcactgtggt	gaataaacgt	atctgctaaa	tcaaaaaaaaa	aaaaaaaaaaa		2150

&lt;210&gt; 66

&lt;211&gt; 1161

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 66

ggcacgagtc	gtccagcccc	cggcgagagc	gggtatgtgg	gcgggaggcc	ggagcagctg	60
tcaggctgaa	gtcctgcgag	cgacgcgcgg	cggggcggcg	agaggaaacg	cggcgccggg	120
ccgggcccctg	gagatgggtcc	ccggcgccgc	gggctgggtg	tgtctcgtgc	tctggctccc	180
cgctgcgctc	gcggccccacg	gcttccgtat	ccatgattat	ttgtactttc	aagtgtctgag	240
tcctggggagc	attcgataca	tcttcacagc	cacacctgcc	aaggactttg	gtggtatctt	300
tcacacaagg	tatgagcaga	ttcaccttgt	ccccgctgaa	cctccagagg	cctgcgggga	360
actcagcaac	ggtttcttca	tccaggacca	gattgctctg	gtggagaggg	ggggctgctc	420
cttccctctcc	aagactcggg	tggtccagga	gcacggcggg	cgggcgggtga	tcattctctga	480
caacgcattg	acaatgacag	cttctacgtg	gagatgatcc	aggacagtac	ccagcgcaca	540
gctgacatcc	ccgcccctctt	cctgctcggc	cgagacggct	acatgatccg	ccgctctctg	600
gaacagcatg	ggctgccatg	ggccatcatt	tccatcccag	tcaatgtcac	cagcatcccc	660
acctttgagc	tgctgcaacc	gccctggacc	ttctggtaga	agagtgtgtc	ccacattcca	720
gccataagtg	actctgagct	gggaaggggga	aaccacaggaa	ttttgctact	tggaatttgg	780
agatagcatc	tggggacaag	tggagccagg	tagaggaaaa	gggtttgggc	gttgctaggc	840
tgaaagggaa	gccacaccac	tggccttccc	ttccccaggg	cccccaaggg	tgtctcatgc	900
tacaagaaga	ggcaagagac	aggccccagg	gcttctggct	agaacccgaa	acaaaaggag	960
ctgaagcgag	gtggcctgag	agccatctgt	gacctgtcac	actcacctgg	ctccagcctc	1020
ccctaccag	ggtctctgca	cagtgcacct	cacagcagtt	gttgagtggtg	tttaaagagc	1080
tgggtgtttg	ggactcaata	aacctctact	gacttttttag	caataaagct	tctcatcagg	1140
gttaaaaaaa	aaaaaaaaaa	a				1161

<210> 67  
 <211> 734  
 <212> DNA  
 <213> Homo sapiens

<400> 67  
 gctcgtgccg ctgctgggca ctgggagcag ggggcggcca aaggcagtgg gtgggcaggt 60  
 ccatgcctcc cctggccccc cagctctgca gggcagtgtt cctggttcct atcttgctgc 120  
 tgctgcaggt gaagcctctg aacgggagcc caggccccc aaatggggagc cagacagaga 180  
 aaacgccctc tgcagaccag aatcaagaac agttcgaaga gcactttgtg gcctcctcag 240  
 tgggtgagat gtggcaggtg gtggacatgg cccagcagga agaagaccag tcgtccaaga 300  
 cggcagctgt tcacaagcac tctttccacc tcagcttctg ctttagtctg gccagtgtca 360  
 tgggttttctc aggagggcca ttgaggcgga cattccccaa tatccaactc tgcttcatgc 420  
 tcaactcactg accctccctc cctcctgggc tccaggtcac aactccccaa ggagatgcag 480  
 gcatggctct ctgcctctga tcaccatcac tgtatctcaa ggttcagcag cagagatacc 540  
 agttgccatc agtgctaact gactgcctct ccagggtcgg agtttcatct cccagggcca 600  
 gagacagcag acccacatcc ttctctccca cactctcctt ggttttgttc aggacagcag 660  
 attagaggca ggaggcaatg acaataaaat aacgataaaa tcttgagaac aaaaaaaaaa 720  
 aaaaaaaact cgag 734

<210> 68  
 <211> 1583  
 <212> DNA  
 <213> Homo sapiens

<400> 68  
 attcggcacg aggaaacctg ctgctttcac agaggaaagg atttgctggc tttcccaagg 60  
 caagaacaat gaaaacaaag tcatgaggag ttctctctac ctcaaataaa ggccgcagct 120  
 cctgctcaag ctattttggc agtctgagag aacagtagat tctgaaccac attgacgcag 180  
 ggagcatggg tatctggacc tcaggcactg atatcttctt aagtcttttg gagatttacg 240  
 tgtctccaag aagccccgga tggatggact ttatccagca tttgggagtt tgctgtttgg 300  
 ttgctcttat ttcagtgggc ctctgtctg tggccgcctg ctggtttctg ccatcaatca 360  
 tagcggccgc tgcctcctgg attatcacgt gtgttctgct gtgttgctcc aagcatgcac 420  
 gatgttttat tcttcttgtc tttctctctt gtggcctgct tgaaggcagg aatgctttga 480  
 ttgcagctgg cacagggatc gtcactcttg gacacgtaga aaatatctt cacaacttta 540  
 aaggtctcct agatgggtatg acttgcaacc taaggggcaa gagcttttcc atacattttc 600  
 cacttttgaa aaaatatatt gaggcaattc agtggattta tggccttgcc actccactaa 660  
 gtgtatttga tgacctgtt tcttgggaacc agaccctggc agtctctctt ttcagtccca 720  
 gccatgtcct ggaggcacag ctaaatgaca gcaaagggga agtccctgagc gtcttgtacc 780  
 agatggcaac aaccacagag gtgttgtcct ccctgggtca gaagctactt gcctttgcag 840  
 ggctttctgt cgtctgtctt ggcactggcc tcttcatgaa gcgatttttg ggcccttgtg 900  
 gttggaagta tgaaaacatc tacatcacca gacaatttgt tcagtttgat gaaagggaga 960  
 gacatcaaca gaggccctgt gtgtctccgc tgaataagga ggaaaggagg aaattcattt 1020  
 ctggcttcca gtcttgaata tgattaggaa gaagcaaata gacatggcaa gtgcagacaa 1080  
 gtcattgagag acccgcacta ctctcagacc acatcgcacc aacaattctc ttcaggtcta 1140  
 ggatggcagt cactattcat gccggataat agagaactat gtgacgcagt cctctcagga 1200  
 gtctgagttt acagagccaa cttgcagcac ctgggttatgc ctcttttcat ctcaaagcca 1260  
 aagagctgcc aggtaaatgg ttatgtgtgtc tatgttccaa acaaaccaca tgatcttgcc 1320  
 tgtgtcacia tgtaacaaga ctctagctgg gtcccttggg gatgagtttc agcatagaat 1380  
 aatgttcaag gaaaagaaaa cgaaaacagt ttaaatctct accacagcct cacaagcaaa 1440  
 tgctaagggg aacatacatg taaaaagcca gcaaactatc ttcaaactct tccgtcctta 1500  
 atgtcttcca tggctattgc ccccaaatg gtctcttttc tccctgtctc cttattaaag 1560  
 aactctttct gaaaaaaaaa aaa 1583

<210> 69  
 <211> 1444  
 <212> DNA  
 <213> Homo sapiens

<400> 69  
 gaattcggca cgaggaagaa tctgagagaa acctgacgca gggagcatgg gtatctggac 60  
 ctgaggcact gatattcttc taagtctttg ggagatttac gtgtctccaa gaagccccgg 120  
 atggatggac tttatccagc atttgggagt ttgtgttttg gttgtcttta tttcagtggg 180

cctcctgtct	gtggccgcct	gctgggtttct	gccatcaatc	atagcggccg	ctgcctcctg	240
gattatcacg	tgtgttctgc	tgtgttgctc	caagcatgca	cgatgtttta	ttcttcttgt	300
ctttctctct	tgtggcctgc	gtgaaggcag	gaatgctttg	attgcagctg	gcacagggat	360
cgtcactctg	ggacacgtag	aaaatatatt	tcacaacttt	aaaggtctcc	tagatggtat	420
gacttgcaac	ctaagggcaa	agagcttttc	catacatttt	ccacttttga	aaaaatatat	480
tgaggcaatt	cagtggattt	atggccttgc	cactccacta	agtgtatttg	atgaccttgt	540
ttcttggaa	cagaccctgg	cagtctctct	tttcagttcc	agccatgtcc	tggaggcaca	600
gctaaatgac	agcaaagggg	aagtcctgag	cgtcttgtag	cagatggcaa	caaccacaga	660
ggtgttgtcc	tccttgggtc	agaagctact	tgcctttgca	gggctttcgc	tcgtcctgct	720
tggcactggc	ctcttcatga	agcgattttt	gggcccctgt	ggttgggaagt	atgaaaacat	780
ctacatcacc	agacaatttg	ttcagtttga	tgaaggggag	agacatcaac	agaggccctg	840
tgtgctcccc	ctgaataagg	aggaaaggag	gaaattcatt	tctggcttcc	agtcctgaaa	900
atgattagga	agaagcaaat	ggacatggca	agtgcagaca	agtcagatgag	gaccccgact	960
actcctcagc	cacatcgcac	caacaattct	cttcaggtct	aggatggcag	tcactattca	1020
tgccggataa	tagagaacta	tgtgacgcag	tctctcagg	agtctgagtt	tacagagcca	1080
acttgcagca	cctgggttatg	cctcctttca	tctcaaagcc	aaagagctgc	caggtaaattg	1140
gttatgtggt	ctatgttcca	aacaaaccac	atgatcttgc	ctgtgtcaca	atgtaacaag	1200
actctagctg	ggccccctgg	tgatgagttt	cagcatagaa	taatgttcaa	ggaaaagaaa	1260
acgaaaacag	tttaaactct	taccacagcc	tcacaagcaa	atgctaaggg	gaacatacat	1320
gtaaaaagcc	agcaaaactat	cttcaaactc	ttccgtcctt	aatgtcttcc	atggctattg	1380
ccccacaaat	ggtctctttt	ctccctgctc	ccttattaaa	gaactctttc	tgaaaaaaaa	1440
aaaa						1444

<210> 70  
 <211> 1892  
 <212> DNA  
 <213> Homo sapiens

<400> 70						
attcggcacg	aggaaacctg	ctgctttcac	agagggaaggc	atttgcctggc	tttcccaagg	60
caagaacaat	gaaaacaaag	tcatgaggag	ttctctctac	ctcaaatgaa	ggccgcagct	120
cctgctcaag	ctatttttggc	agtctgagag	aacagtacat	tctgaaccac	attgacgcag	180
ggagcatggg	tatctggacc	tcaggcactg	atatcttcc	aagtctttgg	gagatttacg	240
tgtctccaag	aagccccgga	tggatggact	ttatccagca	tttgggagtt	tgctgttttg	300
ttgctcttat	ttcagtgggc	ctcctgtctg	tggccgcctg	ctgggtttctg	ccatcaatca	360
tagcggccgc	tgcctcctgg	attatcacgt	gtgttctgct	gtgttgctcc	aagcatgcac	420
gatgttttat	tcttcttctt	ttctctctct	gtggcctgcg	tgaaggcagg	aatgctttga	480
ttgcagctgg	cacagggatc	gtcatcttgg	gacacgtaga	aaatatattt	cacaacttta	540
aaggtctcct	agatgggatg	acttgcaacc	taagggcaaa	gagcttttcc	atacattttc	600
cacttttgaa	aaaatatatt	gaggcaattc	agtggattta	tggccttgcc	actccactaa	660
gtgtatttga	tgaccttgtt	tcttggaaac	agaccctggc	agtctctctt	ttcagtccca	720
gccatgtcct	ggaggcacag	ctaaatgaca	gcaaagggga	agtccctgagc	gtcttgtacc	780
agatggcaac	aaccacagag	gtgttgtcct	cctgggtca	gaagctactt	gcctttgcag	840
ggctttcgct	cgctctgctt	ggcactggcc	tcttcatgaa	gcgatttttg	ggcccttgtg	900
gttggaaagta	tgaaaacatc	tacatcacca	gacaatttgt	tcagtttgat	gaaagggaga	960
gacatcaaca	gaggccctgt	atgctcccgc	tgaataagga	ggaaaggagg	aaaaacaagg	1020
aactcaagat	attatccatg	attcttccct	taatatatct	gtgtttgaac	ccaactgtat	1080
cccaaaacca	aaattccttc	tatctgagac	ctgggttcc	ctcagtgtta	ttcttttgat	1140
attagtgatg	ctgggactgt	tgctctctat	ccttatgcaa	cttaaaatcc	tgggtgtcagc	1200
atctttctac	cccagcgtgg	agagggaagcg	catccaatat	ctgcatgcaa	agctgcttaa	1260
aaaaagatca	aagcagccgc	tgggagaagt	caaaagacgg	ctgagctctt	atcttacaaa	1320
gattcatttc	tggcttccag	tcctgaaaat	gattaggaag	aagcaaatgg	acatggcaag	1380
tgacagacaag	tcatgagaga	ccccgactac	tcctcagcca	catcgcacca	acaattctct	1440
tcaggtctag	gatggcagtc	actatttcag	ccggataata	gagaactatg	tgacgcagtc	1500
ctctcaggag	tctgagttta	cagagccaac	ttgcagcacc	tgggttatgcc	tcctttcatc	1560
tcaaagccaa	agagctgcca	ggtaaatggt	tatgtgtgct	atgttccaaa	caaaccacat	1620
gatcttgcct	gtgtcacaa	gtaacaagac	tctagctggg	tccttgggtg	atgagtttca	1680
gcatagaata	atgttcaagg	aaaagaaaac	gaaaacagtt	taaatctcta	ccacagcctc	1740
acaagcaaat	gctaagggga	acatacatgt	aaaaagccag	caaactatct	tcaaaactct	1800
ccgtccttaa	tgtcttccat	ggctattgcc	cccacaatgg	tctcttttct	cctgtctccc	1860
ttattaaaga	actcttttctg	aaaaaaaaaa	aa			1892

<210> 71  
 <211> 1439



<212> DNA  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (1281)  
<223> n equals a,t,g, or c

<400> 71  
gaattcggca cgaggaagaa tctgagagaa acctgacgca gggagcatgg gtatctggac 60  
ctcaggcact gatattctcc taagtctttg ggagatttac gtgtctccaa gaagccccgg 120  
atggatggac tttatccagc atttgggagt ttgtctgttg gttgctctta tttcagtggg 180  
cctcctgtct gtggccgcct gctggtttct gccatcaatc atagcggccg ctgcctcctg 240  
gattatcacg tgtgttctgc tgtgttgctc caagcatgca cgaatgttta ttcttcttgt 300  
ctttctctct tgtggcctgc gtgaaggcag gaatgctttg attgcagctg gsacagggat 360  
cgtcatcttg ggacacgtag aaaatatatt tcacaacttt aaaggctcycc tagatgggat 420  
ratttgcaac ctaagggcaa agagcttttc catacatttt ccaactttkga aaaaatatat 480  
tgaggcaatt cagtggattt atggccttgc cactccacta agtgtatytg atgaccttgt 540  
ttcttggaaac cagaccctgg cagtctctct tttcagtcce agccatgtcc tggaggcaca 600  
gcyaatatgac agcaaagggg aagtcctgag cgtcttgtag cagatggcaa caaccacaga 660  
ggtgttggcc tcccctgggt cagaagctac ttgcctttgc agggctttcg ctgcctctgc 720  
ttggcactgg cctcttcatg aagcgatttt tgggcccctg tggttggaag tatgaaaaca 780  
tctacatcac cagacaattt gttagatttg atgaaagggg gagacatcaa cagaggccct 840  
gtgtgctccc gctgaataag gaggaaagga ggaaattcat ttctggcttc cagtccctgaa 900  
aatgattagg aagaagcaaa tggacatggc ragygcagac aagtcatgag agaccccgac 960  
tactctcag ccacatcgca ccaacaattc tttcaggtc taggatggca gtcactattc 1020  
atgccggata atagagaact atgtgacgca gtctctctag gagtctgagt ttacagagcc 1080  
aacttgcagc acctgggttat gcctcctttc atctcaaagc caaagagctg ccaggtaaat 1140  
ggttatgtgg tctatgttcc aaacaaacca catgatcttg cctgtgtcac aatgtaacaa 1200  
gactctagct ggggtcccctg gtgatgagtt tcagcataga ataatgttca aggaaaagaa 1260  
aacgaaaaca gtttaaatynt ntaccacagc ctcaacaagc aatgtctaagg ggaacataca 1320  
tgtaaaagc cagcaaaacta tcttcaaaact cttccgtcct taatgtcttc catggctatt 1380  
gccccacaa tgggtctcttt tctccctgct cccttattaa agaactcttt ctgaaaccg 1439

<210> 72  
<211> 1395  
<212> DNA  
<213> Homo sapiens

<400> 72  
gaattccccg ggccccggga atccccgggc ccaatctcaa gatcgacagc acccctgtaa 60  
agccggctgg cggtggctgt tgctaggagg ggcacatgga gtgggacagg agggggcacc 120  
ttctccagat gatgtccctg gagggggcag gaggtacctc cctctccctc tccctgggca 180  
tttgagtctg tggctttggg gtgtcctggg ctccccatct ccttctggcc catctgcctg 240  
ctgccctgag ccccggttct gtcagggtcc ctaaggaggg acactcaggg cctgtggcca 300  
ggcagggcgg aggcctgctg tgctgttgcc tctaggtgac ttccaagat gccccctac 360  
acacctttct ttggaacgag ggctcttctg tgggtgtccc tcccaccccc atgtatgctg 420  
cactgggttc tctccttctt ctctctgctg tctgcccac gaactgaggg tctccccggc 480  
ctctactgcc ctggctgcag tcagtgccca gggcgaggaa tgtggccagg ggatccagga 540  
cctgggatcc agggccctgg gctggacctc aggacaggca tggaggccac agggggcccag 600  
cagccccacc tttcctctcc ccaactgcctc ctctcccttc ctacactccc agctcgagcc 660  
gtccagctgc ggtgggatct gagtatatct agggcggtg ggcgggtagc agtgcctggc 720  
ctgtgtcttg agcctggagg gagtctgctc ctgcccctcc cctgcccctg agagacagac 780  
ccatgcgctg cctgcccacc gtgccccttt gtccccatgt caggcgaggg cggaaggccc 840  
accgtgcccag aggcctggga ccagccttaa cctcactct gctagcacct cctccctttc 900  
cccaaggtag cacatctggc tcaactccca ctccgtctct ggagcccacc aggggaaggcc 960  
ctcatccctt gccgtactt ctctggggaa tgtgggttcc atccaggatt gggggcctct 1020  
ctgctcacc actctgcacc caggatccta gtcccctgcc ctctggcaca gctgcttctt 1080  
gcaagaaagc aagtcttttg tctccctgag aagccatgtc cctcgtgctg tctcttgctt 1140  
gtcccacctg tgccctgccc tccagcttgt atttaagtc ctgggctgcc cccttggggg 1200  
gcccccgct cccaggttcc cctctggtgt catgtcagge attttgcaag gaaaagccac 1260  
ttggggaaag atggaaaagg acaaaaaaaa ttaataaatt tccattggcc ctcggtgag 1320  
ctgagggttt ttgcaaggaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380  
aaaaaaaaa ctcca 1395



<210> 73  
 <211> 1293  
 <212> DNA  
 <213> Homo sapiens.

<220>  
 <221> SITE  
 <222> (1214)  
 <223> n equals a,t,g, or c

<400> 73  
 ggacagagca ggaacccctt cctgcccccg ttgccgaggc agcactgccc tctgctagga 60  
 acagctccgt gttggcctct ctgtccccac acaactgggc tgcagggctt ctccgagact 120  
 cttcagttca ggtatcaacc ctkggctgtc tccctggratg tggggggcgr atgttctttc 180  
 cttgectccc cacgctcytc ytgcgatcc ttcactccgg gtgggtcggc ctcttctctc 240  
 tgatcagctc cagagcccy tctagttccc tggcatggaa acacggcccg ggtragctgt 300  
 ggtggccccc raggcctctc cgtctctgca caggccttgc ttcttgccgg tgacgaggtc 360  
 ctggactctc tcctgcccag gcttctgggt gctttcctta gttcagcacc agtgctctgt 420  
 gtgggcagcg tctccccga ggatccgcag ctccgggtta cccgcaggcg tccatctccg 480  
 gtatgggtgt gcccttcaact gatcctgggt gtatttctgt ttcttgcttt cctcatcgcc 540  
 tcctgtttcg gttgatctct tctttttgct ggtgcccgtc tcacagtagc ttcttgagaa 600  
 cggggacctg gcaggtacac ttcagacctc ctgtgtctga aatagtgtcc tgggtctgac 660  
 ctgcacttga gtgtcgggtga ggcctgggca gggttccggg tgggagctca gtttctgctc 720  
 gagtttctca ggccccaacc atggcctgtg gtggcttcac gggctacaag gcaaaggacg 780  
 caaacgaaga ggcttcacgt gacagggttg tatgctcagc cagctctgga ggctggagtc 840  
 tgagctggca gcactgacag ggtcagctct cctcggaggc tgctggggag gagcctctg 900  
 cctcttccgg gctccggggg cctctggcac ccccggtgtc cccgggcttg gagacgcagc 960  
 actcccatgt ctgccggttc ccctggccgc ctctctgtgt tcattgtctg ttctcttcat 1020  
 atagggacac cagtcatcga attggagggt cactctactc aagtatgacg tcaccgtgat 1080  
 ttacttgatt ttatgtccca ggccgtatcc taacaagggc acatcctgtg ttctgggaag 1140  
 ggcgtgtcgc tggggaaata ctcttcaccc ggctgcaacc tctcactgta gaactgcctc 1200  
 tgtggagaag ccnaagggc atttgccggt tctaggagcc aagtaggagg aggctgggat 1260  
 ccgtgtktca ggccgggactc caggcttggg cgg 1293

<210> 74  
 <211> 3147  
 <212> DNA  
 <213> Homo sapiens

<400> 74  
 tttttatggg aattaaaaaa ttaaaaaaac tgaaacttgt gaaaaaaaat gttattttaat 60  
 tgtaaaatct ccaccccttg agcatatggt ttccaggtctg ggtgactaat tagactggga 120  
 aacaagggca ggaacgatgg ccctgtgctt gctctgcccg ctgectctgt ggatgtgtgg 180  
 gccgtggct tcagtcctgc ttttttgatg gccgttgttt acgctatgta tttttgcagg 240  
 aggcctgagg tgggctgggt tctcctccta tggcagggtc tcaactctct cctccgttgg 300  
 ggcttcgctg tcccttgaga atccttcttc atcttcttgt aatgaccttc ggtgacaaca 360  
 gatctcaatg aggcagagaa gtataatcaa aatcgtagt attccagtca caattaacgc 420  
 caagatgagt tttttggtat agccatatcc tggaaagtct tttgtgaact caagcgactt 480  
 ctctttctgt tcaactctggg ctctctgtgt ctcattaatg tagttctcag tcttccattg 540  
 gtccgtatcc cattctatct tggatgcctt tacttctctg tgcccactga gaagcttcat 600  
 cagggtggct gtccctggaga cgagcttggc acagggtcact tgcacatggg ccccgagagca 660  
 gtccatcttc aaggctccga taacatgagc aatgagcctt ctacacattgt tggttggggat 720  
 aagggaactgt agctgctggg ttagctgaat ttcaaactga tcacctgggg acgagagcaa 780  
 tgggtaattg aagcttttgg gctcggggga caggctcagt cccacgttgt tgtattccca 840  
 ttttgtctca gtttgtttaa cagttggccc taagttgaat gcagtcocag cggaatctgc 900  
 ctcaggagga tgattgtagt ttgtgttttc agagatgggt acttctggca tgttagtgtt 960  
 ttccataaaa acattttctt ccaaggcatt tcttgaggt gtgtctttta tattagtggg 1020  
 ttctataaaa tgttctgaag gagcagatac ttccagaaaa gggttttctt gaggactcag 1080  
 gtctcctaag gatgaaaaag ccccttctga aggggaattt atgaggctct tcgctgcaga 1140  
 gaacggaggc ctgtttgcga gcatacagct actcagataa ctttcttttc tgaactttgg 1200  
 actctttttg accttgggtg ttctgtgggt catgcccggag cgagttttgt gaaagcggta 1260  
 tttttttctg gaatgtgaaa ttgggttaga agccttcata tttgtaactc tagcctttgc 1320  
 actttctaaa atggaaatag cgtgtgtgtg tctttccatc tgtctctcac ctgtggtagg 1380  
 gcttttgcag ggctggagggt agaaggcgcg cccttggaga agggtttcag cacagagact 1440

gctgccttat	gctcctgggt	gaacgaaggc	ttgggtgtaga	cgccgctttcc	cgctaacttc	1500
tcaggccctt	gctgtgtgtg	aggctgttcc	agctcccttg	gggctggact	cccagaccct	1560
ttttcttcgg	cagcgttctc	cacagatgcc	tgggcaccct	gttccctcct	gatgctctgc	1620
cttccacact	ctttgaagtg	ccttttctgg	atgctccttg	ggcccatgag	gactctattc	1680
actttttgct	ggttttggcc	tacagtttga	atctttgcca	ggctgtttcc	tgtgggttggc	1740
agtttaaatga	acggtagtaa	cagtgtattc	acatctaggt	ttactgtctga	gaaatatggc	1800
aaatgtaact	tagtgtactg	ataaaatcac	tctcgtcatt	ggtgtctagc	tgctcactcc	1860
caaagcctga	caagttgatg	ccactgctgt	ctgagggctc	ctctggctca	acaatcagct	1920
cagtgccttg	tagttcttcc	gggcttgtaa	caccttcctg	aacgctcctt	ctggattccc	1980
gaccgatgct	tcttcagctg	tcaaaaaaga	agagactgct	ttgatcatga	aagatgatgg	2040
gatgggatgc	atcagtcctc	agctgtacac	cccagtcaca	cagagtagga	gtcagcaaac	2100
attcgagtgc	cattcagaga	ggagaaacac	acacccaatc	ctaaacctat	gaaatggcaa	2160
caacaaaagg	agaaaataca	tcttttgaaa	acacggccac	ctacttgga	cattccatag	2220
tgtgacatag	agtaactctg	tttaggatta	tttcgttgat	ccccagaggc	caattgccc	2280
gtgctcagtc	aaagcccaag	gtggaagaca	agtgccttcc	tgatgagctg	gcctctctgc	2340
agactgctcc	gtaccctgtg	ctgtcctgcc	tcagatgcag	agagagcaca	aggctcctgc	2400
tctcctcgtc	ctcgggtgcac	ctgtgttcgt	gctaccatca	cagctgaatg	caatgaaagg	2460
cggtcctctg	agaggagcag	ggtggagatg	ctaaagtgg	ggccccgtcc	cattgctgat	2520
agatcctcat	ctggcatgcg	ctccaccctc	cccattctct	gtccccacgt	atcgtagccc	2580
catcacagaa	gatgcgacat	ggaaaaacgc	actgtgtcca	ccctagtctt	taaatttggg	2640
cagggatttg	gggtgtatgt	taagagtttt	tcaaatttgc	cagattgtat	gcctatgttg	2700
ttaaatacac	aatgaatccc	tggatatgata	gcagtttctg	gataaacatt	acttgaggtc	2760
ctaaaatgca	gaagggaaaa	agcaactttt	gtcagatgcc	tactttgctt	tcatttcac	2820
tctaataatt	tggatgggga	atcatccaaa	gcttctgact	gcatgaagg	caggtgtgcc	2880
agtgtgcagc	tgggttttct	ttctgggaatt	aaaagtactt	tgggtgtgtg	tgagggtcag	2940
aggaagaagt	aaagattgtg	agaaagggga	agaaacatgg	gcttggggag	aaccagaat	3000
tggggccaga	agacctggca	ctaggctaca	gcacttagca	cctctgatct	tgtttttcc	3060
catctgtaaa	aggaggttaa	caaagctttt	ctgcccactt	cttggggaga	agggaataac	3120
ataattggta	aaaaaaaaaa	aaaaaaa				3147

<210> 75  
 <211> 1989  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (31)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (161)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (162)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (1702)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (1943)  
 <223> n equals a,t,g, or c

<400> 75						
ttaaataaaa	tcaaaattgg	ccatttgaca	naagttgggt	tttccctttt	ctgcattttt	60
aggacctcaa	agtaatgttt	atccagaaac	tgctatcatt	accagggatt	cattcgtgta	120
tttaacaaca	tggggcatac	attttgccca	aatttgaaaa	nntcttaaca	tacaccccaa	180
aatccctgcc	ccaaatttaa	gaactagggt	ggacacagtg	cgttttttcca	tgctgcacat	240

tctgtgatgg	ggctacgata	cgtggggagca	gagaatgggg	aggttggagc	gcatgccaga	300
tgaggatcta	tcagcaatgg	gacgggkcct	ccacttttagc	atctcyaccc	tgctcctytc	360
agaggaccgc	ctttcattgc	attcagctgt	gatggtagca	cgaacacagg	tgaccgagg	420
acgaggagag	caggagcctt	gtgctctctc	tgcatctgag	gcaggacagc	acagggtagg	480
gagcagtctg	cagagaggcc	agctcatcag	ggaagcactt	gtcttccacc	ttgggctttg	540
actgagcact	gggcaattgg	mcycctgggga	tcaaygaaat	aatcctaarc	agagttactc	600
tatgtcacac	tatggaatgt	tccaagtasr	tggccgtgtt	ttcaaaagat	rtattttctc	660
cttttgttgt	tgccatttca	taggttttagg	attgggtgtg	tgktctctct	ctctgaatgg	720
cactcraatg	tttgctgact	cctactctgt	gtgactgggg	tgtacagcta	tggactgatg	780
catcccatcc	catcatcttt	catgatcaaa	gcagtctctt	cttttttgac	agctgaagaa	840
gcatcggtag	ggaatccaga	aggagcgttc	atgaagggtg	tacaagcccg	gaagaactam	900
acaagcactg	agctgattgt	tgagccagag	gagccctcag	acagcagtgg	catcaacttg	960
tcaggctttg	ggagttagca	gctagacacc	aatgacgaga	gtgatkttat	cagtacacta	1020
agttacatct	tgccwtattt	ctcagcrgta	aacctagatg	tgraatcamt	gttactaccg	1080
ttcattaaac	tgccaaccmc	aggaaacagc	ctggcaaaga	ttcaaactgt	aggccaaaac	1140
crgcararag	tgaakagagt	cctcatgggc	ccaaggagca	tccagaaaag	gcacttcaaa	1200
gaggttggaa	ggcagagcat	caggagggaa	cagggtgccc	aggcatctgt	ggagaacgct	1260
gccgaagaaa	aaaggctcgg	gagtccagcc	ccaagggags	tggaacagcc	ycacacacag	1320
cagggccttg	agaagtttagc	gggaaacgcc	rtctacacca	agccttcstt	cacccaagag	1380
cataagggcag	cagtctctgt	gctgamaccc	ttctccaagg	gcgcgccttc	tacctccagc	1440
cctgcaaaaag	ccctaccaca	ggtgagagac	agatggaaag	acwwmacmca	crctatttcc	1500
atttttagaaa	gtgcaaaggc	tagagttaca	aatatgaagg	cttctaaacc	aatttcacat	1560
tccagaaaaa	aataccgctt	tcacaaaact	cgctcccgcg	tgacccacag	aacacccaag	1620
gtcaaaaaga	gtccaaagtt	cagaaagaaa	agttatctga	gtagactgat	gctcgcaaac	1680
aggcctccgt	tctctgcagc	gnagagcctc	ataaaattccc	cttcacaagg	ggctttttca	1740
tccttagggag	acctgagtc	tcaagaaaac	ccttttytgg	ragtatctgc	tccttcagaa	1800
catttttatag	aaaccactaa	tataaaagac	acaactgcaa	gaaatgcctt	ggaagaaaat	1860
gttttttatgg	aaaacactaa	catgccagaa	gtcaccatct	ctgaaaacac	aaactacaat	1920
catcctcctg	aggcagattc	cgntggggact	gcattcaact	tagggccaac	tgtaaataaa	1980
actgagaca						1989

<210> 76  
 <211> 1879  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (41)  
 <223> n equals a,t,g, or c

<400> 76						
agacctttga	taacataacc	attagcagag	aggctcaggg	ngagggtccct	gcctcgggact	60
caaagaccga	atgcacggcc	ttgtagggga	cgccccagat	tgctcagggat	kgggggatgg	120
tccttggagt	tttgcattgt	ctcctccctc	ccacttctgc	accctttcac	cacctcgagg	180
agatttgctc	cccattagcg	aatgaaattg	atgcagtcct	acctaactcg	attccctttg	240
gcttgggtgg	taggcctgca	gggcactttt	attccaaccc	ctggtcaytc	agtamtstkt	300
tactccagga	aggcacagga	tggtacctaa	agagaattag	agaatgaacc	tggckrgacg	360
gatgtctaat	cctgcrctta	gctgggttgg	tcagtagaac	ctattttcag	actcaaaaac	420
catcttcaga	aagaaaaggc	ccaggggaagg	aatgtatgag	aggctctccc	agatgaggaa	480
gtgtactctc	tatgactatc	aagctcaggg	ctctcccttt	ttttaaacca	aagtctggca	540
accaagagca	gcagctccat	ggcctccttg	ccccagatca	gcctgggtca	ggggacatag	600
tgtcatttgt	tggaaaactgc	agacacaagg	tgtgggtcta	tcccacttcc	tagtgctccc	660
cacattcccc	atcagggtct	cctcacgtgg	amaggktgtc	tartccaggg	agttcacttg	720
cagtttccct	gtcctcatgc	ytcggggatg	ggagccmcgm	cygaactaga	gttcaggctg	780
gatacatgtg	ctcacctgct	gctcttgtct	tcctaagaga	cagagagtgg	ggcagatgga	840
ggagaagaaa	gtgaggaatg	agtagcatag	cattctgcca	aaagggcccc	agattcttaa	900
tttagcaaac	taagaagccc	aattcaaaaag	catttgtggct	aaagtctaac	gctcctctct	960
tggctcagata	acaaaagccc	tccctgtttgg	atcttttgaa	ataaaaacgtg	caagttatcc	1020
aggctcgtag	cctgcatgct	gccaccttga	atcccaggga	gtatctgcac	ctggaatagc	1080
tctccacccc	tctctgcctc	cttactttct	gtgcaagatg	acttctctgg	ttacttctct	1140
tctttccatc	cacccaccca	ctggaatctc	tttccaaaca	tttttccatt	ttcccacaga	1200
tgggctttga	ttagctgtcc	tctctccatg	cctgcaaagc	tccagatttt	tggggaaagc	1260
tgtacccaac	tggactgccc	agtgaactgg	gatcattgag	tacagtcgag	cacacgtgtg	1320
tgmattgggtc	aaaggggtgt	gttccctctc	atcctagatg	ccttctctgt	gccttccaca	1380

41

gcctcctgcc	tgattacacc	actgcccccg	ccccaccctc	agccatccca	attcttcctg	1440
gccagtgcgc	tccagcctta	tctaggaaag	gargagtggg	tgtagccgtg	cagcaagatt	1500
ggggcctccc	ccatcccagc	ttctccacca	tcccagcaag	tcaggatata	agacartcct	1560
cccctgaccc	tcccccttgt	agatatcaat	tcccaaacag	agccaaatac	tctatatcta	1620
tagtcacagc	cctgtacagc	atttttcata	agttatatag	taaatggtct	gcatgatttg	1680
tgcttctagt	gctctcattt	ggaaatgagg	caggcttctt	ctatgaaatg	taaagaaaga	1740
aaccactttg	tatatatttg	aataccacct	ctgtggccat	gcctgccccg	cccactctgt	1800
atatatgtaa	gttaaaccgc	ggcaggggct	gtggccgtct	ttgtactctg	gtgattttta	1860
aaaattgaat	ctttgtact					1879

<210> 77  
 <211> 1879  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (41)  
 <223> n equals a,t,g, or c

<400> 77						
agacctttga	taacataacc	attagcagag	aggctcaggg	ngaggtcctt	gcctcggact	60
caaagaccga	atgcacggcc	ttgtagggga	cgccccagat	tgtaggggat	kggggggatgg	120
tccttgaggat	tttgcatgct	ctcctccctc	ccacttctgc	accctttcac	cacctcgagg	180
agatttgctc	cccattagcg	aatgaaattg	atgcagtcct	acctaactcg	attccctttg	240
gcttggtggg	taggcctgca	gggcactttt	attccaaccc	ctggtcaytc	agtamtstkt	300
tactccagga	aggcacagga	tggtacctaa	agagaattag	agaatgaacc	tggckrgacg	360
gatgtctaata	cctgcrctta	gctgggttgg	tcagtagaac	ctattttcag	actcaaaaac	420
catcttcaga	aagaaaaggc	ccaggggaagg	aatgtatgag	aggctctccc	agatgaggaa	480
gtgtactctc	tatgactatc	aagctcaggg	ctctcccttt	ttttaaacca	aagtctggca	540
accaagagca	gcagctccat	ggcctccttg	ccccagatca	gcctgggtca	ggggacatag	600
tgtcattgtt	tggaaactgc	agacacaagg	tgtgggtcta	tcccacttcc	tagtgctccc	660
cacattcccc	atcagggctt	cctcacgtgg	amaggtktgc	tartccaggc	agttcacttg	720
cagtttcctt	gtcctcatgc	ytcggggatg	ggagccmcgm	cygaactaga	gttcaggctg	780
gatacatgtg	ctcacctgct	gctcttgtct	tcctaagaga	cagagagtgg	ggcagatgga	840
ggagaagaaa	gtgaggaatg	agtagcatag	cattctgcca	aaagggcccc	agattcttaa	900
tttagcaaac	taagaagccc	aattcaaaaag	cattgtggct	aaagtctaac	gctcctctct	960
tgggtcagata	acaaaagccc	tccctgttgg	atcttttgaa	ataaaaacgtg	caagttatcc	1020
aggctcgtag	cctgcatgct	gccaccttga	atcccaggga	gtatctgcac	ctggaatagc	1080
tctccacccc	tctctgcctc	cttactttct	gtgcaagatg	acttcctggg	tttaacttct	1140
tctttccatc	cacccaccca	ctggaatctc	tttccaaaca	tttttccatt	ttcccacaga	1200
tgggctttga	ttagctgtcc	tctctccatg	cctgcaaagc	tccagatttt	tggggaaagc	1260
tgtacccaac	tggactgccc	agtgaactgg	gatcattgag	tacagtcgag	cacacgtgtg	1320
tgcattgggtc	aaaggggtgt	gttcctttct	atcctagatg	ccttctctgt	gccttccaca	1380
gcctcctgcc	tgattacacc	actgcccccg	ccccaccctc	agccatccca	attcttcctg	1440
gccagtgcgc	tccagcctta	tctaggaaag	gargagtggg	tgtagccgtg	cagcaagatt	1500
ggggcctccc	ccatcccagc	ttctccacca	tcccagcaag	tcaggatata	agacartcct	1560
cccctgaccc	tcccccttgt	agatatcaat	tcccaaacag	agccaaatac	tctatatcta	1620
tagtcacagc	cctgtacagc	atttttcata	agttatatag	taaatggtct	gcatgatttg	1680
tgcttctagt	gctctcattt	ggaaatgagg	caggcttctt	ctatgaaatg	taaagaaaga	1740
aaccactttg	tatatatttg	aataccacct	ctgtggccat	gcctgccccg	cccactctgt	1800
atatatgtaa	gttaaaccgc	ggyaggggct	gtggccgtct	ttgtactctg	gtgattttta	1860
aaaattgaat	ctttgtact					1879

<210> 78  
 <211> 955  
 <212> DNA  
 <213> Homo sapiens

<400> 78						
ccacgcgtcc	gggggactct	gcaataaggc	agtgaagacc	ctagcccagt	gcctggcagc	60
tgctgtgatg	atgattatta	ttattaatgt	cacccccgct	ccccgccacg	cacacatggg	120
ctagaggggt	gacttccaca	cccctggctt	agactgtcct	gcaggctggg	tgttttcttt	180
gtgattccca	aggccccaag	ccagtgggga	aatttccgcc	acttccatgt	gccctgccac	240

gacttcctgc	catctgctga	ctcgggtgtga	catgacacac	ggctgcctct	ccctggccag	300
catggccgcg	gggcttgggt	ctgtctcact	gttcttgttt	gttcaacagt	ggactccaac	360
gacagcctct	acgggggaga	ctccaagttc	ctggcagaaa	acaacaagct	gtgtgagacg	420
gtgatggctc	agatcctaga	gcatctgaaa	accctggcca	aggacgaggc	cctgaagcgc	480
cagagctcgt	tgggcctttc	cttcttttaac	agcatcttgg	cccatgggga	cctacgcaac	540
aacaagctca	accagctctc	cgtcaacctg	tggcacctgg	cacagaggca	cggctgtgca	600
gacaccagga	ccatgggtgaa	aacgctagaa	tacatcaaga	agcaaagcaa	acaaccagac	660
atgactcatc	tgacggagct	ggccctcaga	ctccctctgc	aaacaaggac	ctgacccccg	720
ggcccatccc	caggctcagg	gactctgggtg	ccaaatccag	aaagatctgc	tctgctgccc	780
tgaactctta	cggcaattta	ggtttctcat	ttttcttttc	tttttacata	tgtacaaatt	840
gttttaagct	ttggcctcta	tccaggttat	tctgacaatg	aagaaatggg	agttgtcaga	900
gcattaaaat	gcaatcttca	ctaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaa	955

<210> 79  
 <211> 2309  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2119)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2138)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2145)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2187)  
 <223> n equals a,t,g, or c

<400> 79						
ggctgctgca	ggcgtccggc	ttggacgaac	cgccgttccc	agtgctggga	ccctttaagt	60
atgcagggtga	tagactagag	aacaagacct	ctgtctccgt	agcatcctgg	agcagctctga	120
atgccagaat	ggataaccgt	tttgctacag	catttgtaat	tgcttggtgtg	cttagcctca	180
tttccaccat	ctacatggca	gcctccattg	gcacagactt	ctgggtatgaa	tatcgaagtc	240
cagttcaaga	aaattccagt	gatttgaata	aaagcatctg	ggatgaattc	attagtgatg	300
aggcagatga	aaagacttat	aatgatgcac	tttttcgata	caatggcaca	gtgggattgt	360
ggagacggtg	tatcaccata	ccccaaaaaca	tgcatttggtg	tagcccacca	gaaaggacag	420
agtcatttga	tgtggtcaca	aaatgtgtga	gtttcacact	aactgagcag	ttcatggaga	480
aatttgttga	tcccggaac	cacaatagcg	ggattgatct	ccttaggacc	tatctttggc	540
gttgccagtt	ccttttacct	tttgtgagtt	taggtttgat	gtgctttggg	gctttgatcg	600
gactttgtgc	ttgcatttgc	cgaagcttat	atcccaccat	tgccacgggc	attctccatc	660
tccttgcagg	tctgtgtaca	ctgggctcag	taagttgtta	tgttgctgga	attgaactac	720
tccaccagaa	actagagctc	cctgacaatg	tatccgggtga	atgttgatgg	tccttctgcc	780
tggcttgtgt	ctctgctccc	ttacagttca	tggcttctgc	tctcttcac	tgggctgctc	840
acaccaaccg	gaaagagtac	acctaatga	aggcatatcg	tgtggcatga	gcaagaaact	900
gcctgcttta	caattgccat	ttttattttt	ttaaaataat	actgatattt	tccccacctc	960
tcaattgttt	ttaattttta	tttgtggata	taccatttta	ttatgaaaat	ctattttatt	1020
tatacacatt	caccactaaa	tacacactta	ataccactaa	aatttatgtg	gtttacttta	1080
agcgatgcca	tctttcaaat	aaactaatct	aggtctagac	agaaagaaat	ggatagagac	1140
ttgacacaaa	tttatgaaag	aaaattggga	gtaggaatgt	gaccgaaaac	aagttgtgct	1200
aatgtctgtt	agacttttca	gtaaaactaa	agtaactgta	tctgttcaac	taaaaactct	1260
atattagttt	ccttgggaaa	cctctcatcg	tcaaaacttt	atgttcactt	tgctgttgta	1320
gatagccagt	caaccagcag	tattagtgtc	gttttcaaa	atttaagctc	tataaaattg	1380
ggaaattatc	taagatcatt	ttccctaagc	attgacacat	agcttcactc	gaggtgagat	1440
atggcagctg	tttgtatctg	cactgtgtct	gtctacaaaa	agtgaataat	acagtgttta	1500
cttgaaattt	taacttttga	actgcaagaa	ttccagttca	gccgggagag	gatttagtatt	1560

atcttttaact	ctccgtaaga	ttttcagtag	caccaaattg	ttttggattt	ttttttctttc	1620
ctctttcacat	accaggggta	ttaaaagtgt	gcttttctttt	tacattatat	tacagttaca	1680
aggtaaaatt	cctcaactgc	tattttattta	ttccagccca	gtactataaa	gaacgtttca	1740
ccataatgac	cctccagagc	tgggaaacct	accacaagat	ctaaagtctt	ggctgtccat	1800
taacctccaa	ctatgggtctt	tattttcttgt	ggtaatatga	tgtgcctttc	cttgcctaaa	1860
tcccttccctg	gtgtgtatca	acattattta	atgtcttcta	attcagtcac	ttttttataa	1920
gtatgtctat	aaacattgaa	ctttaaaaaa	cttattttatt	tattccacta	ctgtagcaat	1980
tgacagatta	aaaaaatgta	acttcataat	ttctttaccat	aacctcaatg	tcttttttaa	2040
aaaataaaat	taaaaatgaa	aagagaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2100
actcgagggg	gggcccggna	cccaattcgc	cctatagnga	gtcgnattac	aattcactgg	2160
ccgtcgtttt	acaacgtcgt	gactggnaaa	accctggcgt	tacccaactt	aatcgccctg	2220
cagcacatcc	cccttttcgcc	agctggcgta	atagcggaag	ggccccgcacc	gatcgccctt	2280
cccaacagtt	gcgcagcctg	aatggcgaa				2309

<210> 80  
<211> 2619  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (81)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (2323)  
<223> n equals a,t,g, or c

<400> 80						
cgctgagaag	gagcagacaa	gatggcgacg	tccgtggggc	accgatgtct	gggattactg	60
cacgggggtcg	cgccgtggcg	nagcagcctc	catccctgtg	agatcactgc	cctgagccaa	120
tccctacagc	ccttacggaa	gctgcctttt	agagcctttc	gcacagatgc	cagaaaaatc	180
cacactgccc	ctgcccgaac	catgttccctg	ctgcgtcccc	tgccccattct	gttgggtgaca	240
ggcggcggggt	atgcagggta	ccggcagtat	gagaagtaca	gggagcgaga	gctggagaag	300
ctgggatttg	agattccacc	caaacttgct	ggtcactggg	aggtggcctt	gtacaagtca	360
gtgccaacgc	gcttgctgtc	acgggcctgg	ggtcgcctca	atcagggtga	gctgccacac	420
tggctgcgca	ggcccgtcta	cagcctgtac	atctggacgt	ttgggggtgaa	catgaaagag	480
gccgctgtgg	aggacctgca	tactaccgc	aacctcagcs	agttcytccg	gcgcaagctg	540
aaagcckcag	gcccggcctg	tytgtggcct	gcacagcgtg	attagcccat	cggatggaag	600
gwtccctcaac	tttgggcagg	tgaagaactg	tgagggtggag	caggtaaagg	gggtcaccta	660
ctccctggag	tcgttccctg	gcccgcgtat	gtgcacagag	gacctgccct	tcccaccagg	720
tgggtcactg	cacaggcggg	gctaggcagc	cctgctgctg	tgtggctgga	ccgggaggga	780
ggggaatgct	ggggaaggaa	ctgaggctgg	catgtggggc	ctccctgaga	atccatgtgc	840
agaccacack	ygggtcccat	tcgcatctac	tttgaccggg	acctgcacac	aaacagccca	900
aggcacagca	agggtcctta	caatgacttc	agcttcgtga	cgcacaccaa	tagagagggc	960
gtccccatgc	gtaagggcga	gcacctgggc	gagttcaacc	tgggctccac	catcgtgctc	1020
atcttcgagg	cccccaagga	cttcaatttc	cagctgaaaa	caggacagaa	aatccgcttt	1080
ggggaagccc	tgggtctcgt	ctagagtctc	tttccctgatt	atggctgcta	agggatcttt	1140
tccaaacaga	gtgagggctc	tttcaagagg	gaggcccatg	aggccatcca	ggtaagggcc	1200
tgctctcagc	tgggtgggag	tctgaccagg	taggacttga	atgattcggc	tmccacctgt	1260
tccagagggtg	cagacaagag	gtggcgagag	ccccrtcatg	ccccctcaacc	tatcccgttc	1320
cttctgccta	caaataaaaa	gtgcaggctg	gaatgatctc	agtcacattt	ggatcttttt	1380
aaacactgta	tagacggaag	agcctgcatt	cctgaccgaa	ccttcagttg	gtctcggttg	1440
tcgttttttc	ttgctgctcc	tccccccatc	acctgagctg	ttttctgttg	gccccctttg	1500
ttttttggcc	ttaacgctcc	tgctgcacag	ggtgagggtc	ctccttggca	cagactgtgg	1560
atgcctctcc	cccagcagag	ccacacagcc	ttcgtgacaa	ctgctttccg	ttcccacatt	1620
cacctcatcc	tgctcttttag	aaaaagcagt	ctttgtgctt	gtggctgaac	gcacacccct	1680
ggactctgct	agtgtcttct	gaggacactg	atgacactga	ttaatgatac	agacctttgc	1740
aggactctgat	gagtgaacct	tctggagctg	gccaggctct	ctgcagcagg	caagaccaat	1800
caatcactga	acctgcctca	tggcaccaga	gtgaacaggg	caggcaggta	gtaggcccag	1860
ctggggaaat	gggagagttc	ctgtccccct	ccacatatcc	ctacatgaaa	tatgggaaag	1920
ttgctgctat	tgattcaggg	tctgtcttgg	aggcagagga	cccttgggtg	atagttggtc	1980
agtgcctgga	aaacctgtcc	cagtttatca	ggaacgcagg	cctggggagc	ccccagtggc	2040
ggggacaggg	ccagatttca	tgttgacctt	ggggatgctg	tgaattttct	ctgcaggaga	2100

gacatcattg	aatttttttca	actgtatcag	tagcacagta	tttttgtatg	aaaagtggga	2160
gacttctgaa	cagtaattca	tttaattgca	aagcattttg	aaataaaaaa	aatcaaactt	2220
aaaactgtgt	tctgttcctg	gaggtggcct	gaggctcccc	gacagcccag	cacctgcgtt	2280
cctgggtgca	acacgctagc	acagggcctg	ccgcaggcct	ggnatgcggg	caacgcaggc	2340
gccaatgggc	tgggcgctgag	cctggagctc	ctctgccagc	agctggatct	gcatttccac	2400
ctgttccagc	tctttctgca	cctgctgctc	tacttctctg	tcctcaggcc	ccggctcctc	2460
tctgttcagc	tccagccacc	tgcgaggcct	gctcgcttgc	cgccgacaga	ccagargttc	2520
tgcttggtgg	tctgggtartg	cagtagttgc	tgctggatct	cctcaagttc	agcctcaagg	2580
tccaggctgc	ctgcagttga	aagtcccga	cgctggggc			2619

<210> 81  
 <211> 884  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (873)  
 <223> n equals a,t,g, or c

<400> 81						
ggccgacgcc	tggggtgtgg	agctgcccc	ccgccacccc	gtgggagagt	ggatcaagaa	60
gaaaaaacct	ggcccgagag	tcgaagggcc	gccccaggcc	aacagaaatc	acccggcctt	120
acctctgtcc	ccacccttac	cttccccac	ataccgcccc	ctgcttgggt	tcccacccca	180
gcgcttgccg	ctgctcccg	tcctgtcccc	acagcctcct	cctcccatc	tccatcacca	240
gggaatgccc	cgggtccac	aggggtcccc	agatgcctgt	ttttcctcag	accatacttt	300
ccagtcggat	caattctatt	gccattcaga	tgctccctca	tcagcccatg	cagggtttctt	360
cgtcgaagac	aattttatgg	ttggctcctca	gctgcctatg	cccttcttcc	ccacaccccc	420
ttatcagcgg	cctgccccag	tggtacatag	gggttttggc	aggtatcgtc	cccgtggccc	480
ctatacgccc	tggggacagc	ggcctcgacc	ttcaaagaga	agggcccccag	ccaatcctga	540
gccaaggcct	caatagacgg	acctaggcct	tatttctctc	ttatgaacat	ggattggaca	600
gatctgacac	ttcctttcca	ttgcttggcc	tgaacagact	gaccttggtt	acttaagcct	660
ggagtcctatg	cctcgtcttc	cttttgttca	ttgctgttac	caagaaagcc	aaggaagagc	720
agcctgactc	attcttcttg	gctgcagcct	cttccccact	tcctgggagt	gacccagcgt	780
tattcctgcc	tcctcactcc	tattctcttt	gcctttgtgt	aaaaataaaa	tggaaataaa	840
caagttgcac	agaaaaaaaa	aaaaaaaaaa	aancccaagg	gggg		884

<210> 82  
 <211> 1086  
 <212> DNA  
 <213> Homo sapiens

<400> 82						
ggattctagg	acagggatgg	gggtgcagca	ctgatccagt	tgacaacagg	aggcagaggc	60
atcatggagg	gtccccgggg	atggctgggt	ctctgtgtgc	tgcccatatc	gctggcctct	120
atggtgaccg	aggacttgtg	ccgagcacca	gacgggaaga	aaggggaggc	aggaagacct	180
ggcagacggg	ggcggccagg	cctcaagggg	gagcaagggg	agccgggggc	ccctggcatc	240
cggacaggca	tccaaggcct	taaaggagac	cagggggaac	ctgggcccct	tggaaacccc	300
ggcaagggtg	gctacccagg	gcccagcggc	cccctcggag	cccgtagcat	cccggaattt	360
aaaggcacca	agggcagccc	aggaacatc	aaggaccagc	cgaggccagc	cttctccgcc	420
attcggcgga	accccccaat	ggggggcaac	gtggtcatct	tcgacacggt	catcaccaac	480
caggaagaac	cgtaccagaa	ccactccggc	cgattcgtct	gcactgtacc	cggctactac	540
tacttcacct	tccaggtgct	gtcccagtgg	gaaatctgcc	tgtccatcgt	ctcctcctca	600
aggggcccagg	tccgacgctc	cctgggcttc	tgtgacacca	ccaacaagg	gctcttccag	660
gtggtgtcag	ggggcatggt	gcttcagctg	cagcaggggt	accaggtctg	ggttgaaaaa	720
gaccccaaaa	agggtcacat	ttaccagggc	tctgaggccg	acagcgtctt	cagcggcttc	780
ctcatcttcc	catctgcctg	agccagggaa	ggacccccct	ccccaccac	ctctctggct	840
tccatgctcc	gcctgtaaaa	tgggggcgct	attgcttcag	ctgctgaagg	gaggggggctg	900
gctctgagag	ccccaggact	ggctgccccg	tgacacatgc	tctaagaagc	tcgtttctta	960
gacctcttcc	tggaataaac	atctgtgtct	gtgtctgctg	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaaaaa	aaaaaactcg	aggggggggc	cggtacccaa	ttcgccggtat	1080
aatgag						1086

45

<210> 83  
 <211> 563  
 <212> PRT  
 <213> Homo sapiens

<400> 83

```

Met Gly Ser Leu Ser Asn Tyr Ala Leu Leu Gln Leu Thr Leu Thr Ala
 1          5          10          15

Phe Leu Thr Ile Leu Val Gln Pro Gln His Leu Leu Ala Pro Val Phe
      20          25          30

Arg Thr Leu Ser Ile Leu Thr Asn Gln Ser Asn Cys Trp Leu Cys Glu
      35          40          45

His Leu Asp Asn Ala Glu Gln Pro Glu Leu Val Phe Val Pro Ala Ser
      50          55          60

Ala Ser Thr Trp Trp Thr Tyr Ser Gly Gln Trp Met Tyr Glu Arg Val
      65          70          75          80

Trp Tyr Pro Gln Ala Glu Val Gln Asn His Ser Thr Ser Ser Tyr Arg
      85          90          95

Lys Val Thr Trp His Trp Glu Ala Ser Met Glu Ala Gln Gly Leu Ser
      100          105          110

Phe Ala Gln Val Arg Leu Leu Glu Gly Asn Phe Ser Leu Cys Val Glu
      115          120          125

Asn Lys Asn Gly Ser Gly Pro Phe Leu Gly Asn Ile Pro Lys Gln Tyr
      130          135          140

Cys Asn Gln Ile Leu Trp Phe Asp Ser Thr Asp Gly Thr Phe Met Pro
      145          150          155          160

Ser Ile Asp Val Thr Asn Glu Ser Arg Asn Asp Asp Asp Asp Pro Ser
      165          170          175

Val Cys Leu Gly Thr Arg Gln Cys Ser Trp Phe Ala Gly Cys Thr Asn
      180          185          190

Arg Thr Trp Asn Ser Ser Ala Val Pro Leu Ile Gly Leu Pro Asn Thr
      195          200          205

Gln Asp Tyr Lys Trp Val Asp Arg Asn Ser Gly Leu Thr Trp Ser Gly
      210          215          220

Asn Asp Thr Cys Leu Tyr Ser Cys Gln Asn Gln Thr Lys Gly Leu Leu
      225          230          235          240

Tyr Gln Leu Phe Arg Asn Leu Phe Cys Ser Tyr Gly Leu Thr Glu Ala
      245          250          255

His Gly Lys Trp Arg Cys Ala Asp Ala Ser Ile Thr Asn Asp Lys Gly
      260          265          270

His Asp Gly His Arg Thr Pro Thr Trp Trp Leu Thr Gly Ser Asn Leu
      275          280          285

Thr Leu Ser Val Asn Asn Ser Gly Leu Phe Phe Leu Cys Gly Asn Gly
      290          295          300

Val Tyr Lys Gly Phe Pro Pro Lys Trp Ser Gly Arg Cys Gly Leu Gly
      305          310          315          320

```



46

Tyr Leu Val Pro Ser Leu Thr Arg Tyr Leu Thr Leu Asn Ala Ser Gln  
 325 330 335  
 Ile Thr Asn Leu Arg Ser Phe Ile His Lys Val Thr Pro His Arg Cys  
 340 345 350  
 Thr Gln Gly Asp Thr Asp Asn Pro Pro Leu Tyr Cys Asn Pro Lys Asp  
 355 360 365  
 Asn Ser Thr Thr Ile Arg Ala Leu Phe Pro Ser Leu Gly Thr Tyr Asp Leu  
 370 375 380  
 Glu Lys Ala Ile Leu Asn Ile Ser Lys Ala Met Glu Gln Glu Phe Ser  
 385 390 395 400  
 Ala Thr Lys Gln Thr Leu Glu Ala His Gln Ser Lys Val Ser Ser Leu  
 405 410 415  
 Ala Ser Ala Ser Arg Lys Asp His Val Leu Asp Ile Pro Thr Thr Gln  
 420 425 430  
 Arg Gln Thr Ala Cys Gly Thr Val Gly Lys Gln Cys Cys Leu Tyr Ile  
 435 440 445  
 Asn Tyr Ser Glu Glu Ile Lys Ser Asn Ile Gln Arg Leu His Glu Ala  
 450 455 460  
 Ser Glu Asn Leu Lys Asn Val Pro Leu Leu Asp Trp Gln Gly Ile Phe  
 465 470 475 480  
 Ala Lys Val Gly Asp Trp Phe Arg Ser Trp Gly Tyr Val Leu Leu Ile  
 485 490 495  
 Val Leu Phe Cys Leu Phe Ile Phe Val Leu Ile Tyr Val Arg Val Phe  
 500 505 510  
 Arg Lys Ser Arg Arg Ser Leu Asn Ser Gln Pro Leu Asn Leu Ala Leu  
 515 520 525  
 Ser Pro Gln Gln Ser Ala Gln Leu Leu Val Ser Glu Thr Ser Cys Gln  
 530 535 540  
 Val Ser Asn Arg Ala Met Lys Gly Leu Thr Thr His Gln Tyr Asp Thr  
 545 550 555 560  
 Ser Leu Leu

&lt;210&gt; 84

&lt;211&gt; 152

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

Met Gly Val His Val Gly Ala Ala Leu Gly Ala Leu Trp Phe Cys Leu  
 1 5 10 15  
 Thr Gly Ala Leu Glu Val Gln Val Pro Glu Asp Pro Val Val Ala Leu  
 20 25 30  
 Val Gly Thr Asp Ala Thr Leu Cys Cys Ser Phe Ser Pro Glu Pro Gly  
 35 40 45  
 Phe Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys  
 50 55 60

47

Gln Leu Val His Ser Phe Ala Glu Gly Gln Asp Gln Gly Ser Ala Tyr  
 65 70 75 80  
 Ala Asn Arg Thr Ala Leu Phe Leu Asp Leu Leu Ala Gln Gly Asn Ala  
 85 90 95  
 Ser Leu Arg Leu Gln Ser Val Arg Val Ala Asp Glu Gly Gln Leu His  
 100 105 110  
 Leu Leu Arg Glu His Pro Gly Phe Arg Gln Arg Cys Arg Gln Pro Ala  
 115 120 125  
 Gly Gly Arg Ser Leu Leu Glu Ala Gln His Asp Pro Gly Ala Gln Gln  
 130 135 140  
 Gly Pro Ala Ala Arg Gly Thr Trp  
 145 150

<210> 85  
 <211> 215  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (7)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 85  
 Met Leu Pro Trp Thr Ala Xaa Gly Leu Ala Leu Ser Leu Arg Leu Ala  
 1 5 10 15  
 Leu Ala Arg Ser Gly Ala Glu Arg Gly Pro Pro Ala Ser Ala Pro Arg  
 20 25 30  
 Gly Asp Leu Met Phe Leu Leu Asp Ser Ser Ala Ser Val Ser His Tyr  
 35 40 45  
 Glu Phe Ser Arg Val Arg Glu Phe Val Gly Gln Leu Val Ala Pro Leu  
 50 55 60  
 Pro Leu Gly Thr Gly Ala Leu Arg Ala Ser Leu Val His Val Gly Ser  
 65 70 75 80  
 Arg Pro Tyr Thr Glu Phe Pro Phe Gly Gln His Ser Ser Gly Glu Ala  
 85 90 95  
 Ala Gln Asp Ala Val Arg Ala Ser Ala Gln Arg Met Gly Asp Thr His  
 100 105 110  
 Thr Gly Leu Ala Leu Val Tyr Ala Lys Glu Gln Leu Phe Ala Glu Ala  
 115 120 125  
 Ser Gly Ala Arg Pro Gly Val Pro Lys Val Leu Val Trp Val Thr Asp  
 130 135 140  
 Gly Gly Ser Ser Asp Pro Val Gly Pro Pro Met Gln Glu Leu Lys Asp  
 145 150 155 160  
 Leu Gly Val Thr Val Phe Ile Val Ser Thr Gly Arg Gly Asn Phe Leu  
 165 170 175  
 Glu Leu Ser Ala Ala Ala Ser Ala Pro Ala Glu Lys His Leu His Phe  
 180 185 190

Val Asp Val Asp Asp Leu His Ile Ile Val Gln Glu Leu Arg Gly Ser  
 195 200 205

Ile Leu Asp Ala Met Arg Pro  
 210 215

<210> 86  
 <211> 831  
 <212> PRT  
 <213> Homo sapiens

<400> 86  
 Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys Leu Leu Thr  
 1 5 10 15

Phe Ile Phe His His Cys Asn His Cys His Glu Glu His Asp His Gly  
 20 25 30

Pro Glu Ala Leu His Arg Gln His Arg Gly Met Thr Glu Leu Glu Pro  
 35 40 45

Ser Lys Phe Ser Lys Gln Ala Ala Glu Asn Glu Lys Lys Tyr Tyr Ile  
 50 55 60

Glu Lys Leu Phe Glu Arg Tyr Gly Glu Asn Gly Arg Leu Ser Phe Phe  
 65 70 75 80

Gly Leu Glu Lys Leu Leu Thr Asn Leu Gly Leu Gly Glu Arg Lys Val  
 85 90 95

Val Glu Ile Asn His Glu Asp Leu Gly His Asp His Val Ser His Leu  
 100 105 110

Asp Ile Leu Ala Val Gln Glu Gly Lys His Phe His Ser His Asn His  
 115 120 125

Gln His Ser His Asn His Leu Asn Ser Glu Asn Gln Thr Val Thr Ser  
 130 135 140

Val Ser Thr Lys Arg Asn His Lys Cys Asp Pro Glu Lys Glu Thr Val  
 145 150 155 160

Glu Val Ser Val Lys Ser Asp Asp Lys His Met His Asp His Asn His  
 165 170 175

Arg Leu Arg His His His Arg Leu His His His Leu Asp His Asn Asn  
 180 185 190

Thr His His Phe His Asn Asp Ser Ile Thr Pro Ser Glu Arg Gly Glu  
 195 200 205

Pro Ser Asn Glu Pro Ser Thr Glu Thr Asn Lys Thr Gln Glu Gln Ser  
 210 215 220

Asp Val Lys Leu Pro Lys Gly Lys Arg Lys Lys Lys Gly Arg Lys Ser  
 225 230 235 240

Asn Glu Asn Ser Glu Val Ile Thr Pro Gly Phe Pro Pro Asn His Asp  
 245 250 255

Gln Gly Glu Gln Tyr Glu His Asn Arg Val His Lys Pro Asp Arg Val  
 260 265 270

His Asn Pro Gly His Ser His Val His Leu Pro Glu Arg Asn Gly His

275					280					285						
Asp	Pro	Gly	Arg	Gly	His	Gln	Asp	Leu	Asp	Pro	Asp	Asn	Glu	Gly	Glu	
290					295					300						
Leu	Arg	His	Thr	Arg	Lys	Arg	Glu	Ala	Pro	His	Val	Lys	Asn	Asn	Ala	320
305					310					315						
Ile	Ile	Ser	Leu	Arg	Lys	Asp	Leu	Asn	Glu	Asp	Asp	His	His	His	Glu	335
				325					330							
Cys	Leu	Asn	Val	Thr	Gln	Leu	Leu	Lys	Tyr	Tyr	Gly	His	Gly	Ala	Asn	
			340					345					350			
Ser	Pro	Ile	Ser	Thr	Asp	Leu	Phe	Thr	Tyr	Leu	Cys	Pro	Ala	Leu	Leu	
		355					360					365				
Tyr	Gln	Ile	Asp	Ser	Arg	Leu	Cys	Ile	Glu	His	Phe	Asp	Lys	Leu	Leu	
	370					375					380					
Val	Glu	Asp	Ile	Asn	Lys	Asp	Lys	Asn	Leu	Val	Pro	Glu	Asp	Glu	Ala	400
385					390					395						
Asn	Ile	Gly	Ala	Ser	Ala	Trp	Ile	Cys	Gly	Ile	Ile	Ser	Ile	Thr	Val	
				405					410					415		
Ile	Ser	Leu	Leu	Ser	Leu	Leu	Gly	Val	Ile	Leu	Val	Pro	Ile	Ile	Asn	
			420					425					430			
Gln	Gly	Cys	Phe	Lys	Phe	Leu	Leu	Thr	Phe	Leu	Val	Ala	Leu	Ala	Val	
		435					440					445				
Gly	Thr	Met	Ser	Gly	Asp	Ala	Leu	Leu	His	Leu	Leu	Pro	His	Ser	Gln	
	450					455					460					
Gly	Gly	His	Asp	His	Ser	His	Gln	His	Ala	His	Gly	His	Gly	His	Ser	480
465					470					475						
His	Gly	His	Glu	Ser	Asn	Lys	Phe	Leu	Glu	Glu	Tyr	Asp	Ala	Val	Leu	
				485					490					495		
Lys	Gly	Leu	Val	Ala	Leu	Gly	Gly	Ile	Tyr	Leu	Leu	Phe	Ile	Ile	Glu	
			500					505					510			
His	Cys	Ile	Arg	Met	Phe	Lys	His	Tyr	Lys	Gln	Gln	Arg	Gly	Lys	Gln	
		515					520					525				
Lys	Trp	Phe	Met	Lys	Gln	Asn	Thr	Glu	Glu	Ser	Thr	Ile	Gly	Arg	Lys	
	530					535					540					
Leu	Ser	Asp	His	Lys	Leu	Asn	Asn	Thr	Pro	Asp	Ser	Asp	Trp	Leu	Gln	560
545					550					555						
Leu	Lys	Pro	Leu	Ala	Gly	Thr	Asp	Asp	Ser	Val	Val	Ser	Glu	Asp	Arg	
				565					570					575		
Leu	Asn	Glu	Thr	Glu	Leu	Thr	Asp	Leu	Glu	Gly	Gln	Gln	Glu	Ser	Pro	
			580					585					590			
Pro	Lys	Asn	Tyr	Leu	Cys	Ile	Glu	Glu	Glu	Lys	Ile	Ile	Asp	His	Ser	
		595					600					605				
His	Ser	Asp	Gly	Leu	His	Thr	Ile	His	Glu	His	Asp	Leu	His	Ala	Ala	
		610				615					620					
Ala	His	Asn	His	His	Gly	Glu	Asn	Lys	Thr	Val	Leu	Arg	Lys	His	Asn	

50

625		630		635		640
His Gln Trp His	His His Lys His Ser His His Ser His Gly Pro Cys His					
	645			650		655
Ser Gly Ser Asp	Leu Lys Glu Thr Gly Ile Ala Asn Ile Ala Trp Met					
	660		665		670	
Val Ile Met Gly Asp Gly Ile His Asn Phe Ser Asp Gly Leu Ala Ile						
	675		680		685	
Gly Ala Ala Phe Ser Ala Gly Leu Thr Gly Gly Ile Ser Thr Ser Ile						
	690		695		700	
Ala Val Phe Cys His Glu Leu Pro His Glu Leu Gly Asp Phe Ala Val						
	705		710		715	720
Leu Leu Lys Ala Gly Met Thr Val Lys Gln Ala Ile Val Tyr Asn Leu						
	725		730		735	
Leu Ser Ala Met Met Ala Tyr Ile Gly Met Leu Ile Gly Thr Ala Val						
	740		745		750	
Gly Gln Tyr Ala Asn Asn Ile Thr Leu Trp Ile Phe Ala Val Thr Ala						
	755		760		765	
Gly Met Phe Leu Tyr Val Ala Leu Val Asp Met Leu Pro Glu Met Leu						
	770		775		780	
His Gly Asp Gly Asp Asn Glu Glu His Gly Phe Cys Pro Val Gly Gln						
	785		790		795	800
Phe Ile Leu Gln Asn Leu Gly Leu Leu Phe Gly Phe Ala Ile Met Leu						
	805		810		815	
Val Ile Ala Leu Tyr Glu Asp Lys Ile Val Phe Asp Ile Gln Phe						
	820		825		830	

<210> 87  
 <211> 480  
 <212> PRT  
 <213> Homo sapiens

<400> 87  
 Met Leu Phe Arg Asn Arg Phe Leu Leu Leu Leu Ala Leu Ala Ala Leu  
 1 5 10 15  
 Leu Ala Phe Val Ser Leu Ser Leu Gln Phe Phe His Leu Ile Pro Val  
 20 25 30  
 Ser Thr Pro Lys Asn Gly Met Ser Ser Lys Ser Arg Lys Arg Ile Met  
 35 40 45  
 Pro Asp Pro Val Thr Glu Pro Pro Val Thr Asp Pro Val Tyr Glu Ala  
 50 55 60  
 Leu Leu Tyr Cys Asn Ile Pro Ser Val Ala Glu Arg Ser Met Glu Gly  
 65 70 75 80  
 His Ala Pro His His Phe Lys Leu Val Ser Val His Val Phe Ile Arg  
 85 90 95  
 His Gly Asp Arg Tyr Pro Leu Tyr Val Ile Pro Lys Thr Lys Arg Pro  
 100 105 110

Glu Ile Asp Cys Thr Leu Val Ala Asn Arg Lys Pro Tyr His Pro Lys  
 115 120 125  
 Leu Glu Ala Phe Ile Ser His Met Ser Lys Gly Ser Gly Ala Ser Phe  
 130 135 140  
 Glu Ser Pro Leu Asn Ser Leu Pro Leu Tyr Pro Asn His Pro Leu Cys  
 145 150 155 160  
 Glu Met Gly Glu Leu Thr Gln Thr Gly Val Val Gln His Leu Gln Asn  
 165 170 175  
 Gly Gln Leu Leu Arg Asp Ile Tyr Leu Lys Lys His Lys Leu Leu Pro  
 180 185 190  
 Asn Asp Trp Ser Ala Asp Gln Leu Tyr Leu Glu Thr Thr Gly Lys Ser  
 195 200 205  
 Arg Thr Leu Gln Ser Gly Leu Ala Leu Leu Tyr Gly Phe Leu Pro Asp  
 210 215 220  
 Phe Asp Trp Lys Lys Ile Tyr Phe Arg His Gln Pro Ser Ala Leu Phe  
 225 230 235 240  
 Cys Ser Gly Ser Cys Tyr Cys Pro Val Arg Asn Gln Tyr Leu Glu Lys  
 245 250 255  
 Glu Gln Arg Arg Gln Tyr Leu Leu Arg Leu Lys Asn Ser Gln Leu Glu  
 260 265 270  
 Lys Thr Tyr Gly Glu Met Ala Lys Ile Val Asp Val Pro Thr Lys Gln  
 275 280 285  
 Leu Arg Ala Ala Asn Pro Ile Asp Ser Met Leu Cys His Phe Cys His  
 290 295 300  
 Asn Val Ser Phe Pro Cys Thr Arg Asn Gly Cys Val Asp Met Glu His  
 305 310 315 320  
 Phe Lys Val Ile Lys Thr His Gln Ile Glu Asp Glu Arg Glu Arg Arg  
 325 330 335  
 Glu Lys Lys Leu Tyr Phe Gly Tyr Ser Leu Leu Gly Ala His Pro Ile  
 340 345 350  
 Leu Asn Gln Thr Ile Gly Arg Met Gln Arg Ala Thr Glu Gly Arg Lys  
 355 360 365  
 Glu Glu Leu Phe Ala Leu Tyr Ser Ala His Asp Val Thr Leu Ser Pro  
 370 375 380  
 Val Leu Ser Ala Leu Gly Leu Ser Glu Ala Arg Phe Pro Arg Phe Ala  
 385 390 395 400  
 Ala Arg Leu Ile Phe Glu Leu Trp Gln Asp Arg Glu Lys Pro Ser Glu  
 405 410 415  
 His Ser Val Arg Ile Leu Tyr Asn Gly Val Asp Val Thr Phe His Thr  
 420 425 430  
 Ser Phe Cys Gln Asp His His Lys Arg Ser Pro Lys Pro Met Cys Pro  
 435 440 445  
 Leu Glu Asn Leu Val Arg Phe Val Lys Arg Asp Met Phe Val Ala Leu  
 450 455 460

52

Gly Gly Ser Gly Thr Asn Tyr Tyr Asp Ala Cys His Arg Glu Gly Phe  
 465 470 475 480

<210> 88  
 <211> 151  
 <212> PRT  
 <213> Homo sapiens

<400> 88  
 Met Phe Leu Met Leu Gly Cys Ala Leu Pro Ile Tyr Asn Lys Tyr Trp  
 1 5 10 15  
 Pro Leu Phe Val Leu Phe Phe Tyr Ile Leu Ser Pro Ile Pro Tyr Cys  
 20 25 30  
 Ile Ala Arg Arg Leu Val Asp Asp Thr Asp Ala Met Ser Asn Ala Cys  
 35 40 45  
 Lys Glu Leu Ala Ile Phe Leu Thr Thr Gly Ile Val Val Ser Ala Phe  
 50 55 60  
 Gly Leu Pro Ile Val Phe Ala Arg Ala His Leu Met Gly Arg Leu Pro  
 65 70 75 80  
 Phe Phe Ser Lys Met Gly Thr Ala Glu Ser Glu Gly Arg Glu Thr Leu  
 85 90 95  
 Thr Gln Gln Leu Pro Leu Pro Ala Ala Ala Met Arg Arg Leu Leu Pro  
 100 105 110  
 Ala Ser Arg Val Ser Thr Gln Pro Val Leu Arg Leu Ala Asp Ser Ala  
 115 120 125  
 Glu Ser Leu Leu Gly Arg Pro Ala Leu Trp Ala Leu Gly Phe Leu Leu  
 130 135 140  
 Cys Pro Pro Ser Gln Ala Gln  
 145 150

<210> 89  
 <211> 132  
 <212> PRT  
 <213> Homo sapiens

<400> 89  
 Met Glu Ile Tyr Leu Ser Leu Gly Val Leu Ala Leu Gly Thr Leu Ser  
 1 5 10 15  
 Leu Leu Ala Val Thr Ser Leu Pro Ser Ile Ala Asn Ser Leu Asn Trp  
 20 25 30  
 Arg Glu Phe Ser Phe Val Gln Ser Ser Leu Gly Phe Val Ala Leu Val  
 35 40 45  
 Leu Ser Thr Leu His Thr Leu Thr Tyr Gly Trp Thr Arg Ala Phe Glu  
 50 55 60  
 Glu Ser Arg Tyr Lys Phe Tyr Leu Pro Pro Thr Phe Thr Leu Thr Leu  
 65 70 75 80  
 Leu Val Pro Cys Val Val Ile Leu Ala Lys Ala Leu Phe Leu Leu Pro

53

				85						90				95			
Cys	Ile	Ser	Arg	Arg	Leu	Ala	Arg	Ile	Arg	Arg	Gly	Trp	Glu	Arg	Glu		
			100					105					110				
Ser	Thr	Ile	Lys	Phe	Thr	Leu	Pro	Thr	Asp	His	Ala	Leu	Ala	Glu	Lys		
		115					120					125					
Thr	Ser	His	Val														
	130																

<210> 90  
 <211> 110  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (98)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (100)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 90																	
Met	Ala	Ala	Pro	Ala	Leu	Gly	Leu	Val	Cys	Gly	Arg	Cys	Pro	Glu	Leu		
1				5					10					15			
Gly	Leu	Val	Leu	Leu	Leu	Leu	Leu	Leu	Ser	Leu	Leu	Cys	Gly	Ala	Ala		
			20					25					30				
Gly	Ser	Gln	Glu	Ala	Gly	Thr	Gly	Ala	Gly	Ala	Gly	Ser	Leu	Ala	Gly		
		35					40					45					
Ser	Cys	Gly	Cys	Gly	Thr	Pro	Gln	Arg	Pro	Gly	Ala	His	Gly	Ser	Ser		
	50					55					60						
Ala	Ala	Ala	His	Arg	Tyr	Ser	Arg	Glu	Ala	Asn	Ala	Pro	Gly	Pro	Val		
65					70					75					80		
Pro	Gly	Glu	Arg	Gln	Leu	Ala	His	Ser	Lys	Val	Leu	His	Arg	Phe	Leu		
				85					90					95			
Arg	Xaa	Gly	Xaa	Gly	Leu	Leu	Gly	Ser	Trp	Thr	Gly	Leu	Glu				
			100					105					110				

<210> 91  
 <211> 188  
 <212> PRT  
 <213> Homo sapiens

<400> 91																	
Met	Val	Pro	Gly	Ala	Ala	Gly	Trp	Cys	Cys	Leu	Val	Leu	Trp	Leu	Pro		
1				5					10					15			
Ala	Cys	Val	Ala	Ala	His	Gly	Phe	Arg	Ile	His	Asp	Tyr	Leu	Tyr	Phe		
			20					25					30				
Gln	Val	Leu	Ser	Pro	Gly	Asp	Ile	Arg	Tyr	Ile	Phe	Thr	Ala	Thr	Pro		
		35					40					45					
Ala	Lys	Asp	Phe	Gly	Gly	Ile	Phe	His	Thr	Arg	Tyr	Glu	Gln	Ile	His		



54

50					55					60					
Leu 65	Val	Pro	Ala	Glu	Pro 70	Pro	Glu	Ala	Cys	Gly 75	Glu	Leu	Ser	Asn	Gly 80
Phe	Phe	Ile	Gln	Asp 85	Gln	Ile	Ala	Leu	Val 90	Glu	Arg	Gly	Gly	Cys 95	Ser
Phe	Leu	Ser	Lys 100	Thr	Arg	Val	Val	Gln 105	Glu	His	Gly	Gly	Arg	Ala	Val
Ile	Ile	Ser 115	Asp	Asn	Ala	Val	Asp 120	Asn	Asp	Ser	Phe	Tyr 125	Val	Glu	Met
Ile	Gln 130	Asp	Ser	Thr	Gln	Arg 135	Thr	Ala	Asp	Ile	Pro 140	Ala	Leu	Phe	Leu
Leu 145	Gly	Arg	Asp	Gly	Tyr 150	Met	Ile	Arg	Arg	Ser 155	Leu	Glu	Gln	His	Gly 160
Leu	Pro	Trp	Ala	Ile 165	Ile	Ser	Ile	Pro	Val 170	Asn	Val	Thr	Ser	Ile 175	Pro
Thr	Phe	Glu 180	Leu	Leu	Gln	Pro	Pro	Trp 185	Thr	Phe	Trp				

&lt;210&gt; 92

&lt;211&gt; 179

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (143)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 92

Met 1	Ala	Gln	Val	Leu 5	Ala	Ser	Glu	Leu	Ser 10	Leu	Val	Ala	Phe	Ile 15	Leu
Leu	Leu	Val	Met 20	Ala	Phe	Ser	Lys	Lys 25	Trp	Leu	Asp	Leu	Ser 30	Arg	Ser
Leu	Phe	Tyr 35	Gln	Arg	Trp	Pro	Val 40	Asp	Val	Ser	Asn	Arg 45	Ile	His	Thr
Ser 50	Ala	His	Val	Met	Ser	Met 55	Gly	Leu	Leu	His	Phe 60	Cys	Lys	Ser	Arg
Ser 65	Cys	Ser	Asp	Leu	Glu 70	Asn	Gly	Lys	Val	Thr 75	Phe	Ile	Phe	Ser	Thr 80
Leu	Met	Leu	Phe 85	Pro	Ile	Asn	Ile	Trp	Ile 90	Phe	Glu	Leu	Glu	Arg 95	Asn
Val	Ser	Ile	Pro 100	Ile	Gly	Trp	Ser	Tyr 105	Phe	Ile	Gly	Trp	Leu 110	Val	Leu
Ile	Leu 115	Tyr	Phe	Thr	Cys	Ala	Ile 120	Leu	Cys	Tyr	Phe	Asn 125	His	Lys	Ser
Phe 130	Trp	Ser	Leu	Ile	Leu	Ser 135	His	Pro	Ser	Gly	Ala 140	Val	Ser	Xaa	Ser
Ser	Ser	Phe	Gly	Ser	Val	Glu	Glu	Ser	Pro	Arg	Ala	Gln	Thr	Ile	Thr

145		150		155		160
Asp Thr Pro Ile Thr	Gln Glu Gly Val	Leu Asp Pro Glu Gln	Lys Asp			
	165	170	175			

```
<210> 93
<211> 259
<212> PRT
<213> Homo sapiens
```

[illegible]

<210> 94  
 <211> 239  
 <212> PRT  
 <213> Homo sapiens

<400> 94  
 Met Ala Pro Leu Leu Pro Ser Leu Pro Leu His Leu His Thr Ser Leu  
     1                    5                    10                    15  
 Cys Leu Arg Leu Cys Leu Ser Leu Ser Leu Ser Ala Trp Leu Ser Trp  
                     20                    25                    30  
 Ser Leu Pro Leu Cys Val Ser Leu Ser Ala Ser Tyr Pro Ala Trp Arg  
                     35                    40                    45  
 Leu Leu Pro Gln Leu His Gly Arg Ser Arg Glu Gln Arg Tyr Thr Lys  
     50                    55                    60  
 Leu Ala Asp Trp Gln Tyr Ile Glu Glu Cys Val Gln Ala Ala Ser Pro  
     65                    70                    75                    80  
 Met Pro Leu Phe Gly Asn Gly Asp Ile Leu Ser Phe Glu Asp Ala Asn  
                     85                    90                    95  
 Arg Ala Met Gln Thr Gly Val Thr Gly Ile Met Ile Ala Arg Gly Ala  
                     100                    105                    110  
 Leu Leu Lys Pro Trp Leu Phe Thr Glu Ile Lys Glu Gln Arg His Trp  
     115                    120                    125  
 Asp Ile Ser Ser Ser Glu Arg Leu Asp Ile Leu Arg Asp Phe Thr Asn  
     130                    135                    140  
 Tyr Gly Leu Glu His Trp Gly Ser Asp Thr Gln Gly Val Glu Lys Thr  
     145                    150                    155                    160  
 Arg Arg Phe Leu Leu Glu Trp Leu Ser Phe Leu Cys Arg Tyr Val Pro  
                     165                    170                    175  
 Val Gly Leu Leu Glu Arg Leu Pro Gln Arg Ile Asn Glu Arg Pro Pro  
     180                    185                    190  
 Tyr Tyr Leu Gly Arg Asp Tyr Leu Glu Thr Leu Met Ala Ser Gln Lys  
     195                    200                    205  
 Ala Ala Asp Trp Ile Arg Ile Ser Glu Met Leu Leu Gly Pro Val Pro  
     210                    215                    220  
 Pro Ser Phe Ala Phe Leu Pro Lys His Lys Ala Asn Ala Tyr Lys  
     225                    230                    235

<210> 95  
 <211> 138  
 <212> PRT  
 <213> Homo sapiens

<400> 95  
 Met Lys Met Met Val Val Leu Leu Met Leu Ser Ser Leu Ser Arg Leu  
     1                    5                    10                    15  
 Leu Gly Leu Met Arg Pro Ser Ser Leu Arg Gln Tyr Leu Asp Ser Val  
                     20                    25                    30  
 Pro Leu Pro Pro Cys Gln Glu Gln Gln Pro Lys Ala Ser Ala Glu Leu

57

35	40	45
Asp His Lys Ala Cys Tyr Leu Cys His Ser Leu Leu Met Leu Ala Gly		
50	55	60
Val Val Val Ser Cys Gln Asp Ile Thr Pro Asp Gln Trp Gly Glu Leu		
65	70	75
Gln Leu Leu Cys Met Gln Leu Asp Arg His Ile Ser Thr Gln Ile Arg		
	85	90
Glu Ser Pro Gln Ala Met His Arg Thr Met Leu Lys Asp Leu Ala Thr		
	100	105
Gln Thr Tyr Ile Arg Trp Gln Glu Leu Leu Thr His Cys Gln Pro Gln		
	115	120
Ala Gln Tyr Phe Ser Pro Trp Lys Asp Ile		
130	135	

<210> 96  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<400> 96
Met Pro Pro Leu Ala Pro Gln Leu Cys Arg Ala Val Phe Leu Val Pro
1 5 10 15
Ile Leu Leu Leu Leu Gln Val Lys Pro Leu Asn Gly Ser Pro Gly Pro
20 25 30
Lys Asp Gly Ser Gln Thr Glu Lys Thr Pro Ser Ala Asp Gln Asn Gln
35 40 45
Glu Gln Phe Glu Glu His Phe Val Ala Ser Ser Val Gly Glu Met Trp
50 55 60
Gln Val Val Asp Met Ala Gln Gln Glu Glu Asp Gln Ser Ser Lys Thr
65 70 75 80
Ala Ala Val His Lys His Ser Phe His Leu Ser Phe Cys Phe Ser Leu
85 90 95
Ala Ser Val Met Val Phe Ser Gly Gly Pro Leu Arg Arg Thr Phe Pro
100 105 110
Asn Ile Gln Leu Cys Phe Met Leu Thr His
115 120

<210> 97  
 <211> 459  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (321)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (345)  
 <223> Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 97

Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu  
 1 5 10 15  
 Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly  
 20 25 30  
 Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His  
 35 40 45  
 Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp  
 50 55 60  
 Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr  
 65 70 75 80  
 Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys  
 85 90 95  
 Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala  
 100 105 110  
 Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu  
 115 120 125  
 Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu  
 130 135 140  
 Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr  
 145 150 155 160  
 Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro  
 165 170 175  
 Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly  
 180 185 190  
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly  
 195 200 205  
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro  
 210 215 220  
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val  
 225 230 235 240  
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly  
 245 250 255  
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser  
 260 265 270  
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn  
 275 280 285  
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met  
 290 295 300  
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly  
 305 310 315 320  
 Xaa Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His  
 325 330 335  
 Pro Gly Glu Lys Gly Glu Lys Lys Xaa Leu Arg Gly Glu Pro Gly Pro

59

	340		345		350
Gln Gly Ser	Ala Gly Gln Arg	Gly Glu Pro Gly Pro	Lys Gly Asp Pro		
355		360	365		
Gly Glu Lys	Ser His Trp Asn	Gln Ser Trp Gly Leu	Gly Gly Pro Cys		
370		375	380		
Arg His Arg	His Pro Gln Pro	Pro Ser Gly Gln Glu	Gly Gly His Ala		
385		390	395		400
Thr Asn Tyr	Arg Asp Arg Gly	Pro Gln Glu Pro	Gly Arg Glu Arg	Leu	
	405		410		415
Arg Val Val	Ala Ala Pro Glu	Ala Asp Gln Ala	Arg Leu Pro	Leu Leu	
	420		425		430
Pro Gly Leu	Gly Gln Leu Pro	Pro Gly Thr Ala	Arg Pro Tyr	Leu Leu	
	435		440		445
Met Ser Ser	Gly Ser Leu Leu	Pro Ser Arg Pro			
450		455			

&lt;210&gt; 98

&lt;211&gt; 352

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (284)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 98

Met Asp Phe	Ile Gln His	Leu Gly Val	Cys Cys Leu	Val Ala Leu	Ile
1	5		10		15
Ser Val Gly	Leu Leu Ser	Val Ala Ala	Cys Trp Phe	Leu Pro	Ser Ile
	20		25		30
Ile Ala Ala	Ala Ala Ser	Trp Ile Ile	Thr Cys Val	Leu Leu	Cys Cys
	35		40		45
Ser Lys His	Ala Arg Cys	Phe Ile Leu	Leu Val Phe	Leu Ser	Cys Gly
	50		55		60
Leu Arg Glu	Gly Arg Asn	Ala Leu Ile	Ala Ala Gly	Thr Gly	Ile Val
	65		70		75
Ile Leu Gly	His Val Glu	Asn Ile Phe	His Asn Phe	Lys Gly	Leu Leu
	85		90		95
Asp Gly Met	Thr Cys Asn	Leu Arg Ala	Lys Ser Phe	Ser Ile	His Phe
	100		105		110
Pro Leu Leu	Lys Lys Tyr	Ile Glu Ala	Ile Gln Trp	Ile Tyr	Gly Leu
	115		120		125
Ala Thr Pro	Leu Ser Val	Phe Asp Asp	Leu Val Ser	Trp Asn	Gln Thr
	130		135		140
Leu Ala Val	Ser Leu Phe	Ser Pro Ser	His Val Leu	Glu Ala	Gln Leu
	145		150		155
Asn Asp Ser	Lys Gly Glu	Val Leu Ser	Val Leu Tyr	Gln Met	Ala Thr

60

165										170					175				
Thr	Thr	Glu	Val	Leu	Ser	Ser	Leu	Gly	Gln	Lys	Leu	Leu	Ala	Phe	Ala				
			180					185					190						
Gly	Leu	Ser	Leu	Val	Leu	Leu	Gly	Thr	Gly	Leu	Phe	Met	Lys	Arg	Phe				
		195					200					205							
Leu	Gly	Pro	Cys	Gly	Trp	Lys	Tyr	Glu	Asn	Ile	Tyr	Ile	Thr	Arg	Gln				
	210					215					220								
Phe	Val	Gln	Phe	Asp	Glu	Arg	Glu	Arg	His	Gln	Gln	Arg	Pro	Cys	Val				
225					230					235					240				
Leu	Pro	Leu	Asn	Lys	Glu	Glu	Arg	Arg	Lys	Tyr	Val	Ile	Ile	Pro	Thr				
			245						250					255					
Phe	Trp	Pro	Thr	Pro	Lys	Glu	Arg	Lys	Asn	Leu	Gly	Leu	Phe	Phe	Leu				
			260					265					270						
Pro	Ile	Leu	Ile	His	Leu	Cys	Ile	Trp	Val	Leu	Xaa	Ala	Ala	Val	Asp				
		275					280					285							
Tyr	Leu	Leu	Tyr	Arg	Leu	Ile	Phe	Ser	Val	Ser	Lys	Gln	Phe	Gln	Ser				
	290					295					300								
Leu	Pro	Gly	Phe	Glu	Val	His	Leu	Lys	Leu	His	Gly	Glu	Lys	Gln	Gly				
305					310					315					320				
Thr	Gln	Asp	Ile	Ile	His	Asp	Ser	Ser	Phe	Asn	Ile	Ser	Val	Phe	Glu				
			325						330					335					
Pro	Asn	Cys	Ile	Pro	Lys	Pro	Trp	Gln	Ala	Leu	Lys	Leu	Leu	Ala	His				
			340					345					350						

<210> 99  
 <211> 257  
 <212> PRT  
 <213> Homo sapiens

<400> 99  
 Met Glu Met Ile Ile Gln Phe Gly Phe Val Thr Leu Phe Val Ala Ser  
 1 5 10 15  
 Phe Pro Leu Ala Pro Leu Phe Ala Leu Leu Asn Asn Ile Ile Glu Ile  
 20 25 30  
 Arg Leu Asp Ala Lys Lys Phe Val Thr Glu Leu Arg Arg Pro Val Ala  
 35 40 45  
 Val Arg Ala Lys Asp Ile Gly Ile Trp Tyr Asn Ile Leu Arg Gly Ile  
 50 55 60  
 Gly Lys Leu Ala Val Ile Ile Asn Ala Phe Val Ile Ser Phe Thr Ser  
 65 70 75 80  
 Asp Phe Ile Pro Arg Leu Val Tyr Leu Tyr Met Tyr Ser Lys Asn Gly  
 85 90 95  
 Thr Met His Gly Phe Val Asn His Thr Leu Ser Ser Phe Asn Val Ser  
 100 105 110

61

Asp Phe Gln Asn Gly Thr Ala Pro Asn Asp Pro Leu Asp Leu Gly Tyr  
 115 120 125  
 Glu Val Gln Ile Cys Arg Tyr Lys Asp Tyr Arg Glu Pro Pro Trp Ser  
 130 135 140  
 Glu Asn Lys Tyr Asp Ile Ser Lys Asp Phe Trp Ala Val Leu Ala Ala  
 145 150 155 160  
 Arg Leu Ala Phe Val Ile Val Phe Gln Asn Leu Val Met Phe Met Ser  
 165 170 175  
 Asp Phe Val Asp Trp Val Ile Pro Asp Ile Pro Lys Asp Ile Ser Gln  
 180 185 190  
 Gln Ile His Lys Glu Lys Val Leu Met Val Glu Leu Phe Met Arg Glu  
 195 200 205  
 Glu Gln Asp Lys Gln Gln Leu Leu Glu Thr Trp Met Glu Lys Glu Arg  
 210 215 220  
 Gln Lys Asp Glu Pro Pro Cys Asn His His Asn Thr Lys Ala Cys Pro  
 225 230 235 240  
 Asp Ser Leu Gly Ser Pro Ala Pro Ser His Ala Tyr His Gly Gly Val  
 245 250 255  
 Leu

<210> 100  
 <211> 127  
 <212> PRT  
 <213> Homo sapiens

<400> 100  
 Met Ala Gln Tyr Ile Leu Val Ile Ile Leu Ile Ser Phe Cys Ser Asp  
 1 5 10 15  
 Ser Leu Ser Gly Arg Ala Gln Asn Gly Thr Glu Ile Asn Gln Thr Val  
 20 25 30  
 Ile Leu Ile Cys Ser Leu Arg Phe Phe Lys Ser Glu Ala Ile Asp Ala  
 35 40 45  
 Cys Leu Met His Pro His Thr Ala Cys Leu Thr Gly Asp Ala Thr Leu  
 50 55 60  
 Leu Ser Ser Ser Ala Met Lys His Lys Arg Gln Arg Lys Ser Arg Tyr  
 65 70 75 80  
 Thr Ser His Arg Glu His Phe Arg Val Pro Gln Arg Trp Trp Gln Glu  
 85 90 95  
 Ala His Ser Arg Val Ser Ile Arg Val Cys Val Trp Val Ser Gly Ile  
 100 105 110  
 Ser Val Ala Pro Ile Phe Leu His Cys Ser Glu His Pro Val Leu  
 115 120 125

<210> 101  
 <211> 136  
 <212> PRT  
 <213> Homo sapiens



&lt;400&gt; 101

Met Leu Met Leu Leu Thr Leu Leu Val Leu Gly Met Val Trp Val Ala  
 1 5 10 15  
 Ser Ala Ile Val Asp Lys Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp  
 20 25 30  
 Phe Trp Glu Tyr Tyr Leu Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu  
 35 40 45  
 Gly Val Leu Leu Leu Leu Gly Glu Cys Thr Gly Ser Gly Arg Glu Trp  
 50 55 60  
 Ala Gly Ser Leu Asp Gln Ser Asn Gln Ala Arg Arg Lys Gly Asn Gly  
 65 70 75 80  
 Gly His Val Arg Glu Gly Val Glu Ser Arg Val Trp Gln Val Thr Gly  
 85 90 95  
 Ser Cys Pro Tyr Ser Val Tyr Ser Thr Gly Ser Arg Pro His Val Leu  
 100 105 110  
 Arg His Trp Glu Ala Ala Ser Gln Ala Pro Ala Ala Gly Arg Pro Gly  
 115 120 125  
 Gly Ala Ala Val Leu Leu Ser Leu  
 130 135

&lt;210&gt; 102

&lt;211&gt; 144

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 102

Met Ser Ala Val Ser Ala Pro Ala Leu Trp Gln Thr Trp Cys Val Pro  
 1 5 10 15  
 Ala Ala Arg Ala Trp Thr Ser Ser Thr Leu Arg His Asp Ala Val Ala  
 20 25 30  
 Arg Pro Asn Pro Ser Thr Ser Leu Thr Pro Gly Leu Leu Thr Ser Ser  
 35 40 45  
 Asp Ser Pro Arg Trp Pro Gly Leu Gln Glu Ala Pro Gly Arg Pro Cys  
 50 55 60  
 Ile Arg Leu Gly Arg Ser Glu Leu Cys Met Tyr Ile Tyr Thr Tyr Ile  
 65 70 75 80  
 Asp Thr Phe Ile Ile Tyr Thr His Ser Leu Tyr Ile Tyr Ile His Cys  
 85 90 95  
 Phe Leu Ala Pro Glu Leu Ile Trp Val Gln Ala His Phe Lys Thr Leu  
 100 105 110  
 Pro Gly Gly Gly Cys Phe Phe Ser Gly Phe Leu Ala Arg Glu Glu Gly  
 115 120 125  
 Glu Gly Thr Gly Trp Val Phe Ser Leu Lys Arg Glu Ser Arg Arg Phe  
 130 135 140

<210> 103  
 <211> 151  
 <212> PRT  
 <213> Homo sapiens

<400> 103  
 Met Leu His Trp Val Leu Ser Phe Phe Phe Leu Leu Ser Cys Pro Arg  
   1                  5                  10                  15  
 Thr Glu Gly Leu Pro Gly Leu Tyr Cys Pro Gly Cys Ser Gln Cys Pro  
                   20                  25                  30  
 Gly Arg Gly Met Trp Pro Gly Asp Pro Gly Pro Gly Ile Gln Gly Pro  
                   35                  40                  45  
 Gly Leu Asp Leu Arg Thr Gly Met Glu Ala Thr Gly Ala Gln Gln Pro  
                   50                  55                  60  
 Thr Leu Ser Ser Pro His Cys Leu Leu Ser Leu Pro Thr Leu Pro Ala  
   65                  70                  75                  80  
 Arg Ala Val Gln Leu Arg Trp Asp Leu Ser Ile Ser Arg Ala Gly Gly  
                   85                  90                  95  
 Arg Val Ala Val Leu Gly Leu Cys Leu Glu Pro Gly Gly Ser Leu Leu  
                   100                  105                  110  
 Leu Pro Pro Ser Ala Leu Pro Glu Thr Asp Pro Cys Ala Ala Cys Pro  
                   115                  120                  125  
 Pro Cys Pro Phe Val Pro Met Ser Gly Gly Gly Gly Arg Pro Thr Val  
   130                  135                  140  
 Pro Glu Ala Gly His Gln Pro  
 145                  150

<210> 104  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 104  
 Met Ala Tyr Leu Thr Leu Phe Gln Met Gly Ser Trp Met Ser Phe Ser  
   1                  5                  10                  15  
 Leu Ser Leu Cys Ser Leu Leu Phe Ile Leu Thr Gly His Cys Leu Ser  
                   20                  25                  30  
 Glu Asn Phe Tyr Val Arg Gly Asp Gly Thr Arg Ala Tyr Phe Phe Thr  
                   35                  40                  45  
 Lys Gly Glu Val His Ser Met Phe Cys Lys Ala Ser Leu Asp Glu Lys  
                   50                  55                  60  
 Gln Asn Leu Val Asp Arg Arg Leu Gln Val Asn Arg Lys Lys Gln Val  
   65                  70                  75                  80  
 Lys Met His Arg Val Trp Ile Gln Gly Lys Phe Gln Lys Pro Leu His  
                   85                  90                  95  
 Gln Thr Gln Asn Ser Ser Asn Met Val Ser Thr Leu Leu Ser Gln Asp  
                   100                  105                  110

<210> 105  
 <211> 80  
 <212> PRT  
 <213> Homo sapiens

<400> 105  
 Met Trp Pro Arg Met Leu Ala Phe Ser Thr Trp Leu Glu Trp Leu Leu  
   1                  5                  10                  15  
 Phe Ser Pro Leu Pro Gln Ser Val Gly Cys Pro Gly Pro Leu Glu Phe  
                   20                  25                  30  
 Tyr Cys Val Gln Asp Arg Arg Pro Pro Ser Leu Pro Asp Gly Ala Asp  
                   35                  40                  45  
 His Phe Ser Ser Pro Thr Arg Ile Thr Ser Ser Ser Ile Ser Pro Ala  
       50                  55                  60  
 Leu Ser Leu Gln Ala Pro Glu Ala Gly Gly Phe Leu Ser Ile Pro Gly  
   65                  70                  75                  80

<210> 106  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 106  
 Met Ser Leu Glu Pro Ser Thr Ser Ser Phe Asn Ile Leu Leu Phe Pro  
   1                  5                  10                  15  
 Ala Phe Leu Arg Val Phe Gly Trp Ala Leu Gly Trp Met Pro Trp Glu  
                   20                  25                  30  
 Tyr Leu Tyr Leu Ser Ser Lys Val Thr Asn Gly Glu Thr Gly Thr Gln  
                   35                  40                  45  
 Arg Gly Thr  
       50

<210> 107  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (10)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 107  
 Met Phe Phe Pro Cys Leu Pro Thr Leu Xaa Leu Arg Ile Leu His Ser  
   1                  5                  10                  15

65

Gly Trp Val Gly Leu Phe Leu Leu Ile Ser Ser Arg Ala Pro Ser Ser  
                   20                                  25                                  30  
 Ser Leu Ala Trp Lys His Gly Pro Gly Glu Leu Trp Trp Pro Arg Xaa  
                   35                                  40                                  45  
 Pro Leu Arg Ser Cys Thr Gly Leu Ala Ser Cys Gly  
                   50                                  55                                  60

<210> 108  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<400> 108  
 Met Trp Pro Phe Leu His Leu Leu Asn Met Pro Phe Thr Leu Thr Gln  
   1                                  5                                  10                                  15  
 Val Val Ala Ser Pro Ser Ser Cys Ser Asn Trp Lys Pro Gln His Pro  
                   20                                  25                                  30  
 Glu Met Pro Pro Pro Gln Ile His Cys Thr His Val Cys Leu Cys Met  
                   35                                  40                                  45  
 Arg Val Cys Ala Arg Val  
                   50

<210> 109  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 109  
 Met Leu Trp Lys Leu Lys Leu Ser Arg Cys Trp Leu Asp Leu Thr Leu  
   1                                  5                                  10                                  15  
 Leu Ile Phe Ser Gln Ile Ser His Met Asp Gln Ile Ile Phe Phe Phe  
                   20                                  25                                  30  
 Val Val Tyr Pro Ile Leu Asn Asn Ile Phe Ser Leu Asn Tyr Cys Arg  
                   35                                  40                                  45  
 Asp Phe Phe Cys Gly Gly Tyr Phe Leu Phe Cys Ser Lys Ile Ile Arg  
                   50                                  55                                  60  
 Cys Lys Ala Ile Leu Cys Leu Thr Val Ala Leu Ser Lys Gln Leu Cys  
   65                                  70                                  75                                  80  
 Ser Gly Val Ala Phe Asp Val Leu Glu Phe Asp Tyr Met Gln Ser Cys  
                   85                                  90                                  95  
 Ile

<210> 110  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (63)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (99)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 110  
 Met Met Thr Met Thr Ser Asp Arg Trp Phe Ser Met Ala Trp Ala Ser  
           1                  5                  10                  15  
 Cys Ser Leu Ser Arg Pro Pro Leu Thr Pro Ser Cys Ser Cys Gln Gln  
                   20                  25                  30  
 Pro Ala Thr Val Ala Leu Leu Leu Gln Thr Ile Ser Val Cys Ser Ala  
                   35                  40                  45  
 Gln Gln Ala Asp Pro Leu Ser Pro Pro Arg Ala Cys Arg Pro Xaa Arg  
           50                  55                  60  
 Gln Phe Pro Val Leu Gln Ser Ala Gly Pro Pro His Ser Pro His Val  
           65                  70                  75                  80  
 Tyr Ala Phe Val Leu Phe Pro Val Ser Ser Arg Trp Gln Gly Gly Asp  
                   85                  90                  95  
 Phe Cys Xaa Ile Cys Cys Cys Phe Pro Gln Cys Leu Gly Arg Cys Leu  
                   100                  105                  110  
 Glu His Thr Arg Cys Ser Ile Asn Pro Xaa  
           115                  120

<210> 111  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<400> 111  
 Met Ser Thr Phe Val Cys Val Cys Val Phe Cys Phe Val Leu Arg Ser  
           1                  5                  10                  15  
 Glu Ala Arg Ala Lys Arg Lys Gln Asp Gln Arg Asn Thr Lys Arg Cys  
                   20                  25                  30  
 Leu Leu Thr Lys Gly Gln Arg Asp Leu Ser Val Asn Gln Ser Lys Ile  
                   35                  40                  45  
 Asn Arg Thr Ala Asn  
           50

<210> 112  
 <211> 80  
 <212> PRT  
 <213> Homo sapiens

<400> 112  
 Met Gly Trp Ile Asp Leu Leu Leu Pro Glu Leu Gly Ala Leu Arg Val  
           1                  5                  10                  15  
 Phe Leu His Leu Phe Leu Val Ala Leu Arg Thr Lys Arg Trp Ile Phe

67

	20		25		30										
Arg	Thr	Leu	Gly	Gln	Leu	Thr	Cys	Val	Asn	Ile	Leu	Gly	Asp	Ser	Arg
		35					40					45			
Lys	Lys	Arg	Glu	Cys	Arg	Leu	Asn	Lys	Arg	Gln	Leu	Gln	Phe	Gly	Glu
	50					55					60				
Lys	Thr	Leu	Gln	Val	Pro	Glu	Arg	Leu	Val	Val	Arg	His	Ser	Pro	Phe
65					70					75					80

<210> 113  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<400> 113  
 Met Leu Val Leu Phe Lys Phe Leu Pro Leu Thr Ser Ser Gly Arg Phe  
 1 5 10 15  
 Leu Ser Val Thr Leu Tyr His Arg Val His His Gln Thr Phe Phe Ala  
 20 25 30  
 Gly Ala Lys Ser Phe Ser Pro Ala Ser Thr Leu Asn Leu Tyr Ile Cys  
 35 40 45  
 Ser Ser Gln Phe Gln Ser Leu Gln Lys Leu Tyr Cys Gly Val Ile Pro  
 50 55 60  
 Val Leu Arg Tyr Ala Ser Ile Glu  
 65 70

<210> 114  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<400> 114  
 Met Val Thr Ser Gly Met Leu Val Phe Ser Ile Lys Thr Phe Ser Ser  
 1 5 10 15  
 Lys Ala Phe Leu Ala Val Val Ser Phe Ile Leu Val Val Ser Ile Lys  
 20 25 30  
 Cys Ser Glu Gly Ala Asp Thr Ser Arg Lys Gly Phe Ser  
 35 40 45

<210> 115  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<400> 115  
 Met Val Leu Leu Leu Leu Leu Leu Gln Lys Ile Pro Gly Thr Pro  
 1 5 10 15  
 Leu Phe Gln Pro Gly Phe Leu Gly Trp Ala Gln Glu Ser Cys Gln Ile  
 20 25 30  
 Gln Ser Tyr Val Gly Ser Lys Leu Pro Leu Cys Cys Phe Cys Gln Ala

68

35 40 45  
 Arg Cys Gly His Ser Lys Phe Ile Cys Val Asn Lys Arg Lys Glu Glu  
     50                      55                      60  
 Pro Ser Gly Cys Asn Arg Thr Asp Ser Ser  
     65                      70

<210> 116  
 <211> 41  
 <212> PRT  
 <213> Homo sapiens

<400> 116  
 Met Asn Leu Met Val Arg Leu Leu Ala Leu Gly Leu Ile Ser Gly Met  
     1                      5                      10                      15  
 Met Ser Asn Ile Thr Gln Ser His Ser Ser Lys Ile Ser Ala Phe Gly  
                     20                      25                      30  
 Ile Phe Ile Gly Pro Glu Gln Phe Leu  
             35                      40

<210> 117  
 <211> 82  
 <212> PRT  
 <213> Homo sapiens

<400> 117  
 Met Asn Arg Ser Thr Arg Ser Tyr Arg Cys Trp Ala Thr Trp Pro Arg  
     1                      5                      10                      15  
 Leu Gly Trp Ala Leu Pro Cys Cys Met Asn Ser Leu Arg Lys Gly Arg  
                     20                      25                      30  
 Lys Phe Ser Gln Ile Thr Thr Ser Leu Met Ala Ser Val Ser Ser Ala  
                     35                      40                      45  
 Ser Met Val Ser Arg Arg Arg Arg Pro Leu Pro Lys His Pro Val Thr  
             50                      55                      60  
 Thr Thr Ser Thr Ala Thr Ala Leu Leu Gly Thr Ser Ser Thr Trp Ser  
     65                      70                      75                      80  
 Lys Ser

<210> 118  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<400> 118  
 Met Gly Gln Arg Gly Val Phe Leu Leu Ile Leu Asp Ala Phe Ser Val  
     1                      5                      10                      15  
 Pro Ser Thr Ala Ser Cys Leu Ile Thr Pro Leu Pro Pro Pro His Pro  
                     20                      25                      30  
 Gln Pro Ser Gln Phe Phe Leu Ala Ser Ala Leu Gln Pro Tyr Leu Gly  
                     35                      40                      45  
 Lys Glu Glu Trp Val

69

50

<210> 119  
 <211> 180  
 <212> PRT  
 <213> Homo sapiens

<400> 119

```

Met Ala Ile Cys Ser Cys Gln Cys Pro Ala Ala Met Ala Phe Cys Phe
 1           5           10           15

Leu Glu Thr Leu Trp Trp Glu Phe Thr Ala Ser Tyr Asp Thr Thr Cys
           20           25           30

Ile Gly Leu Ala Ser Arg Pro Tyr Ala Phe Leu Glu Phe Asp Ser Ile
           35           40           45

Ile Gln Lys Val Lys Trp His Phe Asn Tyr Val Ser Ser Ser Gln Met
           50           55           60

Glu Cys Ser Leu Glu Lys Ile Gln Glu Glu Leu Lys Leu Gln Pro Pro
 65           70           75           80

Ala Val Leu Thr Leu Glu Asp Thr Asp Val Ala Asn Gly Val Met Asn
           85           90           95

Gly His Thr Pro Met His Leu Glu Pro Ala Pro Asn Phe Arg Met Glu
           100          105          110

Pro Val Thr Ala Leu Gly Ile Leu Ser Leu Ile Leu Asn Ile Met Cys
           115          120          125

Ala Ala Leu Asn Leu Ile Arg Gly Val His Leu Ala Glu His Ser Leu
           130          135          140

Gln Val Ala His Glu Glu Ile Gly Asn Ile Leu Ala Phe Leu Val Pro
           145          150          155          160

Phe Val Ala Cys Ile Phe Gln Asp Pro Arg Ser Trp Phe Cys Trp Leu
           165          170          175

Asp Gln Thr Ser
           180

```

<210> 120  
 <211> 599  
 <212> PRT  
 <213> Homo sapiens

<400> 120

```

Met Glu Leu Leu Gly Pro Val Pro Pro Glu Gln Gln Phe Ile Asn Gln
 1           5           10           15

Lys Met Arg Pro Gly Ser Gly Met Leu Ser Ile Arg Val Ile Pro Asp
           20           25           30

Gly Pro Thr Arg Ala Leu Gln Ile Thr Asp Phe Cys His Arg Lys Ser
           35           40           45

Ser Arg Ser Tyr Glu Val Asp Glu Leu Pro Val Thr Glu Gln Glu Leu
           50           55           60

Gln Lys Leu Lys Asn Pro Asp Thr Glu Gln Glu Leu Glu Val Leu Val
           65           70           75           80

```



Arg	Leu	Glu	Gly	Gly	Ile	Gly	Leu	Ser	Leu	Ile	Asn	Lys	Val	Pro	Glu
				85					90					95	
Glu	Leu	Val	Phe	Ala	Ser	Leu	Thr	Gly	Ile	Asn	Val	His	Tyr	Thr	Gln
			100					105					110		
Leu	Ala	Thr	Ser	His	Met	Leu	Glu	Leu	Ser	Ile	Gln	Asp	Val	Gln	Val
		115					120					125			
Asp	Asn	Gln	Leu	Ile	Gly	Thr	Thr	Gln	Pro	Phe	Met	Leu	Tyr	Val	Thr
	130					135					140				
Pro	Leu	Ser	Asn	Glu	Asn	Glu	Val	Ile	Glu	Thr	Gly	Pro	Ala	Val	Gln
145					150					155					160
Val	Asn	Ala	Val	Lys	Phe	Pro	Ser	Lys	Ser	Ala	Leu	Thr	Asn	Ile	Tyr
				165					170					175	
Lys	His	Leu	Met	Ile	Thr	Ala	Gln	Arg	Phe	Thr	Val	Gln	Ile	Glu	Glu
			180					185					190		
Lys	Leu	Leu	Leu	Lys	Leu	Leu	Ser	Phe	Phe	Gly	Tyr	Asp	Gln	Ala	Glu
		195					200					205			
Ser	Glu	Val	Glu	Lys	Tyr	Asp	Glu	Asn	Leu	His	Glu	Lys	Thr	Ala	Glu
	210					215					220				
Gln	Gly	Gly	Thr	Pro	Ile	Arg	Tyr	Tyr	Phe	Glu	Asn	Leu	Lys	Ile	Ser
225					230					235					240
Ile	Pro	Gln	Ile	Lys	Leu	Ser	Val	Phe	Thr	Ser	Asn	Lys	Leu	Pro	Leu
				245					250					255	
Asp	Leu	Lys	Ala	Leu	Lys	Ser	Thr	Leu	Gly	Phe	Pro	Leu	Ile	Arg	Phe
			260					265					270		
Glu	Asp	Ala	Val	Ile	Asn	Leu	Asp	Pro	Phe	Thr	Arg	Val	His	Pro	Tyr
		275					280					285			
Glu	Thr	Lys	Glu	Phe	Ile	Ile	Asn	Asp	Ile	Leu	Lys	His	Phe	Gln	Glu
	290					295					300				
Glu	Leu	Leu	Ser	Gln	Ala	Ala	Arg	Ile	Leu	Gly	Ser	Val	Asp	Phe	Leu
305					310					315					320
Gly	Asn	Pro	Met	Gly	Leu	Leu	Asn	Asp	Val	Ser	Glu	Gly	Val	Thr	Gly
				325					330					335	
Leu	Ile	Lys	Tyr	Gly	Asn	Val	Gly	Gly	Leu	Ile	Arg	Asn	Val	Thr	His
			340					345					350		
Gly	Val	Ser	Asn	Ser	Ala	Gly	Lys	Phe	Ala	Gly	Thr	Leu	Ser	Asp	Gly
		355					360					365			
Leu	Gly	Lys	Thr	Met	Asp	Asn	Arg	His	Gln	Ser	Glu	Arg	Glu	Tyr	Ile
	370					375					380				
Arg	Tyr	His	Ala	Ala	Thr	Ser	Gly	Glu	His	Leu	Val	Ala	Gly	Ile	His
385					390					395					400
Gly	Leu	Ala	His	Gly	Ile	Ile	Gly	Gly	Leu	Thr	Ser	Val	Ile	Thr	Ser
				405					410					415	
Thr	Val	Glu	Gly	Val	Lys	Thr	Glu	Gly	Gly	Val	Ser	Gly	Phe	Ile	Ser
			420					425					430		

```

<400> 121
Met Tyr Pro Pro Val Ala Pro Ser Phe Trp Gly Cys Val Cys Phe Phe
  1          5          10          15
Trp Ala Val Pro Leu Val Cys Cys Arg Asp Ser Trp Lys Gly Leu Ser
      20          25          30
Leu Phe Val Gly Ser Gly Gly Leu Gly Leu Val Glu His
      35          40          45

```

```

<400> 122
Met  Phe  Phe  Gln  Gly  Trp  Val  Asp  Arg  Trp  Leu  Leu  Gly  Cys  Leu  Ala
  1          5          10          15
Pro  Gly  Gly  Phe  Ala  Ile  His  Glu  Ala  Arg  Ala  Gly  Asn  Thr  Val  Ser
          20          25          30
Leu  Pro  Met  Val  Asp  Pro  Cys  Glu  Cys  Gln  Glu  Ala  Ser  Ser  Ser  Val
          35          40          45

```

72

Leu Glu Met Ile Ser Ala Thr Ile Leu  
 50 55

<210> 123  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 123  
 Met Thr His Gly Cys Leu Ser Leu Ala Ser Met Ala Ala Gly Leu Gly  
 1 5 10 15  
 Ser Val Ser Leu Phe Leu Phe Val Gln Gln Trp Thr Pro Thr Thr Ala  
 20 25 30  
 Ser Thr Gly Glu Thr Pro Ser Ser Trp Gln Lys Thr Thr Ser Cys Val  
 35 40 45  
 Arg Arg  
 50

<210> 124  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<400> 124  
 Met His Trp Thr Phe Ser Ser Ser Leu Gly Cys Leu Tyr His Phe Ser  
 1 5 10 15  
 Leu Ser Phe Ser Gly Leu His Thr Val Leu Lys Ser Ser Pro Ser Ser  
 20 25 30  
 Arg Phe Leu Leu Pro Cys Ser Ser Gln Val Thr Gln Pro Ser Pro Val  
 35 40 45  
 Gly Gln Pro Arg Leu Val Val Gln Leu Pro Pro Val Lys Val Ile Gly  
 50 55 60  
 His Arg Thr Gly Gln Cys Arg Gly Pro Gly  
 65 70

<210> 125  
 <211> 253  
 <212> PRT  
 <213> Homo sapiens

<400> 125  
 Met Asp Asn Arg Phe Ala Thr Ala Phe Val Ile Ala Cys Val Leu Ser  
 1 5 10 15  
 Leu Ile Ser Thr Ile Tyr Met Ala Ala Ser Ile Gly Thr Asp Phe Trp  
 20 25 30  
 Tyr Glu Tyr Arg Ser Pro Val Gln Glu Asn Ser Ser Asp Leu Asn Lys  
 35 40 45  
 Ser Ile Trp Asp Glu Phe Ile Ser Asp Glu Ala Asp Glu Lys Thr Tyr  
 50 55 60  
 Asn Asp Ala Leu Phe Arg Tyr Asn Gly Thr Val Gly Leu Trp Arg Arg  
 65 70 75 80

Cys	Ile	Thr	Ile	Pro 85	Lys	Asn	Met	His	Trp 90	Tyr	Ser	Pro	Pro	Glu 95	Arg
Thr	Glu	Ser	Phe 100	Asp	Val	Val	Thr	Lys 105	Cys	Val	Ser	Phe	Thr 110	Leu	Thr
Glu	Gln	Phe 115	Met	Glu	Lys	Phe	Val 120	Asp	Pro	Gly	Asn	His 125	Asn	Ser	Gly
Ile	Asp 130	Leu	Leu	Arg	Thr	Tyr 135	Leu	Trp	Arg	Cys	Gln 140	Phe	Leu	Leu	Pro
Phe 145	Val	Ser	Leu	Gly	Leu 150	Met	Cys	Phe	Gly	Ala 155	Leu	Ile	Gly	Leu	Cys 160
Ala	Cys	Ile	Cys	Arg 165	Ser	Leu	Tyr	Pro	Thr 170	Ile	Ala	Thr	Gly	Ile 175	Leu
His	Leu	Leu	Ala 180	Gly	Leu	Cys	Thr	Leu 185	Gly	Ser	Val	Ser	Cys 190	Tyr	Val
Ala	Gly	Ile 195	Glu	Leu	Leu	His	Gln 200	Lys	Leu	Glu	Leu	Pro 205	Asp	Asn	Val
Ser	Gly 210	Glu	Phe	Gly	Trp	Ser 215	Phe	Cys	Leu	Ala	Cys 220	Val	Ser	Ala	Pro
Leu 225	Gln	Phe	Met	Ala	Ser 230	Ala	Leu	Phe	Ile	Trp 235	Ala	Ala	His	Thr	Asn 240
Arg	Lys	Glu	Tyr	Thr 245	Leu	Met	Lys	Ala	Tyr 250	Arg	Val	Ala			

<210> 126

<211> 89

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 126

Met Phe Leu Leu Arg Pro Leu Pro Ile Leu Leu Val Thr Gly Gly Gly  
1 5 10 15

Tyr Ala Gly Tyr Arg Gln Tyr Glu Lys Tyr Arg Glu Arg Glu Leu Glu  
20 25 30

Lys Leu Gly Leu Glu Ile Pro Pro Lys Leu Ala Gly His Trp Glu Val  
35 40 45

Ala Leu Tyr Lys Ser Val Pro Thr Arg Leu Leu Ser Arg Ala Trp Gly  
50 55 60

Arg Leu Asn Gln Val Glu Leu Pro His Trp Leu Arg Arg Pro Val Tyr  
65 70 75 80

Ser Leu Tyr Ile Trp Thr Xaa Gly Gly  
85

<210> 127

<211> 49

74

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 127

Met Gln Val Ser Ser Trp Val Val Phe Gln Leu Val Trp Asn Ser Leu  
 1 5 10 15  
 Val Leu Thr Gln Thr Gly Ile Lys His Tyr Phe Arg Phe Ser Leu Cys  
 20 25 30  
 Gln Phe Leu Ser Ser Tyr Asn His Val Asn Gln Asp Val Arg Thr Ser  
 35 40 45  
 Ile

&lt;210&gt; 128

&lt;211&gt; 90

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

Met Asp Trp Ala Val Leu Thr Val Val Leu Gly Pro Cys Val Pro Gly  
 1 5 10 15  
 Leu Ser Gly Ser Pro Pro Trp Pro Leu Pro Ser Ser His Leu Leu Glu  
 20 25 30  
 Ala Lys Leu Cys Glu Thr Trp His Ser Phe Gln Thr Ser Val Pro Pro  
 35 40 45  
 Arg Pro Cys Ala Gly Val Thr Pro Glu Leu Arg Met Ser Ala Arg Ser  
 50 55 60  
 Arg Gln Tyr Arg Glu Gly Thr Gln Arg Lys Ala Ser Gln Leu Ser Lys  
 65 70 75 80  
 Asp Arg Asp Arg Leu Trp Ser Gly Arg Ala  
 85 90

&lt;210&gt; 129

&lt;211&gt; 94

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 129

Met Trp Pro Trp Trp Leu Met Val Glu Arg Thr Val Val Leu Leu Leu  
 1 5 10 15  
 Ile Thr Tyr Leu Val Pro Val Gly Gly Ser Ala Val Gly Pro Pro Gly  
 20 25 30  
 Pro Gly Cys Asn Val Ser Thr Ser Pro Pro Pro Pro Ala Thr Arg Cys  
 35 40 45  
 Pro Asp Glu Ser Glu Leu Tyr Arg Asp Pro Gly Glu Ala Pro Leu Glu  
 50 55 60  
 Ala Asp Gln Ala Glu Arg Gly Ala Ala His Glu Gly Gly His Pro Gly  
 65 70 75 80  
 Arg Asp Pro Trp Gly Ala Arg Arg Gly Pro Pro Arg Cys Gly  
 85 90

75

<210> 130  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<400> 130  
 Met Ser Pro His Gln Pro Met Gln Val Ser Ser Ser Lys Thr Ile Leu  
     1                    5                    10                    15  
 Trp Leu Val Leu Ser Cys Leu Cys Pro Ser Ser Pro His Pro Val Ile  
                     20                    25                    30  
 Ser Gly Leu Pro Gln Trp Tyr Ile Gly Val Leu Ala Gly Ile Val Pro  
                     35                    40                    45  
 Val Ala Pro Ile Arg Pro Gly Asp Ser Gly Leu Asp Leu Gln Arg Glu  
                     50                    55                    60  
 Gly Pro Gln Pro Ile Leu Ser Gln Gly Leu Asn Arg Arg Thr  
     65                    70                    75

<210> 131  
 <211> 615  
 <212> PRT  
 <213> Homo sapiens

<400> 131  
 Met Ile Leu Phe Leu Leu Ala Phe Leu Leu Phe Cys Gly Leu Leu Phe  
     1                    5                    10                    15  
 Tyr Ile Asn Leu Ala Asp His Trp Lys Ala Leu Ala Phe Arg Leu Glu  
                     20                    25                    30  
 Glu Glu Gln Lys Met Arg Pro Glu Ile Ala Gly Leu Lys Pro Ala Asn  
                     35                    40                    45  
 Pro Pro Val Leu Pro Ala Pro Gln Lys Ala Asp Thr Asp Pro Glu Asn  
                     50                    55                    60  
 Leu Pro Glu Ile Ser Ser Gln Lys Thr Gln Arg His Ile Gln Arg Gly  
     65                    70                    75                    80  
 Pro Pro His Leu Gln Ile Arg Pro Pro Ser Gln Asp Leu Lys Asp Gly  
                     85                    90                    95  
 Thr Gln Glu Glu Ala Thr Lys Arg Gln Glu Ala Pro Val Asp Pro Arg  
                     100                    105                    110  
 Pro Glu Gly Asp Pro Gln Arg Thr Val Ile Ser Trp Arg Gly Ala Val  
                     115                    120                    125  
 Ile Glu Pro Glu Gln Gly Thr Glu Leu Pro Ser Arg Arg Ala Glu Val  
     130                    135                    140  
 Pro Thr Lys Pro Pro Leu Pro Pro Ala Arg Thr Gln Gly Thr Pro Val  
     145                    150                    155                    160  
 His Leu Asn Tyr Arg Gln Lys Gly Val Ile Asp Val Phe Leu His Ala  
                     165                    170                    175  
 Trp Lys Gly Tyr Arg Lys Phe Ala Trp Gly His Asp Glu Leu Lys Pro  
                     180                    185                    190  
 Val Ser Arg Ser Phe Ser Glu Trp Phe Gly Leu Gly Leu Thr Leu Ile

195					200					205					
Asp	Ala	Leu	Asp	Thr	Met	Trp	Ile	Leu	Gly	Leu	Arg	Lys	Glu	Phe	Glu
210						215					220				
Glu	Ala	Arg	Lys	Trp	Val	Ser	Lys	Lys	Leu	His	Phe	Glu	Lys	Asp	Val
225					230					235					240
Asp	Val	Asn	Leu	Phe	Glu	Ser	Thr	Ile	Arg	Ile	Leu	Gly	Gly	Leu	Leu
				245					250					255	
Ser	Ala	Tyr	His	Leu	Ser	Gly	Asp	Ser	Leu	Phe	Leu	Arg	Lys	Ala	Glu
			260					265					270		
Asp	Phe	Gly	Asn	Arg	Leu	Met	Pro	Ala	Phe	Arg	Thr	Pro	Ser	Lys	Ile
		275					280					285			
Pro	Tyr	Ser	Asp	Val	Asn	Ile	Gly	Thr	Gly	Val	Ala	His	Pro	Pro	Arg
						295					300				
Trp	Thr	Ser	Asp	Ser	Thr	Val	Ala	Glu	Val	Thr	Ser	Ile	Gln	Leu	Glu
305					310					315					320
Phe	Arg	Glu	Leu	Ser	Arg	Leu	Thr	Gly	Asp	Lys	Lys	Phe	Gln	Glu	Ala
				325					330					335	
Val	Glu	Lys	Val	Thr	Gln	His	Ile	His	Gly	Leu	Ser	Gly	Lys	Lys	Asp
			340					345					350		
Gly	Leu	Val	Pro	Met	Phe	Ile	Asn	Thr	His	Ser	Gly	Leu	Phe	Thr	His
		355					360					365			
Leu	Gly	Val	Phe	Thr	Leu	Gly	Ala	Arg	Ala	Asp	Ser	Tyr	Tyr	Glu	Tyr
						375					380				
Leu	Leu	Lys	Gln	Trp	Ile	Gln	Gly	Gly	Lys	Gln	Glu	Thr	Gln	Leu	Leu
385					390					395					400
Glu	Asp	Tyr	Val	Glu	Ala	Ile	Glu	Gly	Val	Arg	Thr	His	Leu	Leu	Arg
				405					410					415	
His	Ser	Glu	Pro	Ser	Lys	Leu	Thr	Phe	Val	Gly	Glu	Leu	Ala	His	Gly
			420					425					430		
Arg	Phe	Ser	Ala	Lys	Met	Asp	His	Leu	Val	Cys	Phe	Leu	Pro	Gly	Thr
			435				440					445			
Leu	Ala	Leu	Gly	Val	Tyr	His	Gly	Leu	Pro	Ala	Ser	His	Met	Glu	Leu
						455					460				
Ala	Gln	Glu	Leu	Met	Glu	Thr	Cys	Tyr	Gln	Met	Asn	Arg	Gln	Met	Glu
465						470					475				480
Thr	Gly	Leu	Ser	Pro	Glu	Ile	Val	His	Phe	Asn	Leu	Tyr	Pro	Gln	Pro
				485					490					495	
Gly	Arg	Arg	Asp	Val	Glu	Val	Lys	Pro	Ala	Asp	Arg	His	Asn	Leu	Leu
			500					505					510		
Arg	Pro	Glu	Thr	Val	Glu	Ser	Leu	Phe	Tyr	Leu	Tyr	Arg	Val	Thr	Gly
			515				520					525			
Asp	Arg	Lys	Tyr	Gln	Asp	Trp	Gly	Trp	Glu	Ile	Leu	Gln	Ser	Phe	Ser
						535					540				
Arg	Phe	Thr	Arg	Val	Pro	Ser	Gly	Gly	Tyr	Ser	Ser	Ile	Asn	Asn	Val

77

545                      550                      555                      560

Gln Asp Pro Gln Lys Pro Glu Pro Arg Asp Lys Met Glu Ser Phe Phe  
                                  565                      570                      575

Leu Gly Glu Thr Leu Lys Tyr Leu Phe Leu Leu Phe Ser Asp Asp Pro  
                                  580                      585                      590

Asn Leu Leu Ser Leu Asp Ala Tyr Val Phe Asn Thr Glu Ala His Pro  
                                  595                      600                      605

Leu Pro Ile Trp Thr Pro Ala  
                                  610                      615

<210> 132  
 <211> 42  
 <212> PRT  
 <213> Homo sapiens

<400> 132

Met Leu Trp Leu Gly Thr Ser Leu Ile Phe Ser Ser Phe Ser Ala Ser  
   1                                 5                                 10                                 15

Phe Asp Gly Val Pro Phe Leu Ser Ser Trp Leu Phe Trp Ser Ser Gly  
                                  20                                 25                                 30

Ser Ser Pro Asn Ser Leu Ile Pro Pro Phe  
                                  35                                 40

<210> 133  
 <211> 99  
 <212> PRT  
 <213> Homo sapiens

<400> 133

Met Glu Gly Pro Arg Gly Trp Leu Val Leu Cys Val Leu Ala Ile Ser  
   1                                 5                                 10                                 15

Leu Ala Ser Met Val Thr Glu Asp Leu Cys Arg Ala Pro Asp Gly Lys  
                                  20                                 25                                 30

Lys Gly Glu Ala Gly Arg Pro Gly Arg Arg Gly Arg Pro Gly Leu Lys  
                                  35                                 40                                 45

Gly Glu Gln Gly Glu Pro Gly Ala Pro Gly Ile Arg Thr Gly Ile Gln  
                                  50                                 55                                 60

Gly Leu Lys Gly Asp Gln Gly Glu Pro Gly Pro Ser Gly Asn Pro Gly  
   65                                 70                                 75                                 80

Lys Val Gly Tyr Pro Gly Pro Ser Gly Pro Leu Arg Ser Pro Trp His  
                                  85                                 90                                 95

Pro Gly Asn

<210> 134  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 134

Met Gly His Leu His Trp Gly Val Ser Gly Asn Phe Phe Phe Pro Arg



78

1		5		10		15									
Leu	Ser	Leu	Phe	Leu	Leu	Phe	Ala	Trp	Leu	Gln	Ile	Thr	Gln	Ala	Asn
			20					25					30		
Glu	Pro	Arg	Leu	Pro	Gly	Lys	Tyr	Ser	Ile	Lys	Ala	Ile	Lys	Ile	Thr
		35					40					45			
Ile	Cys	Ile	Thr	Phe	Arg	Thr	Ser	Ala							
	50					55									

&lt;210&gt; 135

&lt;211&gt; 316

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Met	Leu	Arg	Arg	Arg	Gly	Ser	Pro	Gly	Met	Gly	Val	His	Val	Gly	Ala
1				5					10					15	
Ala	Leu	Gly	Ala	Leu	Trp	Phe	Cys	Leu	Thr	Gly	Ala	Leu	Glu	Val	Gln
			20					25					30		
Val	Pro	Glu	Asp	Pro	Val	Val	Ala	Leu	Val	Gly	Thr	Asp	Ala	Thr	Leu
		35					40					45			
Cys	Cys	Ser	Phe	Ser	Pro	Glu	Pro	Gly	Phe	Ser	Leu	Ala	Gln	Leu	Asn
	50					55					60				
Leu	Ile	Trp	Gln	Leu	Thr	Asp	Thr	Lys	Gln	Leu	Val	His	Ser	Phe	Ala
65					70				75						80
Glu	Gly	Gln	Asp	Gln	Gly	Ser	Ala	Tyr	Ala	Asn	Arg	Thr	Ala	Leu	Phe
				85				90						95	
Pro	Asp	Leu	Leu	Ala	Gln	Gly	Asn	Ala	Ser	Leu	Arg	Leu	Gln	Arg	Val
		100					105						110		
Arg	Val	Ala	Asp	Glu	Gly	Ser	Phe	Thr	Cys	Phe	Val	Ser	Ile	Arg	Asp
	115						120					125			
Phe	Gly	Ser	Ala	Ala	Val	Ser	Leu	Gln	Val	Ala	Ala	Pro	Tyr	Ser	Lys
	130					135				140					
Pro	Ser	Met	Thr	Leu	Glu	Pro	Asn	Lys	Asp	Leu	Arg	Pro	Gly	Asp	Thr
145					150				155					160	
Val	Thr	Ile	Thr	Cys	Ser	Ser	Tyr	Gln	Gly	Tyr	Pro	Glu	Ala	Glu	Val
				165					170					175	
Phe	Trp	Gln	Asp	Gly	Gln	Gly	Val	Pro	Leu	Thr	Gly	Asn	Val	Thr	Thr
		180					185						190		
Ser	Gln	Met	Ala	Asn	Glu	Gln	Gly	Leu	Phe	Asp	Val	His	Ser	Ile	Leu
	195						200					205			
Arg	Val	Val	Leu	Gly	Ala	Asn	Gly	Thr	Tyr	Ser	Cys	Leu	Val	Arg	Asn
	210					215					220				
Pro	Val	Leu	Gln	Gln	Asp	Ala	His	Ser	Ser	Val	Thr	Ile	Thr	Gly	Gln
225					230					235					240
Pro	Met	Thr	Phe	Pro	Pro	Glu	Ala	Leu	Trp	Val	Thr	Val	Gly	Leu	Ser
				245					250					255	

Val	Cys	Leu	Ile	Ala	Leu	Leu	Val	Ala	Leu	Ala	Phe	Val	Cys	Trp	Arg
			260					265					270		
Lys	Ile	Lys	Gln	Ser	Cys	Glu	Glu	Glu	Asn	Ala	Gly	Ala	Glu	Asp	Gln
		275					280					285			
Asp	Gly	Glu	Gly	Glu	Gly	Ser	Lys	Thr	Ala	Leu	Gln	Pro	Leu	Lys	His
	290					295					300				
Ser	Asp	Ser	Lys	Glu	Asp	Asp	Gly	Gln	Glu	Ile	Ala				
305					310					315					

```
<210> 136
<211> 302
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (128)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 136															
Met 1	Arg	Leu	Gly	Ser 5	Pro	Gly	Leu	Leu	Phe 10	Leu	Leu	Phe	Ser	Ser 15	Leu
Arg	Ala	Asp	Thr 20	Gln	Glu	Lys	Glu	Val 25	Arg	Ala	Met	Val	Gly 30	Ser	Asp
Val	Glu	Leu 35	Ser	Cys	Ala	Cys	Pro 40	Glu	Gly	Ser	Arg	Phe 45	Asp	Leu	Asn
Asp	Val 50	Tyr	Val	Tyr	Trp	Gln 55	Thr	Ser	Glu	Ser	Lys 60	Thr	Val	Val	Thr
Tyr 65	His	Ile	Pro	Gln	Asn 70	Ser	Ser	Leu	Glu	Asn 75	Val	Asp	Ser	Arg	Tyr 80
Arg	Asn	Arg	Ala	Leu 85	Met	Ser	Pro	Ala	Gly 90	Met	Leu	Arg	Gly	Asp 95	Phe
Ser	Leu	Arg	Leu 100	Phe	Asn	Val	Thr	Pro 105	Gln	Asp	Glu	Gln	Lys 110	Phe	His
Cys	Leu 115	Val	Leu	Ser	Gln	Ser	Leu 120	Gly	Phe	Gln	Glu	Val 125	Leu	Ser	Xaa
Glu 130	Val	Thr	Leu	His	Val	Ala 135	Ala	Asn	Phe	Ser	Val 140	Pro	Val	Val	Ser
Ala 145	Pro	His	Ser	Pro	Ser 150	Gln	Asp	Glu	Leu	Thr 155	Phe	Thr	Cys	Thr	Ser
Ile	Asn	Gly	Tyr	Pro 165	Arg	Pro	Asn	Val	Tyr 170	Trp	Ile	Asn	Lys	Thr 175	Asp
Asn	Ser	Leu 180	Leu	Asp	Gln	Ala	Leu 185	Gln	Asn	Asp	Thr	Val	Phe 190	Leu	Asn
Met	Arg	Gly 195	Leu	Tyr	Asp	Val	Val 200	Ser	Val	Leu	Arg	Ile 205	Ala	Arg	Thr
Pro 210	Ser	Val	Asn	Ile	Gly	Cys 215	Cys	Ile	Glu	Asn 220	Val	Leu	Leu	Gln	Gln

80

Asn Leu Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp  
 225 230 235 240  
 Lys Ile Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr  
 245 250 255  
 Trp Ser Ile Leu Ala Val Leu Cys Leu Leu Val Val Val Ala Val Ala  
 260 265 270  
 Ile Gly Trp Val Cys Arg Asp Arg Cys Leu Gln His Ser Tyr Ala Gly  
 275 280 285  
 Ala Trp Ala Val Ser Pro Glu Thr Glu Leu Thr Gly His Val  
 290 295 300

&lt;210&gt; 137

&lt;211&gt; 374

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

Met Ala Ala Pro Ala Leu Gly Leu Val Cys Gly Arg Cys Pro Glu Leu  
 1 5 10 15  
 Gly Leu Val Leu Leu Leu Leu Leu Ser Leu Leu Cys Gly Ala Ala  
 20 25 30  
 Gly Ser Gln Glu Ala Gly Thr Gly Ala Gly Ser Leu Ala Gly  
 35 40 45  
 Ser Cys Gly Cys Gly Thr Pro Gln Arg Pro Gly Ala His Gly Ser Ser  
 50 55 60  
 Ala Ala Ala His Arg Tyr Ser Arg Glu Ala Asn Ala Pro Gly Pro Val  
 65 70 75 80  
 Pro Gly Glu Arg Gln Leu Ala His Ser Lys Met Val Pro Ile Pro Ala  
 85 90 95  
 Gly Val Phe Thr Met Gly Thr Asp Asp Pro Gln Ile Lys Gln Asp Gly  
 100 105 110  
 Glu Ala Pro Ala Arg Arg Val Thr Ile Asp Ala Phe Tyr Met Asp Ala  
 115 120 125  
 Tyr Glu Val Ser Asn Thr Glu Phe Glu Lys Phe Val Asn Ser Thr Gly  
 130 135 140  
 Tyr Leu Thr Glu Ala Glu Lys Phe Gly Asp Ser Phe Val Phe Glu Gly  
 145 150 155 160  
 Met Leu Ser Glu Gln Val Lys Thr Asn Ile Gln Gln Ala Val Ala Ala  
 165 170 175  
 Ala Pro Trp Trp Leu Pro Val Lys Gly Ala Asn Trp Arg His Pro Glu  
 180 185 190  
 Gly Pro Asp Ser Thr Ile Leu His Arg Pro Asp His Pro Val Leu His  
 195 200 205  
 Val Ser Trp Asn Asp Ala Val Ala Tyr Cys Thr Trp Ala Gly Lys Arg  
 210 215 220  
 Leu Pro Thr Glu Ala Glu Trp Glu Tyr Ser Cys Arg Gly Gly Leu His  
 225 230 235 240

[illegible]

```
<210> 138
<211> 127
<212> PRT
<213> Homo sapiens
```

<400> 138															
Met	Val	Pro	Gly	Ala	Ala	Gly	Trp	Cys	Cys	Leu	Val	Leu	Trp	Leu	Pro
1				5					10					15	
Ala	Cys	Val	Ala	Ala	His	Gly	Phe	Arg	Ile	His	Asp	Tyr	Leu	Tyr	Phe
			20					25					30		
Gln	Val	Leu	Ser	Pro	Gly	Asp	Ile	Arg	Tyr	Ile	Phe	Thr	Ala	Thr	Pro
		35					40					45			
Ala	Lys	Asp	Phe	Gly	Gly	Ile	Phe	His	Thr	Arg	Tyr	Glu	Gln	Ile	His
	50					55					60				
Leu	Val	Pro	Ala	Glu	Pro	Pro	Glu	Ala	Cys	Gly	Glu	Leu	Ser	Asn	Gly
65					70					75					80
Phe	Phe	Ile	Gln	Asp	Gln	Ile	Ala	Leu	Val	Glu	Arg	Gly	Gly	Cys	Ser
				85					90					95	
Phe	Leu	Ser	Lys	Thr	Arg	Val	Val	Gln	Glu	His	Gly	Gly	Arg	Ala	Val
			100					105					110		
Ile	Ile	Ser	Asp	Asn	Ala	Leu	Thr	Met	Thr	Ala	Ser	Thr	Trp	Arg	
		115					120					125			

```
<210> 139  
<211> 122  
<212> PRT  
<213> Homo sapiens
```

<400> 139

82

Met Pro Pro Leu Ala Pro Gln Leu Cys Arg Ala Val Phe Leu Val Pro  
 1 5 10 15  
 Ile Leu Leu Leu Leu Gln Val Lys Pro Leu Asn Gly Ser Pro Gly Pro  
 20 25 30  
 Lys Asp Gly Ser Gln Thr Glu Lys Thr Pro Ser Ala Asp Gln Asn Gln  
 35 40 45  
 Glu Gln Phe Glu Glu His Phe Val Ala Ser Ser Val Gly Glu Met Trp  
 50 55 60  
 Gln Val Val Asp Met Ala Gln Gln Glu Glu Asp Gln Ser Ser Lys Thr  
 65 70 75 80  
 Ala Ala Val His Lys His Ser Phe His Leu Ser Phe Cys Phe Ser Leu  
 85 90 95  
 Ala Ser Val Met Val Phe Ser Gly Gly Pro Leu Arg Arg Thr Phe Pro  
 100 105 110  
 Asn Ile Gln Leu Cys Phe Met Leu Thr His  
 115 120

<210> 140  
 <211> 257  
 <212> PRT  
 <213> Homo sapiens

<400> 140  
 Met Asp Phe Ile Gln His Leu Gly Val Cys Cys Leu Val Ala Leu Ile  
 1 5 10 15  
 Ser Val Gly Leu Leu Ser Val Ala Ala Cys Trp Phe Leu Pro Ser Ile  
 20 25 30  
 Ile Ala Ala Ala Ala Ser Trp Ile Ile Thr Cys Val Leu Leu Cys Cys  
 35 40 45  
 Ser Lys His Ala Arg Cys Phe Ile Leu Leu Val Phe Leu Ser Cys Gly  
 50 55 60  
 Leu Arg Glu Gly Arg Asn Ala Leu Ile Ala Ala Gly Thr Gly Ile Val  
 65 70 75 80  
 Ile Leu Gly His Val Glu Asn Ile Phe His Asn Phe Lys Gly Leu Leu  
 85 90 95  
 Asp Gly Met Thr Cys Asn Leu Arg Ala Lys Ser Phe Ser Ile His Phe  
 100 105 110  
 Pro Leu Leu Lys Lys Tyr Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu  
 115 120 125  
 Ala Thr Pro Leu Ser Val Phe Asp Asp Leu Val Ser Trp Asn Gln Thr  
 130 135 140  
 Leu Ala Val Ser Leu Phe Ser Pro Ser His Val Leu Glu Ala Gln Leu  
 145 150 155 160  
 Asn Asp Ser Lys Gly Glu Val Leu Ser Val Leu Tyr Gln Met Ala Thr  
 165 170 175  
 Thr Thr Glu Val Leu Ser Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala  
 180 185 190

Gly Leu Ser Leu Val Leu Leu Gly Thr Gly Leu Phe Met Lys Arg Phe  
 195 200 205  
 Leu Gly Pro Cys Gly Trp Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln  
 210 215 220  
 Phe Val Gln Phe Asp Glu Arg Glu Arg His Gln Gln Arg Pro Cys Val  
 225 230 235 240  
 Leu Pro Leu Asn Lys Glu Glu Arg Arg Lys Phe Ile Ser Gly Phe Gln  
 245 250 255

Ser

<210> 141  
 <211> 257  
 <212> PRT  
 <213> Homo sapiens

<400> 141  
 Met Asp Phe Ile Gln His Leu Gly Val Cys Cys Leu Val Ala Leu Ile  
 1 5 10 15  
 Ser Val Gly Leu Leu Ser Val Ala Ala Cys Trp Phe Leu Pro Ser Ile  
 20 25 30  
 Ile Ala Ala Ala Ala Ser Trp Ile Ile Thr Cys Val Leu Leu Cys Cys  
 35 40 45  
 Ser Lys His Ala Arg Cys Phe Ile Leu Leu Val Phe Leu Ser Cys Gly  
 50 55 60  
 Leu Arg Glu Gly Arg Asn Ala Leu Ile Ala Ala Gly Thr Gly Ile Val  
 65 70 75 80  
 Ile Leu Gly His Val Glu Asn Ile Phe His Asn Phe Lys Gly Leu Leu  
 85 90 95  
 Asp Gly Met Thr Cys Asn Leu Arg Ala Lys Ser Phe Ser Ile His Phe  
 100 105 110  
 Pro Leu Leu Lys Lys Tyr Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu  
 115 120 125  
 Ala Thr Pro Leu Ser Val Phe Asp Asp Leu Val Ser Trp Asn Gln Thr  
 130 135 140  
 Leu Ala Val Ser Leu Phe Ser Pro Ser His Val Leu Glu Ala Gln Leu  
 145 150 155 160  
 Asn Asp Ser Lys Gly Glu Val Leu Ser Val Leu Tyr Gln Met Ala Thr  
 165 170 175  
 Thr Thr Glu Val Leu Ser Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala  
 180 185 190  
 Gly Leu Ser Leu Val Leu Leu Gly Thr Gly Leu Phe Met Lys Arg Phe  
 195 200 205  
 Leu Gly Pro Cys Gly Trp Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln  
 210 215 220  
 Phe Val Gln Phe Asp Glu Arg Glu Arg His Gln Gln Arg Pro Cys Val

```
<210> 142
<211> 291
<212> PRT
<213> Homo sapiens
```

<400> 142															
Met 1	Asp	Phe	Ile	Gln 5	His	Leu	Gly	Val	Cys 10	Cys	Leu	Val	Ala	Leu 15	Ile
Ser	Val	Gly	Leu 20	Leu	Ser	Val	Ala	Ala 25	Cys	Trp	Phe	Leu	Pro 30	Ser	Ile
Ile	Ala	Ala 35	Ala	Ala	Ser	Trp	Ile 40	Ile	Thr	Cys	Val	Leu 45	Leu	Cys	Cys
Ser	Lys 50	His	Ala	Arg	Cys	Phe 55	Ile	Leu	Leu	Val	Phe 60	Leu	Ser	Cys	Gly
Leu 65	Arg	Glu	Gly	Arg	Asn 70	Ala	Leu	Ile	Ala	Ala 75	Gly	Thr	Gly	Ile	Val 80
Ile	Leu	Gly	His	Val 85	Glu	Asn	Ile	Phe	His 90	Asn	Phe	Lys	Gly	Leu 95	Leu
Asp	Gly	Met	Thr 100	Cys	Asn	Leu	Arg	Ala 105	Lys	Ser	Phe	Ser	Ile 110	His	Phe
Pro	Leu	Leu 115	Lys	Lys	Tyr	Ile	Glu 120	Ala	Ile	Gln	Trp	Ile 125	Tyr	Gly	Leu
Ala	Thr 130	Pro	Leu	Ser	Val	Phe 135	Asp	Asp	Leu	Val	Ser 140	Trp	Asn	Gln	Thr
Leu 145	Ala	Val	Ser	Leu	Phe 150	Ser	Pro	Ser	His	Val 155	Leu	Glu	Ala	Gln	Leu 160
Asn	Asp	Ser	Lys	Gly 165	Glu	Val	Leu	Ser	Val 170	Leu	Tyr	Gln	Met	Ala 175	Thr
Thr	Thr	Glu	Val 180	Leu	Ser	Ser	Leu	Gly 185	Gln	Lys	Leu	Leu	Ala 190	Phe	Ala
Gly	Leu	Ser 195	Leu	Val	Leu	Leu	Gly 200	Thr	Gly	Leu	Phe	Met 205	Lys	Arg	Phe
Leu	Gly 210	Pro	Cys	Gly	Trp	Lys 215	Tyr	Glu	Asn	Ile	Tyr 220	Ile	Thr	Arg	Gln
Phe 225	Val	Gln	Phe	Asp	Glu 230	Arg	Glu	Arg	His	Gln 235	Gln	Arg	Pro	Cys	Met 240
Leu	Pro	Leu	Asn	Lys 245	Glu	Glu	Arg	Arg	Lys 250	Asn	Lys	Glu	Leu	Lys 255	Ile
Leu	Ser	Met	Ile 260	Leu	Pro	Leu	Ile	Tyr 265	Leu	Cys	Leu	Asn	Pro 270	Thr	Val

85

Ser Gln Asn Gln Asn Ser Phe Tyr Leu Arg Pro Gly Phe Leu Ser Val  
                   275                                  280                                  285

Leu Phe Phe  
       290

<210> 143  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Met His Asp Val Leu Phe Phe Leu Ser Phe Ser Leu Val Ala Cys Val  
       1                                  5                                  10                                  15

Lys Ala Gly Met Leu  
                   20

<210> 144  
 <211> 173  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Met Pro Pro Tyr Thr Pro Phe Phe Gly Thr Arg Ala Leu Leu Ser Val  
       1                                  5                                  10                                  15

Ser Leu Pro Pro Cys Met Leu His Trp Val Leu Ser Phe Phe Phe  
                   20                                  25                                  30

Leu Leu Ser Cys Pro Arg Thr Glu Gly Leu Pro Gly Leu Tyr Cys Pro  
                   35                                  40                                  45

Gly Cys Ser Gln Cys Pro Gly Arg Gly Met Trp Pro Gly Asp Pro Gly  
                   50                                  55                                  60

Pro Gly Ile Gln Gly Pro Gly Leu Asp Leu Arg Thr Gly Met Glu Ala  
       65                                  70                                  75                                  80

Thr Gly Ala Gln Gln Pro Thr Leu Ser Ser Pro His Cys Leu Leu Ser  
                   85                                  90                                  95

Leu Pro Thr Leu Pro Ala Arg Ala Val Gln Leu Arg Trp Asp Leu Ser  
                   100                                  105                                  110

Ile Ser Arg Ala Gly Gly Arg Val Ala Val Leu Gly Leu Cys Leu Glu  
                   115                                  120                                  125

Pro Gly Gly Ser Leu Leu Leu Pro Pro Ser Ala Leu Pro Glu Thr Asp  
       130                                  135                                  140

Pro Cys Ala Ala Cys Pro Pro Cys Pro Phe Val Pro Met Ser Gly Gly  
       145                                  150                                  155                                  160

Gly Gly Arg Pro Thr Val Pro Glu Ala Gly His Gln Pro  
                   165                                  170

<210> 145  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<220>



<221> SITE  
 <222> (10)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (42)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 145  
 Met Phe Phe Pro Cys Leu Pro Thr Leu Xaa Leu Arg Ile Leu His Ser  
   1                  5                  10                  15  
 Gly Trp Val Gly Leu Phe Leu Leu Ile Ser Ser Arg Ala Pro Ser Ser  
                   20                  25                  30  
 Ser Leu Ala Trp Lys His Gly Pro Gly Xaa Leu Trp Trp Pro Arg Arg  
           35                  40                  45  
 Pro Leu Arg Ser Cys Thr Gly Leu Ala Ser Cys Gly  
       50                  55                  60  
  
 <210> 146  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 146  
 Met Val Thr Ser Gly Met Leu Val Phe Ser Ile Lys Thr Phe Ser Ser  
   1                  5                  10                  15  
 Lys Ala Phe Leu Ala Val Val Ser Phe Ile Leu Val Val Ser Ile Lys  
                   20                  25                  30  
 Cys Ser Glu Gly Ala Asp Thr Ser Arg Lys Gly Phe Ser  
       35                  40                  45  
  
 <210> 147  
 <211> 404  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (41)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (77)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (96)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (98)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE

<222> (108)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (124)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (126)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (175)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (192)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (210)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (236)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (239)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (309)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (335)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (389)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 147  
 Met His Pro Ile Pro Ser Ser Phe Met Ile Lys Ala Val Ser Ser Phe  
   1                  5                  10                  15  
 Leu Thr Ala Glu Glu Ala Ser Val Gly Asn Pro Glu Gly Ala Phe Met  
                   20                  25                  30  
 Lys Val Leu Gln Ala Arg Lys Asn Xaa Thr Ser Thr Glu Leu Ile Val

88

35					40					45					
Glu	Pro	Glu	Glu	Pro	Ser	Asp	Ser	Ser	Gly	Ile	Asn	Leu	Ser	Gly	Phe
	50					55					60				
Gly	Ser	Glu	Gln	Leu	Asp	Thr	Asn	Asp	Glu	Ser	Asp	Xaa	Ile	Ser	Thr
65					70					75					80
Leu	Ser	Tyr	Ile	Leu	Pro	Tyr	Phe	Ser	Ala	Val	Asn	Leu	Asp	Val	Xaa
				85					90					95	
Ser	Xaa	Leu	Leu	Pro	Phe	Ile	Lys	Leu	Pro	Thr	Xaa	Gly	Asn	Ser	Leu
			100					105					110		
Ala	Lys	Ile	Gln	Thr	Val	Gly	Gln	Asn	Xaa	Gln	Xaa	Val	Xaa	Arg	Val
		115					120					125			
Leu	Met	Gly	Pro	Arg	Ser	Ile	Gln	Lys	Arg	His	Phe	Lys	Glu	Val	Gly
	130					135					140				
Arg	Gln	Ser	Ile	Arg	Arg	Glu	Gln	Gly	Ala	Gln	Ala	Ser	Val	Glu	Asn
145					150					155					160
Ala	Ala	Glu	Glu	Lys	Arg	Leu	Gly	Ser	Pro	Ala	Pro	Arg	Glu	Xaa	Glu
				165					170					175	
Gln	Pro	His	Thr	Gln	Gln	Gly	Pro	Glu	Lys	Leu	Ala	Gly	Asn	Ala	Xaa
			180					185					190		
Tyr	Thr	Lys	Pro	Ser	Phe	Thr	Gln	Glu	His	Lys	Ala	Ala	Val	Ser	Val
		195					200					205			
Leu	Xaa	Pro	Phe	Ser	Lys	Gly	Ala	Pro	Ser	Thr	Ser	Ser	Pro	Ala	Lys
	210					215					220				
Ala	Leu	Pro	Gln	Val	Arg	Asp	Arg	Trp	Lys	Asp	Xaa	Thr	His	Xaa	Ile
225					230					235					240
Ser	Ile	Leu	Glu	Ser	Ala	Lys	Ala	Arg	Val	Thr	Asn	Met	Lys	Ala	Ser
				245					250					255	
Lys	Pro	Ile	Ser	His	Ser	Arg	Lys	Lys	Tyr	Arg	Phe	His	Lys	Thr	Arg
			260					265					270		
Ser	Arg	Met	Thr	His	Arg	Thr	Pro	Lys	Val	Lys	Lys	Ser	Pro	Lys	Phe
		275					280					285			
Arg	Lys	Lys	Ser	Tyr	Leu	Ser	Arg	Leu	Met	Leu	Ala	Asn	Arg	Pro	Pro
	290					295					300				
Phe	Ser	Ala	Ala	Xaa	Ser	Leu	Ile	Asn	Ser	Pro	Ser	Gln	Gly	Ala	Phe
305					310					315					320
Ser	Ser	Leu	Gly	Asp	Leu	Ser	Pro	Gln	Glu	Asn	Pro	Phe	Leu	Xaa	Val
				325					330					335	
Ser	Ala	Pro	Ser	Glu	His	Phe	Ile	Glu	Thr	Thr	Asn	Ile	Lys	Asp	Thr
			340					345					350		
Thr	Ala	Arg	Asn	Ala	Leu	Glu	Glu	Asn	Val	Phe	Met	Glu	Asn	Thr	Asn
		355					360					365			
Met	Pro	Glu	Val	Thr	Ile	Ser	Glu	Asn	Thr	Asn	Tyr	Asn	His	Pro	Pro
	370					375					380				
Glu	Ala	Asp	Ser	Xaa	Gly	Thr	Ala	Phe	Asn	Leu	Gly	Pro	Thr	Val	Lys

89

385 390 395 400

Gln Thr Glu Thr

<210> 148  
<211> 53  
<212> PRT  
<213> Homo sapiens

<400> 148  
Met Gly Gln Arg Gly Val Phe Leu Leu Ile Leu Asp Ala Phe Ser Val  
1 5 10 15  
Pro Ser Thr Ala Ser Cys Leu Ile Thr Pro Leu Pro Pro Pro His Pro  
20 25 30  
Gln Pro Ser Gln Phe Phe Leu Ala Ser Ala Leu Gln Pro Tyr Leu Gly  
35 40 45  
Lys Glu Glu Trp Val  
50

<210> 149  
<211> 53  
<212> PRT  
<213> Homo sapiens

<400> 149  
Met Gly Gln Arg Gly Val Phe Leu Leu Ile Leu Asp Ala Phe Ser Val  
1 5 10 15  
Pro Ser Thr Ala Ser Cys Leu Ile Thr Pro Leu Pro Pro Pro His Pro  
20 25 30  
Gln Pro Ser Gln Phe Phe Leu Ala Ser Ala Leu Gln Pro Tyr Leu Gly  
35 40 45  
Lys Glu Glu Trp Val  
50

<210> 150  
<211> 50  
<212> PRT  
<213> Homo sapiens

<400> 150  
Met Thr His Gly Cys Leu Ser Leu Ala Ser Met Ala Ala Gly Leu Gly  
1 5 10 15  
Ser Val Ser Leu Phe Leu Phe Val Gln Gln Trp Thr Pro Thr Thr Ala  
20 25 30  
Ser Thr Gly Glu Thr Pro Ser Ser Trp Gln Lys Thr Thr Ser Cys Val  
35 40 45  
Arg Arg  
50

<210> 151  
<211> 253  
<212> PRT

<213> Homo sapiens

<400> 151

```

Met Asp Asn Arg Phe Ala Thr Ala Phe Val Ile Ala Cys Val Leu Ser
 1          5          10          15
Leu Ile Ser Thr Ile Tyr Met Ala Ala Ser Ile Gly Thr Asp Phe Trp
          20          25          30
Tyr Glu Tyr Arg Ser Pro Val Gln Glu Asn Ser Ser Asp Leu Asn Lys
          35          40          45
Ser Ile Trp Asp Glu Phe Ile Ser Asp Glu Ala Asp Glu Lys Thr Tyr
          50          55          60
Asn Asp Ala Leu Phe Arg Tyr Asn Gly Thr Val Gly Leu Trp Arg Arg
          65          70          75          80
Cys Ile Thr Ile Pro Lys Asn Met His Trp Tyr Ser Pro Pro Glu Arg
          85          90          95
Thr Glu Ser Phe Asp Val Val Thr Lys Cys Val Ser Phe Thr Leu Thr
          100          105          110
Glu Gln Phe Met Glu Lys Phe Val Asp Pro Gly Asn His Asn Ser Gly
          115          120          125
Ile Asp Leu Leu Arg Thr Tyr Leu Trp Arg Cys Gln Phe Leu Leu Pro
          130          135          140
Phe Val Ser Leu Gly Leu Met Cys Phe Gly Ala Leu Ile Gly Leu Cys
          145          150          155          160
Ala Cys Ile Cys Arg Ser Leu Tyr Pro Thr Ile Ala Thr Gly Ile Leu
          165          170          175
His Leu Leu Ala Gly Leu Cys Thr Leu Gly Ser Val Ser Cys Tyr Val
          180          185          190
Ala Gly Ile Glu Leu Leu His Gln Lys Leu Glu Leu Pro Asp Asn Val
          195          200          205
Ser Gly Glu Phe Gly Trp Ser Phe Cys Leu Ala Cys Val Ser Ala Pro
          210          215          220
Leu Gln Phe Met Ala Ser Ala Leu Phe Ile Trp Ala Ala His Thr Asn
          225          230          235          240
Arg Lys Glu Tyr Thr Leu Met Lys Ala Tyr Arg Val Ala
          245          250

```

<210> 152

<211> 127

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (107)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (109)

<223> Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (116)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 152

Met Phe Leu Leu Arg Pro Leu Pro Ile Leu Leu Val Thr Gly Gly Gly  
 1 5 10 15  
 Tyr Ala Gly Tyr Arg Gln Tyr Glu Lys Tyr Arg Glu Arg Glu Leu Glu  
 20 25 30  
 Lys Leu Gly Leu Glu Ile Pro Pro Lys Leu Ala Gly His Trp Glu Val  
 35 40 45  
 Ala Leu Tyr Lys Ser Val Pro Thr Arg Leu Leu Ser Arg Ala Trp Gly  
 50 55 60  
 Arg Leu Asn Gln Val Glu Leu Pro His Trp Leu Arg Arg Pro Val Tyr  
 65 70 75 80  
 Ser Leu Tyr Ile Trp Thr Phe Gly Val Asn Met Lys Glu Ala Ala Val  
 85 90 95  
 Glu Asp Leu His His Tyr Arg Asn Leu Ser Xaa Phe Xaa Arg Arg Lys  
 100 105 110  
 Leu Lys Ala Xaa Gly Pro Ala Cys Leu Trp Pro Ala Gln Arg Asp  
 115 120 125

&lt;210&gt; 153

&lt;211&gt; 78

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Met Ser Pro His Gln Pro Met Gln Val Ser Ser Ser Lys Thr Ile Leu  
 1 5 10 15  
 Trp Leu Val Leu Ser Cys Leu Cys Pro Ser Ser Pro His Pro Val Ile  
 20 25 30  
 Ser Gly Leu Pro Gln Trp Tyr Ile Gly Val Leu Ala Gly Ile Val Pro  
 35 40 45  
 Val Ala Pro Ile Arg Pro Gly Asp Ser Gly Leu Asp Leu Gln Arg Glu  
 50 55 60  
 Gly Pro Gln Pro Ile Leu Ser Gln Gly Leu Asn Arg Arg Thr  
 65 70 75

&lt;210&gt; 154

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Met Glu Gly Pro Arg Gly Trp Leu Val Leu Cys Val Leu Ala Ile Ser  
 1 5 10 15  
 Leu Ala Ser Met Val Thr Glu Asp Leu Cys Arg Ala Pro Asp Gly Lys  
 20 25 30

Lys Gly Glu Ala Gly Arg Pro Gly Arg Arg Gly Arg Pro Gly Leu Lys  
                   35                  40                  45  
 Gly Glu Gln Gly Glu Pro Gly Ala Pro Gly Ile Arg Thr Gly Ile Gln  
           50                  55                  60  
 Gly Leu Lys Gly Asp Gln Gly Glu Pro Gly Pro Ser Gly Asn Pro Gly  
   65                  70                  75                  80  
 Lys Val Gly Tyr Pro Gly Pro Ser Gly Pro Leu Gly Ala Arg Gly Ile  
                   85                  90                  95  
 Pro Gly Ile Lys Gly Thr Lys Gly Ser Pro Gly Asn Ile Lys Asp Gln  
                  100                 105                 110  
 Pro Arg Pro Ala Phe Ser Ala Ile Arg Arg Asn Pro Pro Met Gly Gly  
          115                 120                 125  
 Asn Val Val Ile Phe Asp Thr Val Ile Thr Asn Gln Glu Glu Pro Tyr  
   130                 135                 140  
 Gln Asn His Ser Gly Arg Phe Val Cys Thr Val Pro Gly Tyr Tyr Tyr  
  145                 150                 155                 160  
 Phe Thr Phe Gln Val Leu Ser Gln Trp Glu Ile Cys Leu Ser Ile Val  
          165                 170                 175  
 Ser Ser Ser Arg Gly Gln Val Arg Arg Ser Leu Gly Phe Cys Asp Thr  
          180                 185                 190  
 Thr Asn Lys Gly Leu Phe Gln Val Val Ser Gly Gly Met Val Leu Gln  
          195                 200                 205  
 Leu Gln Gln Gly Asp Gln Val Trp Val Glu Lys Asp Pro Lys Lys Gly  
   210                 215                 220  
 His Ile Tyr Gln Gly Ser Glu Ala Asp Ser Val Phe Ser Gly Phe Leu  
  225                 230                 235                 240  
 Ile Phe Pro Ser Ala  
                  245

&lt;210&gt; 155

&lt;211&gt; 194

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Ala Arg Leu Gly Arg Val Pro Glu Ser Gln Ser Arg Arg Gly Ala Ala  
   1                  5                 10                 15  
 Gly Ala Ala Phe His His Gly Glu Pro Ser Cys Gln Pro Pro His Arg  
          20                 25                 30  
 Lys Met Leu Arg Arg Arg Gly Ser Pro Gly Met Gly Val His Val Gly  
   35                 40                 45  
 Ala Ala Leu Gly Ala Leu Trp Phe Cys Leu Thr Gly Ala Leu Glu Val  
   50                 55                 60  
 Gln Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr  
   65                 70                 75                 80  
 Leu Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala Gln Leu  
          85                 90                 95

Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu Val His Ser Phe  
                   100                  105                  110  
 Ala Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala Asn Arg Thr Ala Leu  
                   115                  120                  125  
 Phe Leu Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg Leu Gln Ser  
           130                  135                  140  
 Val Arg Val Ala Asp Glu Gly Gln Leu His Leu Leu Arg Glu His Pro  
   145                  150                  155                  160  
 Gly Phe Arg Gln Arg Cys Arg Gln Pro Ala Gly Gly Arg Ser Leu Leu  
                   165                  170                  175  
 Glu Ala Gln His Asp Pro Gly Ala Gln Gln Gly Pro Ala Ala Arg Gly  
                   180                  185                  190  
 Thr Trp

<210> 156  
 <211> 387  
 <212> PRT  
 <213> Homo sapiens

<400> 156  
 Pro Trp Ser Pro Thr Arg Thr Cys Gly Pro Gly Asp Met Val Thr Ile  
   1                  5                  10                  15  
 Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln  
           20                  25                  30  
 Asp Gly Gln Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met  
           35                  40                  45  
 Ala Asn Glu Gln Gly Leu Phe Asp Val His Ser Ile Leu Arg Val Val  
           50                  55                  60  
 Leu Gly Ala Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val Leu  
   65                  70                  75                  80  
 Gln Gln Asp Ala His Ser Ser Val Thr Ile Thr Pro Gln Arg Ser Pro  
           85                  90                  95  
 Thr Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val Val Ala Leu  
           100                  105                  110  
 Val Gly Thr Asp Ala Thr Leu His Cys Ser Phe Ser Pro Glu Pro Gly  
           115                  120                  125  
 Phe Ser Leu Thr Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys  
   130                  135                  140  
 Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln Gly Ser Ala Tyr  
   145                  150                  155                  160  
 Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala  
           165                  170                  175  
 Ser Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr  
           180                  185                  190  
 Cys Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln



195					200					205					
Val	Ala	Ala	Pro	Tyr	Ser	Lys	Pro	Ser	Met	Thr	Leu	Glu	Pro	Asn	Lys
210					215					220					
Asp	Leu	Arg	Pro	Gly	Asp	Thr	Val	Thr	Ile	Thr	Cys	Ser	Ser	Tyr	Arg
225					230					235					240
Gly	Tyr	Pro	Glu	Ala	Glu	Val	Phe	Trp	Gln	Asp	Gly	Gln	Gly	Val	Pro
				245					250					255	
Leu	Thr	Gly	Asn	Val	Thr	Thr	Ser	Gln	Met	Ala	Asn	Glu	Gln	Gly	Leu
			260					265					270		
Phe	Asp	Val	His	Ser	Val	Leu	Arg	Val	Val	Leu	Gly	Ala	Asn	Gly	Thr
	275						280					285			
Tyr	Ser	Cys	Leu	Val	Arg	Asn	Pro	Val	Leu	Gln	Gln	Asp	Ala	His	Gly
	290					295					300				
Ser	Val	Thr	Ile	Thr	Gly	Gln	Pro	Met	Thr	Phe	Pro	Pro	Glu	Ala	Leu
305					310					315					320
Trp	Val	Thr	Val	Gly	Leu	Ser	Val	Cys	Leu	Ile	Ala	Leu	Leu	Val	Ala
				325					330					335	
Leu	Pro	Phe	Val	Cys	Trp	Arg	Lys	Ile	Lys	Gln	Ser	Cys	Glu	Glu	Glu
			340					345					350		
Asn	Ala	Gly	Ala	Glu	Asp	Gln	Asp	Gly	Glu	Gly	Glu	Gly	Ser	Lys	Thr
		355					360					365			
Ala	Leu	Gln	Pro	Leu	Lys	His	Ser	Asp	Ser	Lys	Glu	Asp	Asp	Gly	Gln
	370					375					380				
Glu	Ile	Ala													
385															

<210> 157  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens

<400> 157  
 Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys Leu Ile  
 1 5 10 15  
 Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys Ile  
 20 25 30

<210> 158  
 <211> 216  
 <212> PRT  
 <213> Homo sapiens

<400> 158  
 Leu Glu Val Gln Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr  
 1 5 10 15  
 Asp Ala Thr Leu Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu  
 20 25 30  
 Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu Val  
 35 40 45

His Ser Phe Ala Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala Asn Arg  
 50 55 60  
 Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser Leu Arg  
 65 70 75 80  
 Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys Phe Val  
 85 90 95  
 Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala  
 100 105 110  
 Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg  
 115 120 125  
 Pro Gly Asp Thr Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro  
 130 135 140  
 Glu Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly  
 145 150 155 160  
 Asn Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp Val  
 165 170 175  
 His Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser Cys  
 180 185 190  
 Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Ser Ser Val Thr  
 195 200 205  
 Ile Thr Gly Gln Pro Met Thr Phe  
 210 215

<210> 159  
 <211> 242  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (5)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (34)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 159  
 Lys Xaa Pro Cys Xaa Tyr Arg Ser Gly Ile Pro Gly Ser Thr His Ala  
 1 5 10 15  
 Ser Val Pro Ser Ala Pro Arg Pro Ser Arg Ala Met Leu Pro Trp Thr  
 20 25 30  
 Ala Xaa Gly Leu Ala Leu Ser Leu Arg Leu Ala Leu Ala Arg Ser Gly  
 35 40 45  
 Ala Glu Arg Gly Pro Pro Ala Ser Ala Pro Arg Gly Asp Leu Met Phe

50					55					60					
Leu 65	Leu	Asp	Ser	Ser	Ala 70	Ser	Val	Ser	His	Tyr 75	Glu	Phe	Ser	Arg	Val 80
Arg	Glu	Phe	Val	Gly 85	Gln	Leu	Val	Ala	Pro 90	Leu	Pro	Leu	Gly	Thr 95	Gly
Ala	Leu	Arg	Ala 100	Ser	Leu	Val	His	Val 105	Gly	Ser	Arg	Pro	Tyr 110	Thr	Glu
Phe	Pro	Phe 115	Gly	Gln	His	Ser	Ser 120	Gly	Glu	Ala	Ala	Gln 125	Asp	Ala	Val
Arg	Ala 130	Ser	Ala	Gln	Arg	Met 135	Gly	Asp	Thr	His	Thr 140	Gly	Leu	Ala	Leu
Val 145	Tyr	Ala	Lys	Glu	Gln 150	Leu	Phe	Ala	Glu	Ala 155	Ser	Gly	Ala	Arg	Pro 160
Gly	Val	Pro	Lys	Val 165	Leu	Val	Trp	Val	Thr 170	Asp	Gly	Gly	Ser	Ser 175	Asp
Pro	Val	Gly 180	Pro	Pro	Met	Gln	Glu	Leu 185	Lys	Asp	Leu	Gly	Val 190	Thr	Val
Phe	Ile 195	Val	Ser	Thr	Gly	Arg	Gly 200	Asn	Phe	Leu	Glu	Leu 205	Ser	Ala	Ala
Ala 210	Ser	Ala	Pro	Ala	Glu	Lys 215	His	Leu	His	Phe	Val 220	Asp	Val	Asp	Asp
Leu 225	His	Ile	Ile	Val	Gln 230	Glu	Leu	Arg	Gly	Ser 235	Ile	Leu	Asp	Ala	Met 240
Arg Pro															

<210> 160  
 <211> 186  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (152)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (180)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (184)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (186)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 160  
 Ala Pro Ala Trp Gly Gly Pro Gln Gly Arg Trp Ser Arg His Leu Ser

97

1	5	10	15
Pro Thr Pro Ala Leu Trp Ala Pro Leu Ala Gly His Leu Met Leu Gln	20	25	30
Gln Thr Ala Val Pro Trp His Arg Pro Ala Pro Gly Gln Cys Gly Cys	35	40	45
His Pro Cys Ala Gly Gln Lys His Ala Pro His Pro Gly Gln Pro His	50	55	60
Pro Ser Cys Ala Gly Arg Arg Gly Thr Arg Cys Met Ala Asp Cys Pro	65	70	75
Arg Ala Pro Asp Trp His Ala Gly Pro Arg Cys Pro Gly Ala Val Glu	85	90	95
Pro Pro Ala Ala Pro Gln Thr Pro Glu Pro Gly Arg Thr Arg Ser Glu	100	105	110
Arg Arg Trp Leu Ser Cys Pro Ala Gly Thr Ser Gly Pro Leu Gly Gly	115	120	125
Leu Met Leu Val Asp Arg Ala Pro Arg Arg Ser Ala Pro Ala Pro Ala	130	135	140
Ala Ser Ser Gly Pro Gly Arg Xaa Pro Ser Arg Gly Ala Ser Arg Ala	145	150	155
Arg Asp Gly Ala Arg Ser Ala Arg Thr Arg Gly Ser Thr Arg Glu Phe	165	170	175
Arg Thr Gly Xaa Cys Arg Val Xaa Ser Xaa	180	185	

<210> 161  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 161  
 Phe Leu Leu Asp Ser Ser Ala Ser Val Ser His Tyr Glu Phe Ser Arg  
 1 5 10 15

Val Arg

<210> 162  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens

<400> 162  
 Gly Ala Leu Arg Ala Ser Leu Val His Val Gly Ser Arg Pro  
 1 5 10

<210> 163  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 163  
 Gly Val Pro Lys Val Leu Val Trp Val Thr Asp Gly

98

1

5

10

&lt;210&gt; 164

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 164

Val Gly Pro Pro Met Gln Glu Leu Lys Asp Leu Gly Val Thr  
 1 5 10

&lt;210&gt; 165

&lt;211&gt; 226

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 165

His Ala Ser Val Pro Ser Ala Pro Arg Pro Ser Arg Ala Met Leu Pro  
 1 5 10 15

Trp Thr Ala Leu Gly Leu Ala Leu Ser Leu Arg Leu Ala Leu Ala Arg  
 20 25 30

Ser Gly Ala Glu Arg Gly Pro Pro Ala Ser Ala Pro Arg Gly Asp Leu  
 35 40 45

Met Phe Leu Leu Asp Ser Ser Ala Ser Val Ser His Tyr Glu Phe Ser  
 50 55 60

Arg Val Arg Glu Phe Val Gly Gln Leu Val Ala Pro Leu Pro Leu Gly  
 65 70 75 80

Thr Gly Ala Leu Arg Ala Ser Leu Val His Val Gly Ser Arg Pro Tyr  
 85 90 95

Thr Glu Phe Pro Phe Gly Gln His Ser Ser Gly Glu Ala Ala Gln Asp  
 100 105 110

Ala Val Arg Ala Ser Ala Gln Arg Met Gly Asp Thr His Thr Gly Leu  
 115 120 125

Ala Leu Val Tyr Ala Lys Glu Gln Leu Phe Ala Glu Ala Ser Gly Ala  
 130 135 140

Arg Pro Gly Val Pro Lys Val Leu Val Trp Val Thr Asp Gly Gly Ser  
 145 150 155 160

Ser Asp Pro Val Gly Pro Pro Met Gln Glu Leu Lys Asp Leu Gly Val  
 165 170 175

Thr Val Phe Ile Val Ser Thr Gly Arg Gly Asn Phe Leu Glu Leu Ser  
 180 185 190

Ala Ala Ala Ser Ala Pro Ala Glu Lys His Leu His Phe Val Asp Val  
 195 200 205

Asp Asp Leu His Ile Ile Val Gln Glu Leu Arg Gly Ser Ile Leu Asp  
 210 215 220

Ala Met  
 225

&lt;210&gt; 166

<211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 166  
 Cys Leu Ile Cys Leu Leu Thr Phe Ile Phe His His Cys Asn His Cys  
     1                    5                    10                    15  
 His Glu Glu His Asp His  
                     20

<210> 167  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 167  
 Leu Leu Thr Phe Ile Phe His His Cys Asn His Cys His Glu Glu His  
     1                    5                    10                    15  
 Asp His Gly Pro Glu Ala  
                     20

<210> 168  
 <211> 231  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 168  
 Tyr Xaa Lys Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg Val Asp  
     1                    5                    10                    15  
 Pro Arg Val Arg Ala Glu Val Leu Arg Ala Thr Arg Gly Gly Ala Ala  
                     20                    25                    30  
 Arg Gly Asn Ala Ala Pro Gly Arg Ala Leu Glu Met Val Pro Gly Ala  
                     35                    40                    45  
 Ala Gly Trp Cys Cys Leu Val Leu Trp Leu Pro Ala Cys Val Ala Ala  
     50                    55                    60  
 His Gly Phe Arg Ile His Asp Tyr Leu Tyr Phe Gln Val Leu Ser Pro  
     65                    70                    75                    80  
 Gly Asp Ile Arg Tyr Ile Phe Thr Ala Thr Pro Ala Lys Asp Phe Gly  
                     85                    90                    95  
 Gly Ile Phe His Thr Arg Tyr Glu Gln Ile His Leu Val Pro Ala Glu  
                     100                    105                    110  
 Pro Pro Glu Ala Cys Gly Glu Leu Ser Asn Gly Phe Phe Ile Gln Asp  
     115                    120                    125  
 Gln Ile Ala Leu Val Glu Arg Gly Gly Cys Ser Phe Leu Ser Lys Thr  
     130                    135                    140  
 Arg Val Val Gln Glu His Gly Gly Arg Ala Val Ile Ile Ser Asp Asn  
     145                    150                    155                    160

100

Ala	Val	Asp	Asn	Asp 165	Ser	Phe	Tyr	Val	Glu 170	Met	Ile	Gln	Asp	Ser 175	Thr
Gln	Arg	Thr	Ala 180	Asp	Ile	Pro	Ala	Leu 185	Phe	Leu	Leu	Gly	Arg 190	Asp	Gly
Tyr	Met	Ile 195	Arg	Arg	Ser	Leu	Glu 200	Gln	His	Gly	Leu	Pro 205	Trp	Ala	Ile
Ile	Ser 210	Ile	Pro	Val	Asn	Val 215	Thr	Ser	Ile	Pro	Thr 220	Phe	Glu	Leu	Leu
Gln 225	Pro	Pro	Trp	Thr	Phe 230	Trp									

<210> 169

<211> 261

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

$\langle 222 \rangle$      $(225)$

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 169

His Glu Leu Lys Met Asp Ala Glu Tyr Ser Gly Asn Glu Phe Pro Arg  
1 5 10 15

Ser Glu Gly Glu Arg Asp Gln His Gln Arg Pro Gly Lys Glu Arg Lys  
20 25 30

Ser Gly Glu Ala Gly Arg Gly Thr Gly Glu Leu Gly Gln Asp Gly Arg  
35 40 45

Leu Leu Ser Ser Thr Leu Ser Leu Ser Ser Asn Arg Ser Leu Gly Gln  
50 55 60

Arg Gln Asn Ser Pro Leu Pro Phe Gln Trp Arg Ile Thr His Ser Phe  
65 70 75 80

Arg Trp Met Ala Gln Val Leu Ala Ser Glu Leu Ser Leu Val Ala Phe  
85 90 95

Ile Leu Leu Leu Val Met Ala Phe Ser Lys Lys Trp Leu Asp Leu Ser  
100 105 110

Arg Ser Leu Phe Tyr Gln Arg Trp Pro Val Asp Val Ser Asn Arg Ile  
115 120 125

His Thr Ser Ala His Val Met Ser Met Gly Leu Leu His Phe Cys Lys  
130 135 140

Ser Arg Ser Cys Ser Asp Leu Glu Asn Gly Lys Val Thr Phe Ile Phe  
145 150 155 160

Ser Thr Leu Met Leu Phe Pro Ile Asn Ile Trp Ile Phe Glu Leu Glu  
165 170 175

Arg Asn Val Ser Ile Pro Ile Gly Trp Ser Tyr Phe Ile Gly Trp Leu  
180 185 190

Val Leu Ile Leu Tyr Phe Thr Cys Ala Ile Leu Cys Tyr Phe Asn His  
195 200 205

101

Lys Ser Phe Trp Ser Leu Ile Leu Ser His Pro Ser Gly Ala Val Ser  
 210 215 220  
 Xaa Ser Ser Ser Phe Gly Ser Val Glu Glu Ser Pro Arg Ala Gln Thr  
 225 230 235 240  
 Ile Thr Asp Thr Pro Ile Thr Gln Glu Gly Val Leu Asp Pro Glu Gln  
 245 250 255  
 Lys Asp Thr His Val  
 260

<210> 170  
 <211> 151  
 <212> PRT  
 <213> Homo sapiens

<400> 170  
 Gly Thr Ser Ser Arg Trp Met Gln Ser Thr Leu Gly Met Ser Ser Pro  
 1 5 10 15  
 Gly Gln Lys Glu Lys Glu Thr Asn Ile Arg Asp Leu Glu Arg Lys Gly  
 20 25 30  
 Arg Val Gly Arg Gln Asp Gly Ala Gln Val Ser Trp Asp Lys Met Gly  
 35 40 45  
 Asp Cys Cys Pro Pro Pro Ser Pro Ser Val Val Thr Gly Pro Trp Ala  
 50 55 60  
 Ser Ala Arg Thr Leu Arg Cys Pro Phe Asn Gly Glu Ser His Thr Ala  
 65 70 75 80  
 Ser Ala Gly Trp Pro Arg Cys Trp Pro Leu Ser Ser Ala Trp Leu Pro  
 85 90 95  
 Leu Ser Tyr Tyr Trp Ser Trp Pro Ser Pro Arg Asn Gly Trp Thr Ser  
 100 105 110  
 Leu Gly Ala Ser Ser Thr Ser Ala Gly Pro Trp Met Ser Ala Thr Glu  
 115 120 125  
 Ser Thr His Gln Pro Thr Leu Cys Pro Trp Gly Ser Cys Thr Phe Ala  
 130 135 140  
 Asn Pro Gly Ala Val Leu Thr  
 145 150

<210> 171  
 <211> 317  
 <212> PRT  
 <213> Homo sapiens

<400> 171  
 Ala Arg Ala Glu Val Ile Leu Cys Thr Lys Glu Val Ser Val Gly Ala  
 1 5 10 15  
 Arg Lys Asn Ala Phe Ala Leu Leu Val Glu Met Gly His Ala Phe Leu  
 20 25 30  
 Arg Phe Gly Ser Asn Gln Glu Glu Ala Leu Gln Cys Tyr Leu Val Leu  
 35 40 45  
 Ile Tyr Pro Gly Leu Val Gly Ala Val Thr Met Val Ser Cys Ser Ile



	50					55					60				
Leu 65	Ala	Leu	Thr	His	Leu 70	Leu	Phe	Glu	Phe	Lys 75	Gly	Leu	Met	Gly	Thr 80
Ser	Thr	Val	Glu	Gln 85	Leu	Leu	Glu	Asn	Val 90	Cys	Leu	Leu	Leu	Ala 95	Ser
Arg	Thr	Arg	Asp 100	Val	Val	Lys	Ser	Ala 105	Leu	Gly	Phe	Ile	Lys 110	Val	Ala
Val	Thr	Val 115	Met	Asp	Val	Ala	His 120	Leu	Ala	Lys	His	Val 125	Gln	Leu	Val
Met	Glu 130	Ala	Ile	Gly	Lys	Leu 135	Ser	Asp	Asp	Met	Arg 140	Arg	His	Phe	Arg
Met 145	Lys	Leu	Arg	Asn	Leu 150	Phe	Thr	Lys	Phe	Ile 155	Arg	Lys	Phe	Gly	Phe 160
Glu	Leu	Val	Lys	Arg 165	Leu	Leu	Pro	Glu	Glu 170	Tyr	His	Arg	Val	Leu 175	Val
Asn	Ile	Arg	Lys 180	Ala	Glu	Ala	Arg	Ala 185	Lys	Arg	His	Arg	Ala 190	Leu	Ser
Gln	Ala	Ala 195	Val	Glu	Glu	Glu	Glu 200	Glu	Glu	Glu	Glu	Glu 205	Glu	Glu	Pro
Ala	Gln 210	Gly	Lys	Gly	Asp	Ser 215	Ile	Glu	Glu	Ile	Leu 220	Ala	Asp	Ser	Glu
Asp 225	Glu	Glu	Asp	Asn	Glu 230	Glu	Glu	Glu	Arg	Ser 235	Arg	Gly	Lys	Glu	Gln 240
Arg	Lys	Leu	Ala	Arg 245	Gln	Arg	Ser	Arg	Ala 250	Trp	Leu	Lys	Glu	Gly 255	Gly
Gly	Asp	Glu	Pro 260	Leu	Asn	Phe	Leu	Asp 265	Pro	Lys	Val	Ala	Gln 270	Arg	Val
Leu	Ala	Thr 275	Gln	Pro	Gly	Pro	Ala 280	Gly	Gln	Glu	Glu	Gly 285	Pro	Gln	Leu
Gln	Gly 290	Glu	Arg	Arg	Trp	Pro 295	Ala	Asp	His	Lys	Gly 300	Gly	Gly	Arg	Arg
Gln 305	Gln	Asp	Gly	Gly	Arg 310	Gly	Arg	Cys	Gln	Arg 315	Arg	Arg			

<210> 172

<211> 167

<212> PRT

<213> Homo sapiens

<400> 172

Gly Thr Arg Glu Gly Glu Gly Arg Lys Cys Pro Trp Lys Gly Leu Arg  
1 5 10 15

Ala Arg Thr Gly Met Gly Gln Glu Val His Gly Ser Cys Trp Ala Leu  
20 25 30

Gly Ala Gly Gly Gly Gln Arg Gln Trp Val Gly Arg Ser Met Pro Pro  
35 40 45

103

Leu Ala Pro Gln Leu Cys Arg Ala Val Phe Leu Val Pro Ile Leu Leu  
     50                    55                    60  
 Leu Leu Gln Val Lys Pro Leu Asn Gly Ser Pro Gly Pro Lys Asp Gly  
     65                    70                    75                    80  
 Ser Gln Thr Glu Lys Thr Pro Ser Ala Asp Gln Asn Gln Glu Gln Phe  
                     85                    90                    95  
 Glu Glu His Phe Val Ala Ser Ser Val Gly Glu Met Trp Gln Val Val  
                     100                    105                    110  
 Asp Met Ala Gln Gln Glu Glu Asp Gln Ser Ser Lys Thr Ala Ala Val  
                     115                    120                    125  
 His Lys His Ser Phe His Leu Ser Phe Cys Phe Ser Leu Ala Ser Val  
     130                    135                    140  
 Met Val Phe Ser Gly Gly Pro Leu Arg Arg Thr Phe Pro Asn Ile Gln  
     145                    150                    155                    160  
 Leu Cys Phe Met Leu Thr His  
                     165

<210> 173  
 <211> 267  
 <212> PRT  
 <213> Homo sapiens

<400> 173  
 Met Ala Gly Gly Trp Ala Ala Glu Ala Val Trp Ala Gly Phe Gly Val  
     1                    5                    10                    15  
 Val Val Val Ala Arg Arg Leu Val Leu Leu Pro Leu Leu Leu His Pro  
                     20                    25                    30  
 Gly Phe Gln Gln Leu Leu Leu Val Leu Leu Leu Pro His Glu Gln Leu  
                     35                    40                    45  
 His His Glu His Leu Leu Leu Val Asp Leu Leu Ala Asp Val Leu Gly  
     50                    55                    60  
 Asp Val Arg Asp Asp Pro Val His Lys Val Ala His Glu His Asp Gln  
     65                    70                    75                    80  
 Val Leu Glu Asp Asp Asp Lys Arg Gln Pro Gly Cys Gln Asp Gly Pro  
                     85                    90                    95  
 Glu Val Leu Gly Asp Val Val Leu Val Phe Arg Pro Arg Arg Leu Ser  
                     100                    105                    110  
 Val Val Phe Ile Pro Ala Asp Leu His Leu Val Ala Gln Val Gln Gly  
                     115                    120                    125  
 Val Ile Gly Gly Arg Ala Val Leu Glu Val Thr Asp Val Glu Gly Gly  
     130                    135                    140  
 Glu Gly Val Val Asp Glu Ala Val His Gly Pro Val Leu Thr Val His  
     145                    150                    155                    160  
 Val Glu Val His Gln Ala Arg Asp Glu Val Arg Arg Glu Gly Asp His  
                     165                    170                    175  
 Glu Gly Ile Asp Asp Asp Ser Lys Leu Pro Asn Ala Ser Glu Asp Ile  
                     180                    185                    190

104

Val Pro Asp Ser Asp Val Phe Gly Ser Asp Ser Tyr Arg Pro Ser Glu  
 195 200 205  
 Leu Ser Asp Lys Leu Phe Gly Val Gln Ala Asp Leu Asp Asp Val Val  
 210 215 220  
 Gln Gln Arg Lys Gln Trp Gly Gln Gly Glu Gly Asp Lys Gln Gly  
 225 230 235 240  
 Asp Glu Ala Lys Leu Asp Asp His Phe His Val Leu Trp Gly Glu Ala  
 245 250 255  
 Arg Glu Gly Leu Gln Val Val Ile His Leu Val  
 260 265

<210> 174  
 <211> 194  
 <212> PRT  
 <213> Homo sapiens

<400> 174  
 Pro Arg Ala Ala Gly Ile Arg His Glu Leu Ile His Gly Leu Trp Asn  
 1 5 10 15  
 Leu Val Phe Leu Phe Ser Asn Leu Ser Leu Ile Phe Leu Met Pro Phe  
 20 25 30  
 Ala Tyr Phe Phe Thr Glu Ser Glu Gly Phe Ala Gly Ser Arg Lys Gly  
 35 40 45  
 Val Leu Gly Arg Val Tyr Glu Thr Val Val Met Leu Met Leu Leu Thr  
 50 55 60  
 Leu Leu Val Leu Gly Met Val Trp Val Ala Ser Ala Ile Val Asp Lys  
 65 70 75 80  
 Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp Phe Trp Glu Tyr Tyr Leu  
 85 90 95  
 Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu Gly Val Leu Leu Leu Leu  
 100 105 110  
 Gly Glu Cys Thr Gly Ser Gly Arg Glu Trp Ala Gly Ser Leu Asp Gln  
 115 120 125  
 Ser Asn Gln Ala Arg Arg Lys Gly Asn Gly Gly His Val Arg Glu Gly  
 130 135 140  
 Val Glu Ser Arg Val Trp Gln Val Thr Gly Ser Cys Pro Tyr Ser Val  
 145 150 155 160  
 Tyr Ser Thr Gly Ser Arg Pro His Val Leu Arg His Trp Glu Ala Ala  
 165 170 175  
 Ser Gln Ala Pro Ala Ala Gly Arg Pro Gly Gly Ala Ala Val Leu Leu  
 180 185 190  
 Ser Leu

<210> 175  
 <211> 171  
 <212> PRT

105

&lt;213&gt; Homo sapiens

&lt;400&gt; 175

His Ala Ser Ala Phe Phe Gly Thr Arg Ala Leu Leu Ser Val Ser Leu  
 1 5 10 15  
 Pro Pro Pro Cys Met Leu His Trp Val Leu Ser Phe Phe Phe Leu Leu  
 20 25 30  
 Ser Cys Pro Arg Thr Glu Gly Leu Pro Gly Leu Tyr Cys Pro Gly Cys  
 35 40 45  
 Ser Gln Cys Pro Gly Arg Gly Met Trp Pro Gly Asp Pro Gly Pro Gly  
 50 55 60  
 Ile Gln Gly Pro Gly Leu Asp Leu Arg Thr Gly Met Glu Ala Thr Gly  
 65 70 75 80  
 Ala Gln Gln Pro Thr Leu Ser Ser Pro His Cys Leu Leu Ser Leu Pro  
 85 90 95  
 Thr Leu Pro Ala Arg Ala Val Gln Leu Arg Trp Asp Leu Ser Ile Ser  
 100 105 110  
 Arg Ala Gly Gly Arg Val Ala Val Leu Gly Leu Cys Leu Glu Pro Gly  
 115 120 125  
 Gly Ser Leu Leu Leu Pro Pro Ser Ala Leu Pro Glu Thr Asp Pro Cys  
 130 135 140  
 Ala Ala Cys Pro Pro Cys Pro Phe Val Pro Met Ser Gly Gly Gly Gly  
 145 150 155 160  
 Arg Pro Thr Val Pro Glu Ala Gly His Gln Pro  
 165 170

&lt;210&gt; 176

&lt;211&gt; 132

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 176

Ser His Thr Arg Pro Thr Glu Gln Pro Ser Val Leu Pro Leu Phe Met  
 1 5 10 15  
 Met Tyr Val Met Met Ala Tyr Leu Thr Leu Phe Gln Met Gly Ser Trp  
 20 25 30  
 Met Ser Phe Ser Leu Ser Leu Cys Ser Leu Leu Phe Ile Leu Thr Gly  
 35 40 45  
 His Cys Leu Ser Glu Asn Phe Tyr Val Arg Gly Asp Gly Thr Arg Ala  
 50 55 60  
 Tyr Phe Phe Thr Lys Gly Glu Val His Ser Met Phe Cys Lys Ala Ser  
 65 70 75 80  
 Leu Asp Glu Lys Gln Asn Leu Val Asp Arg Arg Leu Gln Val Asn Arg  
 85 90 95  
 Lys Lys Gln Val Lys Met His Arg Val Trp Ile Gln Gly Lys Phe Gln  
 100 105 110  
 Lys Pro Leu His Gln Thr Gln Asn Ser Ser Asn Met Val Ser Thr Leu  
 115 120 125

106

Leu Ser Gln Asp  
130

<210> 177  
<211> 167  
<212> PRT  
<213> Homo sapiens

<400> 177  
Ala Arg Glu Ser Ser Trp Asp His Val Lys Thr Ser Ala Thr Asn Arg  
1 5 10 15  
Phe Ser Arg Met His Cys Pro Thr Val Pro Asp Glu Lys Asn His Tyr  
20 25 30  
Glu Lys Ser Ser Gly Ser Ser Glu Gly Gln Ser Lys Thr Glu Ser Asp  
35 40 45  
Phe Ser Asn Leu Asp Ser Glu Lys His Lys Lys Gly Pro Met Glu Thr  
50 55 60  
Gly Leu Phe Pro Gly Ser Asn Ala Thr Phe Arg Ile Leu Glu Val Gly  
65 70 75 80  
Cys Gly Ala Gly Asn Ser Val Phe Pro Ile Leu Asn Thr Leu Glu Asn  
85 90 95  
Ser Pro Glu Ser Phe Leu Tyr Cys Cys Asp Phe Ala Ser Gly Ala Val  
100 105 110  
Glu Leu Val Lys Ser His Ser Ser Tyr Arg Ala Thr Gln Cys Phe Ala  
115 120 125  
Phe Val His Asp Val Cys Asp Asp Gly Leu Pro Tyr Pro Phe Pro Asp  
130 135 140  
Gly Ile Leu Asp Val Ile Leu Leu Val Phe Val Leu Ser Ser Ile His  
145 150 155 160  
Pro Asp Arg Thr Leu Phe Ile  
165

<210> 178  
<211> 116  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (66)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (104)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 178  
His Glu Gln Glu Pro Leu Pro Ala Pro Val Ala Glu Ala Ala Leu Pro  
1 5 10 15  
Ser Ala Arg Asn Ser Ser Val Leu Ala Ser Leu Ser Pro His Thr Gly  
20 25 30

107

Pro Ala Gly Leu Leu Arg Asp Ser Ser Val Gln Val Ser Thr Leu Gly  
                   35                  40                  45  
 Cys Leu Leu Gly Cys Gly Gly Arg Met Phe Phe Pro Cys Leu Pro Thr  
           50                  55                  60  
 Leu Xaa Leu Arg Ile Leu His Ser Gly Trp Val Gly Leu Phe Leu Leu  
       65                  70                  75                  80  
 Ile Ser Ser Arg Ala Pro Ser Ser Ser Leu Ala Trp Lys His Gly Pro  
                   85                  90                  95  
 Gly Glu Leu Trp Trp Pro Arg Xaa Pro Leu Arg Ser Cys Thr Gly Leu  
                   100                  105                  110  
 Ala Ser Cys Gly  
           115

<210> 179  
 <211> 189  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (130)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (166)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (189)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 179  
 Leu Thr Pro Ala Leu Pro Ser Pro Arg Ser Ala Ser Pro Leu Leu Ser  
   1                  5                  10                  15  
 Pro Glu Ser Leu Gln Ser Pro Gln Trp Pro Ser Ser Ser Leu Ser Ile  
           20                  25                  30  
 His Ser Leu Pro Val Ala Gly Lys Pro Ser Leu Ile Thr Ser Leu Phe  
           35                  40                  45  
 Thr Glu Pro Cys Asp Gly Phe Met Ala Ile Arg Gly Ser Asn Thr Gln  
       50                  55                  60  
 Gly Leu Thr Met Met Thr Met Thr Ser Asp Arg Trp Phe Ser Met Ala  
       65                  70                  75                  80  
 Trp Ala Ser Cys Ser Leu Ser Arg Pro Pro Leu Thr Pro Ser Cys Ser  
           85                  90                  95  
 Cys Gln Gln Pro Ala Thr Val Ala Leu Leu Leu Gln Thr Ile Ser Val  
           100                  105                  110  
 Cys Ser Ala Gln Gln Ala Asp Pro Leu Ser Pro Pro Arg Ala Cys Arg  
           115                  120                  125  
 Pro Xaa Arg Gln Phe Pro Val Leu Gln Ser Ala Gly Pro Pro His Ser

108

130		135		140
Pro His Val Tyr Ala Phe Val Leu Phe Pro Val Ser Ser Arg Trp Gln				
145		150		155
Gly Gly Asp Phe Cys Xaa Ile Cys Cys Cys Phe Pro Gln Cys Leu Gly				
	165		170	175
Arg Cys Leu Glu His Thr Arg Cys Ser Ile Asn Pro Xaa				
	180		185	

<210> 180  
 <211> 98  
 <212> PRT  
 <213> Homo sapiens

<400> 180  
 Arg Leu Cys Arg Glu Thr Ala Leu Met Ser Leu Cys Leu Val Leu Met  
 1 5 10 15  
 Arg Arg Met Gly Trp Ile Asp Leu Leu Leu Pro Glu Leu Gly Ala Leu  
 20 25 30  
 Arg Val Phe Leu His Leu Phe Leu Val Ala Leu Arg Thr Lys Arg Trp  
 35 40 45  
 Ile Phe Arg Thr Leu Gly Gln Leu Thr Cys Val Asn Ile Leu Gly Asp  
 50 55 60  
 Ser Arg Lys Lys Arg Glu Cys Arg Leu Asn Lys Arg Gln Leu Gln Phe  
 65 70 75 80  
 Gly Glu Lys Thr Leu Gln Val Pro Glu Arg Leu Val Val Arg His Ser  
 85 90 95  
 Pro Phe

<210> 181  
 <211> 310  
 <212> PRT  
 <213> Homo sapiens

<400> 181  
 Met Leu Leu Pro Phe Ile Lys Leu Pro Thr Thr Gly Asn Ser Leu Ala  
 1 5 10 15  
 Lys Ile Gln Thr Val Gly Gln Asn Gln Gln Lys Val Asn Arg Val Leu  
 20 25 30  
 Met Gly Pro Arg Ser Ile Gln Lys Arg His Phe Lys Glu Val Gly Arg  
 35 40 45  
 Gln Ser Ile Arg Arg Glu Gln Gly Ala Gln Ala Ser Val Glu Asn Ala  
 50 55 60  
 Ala Glu Glu Lys Arg Leu Gly Ser Pro Ala Pro Arg Glu Leu Glu Gln  
 65 70 75 80  
 Pro His Thr Gln Gln Gly Pro Glu Lys Leu Ala Gly Asn Ala Ile Tyr  
 85 90 95  
 Thr Lys Pro Ser Phe Thr Gln Glu His Lys Ala Ala Val Ser Val Leu  
 100 105 110

Thr Pro Phe Ser Lys Gly Ala Pro Ser Thr Ser Ser Pro Ala Lys Ala  
 115 120 125  
 Leu Pro Gln Val Arg Asp Arg Trp Lys Asp Asn Thr His Thr Ile Ser  
 130 135 140  
 Ile Leu Glu Ser Ala Lys Ala Arg Val Thr Asn Met Lys Ala Ser Lys  
 145 150 155 160  
 Pro Ile Ser His Ser Arg Lys Lys Tyr Arg Phe His Lys Thr Arg Ser  
 165 170 175  
 Arg Met Thr His Arg Thr Pro Lys Val Lys Lys Ser Pro Lys Phe Arg  
 180 185 190  
 Lys Lys Ser Tyr Leu Ser Arg Leu Met Leu Ala Asn Arg Pro Pro Phe  
 195 200 205  
 Ser Ala Ala Lys Ser Leu Ile Asn Ser Pro Ser Gln Gly Ala Phe Ser  
 210 215 220  
 Ser Leu Gly Asp Leu Ser Pro Gln Glu Asn Pro Phe Leu Glu Val Ser  
 225 230 235 240  
 Ala Pro Ser Glu His Phe Ile Glu Thr Thr Asn Ile Lys Asp Thr Thr  
 245 250 255  
 Ala Arg Asn Ala Leu Glu Glu Asn Val Phe Met Glu Asn Thr Asn Met  
 260 265 270  
 Pro Glu Val Thr Ile Ser Glu Asn Thr Asn Tyr Asn His Pro Pro Glu  
 275 280 285  
 Ala Asp Ser Ala Gly Thr Ala Phe Asn Leu Gly Pro Thr Val Lys Gln  
 290 295 300  
 Thr Glu Thr Asn Ser Cys  
 305 310

&lt;210&gt; 182

&lt;211&gt; 139

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 182

Leu Lys Glu Met Ala Glu Leu His His Gly Arg Ser Thr Ser Leu Cys  
 1 5 10 15  
 Ile Leu Pro Leu Gln Arg Thr Arg Ile His Ser Met Ser Ala Ser Leu  
 20 25 30  
 Trp Cys Phe Arg Ser Gln Gln Ser Ile Pro Met Arg Cys His Arg Ser  
 35 40 45  
 Leu Ser Glu Ile Pro Glu Asp Phe Gln Met Asn Arg Ser Thr Arg Ser  
 50 55 60  
 Tyr Arg Cys Trp Ala Thr Trp Pro Arg Leu Gly Trp Ala Leu Pro Cys  
 65 70 75 80  
 Cys Met Asn Ser Leu Arg Lys Gly Arg Lys Phe Ser Gln Ile Thr Thr  
 85 90 95  
 Ser Leu Met Ala Ser Val Ser Ser Ala Ser Met Val Ser Arg Arg Arg



110

			100						105							110			
Arg	Pro	Leu	Pro	Lys	His	Pro	Val	Thr	Thr	Thr	Ser	Thr	Ala	Thr	Ala				
		115					120					125							
Leu	Leu	Gly	Thr	Ser	Ser	Thr	Trp	Ser	Lys	Ser									
		130				135													

<210> 183  
 <211> 103  
 <212> PRT  
 <213> Homo sapiens

<400> 183

Thr	Arg	Pro	Asp	Trp	Val	Leu	Pro	Ser	Glu	Val	Glu	Val	Leu	Glu	Ser				
1				5					10					15					
Ile	Tyr	Leu	Asp	Glu	Leu	Gln	Val	Ile	Lys	Gly	Asn	Gly	Arg	Thr	Ser				
			20					25					30						
Pro	Trp	Glu	Ile	Tyr	Ile	Thr	Leu	His	Pro	Ala	Thr	Ala	Glu	Asp	Gln				
		35					40					45							
Asp	Ser	Gln	Tyr	Val	Cys	Phe	Thr	Leu	Val	Leu	Gln	Val	Pro	Ala	Glu				
	50					55					60								
Tyr	Pro	His	Glu	Val	Pro	Gln	Ile	Ser	Ile	Arg	Asn	Pro	Arg	Gly	Leu				
65					70					75					80				
Ser	Asp	Glu	Gln	Ile	His	Thr	Ile	Leu	Gln	Val	Leu	Gly	His	Val	Ala				
				85					90					95					
Lys	Ala	Gly	Leu	Gly	Thr	Ala													
			100																

<210> 184  
 <211> 347  
 <212> PRT  
 <213> Homo sapiens

<400> 184

Met	Leu	Tyr	Glu	Leu	Ile	Glu	Lys	Gly	Lys	Glu	Ile	Leu	Thr	Asp	Asn				
1				5					10					15					
Asn	Ile	Pro	His	Gly	Gln	Cys	Val	Ile	Cys	Leu	Tyr	Gly	Phe	Gln	Glu				
			20					25					30						
Lys	Glu	Ala	Phe	Thr	Lys	Thr	Pro	Cys	Tyr	His	Tyr	Phe	His	Cys	His				
		35					40					45							
Cys	Leu	Ala	Arg	Tyr	Ile	Gln	His	Met	Glu	Gln	Glu	Leu	Lys	Ala	Gln				
	50					55					60								
Gly	Gln	Glu	Gln	Glu	Gln	Glu	Arg	Gln	His	Ala	Thr	Thr	Lys	Gln	Lys				
65					70					75					80				
Ala	Val	Gly	Val	Gln	Cys	Pro	Val	Cys	Arg	Glu	Pro	Leu	Val	Tyr	Asp				
				85				90						95					
Leu	Ala	Ser	Leu	Lys	Ala	Ala	Pro	Glu	Pro	Gln	Gln	Pro	Met	Glu	Leu				
			100				105						110						
Tyr	Gln	Pro	Ser	Ala	Glu	Ser	Leu	Arg	Gln	Gln	Glu	Glu	Arg	Lys	Arg				
		115					120						125						

111

Leu Tyr Gln Arg Gln Gln Glu Arg Gly Gly Ile Ile Asp Leu Glu Ala  
 130 135 140  
 Glu Arg Asn Arg Tyr Phe Ile Ser Leu Gln Gln Pro Pro Ala Pro Ala  
 145 150 155 160  
 Glu Pro Glu Ser Ala Val Asp Val Ser Lys Gly Ser Gln Pro Pro Ser  
 165 170 175  
 Thr Leu Ala Ala Glu Leu Ser Thr Ser Pro Ala Val Gln Ser Thr Leu  
 180 185 190  
 Pro Pro Pro Leu Pro Val Ala Thr Gln His Ile Cys Glu Lys Ile Pro  
 195 200 205  
 Gly Thr Arg Ser Asn Gln Gln Arg Leu Gly Glu Thr Gln Lys Ala Met  
 210 215 220  
 Leu Asp Pro Pro Lys Pro Ser Arg Gly Pro Trp Arg Gln Pro Glu Arg  
 225 230 235 240  
 Arg His Pro Lys Gly Gly Glu Cys His Ala Pro Lys Gly Thr Arg Asp  
 245 250 255  
 Thr Gln Glu Leu Pro Pro Pro Glu Gly Pro Leu Lys Glu Pro Met Asp  
 260 265 270  
 Leu Lys Pro Glu Pro His Ser Gln Gly Val Glu Gly Pro Pro Gln Glu  
 275 280 285  
 Lys Gly Pro Gly Ser Trp Gln Gly Pro Pro Pro Arg Arg Thr Arg Asp  
 290 295 300  
 Cys Val Arg Trp Glu Arg Ser Lys Gly Arg Thr Pro Gly Ser Ser Tyr  
 305 310 315 320  
 Pro Arg Leu Pro Arg Gly Gln Gly Ala Tyr Arg Pro Gly Thr Arg Arg  
 325 330 335  
 Glu Ser Leu Gly Leu Glu Ser Lys Asp Gly Ser  
 340 345

&lt;210&gt; 185

&lt;211&gt; 147

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 185

His Asp Thr Arg Leu Pro Leu Pro Gly Gln His Gly Arg Gly Ala Trp  
 1 5 10 15  
 Val Cys Leu Thr Val Leu Val Cys Ser Thr Val Asp Ser Asn Asp Ser  
 20 25 30  
 Leu Tyr Gly Gly Asp Ser Lys Phe Leu Ala Glu Asn Asn Lys Leu Cys  
 35 40 45  
 Glu Thr Val Met Ala Gln Ile Leu Glu His Leu Lys Thr Leu Ala Lys  
 50 55 60  
 Asp Glu Ala Leu Lys Arg Gln Ser Ser Leu Gly Leu Ser Phe Phe Asn  
 65 70 75 80  
 Ser Ile Leu Ala His Gly Asp Leu Arg Asn Asn Lys Leu Asn Gln Leu

112

			85						90				95		
Ser	Val	Asn	Leu	Trp	His	Leu	Ala	Gln	Arg	His	Gly	Cys	Ala	Asp	Thr
			100					105					110		
Arg	Thr	Met	Val	Lys	Thr	Leu	Glu	Tyr	Ile	Lys	Lys	Gln	Ser	Lys	Gln
		115					120					125			
Pro	Asp	Met	Thr	His	Leu	Thr	Glu	Leu	Ala	Leu	Arg	Leu	Pro	Leu	Gln
	130					135					140				
Thr	Arg	Thr													
145															

<210> 186  
 <211> 75  
 <212> PRT  
 <213> Homo sapiens

<400> 186															
Met	Leu	Phe	Val	Asp	Ser	Gly	Ser	Thr	Arg	Leu	Arg	Lys	Lys	Thr	Leu
1				5					10					15	
Ser	Gly	Asp	Phe	Ile	Phe	Met	Asn	Arg	Cys	Gln	Ser	Ser	Arg	Gln	Pro
			20					25					30		
Arg	Pro	Ala	Gly	Val	Asn	Lys	His	Leu	Trp	Gly	Cys	Pro	Ala	Ser	Ser
		35					40					45			
Arg	Thr	Ser	His	Glu	Trp	Leu	Leu	Trp	Pro	Lys	Ala	Val	Leu	Gln	Ala
	50					55					60				
Lys	Gln	Thr	Ala	Leu	Gly	Trp	Asn	Ser	Pro	Thr					
65					70					75					

<210> 187  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 187															
Cys	Gln	Ser	Ser	Arg	Gln	Pro	Arg	Pro	Ala	Gly	Val	Asn	Lys	His	Leu
1				5					10					15	
Trp	Gly	Cys	Pro	Ala	Ser	Ser	Arg	Thr	Ser	His	Glu	Trp	Leu	Leu	Trp
			20					25					30		
Pro	Lys	Ala	Val	Leu	Gln	Ala	Lys	Gln	Thr	Ala	Leu	Gly	Trp	Asn	Ser
		35					40					45			
Pro	Thr														
50															

<210> 188  
 <211> 33  
 <212> PRT  
 <213> Homo sapiens

<400> 188															
Lys	Trp	Gly	Cys	Phe	Cys	Lys	Gly	Ser	Ser	Phe	Thr	Pro	His	Ser	Cys
1				5					10					15	
Pro	Pro	Glu	Ala	Pro	Leu	Phe	Pro	Ala	Val	Leu	Leu	Val	Ser	Thr	Leu

113

20

25

30

Gly

&lt;210&gt; 189

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 189

Cys Pro Pro Glu Ala Pro Leu Phe Pro Ala Val Leu Leu Val Ser Thr  
 1 5 10 15

Leu Gly

&lt;210&gt; 190

&lt;211&gt; 154

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (152)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 190

Glu Gly Ala Asp Lys Met Ala Thr Ser Val Gly His Arg Cys Leu Gly  
 1 5 10 15

Leu Leu His Gly Val Ala Pro Trp Arg Ser Ser Leu His Pro Cys Glu  
 20 25 30

Ile Thr Ala Leu Ser Gln Ser Leu Gln Pro Leu Arg Lys Leu Pro Phe  
 35 40 45

Arg Ala Phe Arg Thr Asp Ala Arg Lys Ile His Thr Ala Pro Ala Arg  
 50 55 60

Thr Met Phe Leu Leu Arg Pro Leu Pro Ile Leu Leu Val Thr Gly Gly  
 65 70 75 80

Gly Tyr Ala Gly Tyr Arg Gln Tyr Glu Lys Tyr Arg Glu Arg Glu Leu  
 85 90 95

Glu Lys Leu Gly Leu Glu Ile Pro Pro Lys Leu Ala Gly His Trp Glu  
 100 105 110

Val Ala Leu Tyr Lys Ser Val Pro Thr Arg Leu Leu Ser Arg Ala Trp  
 115 120 125

Gly Arg Leu Asn Gln Val Glu Leu Pro His Trp Leu Arg Arg Pro Val  
 130 135 140

Tyr Ser Leu Tyr Ile Trp Thr Xaa Gly Gly  
 145 150

&lt;210&gt; 191

&lt;211&gt; 142

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

114

&lt;400&gt; 191

Arg Glu Gln Leu Ser Cys Phe Ser Ser His Thr Trp Cys Pro Trp Glu  
 1 5 10 15  
 Gly Val Leu Trp Ala Pro Gln Ala Gln Gly Val Met Ser Ala Pro Pro  
 20 25 30  
 Pro His Pro Gln Pro Pro Ala Ala Pro Thr Ser Arg Asn Tyr Thr Glu  
 35 40 45  
 Ile Arg Glu Lys Leu Arg Ser Arg Leu Thr Arg Arg Lys Glu Glu Leu  
 50 55 60  
 Pro Met Lys Gly Gly Thr Leu Gly Gly Ile Pro Gly Glu Pro Ala Val  
 65 70 75 80  
 Asp His Arg Asp Val Asp Glu Leu Leu Glu Phe Ile Asn Ser Thr Glu  
 85 90 95  
 Pro Lys Val Pro Asn Ser Ala Arg Ala Ala Lys Arg Ala Arg His Lys  
 100 105 110  
 Leu Lys Lys Lys Val Gly Val Gly Arg Ala Gln Leu Cys Arg Leu Ser  
 115 120 125  
 Ser Leu Arg Thr Leu Ala Pro Thr Pro Arg Thr Ser Gly Ala  
 130 135 140

&lt;210&gt; 192

&lt;211&gt; 63

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 192

Ala Arg Gly Ser Gly Gln Gly Glu Glu Ala Val Gln Lys Ser His Lys  
 1 5 10 15  
 Val Lys Arg Arg Gly Pro Leu Val Arg Val Glu Gln Leu Arg Ile Glu  
 20 25 30  
 Glu Met Lys Val Ile Lys Leu Leu Val Thr Phe Glu Leu Gly Val Ile  
 35 40 45  
 Ile Leu Ile Leu Glu Met Thr Lys Leu Arg Leu Thr Lys Thr Arg  
 50 55 60

&lt;210&gt; 193

&lt;211&gt; 218

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 193

Thr Leu Leu Lys Gly Thr Lys Leu Glu Leu His Arg Gly Gly Gly Arg  
 1 5 10 15  
 Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Pro  
 20 25 30  
 Thr Pro Gly Val Trp Ser Cys Pro Thr Ala Thr Pro Trp Ala Ser Gly  
 35 40 45  
 Ser Arg Arg Lys Asn Leu Ala Arg Glu Ser Lys Gly Arg Pro Arg Pro  
 50 55 60

115

Thr Glu Ile Thr Arg Pro Tyr Leu Cys Pro His Pro Tyr Leu Pro Pro  
 65 70 75 80  
 His Thr Ala Pro Cys Leu Gly Ser His Pro Ser Ala Cys Arg Cys Ser  
 85 90 95  
 Arg Ser Cys Pro His Ser Leu Leu Leu Pro Phe Ser Ile Thr Arg Glu  
 100 105 110  
 Cys Pro Gly Ser His Arg Val Pro Gln Met Pro Val Phe Pro Gln Thr  
 115 120 125  
 Ile Leu Ser Ser Arg Ile Asn Ser Ile Ala Ile Gln Met Ser Pro His  
 130 135 140  
 Gln Pro Met Gln Val Ser Ser Ser Lys Thr Ile Leu Trp Leu Val Leu  
 145 150 155 160  
 Ser Cys Leu Cys Pro Ser Ser Pro His Pro Val Ile Ser Gly Leu Pro  
 165 170 175  
 Gln Trp Tyr Ile Gly Val Leu Ala Gly Ile Val Pro Val Ala Pro Ile  
 180 185 190  
 Arg Pro Gly Asp Ser Gly Leu Asp Leu Gln Arg Glu Gly Pro Gln Pro  
 195 200 205  
 Ile Leu Ser Gln Gly Leu Asn Arg Arg Thr  
 210 215

&lt;210&gt; 194

&lt;211&gt; 704

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 194

Val Asp Gly Ala Ala Met Ala Ala Cys Glu Gly Arg Arg Ser Gly Ala  
 1 5 10 15  
 Leu Gly Ser Ser Gln Ser Asp Phe Leu Thr Pro Pro Val Gly Gly Ala  
 20 25 30  
 Pro Trp Ala Val Ala Thr Thr Val Val Met Tyr Pro Pro Pro Pro  
 35 40 45  
 Pro Pro His Arg Asp Phe Ile Ser Val Thr Leu Ser Phe Gly Glu Ser  
 50 55 60  
 Tyr Asp Asn Ser Lys Ser Trp Arg Arg Arg Ser Cys Trp Arg Lys Trp  
 65 70 75 80  
 Lys Gln Leu Ser Arg Leu Gln Arg Asn Met Ile Leu Phe Leu Leu Ala  
 85 90 95  
 Phe Leu Leu Phe Cys Gly Leu Leu Phe Tyr Ile Asn Leu Ala Asp His  
 100 105 110  
 Trp Lys Ala Leu Ala Phe Arg Leu Glu Glu Glu Gln Lys Met Arg Pro  
 115 120 125  
 Glu Ile Ala Gly Leu Lys Pro Ala Asn Pro Pro Val Leu Pro Ala Pro  
 130 135 140  
 Gln Lys Ala Asp Thr Asp Pro Glu Asn Leu Pro Glu Ile Ser Ser Gln  
 145 150 155 160

Lys	Thr	Gln	Arg	His	Ile	Gln	Arg	Gly	Pro	Pro	His	Leu	Gln	Ile	Arg	
				165					170					175		
Pro	Pro	Ser	Gln	Asp	Leu	Lys	Asp	Gly	Thr	Gln	Glu	Glu	Ala	Thr	Lys	
			180					185					190			
Arg	Gln	Glu	Ala	Pro	Val	Asp	Pro	Arg	Pro	Glu	Gly	Asp	Pro	Gln	Arg	
		195					200					205				
Thr	Val	Ile	Ser	Trp	Arg	Gly	Ala	Val	Ile	Glu	Pro	Glu	Gln	Gly	Thr	
	210					215					220					
Glu	Leu	Pro	Ser	Arg	Arg	Ala	Glu	Val	Pro	Thr	Lys	Pro	Pro	Leu	Pro	
225					230					235					240	
Pro	Ala	Arg	Thr	Gln	Gly	Thr	Pro	Val	His	Leu	Asn	Tyr	Arg	Gln	Lys	
				245					250					255		
Gly	Val	Ile	Asp	Val	Phe	Leu	His	Ala	Trp	Lys	Gly	Tyr	Arg	Lys	Phe	
			260					265					270			
Ala	Trp	Gly	His	Asp	Glu	Leu	Lys	Pro	Val	Ser	Arg	Ser	Phe	Ser	Glu	
		275					280					285				
Trp	Phe	Gly	Leu	Gly	Leu	Thr	Leu	Ile	Asp	Ala	Leu	Asp	Thr	Met	Trp	
	290					295					300					
Ile	Leu	Gly	Leu	Arg	Lys	Glu	Phe	Glu	Glu	Ala	Arg	Lys	Trp	Val	Ser	
305					310					315					320	
Lys	Lys	Leu	His	Phe	Glu	Lys	Asp	Val	Asp	Val	Asn	Leu	Phe	Glu	Ser	
				325					330					335		
Thr	Ile	Arg	Ile	Leu	Gly	Gly	Leu	Leu	Ser	Ala	Tyr	His	Leu	Ser	Gly	
			340					345					350			
Asp	Ser	Leu	Phe	Leu	Arg	Lys	Ala	Glu	Asp	Phe	Gly	Asn	Arg	Leu	Met	
		355					360					365				
Pro	Ala	Phe	Arg	Thr	Pro	Ser	Lys	Ile	Pro	Tyr	Ser	Asp	Val	Asn	Ile	
		370				375					380					
Gly	Thr	Gly	Val	Ala	His	Pro	Pro	Arg	Trp	Thr	Ser	Asp	Ser	Thr	Val	
385					390					395					400	
Ala	Glu	Val	Thr	Ser	Ile	Gln	Leu	Glu	Phe	Arg	Glu	Leu	Ser	Arg	Leu	
				405					410					415		
Thr	Gly	Asp	Lys	Lys	Phe	Gln	Glu	Ala	Val	Glu	Lys	Val	Thr	Gln	His	
			420					425					430			
Ile	His	Gly	Leu	Ser	Gly	Lys	Lys	Asp	Gly	Leu	Val	Pro	Met	Phe	Ile	
		435					440					445				
Asn	Thr	His	Ser	Gly	Leu	Phe	Thr	His	Leu	Gly	Val	Phe	Thr	Leu	Gly	
						455					460					
Ala	Arg	Ala	Asp	Ser	Tyr	Tyr	Glu	Tyr	Leu	Leu	Lys	Gln	Trp	Ile	Gln	
465					470					475					480	
Gly	Gly	Lys	Gln	Glu	Thr	Gln	Leu	Leu	Glu	Asp	Tyr	Val	Glu	Ala	Ile	
				485					490					495		
Glu	Gly	Val	Arg	Thr	His	Leu	Leu	Arg	His	Ser	Glu	Pro	Ser	Lys	Leu	
			500					505					510			

Thr	Phe	Val	Gly	Glu	Leu	Ala	His	Gly	Arg	Phe	Ser	Ala	Lys	Met	Asp
		515					520					525			
His	Leu	Val	Cys	Phe	Leu	Pro	Gly	Thr	Leu	Ala	Leu	Gly	Val	Tyr	His
	530					535					540				
Gly	Leu	Pro	Ala	Ser	His	Met	Glu	Leu	Ala	Gln	Glu	Leu	Met	Glu	Thr
545					550					555					560
Cys	Tyr	Gln	Met	Asn	Arg	Gln	Met	Glu	Thr	Gly	Leu	Ser	Pro	Glu	Ile
				565					570					575	
Val	His	Phe	Asn	Leu	Tyr	Pro	Gln	Pro	Gly	Arg	Arg	Asp	Val	Glu	Val
			580					585					590		
Lys	Pro	Ala	Asp	Arg	His	Asn	Leu	Leu	Arg	Pro	Glu	Thr	Val	Glu	Ser
		595					600					605			
Leu	Phe	Tyr	Leu	Tyr	Arg	Val	Thr	Gly	Asp	Arg	Lys	Tyr	Gln	Asp	Trp
	610					615					620				
Gly	Trp	Glu	Ile	Leu	Gln	Ser	Phe	Ser	Arg	Phe	Thr	Arg	Val	Pro	Ser
625					630					635					640
Gly	Gly	Tyr	Ser	Ser	Ile	Asn	Asn	Val	Gln	Asp	Pro	Gln	Lys	Pro	Glu
				645					650					655	
Pro	Arg	Asp	Lys	Met	Glu	Ser	Phe	Phe	Leu	Gly	Glu	Thr	Leu	Lys	Tyr
			660					665					670		
Leu	Phe	Leu	Leu	Phe	Ser	Asp	Asp	Pro	Asn	Leu	Leu	Ser	Leu	Asp	Ala
		675					680					685			
Tyr	Val	Phe	Asn	Thr	Glu	Ala	His	Pro	Leu	Pro	Ile	Trp	Thr	Pro	Ala
	690					695					700				



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24008

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, STN (Database: Biosis, Embase, Medline, Scisearch, Lifesci, Caplus)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank (N_Geneseq_36); Accession NO: V86545; AGOSTINO et al.; New polynucleotides encoding human secreted proteins-derived from e.g. human blood, kidney, foetal lung, placenta, testes, brain, ovary, pituitary, retina and colon cDNA libraries; 15 OCT 1998; having 100% sequence identity with SEQ ID NO:11. See entire document.	1-7, 21

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 JANUARY 2001

Date of mailing of the international search report

06 FEB 2001

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RITA MITRA

Telephone No. (703) 308-0196

 TERRY J. DEY  
 PARALEGAL SPECIALIST  
 TECHNOLOGY CENTER 1600

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/24008

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank (N_Geneseq_36); Accession NO: T23968; MATSUBARA et al.; "Identifying gene signatures in 3'-directed human cDNA library- e.g. for diagnosis of abnormal cell function by preparing cDNA that reflects relative abundance of corresponding mRNA in specific human tissues"; 01 June 1995; having 98.9% sequence identity with SEQ ID NO: 11, see entire document.	1-7, 21
X	Database GenBank (EST); Accession NO: AI92802; NCI-CGAP; "Tumor Gene Index"; 02 September 1999; having 100% sequence identity with SEQ ID NO: 11; Vector: pT7T3D; host cell: DH10B, see entire document.	1-10, 21
X	Database GenBank (EST); Accession NO: H08444; HILLIER et al.; source: clone_lib="Soares infant brain 1NIB"; 23 June 1995; having 98.7% sequence identity with SEQ ID No: 11; Vector: Lafmid BA; host cell: DH10B, see entire document.	1-10, 21

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24008

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 14, 15 and 21, in part

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/24008

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

C07H 21/04, 21/02; C07K 5/00, 14/00; C12Q 1/68; C12N 1/12, 15/63, 15/85, 15/86

## A. CLASSIFICATION OF SUBJECT MATTER: US CL :

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups 1-72, claim(s) 1-10, 14, 15 and 21, all in part, drawn to an isolated nucleic acid of SEQ ID NO X or a peptide of SEQ ID NO Y, wherein X and Y are values that correlate to those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For example,

If group 1 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein X is 11 and Y is 83.

If group 2 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein X is 12 and Y is 84.

Groups 73-144, claim(s) 11, 12, 16 and 23, all in part, each group directed to a peptide of SEQ ID NO; Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 73 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein Y is 83.

If group 74 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein Y is 84.

Groups 145-216, claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 145 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein Y is 83.

If group 146 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein Y is 84.

Groups 217-288, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 217 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein Y is 83.

If group 218 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein Y is 84.

Groups 289-360, claims 18 and 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 289 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein X is 11.

If group 290 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein X is 12.

Groups 361-432, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 361 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein Y is 83.

If group 362 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein Y is 84.

Groups 433-504, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 433 is elected, this correlates to Gene no 1, cDNA clone ID HETHR73 of Table 1, wherein X is 11.

If group 434 is elected, this correlates to Gene No 2, cDNA clone ID HDPFB02, wherein X is 12.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24008

The inventions listed as Groups 1-504 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each invention are unrelated, each to each other. Where, for example, claim 1, items (e) through (f) do not require a polynucleotide of any degree of specificity to a sequence, it is apparent that Lindeskog et al. (1999, Virology Vol 258(2) 441-450) discloses a DNA encoding a polypeptide wherein said DNA renders claim 1, among the other, not novel. Thus the technical feature of the polynucleotide sequence is not special and the groups are not so linked under PCT Rule 13.1. Additionally the claimed methods produce different products and/or different results which are not coextensive and which do not share the same technical feature.